Assignee: Curis, Inc. (Cambridge, MA)
Assignee: Organogenesis, Inc. (Canton, MA)
Inventors: Dilmanian; F. Avraham (Yaphank, NY), McDonald, III; John W. (Baltimore, MD)
Inventors: Stanton; Lawrence W. (Singapore, SG), Brandenberger; Ralph (Menlo Park, CA), Gold; Joseph D. (San Francisco, CA), Irving; John M. (San Mateo, CA), Mandalam; Ramkumar (Union City, CA), Mok; Michael (Palo Alto, CA)
Inventors: Spindler; Stephen R. (Riverside, CA), Dhahbi; Joseph M. (Alameda, CA)
Inventors: Friedlander; Martin (Del Mar, CA), Otani; Atsushi (San Diego, CA), Da Silva; Karen (Irvine, CA)
Inventors: Hogan; Brigid L. M. (Brentwood, TN)
Inventors: Qasba; Pankaj (Columbia, MD), Thiede; Mark A. (Forest Hill, MD)
Inventors: Goldman; Steven A. (South Salem, NY), Roy; Neeta Singh (New York, NY)
Assignee: Cornell Research Foundation, Inc. (Ithaca, NY)
Inventors: Uchida; Nobuko (Palo Alto, CA), Buck; David W. (Santa Clara, CA), Weissman; Irving (Redwood City, CA)
Assignee: Stemcells California, Inc. (Palo Alto, CA)
Inventors: Radice; Marco (Modena, IT), Pastorello; Andrea (Abano Terme, IT), Pavesio; Alessandra (Padua, IT), Callergaro; Lanfranco (Thiene, IT)
Assignee: Fidia Advanced Biopolymers, SRL. (Abano Terme, IT)
Inventors: Goodman; Chris B. (Green Brook, NJ), Robinson; Wayne Malcolm (Hampton, NJ), Feingold; Barnett Dov (New York, NY)
Inventors: Xu; Ren-He (Madison, WI), Thomson; James A. (Madison, WI)
Assignee: WiCell Research Institute, Inc. (Madison, WI)
Inventors: Cox, III; George N. (Louisville, CO)
Assignee: Bolder Biotechnology, Inc. (Boulder, CO)
Inventors: Hoemann; Caroline D. (Montreal, CA), Buschmann; Michael D. (Montreal, CA), McKee; Marc D. (Westmount, CA)
Inventors: Rolland; Eric (Divonne les bains, FR), Hunziker; Thomas (Oberhofen, CH), Mis; Beatrice (Lausanne, CH), Rinsch; Christopher (Lausanne, CH)
Assignee: DFB Pharmaceuticals, Inc. (Fort Worth, TX)
Inventors: Zsebo; Krisztina M. (Thousand Oaks, CA), Bosselman; Robert A. (Thousand Oaks, CA), Suggs; Sidney V. (Newbury Park, CA), Martin; Francis H. (Thousand Oaks, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Inventors: Miao; Ningning (Cambridge, MA), Wang; Monica (Marblehead, MA), Mahanthappa; Nagesh K. (Cambridge, MA), Pang; Kevin (Belmont, MA)
Assignee: Curis, Inc. (Cambridge, MA)
Date of First Priority Issue: Thursday July 24th, 1997
Patent Number: 7,145,055
The use of immunodeficient animals in stem cell research is very important since most researchers are interested in the in vivo activities of human stem cells without having to actually perform clinical trials.
The solution to this has been the use of animal strains that are either genetically immune deficient, or induced to be immune deficient. Previously the NOD-SCID mouse was used to... Inventors: Method of producing a mouse suitable for the engraftment, differentiation and proliferation of heterolIto; Mamoru (Kanagawa, JP), Kobayashi; Kimio (Kanagawa, JP), Nakahata; Tatsutoshi (Kyoto, JP), Tsuji; Koichiro (Tokyo, JP), Habu; Sonoko (Tokyo, JP), Koy
Assignee: Central Institute for Experimental Animals (Kanagawa, JP)
Date of First Priority Issue: Friday December 1st, 2000
Patent Number: 7,145,057
Trangenic animals have been very useful in the basic sciences in terms of elucidating biological activities of specific proteins in an in vivo situation. In terms of developing therapeutics, transgenic animals are useful for a wide variety of practical purposes ranging from in vivo production of recombinant proteins for human use, to serving as bioincubators for tissue and three-dimensional... Inventors: Van de Lavoir; Marie-Cecile (San Francisco, CA), Etches; Robert J. (San Mateo, CA), Heyer; Babette (Menlo Park, CA), Diamond; Jennifer (Millbrae, CA), Mather; Christine (Millbrae, CA), Beemer; Kathleen (Pacifica, CA), Myers; Heather (Danville, CA)
Assignee: Origen Therapeutics, Inc. (Burlingame, CA)
Date of First Priority Issue: Friday February 1st, 2002
1 Comment
Patent Number: 7,141,428
Stem cells are increasingly seen as a source for the generation of new neurons. In this patent, ways of protecting neurons and stimulating axon regrowth are thought. Specifically, the patent deals with two GTPases called Rho and Rac. Rac activation causes axon spreading, while Rho activation causes axon retraction. In many neurodegenerative diseases, axons are retracted and important neural... Inventors: McKerracher; Lisa (Ile des Soeurs, Quebec, CA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Thursday November 2nd, 2000
1 Comment
Patent Number: 7,141,551
Perlecan is a proteoglycan (A molecule that contains both protein and glycosaminoglycans, which are a type of polysaccharide) that is found in the basement membrane. Upregulation of perlecan expression is observed during wound healing, as well as VEGF-mediated tumor angiogenesis. It is known that perlcan binds to numerous growth factors including FGF family members. It is also known that... Inventors: DeCarlo; Arthur A. (Weston, FL), Whitelock; John (Homebush 2140, Sydney, AU)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Tuesday April 22nd, 2003
Patent Number: 7,141,363
Chemotactic gradients are critically important in stem cell function. This is demonstrated not only in the fact that the bone marrow constitutively secretes SDF-1 in order to allow systemically infused stem cells to home back to the bone marrow, but also in regenerative medicine where injured tissue releases chemokines to attract endogenous stem cells.
The current patent deals with the... Inventors: Poznansky; Mark C. (Charlestown, MA), Luster; Andrew D. (Wellesley, MA), Scadden; David T. (Weston, MA)
Assignee: The General Hospital Corporation (Boston, MA)
Date of First Priority Issue: Thursday April 8th, 1999
Patent Number: 7,138,275
This patent is highly interesting in that the inventors claim to have devised a simple and easy to implement methodology for generation of autologous stem cells. Essentially, the invention teaches that culturing of peripheral blood monocytes in the presence of IL-3 and M-CSF for approximately 6 days, somehow induces a program of de-differentiation in the monocytes to endow them with stem cell... Inventors: Kremer; Bernd Karl Friedrich (Kiel, DE), Fandrich; Fred (Kiel, DE), Ruhnke; Maren ne (Kiel, DE)
Assignee: Blasticon Biotechnologische Forschung GmbH (Keil, DE)
Date of First Priority Issue: Thursday March 28th, 2002
8 Comments
Patent Number: 7,138,276
Notch is a receptor for Delta and Serrate that is found in Drosophila and involved in controlling nerve cell differentiation during development. The human equivalent of Notch is called TAN-1, and is expressed on hematopoietic stem cells.
Other patents have used Notch ligand homologues to stimulate fetal hemoglobin synthesis as... Inventors: Sakano; Seiji (Shizuoka, JP), Itoh; Akira (Shizuoka, JP)
Assignee: Asahi Kasei Kabushiki Kaisha (Osaka, JP)
Date of First Priority Issue: Tuesday July 16th, 1996
Patent Number: 7,138,492
It is known that hedgehog proteins are important in specifying what cells give rise to what tissues during development. Others have patented using hedgehog proteins for stimulating insulin production. In this patent the inventors found a new use for hedgehog proteins besides their known role in embryogenesis. Initially, the... Inventors: Miao; Ningning (Palo Alto, CA), Wang; Monica (Marblehead, MA), Mahanthappa; Nagesh K. (Cambridge, MA), Jin; Ping (Boston, MA), Pang; Kevin (Belmont, MA)
Assignee: Curis, Inc. (Cambridge, MA)
Date of First Priority Issue: Thursday July 24th, 1997
Patent Number: 7,135,336
The concept of "de-differentiation" of cells is very attractive from a therapeutic perspective since it offers the possibility of generating autologous stem cells from somatic tissue. If one could devise a method for generating even minute numbers of totipotent stem cells from autologous tissue, these cells could be expanded and used to treat almost any illness.
The use of nuclear transfer for... Inventors: Paylian; Sergei (Knoxville, TN)
Assignee: University of South Florida (Tampa, FL)
Date of First Priority Issue: Wednesday April 21st, 2004
Patent Number: 7,135,171
Numerous ways exist of augmenting angiogenesis. These range from administration of cytokines such as FGF (US Patent #6451303) to administration of cells (US Patent 5980887). The current patent teaches the administration of endothelial progenitor cells, not some much for... Inventors: Edelberg; Jay (New York, NY), Rafii; Shahin (Great Neck, NY), Hong; Mun (New York, NY), Lanza; Robert P. (Clinton, MA), West; Michael D. (Southborough, MA)
Assignee: Cornell Research Foundation, Inc. (Ithaca, NY)
Date of First Priority Issue: Thursday August 9th, 2001
Patent Number: 7,135,172
Retinal degeneration is a major cause of blindness, percipitated by numerous conditions, including adult macular degeneration. While numerous companies are currently seeking ways of blocking angiogenesis and thereby blocking the retinal degeneration process, when this process has already occurred, there are no options for treatment.
Intensive research is being carried out on ways of using stem... Inventors: Loftus; David J. (Palo Alto, CA), Leng; Theodore (Mountain View, CA), Huie; Philip (Cupertino, CA), Fishman; Harvey (Menlo Park, CA)
Assignee: The United States of America as represented by the Administrator of the National Aeronautics and Space Administration (Washington, DC)
Date of First Priority Issue: Wednesday September 4th, 2002
1 Comment
Patent Number: 7,135,459
This patent covers the use of zFGF-5 (currently known as FGF-18) for expansion in vitro and in vivo of chondrocytes and neural stem cells. According to the Zymogenetics website, FGF-18 is out-licensed to Serono for use in cartilage repair and stroke. The product is in preclinical phases of testing.
While the specification provides numerous uses for FGF-18, the claims are restricted to one... Inventors: Deisher; Theresa A. (Seattle, WA), Conklin; Darrell C. (Seattle, WA)
Assignee: ZymoGenetics, Inc. (Seattle, WA)
Date of First Priority Issue: Monday October 16th, 2006
Patent Number: 7,132,286
This patent covers the use of valproic acid for inducing differentiation of neurons from neural stem cells.
This patent seems to be restricted in the claims to the in vitro differentiation of neurons. What is interesting is whether the concentrations claimed in the patent are actually achievable in vivo.
Since valproic acid is clinically used as an anticonvulsant, it is interesting to... Inventors: Laeng; Pascal (Washington, DC), Mallon; Barbara (Gaithersburg, MD), Pitts; Lee (Falls Church, VA)
Assignee: Psychiatric Genomics, Inc. (Gaithersburg, MD)
Date of First Priority Issue: Monday June 18th, 2001
Patent Number: 7,132,287
This patent teaches that culture of neuronal stem cells in the presence of an 5HT1A agonist (for example serotonin) will induce differentation into neurons. Inventors: Rajan; Prithi (Rockville, MD), Altar; C. Anthony (Garrett Park, MD)
Assignee: Psychiatric Genomics, Inc. (Gaithersburg, MD)
Date of First Priority Issue: Monday June 18th, 2001
Patent Number: 7,129,034
This patent teaches the generation of neurons from culturing of whole bone marrow in basic fibroblast growth factor and epidermal growth factor.
This patent may be useful as a simple and easy to generate source of cells for therapy of neurodegenerative diseases. Inventors: Yu; John S. (Los Angeles, CA), Kabos; Peter (Los Angeles, CA), Ehtesham; Moneeb (Nashville, TN)
Assignee: Cedars-Sinai Medical Center (Los Angeles, CA)
Date of First Priority Issue: Thursday October 25th, 2001
Patent Number: 7,126,039
This patent teaches ways of inactivating xenogeneic carbohydrate antigens and replacing them with non-immunogenic antigens so that various porcine and animal tissue may be transplanted into humans without the fear of hyperacute rejection.
Since the problem of allogeneic rejection is still an issue, the clinical translation of this technology will most likely be long-term. Specifically, if it... Inventors: Denning; Chris (Loughborough, GB), Clark; A. John (Midlothian, GB), Schiff; J. Michael (Menlo Park, CA)
Assignee: Geron Corporation (Menlo Park, CA)
Date of First Priority Issue: Sunday March 11th, 2001
Patent Number: 7,125,714
This patent covers a stem cell that expresses both CD34 and VEGFR-3. What is nice about this patent is that it covers cells with CD34 and VEGFR-3 from ANY source. Inventors: Alitalo; Kari (Helsinki, FI), Joukov; Vladimir (Boston, MA)
Assignee: Licentia Ltd. (Helsinki, FI); Ludwig Institute for Cancer Research (New York, NY)
Date of First Priority Issue: Wednesday February 5th, 1997
Patent Number: 7,118,748
This patent covers the use of angiogensinogen I, II and specific derivatives for stimulation of hematopoietic and stem cell proliferation. Inventors: Rodgers; Kathleen E. (Long Beach, CA), diZerega; Gere S. (Pasadena, CA)
Assignee: University of Southern California (Los Angeles, CA)
Date of First Priority Issue: Thursday May 8th, 1997
Patent Number: 7,122,200
This patent covers ways of generating an artificial urinary tract through tissues engineering and culture of stem cells. Inventors: Kropp; Bradley P. (Edmond, OK), Cheng; Earl Y. (Edmond, OK), Zhang; Yuan Yuan (Edmond, OK), Cowan; Rick (Oklahoma City, OK), Moore; Peter (Perry, OK)
Assignee: The Board of Regents of the University of Oklahoma (Norman, OK)
Date of First Priority Issue: Friday December 8th, 2000
Patent Number: 7,118,746
This patent covers protection of keratinocytes from a variety of stresses by administration of conditioned media from a variety of stem cell sources.
This patent is useful for cosmetics and also for skin regeneration. Inventors: Naughton; Gail K. (Del Mar, CA), Horwitz; David L. (San Diego, CA), Applegate; Mark A. (San Diego, CA), Zeltinger; Joan (San Diego, CA), Mansbridge; Jonathan N. (La Jolla, CA), Kern; Andreas (San Diego, CA), Landeen; Lee K. (San Diego, CA), Ratcliffe; Ant
Assignee: SkinMedica, Inc. (Carlsbad, CA)
Date of First Priority Issue: Friday May 12th, 2000
Patent Number: 7,122,177
This patent covers the use of xenogeneic islet cells derived from fetal or neonatal pigs -20 to +10 days after birth, treating the cells with nicotinamide, lignocaine and a quinolone antibiotic, in order to generate a population of cells that may be encapsulated and used for treatment of diabetes in a human. Inventors: Elliott; Robert Bartlett (Auckland, NZ), Calafiore; Riccardo (Perugia, IT), Basta; Gusseppe (Perugia, IT)
Assignee: Diabcell PTY Ltd. (Parkside, AU)
Date of First Priority Issue: Thursday January 20th, 2000
Patent Number: 7,122,178
This patent covers a progenitor cell that gives rise to mesenchymal stem cells. The population appears to be highly expressing the marker STRO-1, capable of differentiating into fibroblasts, and have at least one of the following markers: THY-1, VCAM-1, STRO-2, and CD146.
These cells are claimed in this patent for augmentation of hematopoiesis.
It will be interesting to compare this patent... Inventors: Simmons; Paul (Kew, AU), Zannettino; Andrew (Highbury, AU), Gronthos; Stan (Bethesda, MD)
Assignee: Angioblast Systems, Incorporated (New York, NY)
Date of First Priority Issue: Wednesday July 7th, 1999
Patent Number: 7,112,653
This patent covers peptides that inhibit hematopoietic stem cell proliferation, thereby allowing protection of these cells from chemotherapy or radiotherapy.
This patent may conceptually be applicable to selectively inhibiting healthy stem cells while allowing leukemic stem cells to proliferate so that chemotherapy or radiotherapy may selectively kill the proliferating leukemic cells. Inventors: Moore; Jeffrey G. (Kennebunkport, ME)
Assignee: Inclone Systems, Incorporated (New York, NY)
Date of First Priority Issue: Monday December 9th, 1996
Patent Number: 7,115,653
This is a composition of matter patent on compounds that modulate hedgehog signalling. Since hedgehog is important not only in stem cell proliferation, but also in cancer, this patent has uses both in regeneration and cancer control. Inventors: Baxter; Anthony David (Hertfordshire, GB), Boyd; Edward Andrew (Oxfordshire, GB), Frank-Kamenetsky; Maria (Brookline, MA), Guicherit; Oivin (Belmont, MA), Porter; Jeffery (Lexington, MA), Price; Stephen (Hartford, GB), Rubin; Lee L. (Wellesley, MA), Stibb
Assignee: Curis, Inc. (Cambridge, MA)
Date of First Priority Issue: Thursday March 30th, 2000
Patent Number: 7,115,582
This patent covers the use of HoxA3, and peptides, and nucleic acids derived from it for tissue regeneration. One particular use is the acceleration of wound healing, particularly for diabetes. Inventors: Boudreau; Nancy (San Francisco, CA), Young; David M. (Larkspur, CA), Myers; Cornelia (San Francisco, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Date of First Priority Issue: Thursday June 21st, 2001
Patent Number: 7,115,571
IL-3 is a potent expander of hematopoietic stem cells. Unfortunately administration of proteins is associated with poor pharmacokinetics and the need to develop special formulations that can systemically deliver the protein.
This patent covers peptide derivatives of IL-3 which have improved activity and pharmacological activity compared to administration of the whole protein.
This patent is... Inventors: Wright; David E. (Ramona, CA), Parks; D. Elliott (Del Mar, CA)
Assignee: Myelos Corporation (Iselin, NJ)
Date of First Priority Issue: Friday June 16th, 2000
Patent Number: 7,115,418
This patent teaches ways of expanding neural stem cells without inducing loss of replicative ability. Specifically, this involves culture with one or more growth factors selected from a group comprising of EGF, amphiregulin, FGF-1, FGF-2 and TGF-beta. Inventors: Weiss; Samuel (Alberta, CA), Reynolds; Brent (Alberta, CA), Hammang; Joseph P. (Barrington, RI), Baetge; E. Edward (Barrington, RI)
Assignee: Neurospheres Holdings Ltd. (Calgary, CA)
Date of First Priority Issue: Monday July 8th, 1991
Patent Number:
This patent covers the extraction and use of a muscle derived stem cell that is positive for the markers desmin, CD34, flk-1 and M-Cadherin, but does not express the hematopoietic marker CD45 nor c-kit.
This cell type is useful for treatment of a variety of disorders associated with muscle degeneration. Although the inventors state that the cell is different than mesenchymal stem cells, in... Inventors: Chancellor; Michael B. (Pittsburg, PA), Huard; Johnny (Pittsburgh, PA), Capelli; Christopher C. (Kenosha, WI), Qu; Zhuqing (Pittsburgh, PA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday May 1st, 1998
Patent Number: 7,115,360
The cancer stem cell is very important since there is numerous investigators in the field that believe the majority of cancer cells making up a tumor mass are only the products of a specific cell subpopulation with high repopulating potential. What this means is that usually the drugs developed for cancer are developed to kill not the stem cell of the tumor, but actually the progeny of the... Inventors: Clarke; Michael F. (Ann Arbor, MI), Morrison; Sean J. (Ann Arbor, MI), Wicha; Max S. (Ann Arbor, MI), al-Hajj; Muhammad (La Jolla, CA)
Assignee: Regents of the University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Thursday August 3rd, 2000
Patent Number: 7,115,267
This patent covers various hemaglobin beta chain derived sequences of peptides, as well as their use in combination with opioids for augmentation of hematopoiesis, as well as for antiviral and anticancer activities.
The products claimed by the patent appear easy to generate and are potentially useful for other regenerative applications besides stimulation of hematopoiesis. Inventors: Wolpe; Stephen D. (Rockville, MD), Tsyrlova; Irena (Gaithersburg, MD)
Assignee: Wellstat Therapeutics Corporation (Gaithersburg, MD)
Date of First Priority Issue: Wednesday April 3rd, 1996
Patent Number: 7,112,437
This patent covers ways of generating human neural stem cells, or committed stem cells, from embryonic stem cells. The patent has 2 independent claims.
The first teaches culturing of the embryonic stem cells with an agent that inhibits a bone morphogenic protein "default pathway" so that the differentiated cell that is produced loses at least one marker of the embryonic stem cell. This... Inventors: Pera; Martin Frederick (Prahran, AU)
Assignee: ES Cell International Pte Ltd. (Singapore, SG)
Date of First Priority Issue: Tuesday June 20th, 2000
Patent Number: 7,109,168
Leukemia inhibitory factor (LIF) is classically known for its ability to maintain murine embryonic stem cells in an undifferentiated state. Various types of non-embryonic stem cells also respond to LIF. For example, LIF supplementation to human fetal cortical cells increases telomerase activity and endows increased self-renewal potential (Wright et al. Human progenitor cells isolated from the... Inventors: Wright; David E. (Ramona, CA), Parks; D. Elliott (Del Mar, CA)
Assignee: Myelos Corporation (Iselin, NJ)
Date of First Priority Issue: Sunday July 16th, 2000
Patent Number: 7,109,032
This patent covers a tissue culture media composition that dose not require the addition of exogenous sera. The tissue culture composition is suitable for expanding mesenchymal stem cells and alleviates the need for serum through addition of the following proteins which are known to stimulate various types of stem cells: basic fibroblast growth factor, leukemia inhibitory factor, and stem cell... Inventors: Cancedda; Ranieri (Genoa, IT), Dozin; Beatrice (Rapallo, IT)
Assignee: Consorzio per la Gestione del Centro di Biotecnologie Avanzate (Genoa, IT)
Date of First Priority Issue: Monday November 9th, 1998
Patent Number: 7,109,030
This is a composition of matter patent on polypeptides homologous to insulin like growth factor binding protein (IGFBP). Various members of the IGFBP family, such as IGFBP-3, stimulate hematopoietic cell proliferation (Liu et al. Functional cloning of IGFBP-3 from human microvascular endothelial cells reveals its novel role in promoting proliferation of primitive CD34+CD38- hematopoietic cells in... Inventors: Dedera; Douglas A. (Castro Valley, CA), Yamazaki; Victoria (Redwood Shores, CA), Asundi; Vinod (Foster City, CA), Liu; Chenghua (San Jose, CA), Tang; Y. Tom (San Jose, CA), Drmanac; Radoje T. (Palo Alto, CA)
Assignee: Nuvelo, Inc. (San Carlos, CA)
Date of First Priority Issue: Friday March 31st, 2000
Patent Number: RE37,978
This patent is useful for anyone who is performing embryonic stem cell differentiation applications and desires a method of purifying unique differentiated cells from the embryonic stem cell. Since embryonic stem cells spontaneously differentiate into various lineages depending on culture conditions, this patent provides means of "fishing out" cells based on activation of cell-specific... Inventor: Field, Loren J. (Indianapolis, IN)
Assignee: Advanced Research & Technology Institute (Indianapolis, IN)
Date of First Priority Issue: Tuesday November 16th, 1993
Patent Number: 6,190,893
This patent is useful for parties interested in altering the biological activity of stromal cells of the bone marrow, particularly in the area of bioengineering. The invention has 5 independent claims. The first covers a method for stimulating biological activities (gene expression, growth, differentiation, transduction, and combo) in bone marrow stromal cells by contacting with an electroactive... Inventors: Shastri, Venkatram R. (Allston, MA); Rahman, Nahid (Cambridge, MA); Martin, Ivan (Cambridge, MA); Langer, Jr., Robert S. (Newton, MA)
Assignee: Massachusetts Institute of Technology (Cambridge, MA)
Date of First Priority Issue: Friday September 18th, 1998
Patent Number: 7101708
This patent is useful for parties looking to increase bone marrow stem cell homing to areas of need. In normal bone marrow transplants, stem cells from the donor are introduced intravenously and find their way to the bone marrow by virtue of bone marrow-secreted stromal derived factor-1 (SDF-1). It was more recently discovered that following tissue injury (for example stroke and myocardial... Inventors: Lapidot, Tsvee (Nes-Ziona, IL); Peled, Amnon (Tel-Aviv, IL)
Assignee: Yeda Research and Development Co. Ltd. (Rehovot, IL)
Date of First Priority Issue: Tuesday July 20th, 1999
Patent Number: 7101710
This patent useful for parties looking for methodologies to purify mesenchymal stem cells from amniotic fluid. The patent has 3 independent claims. Essentially all three are directed towards a two step culture process where amniotic fluid cells are first grown in a vessel, subsequently non-adherent cells are isolated, and allowed to expand. The difference between the claims is the media used... Inventors: Tsai, Ming-Song (Taipei, TW); Hwang, Shiaw-min (Hsinchu 300, TW)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Wednesday February 12th, 2003
Patent Number: 7109028
This patent is useful for parties seeking to purify hepatic progenitor cells, or hepatic stem cells. The patent has one independent claim that essentially teaches how to "negatively deplete" a single cell suspension of hepatocytes for all cells except hepatic stem cells. The patent also claims the marker OC3 as expressed on hepatic stem cells. A publication that appears to relate to the... Inventors: Reid, Lola M. (Chapel Hill, NC); Sigal, Samuel H. (Riverdale, NY); Brill, Shlomo (Ramat-Gan, IL); Holst, Patricia A. (Ossining, NY)
Assignee: Albert Einstein College of Medicine of Yeshiva University (Bronx, NY)
Date of First Priority Issue: Monday July 8th, 1991
2 Comments
Patent Number: 7109032
This patent is useful for parties seeking to expand mesenchymal stem cells, particularly for clinical applications. The invention generally teaches tissue culture media and techniques that alleviate the need for using serum. Since serum is usually from animal origin (fetal calf serum) or in some cases of human origin, there exists possibilities of contaminating cellular sources. The invention... Inventors: Cancedda, Ranieri (Genoa, IT); Dozin, Beatrice (Rapallo, IT)
Assignee: Consorzio per la Gestione del Centro di Biotecnologie Avanzate (Genoa, IT); Istituto Nazionale per la Ricerca Sul Cancro (Genoa, IT)
Date of First Priority Issue: Thursday September 10th, 1998
Patent Number: 7101704
This patent covers mesenchymal and adipocyte lineage cells that have been induced to present exogenous antigen. The patent is useful for companies that are interested in stimulating an immune response through having the mesenchymal or adipocyte-lineage cell to act as an antigen presenting cell. The patent has 2 independent claims. The first covers mesenchymal stem cells that have been treated... Inventor: Mosca, Joseph (Ellicott City, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Saturday September 20th, 1997
Patent Number: 7101546
This invention is useful for treatment of diabetes using encapsulated cells. The invention consists of one independent claim that appears to cover a method for treating diabetes by administration of encapsulated cells that have a specific set of biological and physical properties. The cells appear to be a type of intermediatery cell, or a progenitor cell that is capable of expansion. Inventors: Tsang, Wen-Ghih (Sherman Oaks, CA); Zheng, Tianli (Culver City, CA); Wang, Yanping (Los Angeles, CA)
Assignee: AmCyte, Inc. (Santa Monica, CA)
Date of First Priority Issue: Wednesday November 21st, 2001
Patent Number: 7101539
This invention covers the newly discovered cytokine IL-20 and its use in stimulation of proliferation of early, but not differentiated hematopoietic progenitors. The patent is similar to a paper published by one of the authors (Liu L et al. 2003 Nov 1;102(9):3206-9.) The patent has 4 independent claims all directed to use of IL-20 and polypeptides derived from it. The first covers a method of... Inventors: Heuer, Josef Georg (Indianapolis, IN); Liu, Ling (Carmel, IN); Noblitt, Timothy W. (Fishers, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Date of First Priority Issue: Wednesday February 28th, 2001
Patent Number: 7101837
Alpha-fetoprotein (AFP) is a 65-kDa oncofetal glycoprotein found in fetal and maternal fluids during pregnancy and is produced by various types of cancers. This patent is useful for parties seeking methods of inducing proliferation of bone marrow cells. Particularly, AFP may be used to stimulate hematopoiesis in patients, as well as potentially for regenerative applications such as... Inventor: Murgita, Robert A. (Montreal, CA)
Assignee: Martinex R & D Inc. (Montreal, CA)
Date of First Priority Issue: Tuesday January 24th, 1995
Patent Number: 7098196
This patent is useful for parties seeking to inhibit signal transduction pathways in stem cells, pathways such as the smoothened-dependent pathway. The patent is primarily important for the treatment of cancer, where one tries to inhibit stem cells that give rise to other tumor cells, although numerous uses in regenerative medicine are also possible. The patent has 5 independent claims, all... Inventors: Beachy, Philip A. (Ruxton, MD); Chen, James K. (Baltimore, MD); Taipale, Anssi J. (Baltimore, MD)
Assignee: Johns Hopkins University School of Medicine (Baltimore, MD)
Date of First Priority Issue: Wednesday October 13th, 1999
Patent Number: 7098027
This patent is useful for inducing remyelination using autologous bone marrow stem cells. Demyelination is a pathology associated with numerous neuronal degenerative diseases such as multiple sclerosis or Krabbe Disease. The patent has 1 independent claim which covers the methodology of extracting bone marrow mononuclear cells from the autologous patient and injecting into the lesion of... Inventors: Honmou, Osamu (Hokkaido, JP); Hashi, Kazuo (Hokkaido, JP); Uede, Teiji (Hokkaido, JP)
Assignee: Renomedix Institute, Inc. (Hokkaido, JP); Aska Pharmaceutical Co., Ltd. (Tokyo, JP); Mitsui Sumitomo Insurance Care Network Co., Ltd. (Tokyo, JP); Hitachi Ltd. (Tokyo, JP)
Date of First Priority Issue: Tuesday June 26th, 2001
Patent Number: 7098026
This is a composition of matter patent covering the human desert hedgehog protein which is critically involved in various stages of development. The hedgehog proteins have applications in stem cell proliferation and differentiation. This patent is critical for anyone looking to use the desert hedgehog protein as a therapeutic. Potential areas of therapeutics include regeneration of epithelial... Inventors: Ariyasu, Toshio (Okayama, JP); Nakamura, Shuji (Okayama, JP); Orita, Kunzo (Okayama, JP)
Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo (Okayama, JP)
Date of First Priority Issue: Wednesday April 22nd, 1998
Patent Number: 7097833
This patent is relevant for parties seeking to induce regeneration of cardiac tissue, or other tissue. Although the specification teaches the use of a variety of various peripheral blood and bone marrow stem cell sources for implantation into diseased, damaged, or otherwise subfunctional cardiac tissue, the issued claims only appear to cover the use of autologous, naturally residing cardiac... Inventor: Freyman, Toby (Watertown, MA)
Assignee: Boston Scientific Scimed, Inc. (Maple Grove, MN)
Date of First Priority Issue: Friday July 19th, 2002
Patent Number: 7097832
This patent is useful for the induction of collateral blood vessel formation (for example angiogenesis) in ischemic tissue. There are numerous conditions that may benefit from induction of said collateral blood vessel formation. For example ischemia of the various organs may be treated using this patent. The patent overall teaches the use of autologous bone marrow cells, either ex vivo... Inventors: Kornowski, Ran (Ramat hasharon, IL); Fuchs, Shmuel (Rockville, MD); Epstein, Stephen E. (Rockville, MD); Leon, Martin B. (New York, NY)
Assignee: Myocardial Therapeutics, Inc. (San Diego, CA)
Date of First Priority Issue: Tuesday March 30th, 1999
Patent Number: 7094882
This patent is useful for the manipulation of stem cell expansion through interfering with Neuregulin-4 signaling by antibody. Specifically, the patent has 2 independent claims that cover an antibody capable of binding to sequences which appear to be those of Neuregulin-4 or its active portions. Inventors: Harari, Daniel (Rehovot, IL); Yarden, Yosef (Rehovot, IL)
Assignee: Yeda Research And Development Co. Ltd. (Rechovot, IL)
Date of First Priority Issue: Friday April 21st, 2000
Patent Number: 7094424
This patent teaches ways of selectively targeting a compound to endothelial cells. This could be used to administer stem cell stimulators in order to increase angiogenesis. The patent has one independent claim,that is "A method for selectively labeling angiogenic endothelial cells in vivo, the method comprising administering to a mammal a liposomal complex comprising cationic lipids and a... Inventors: McDonald, Donald M. (San Francisco, CA); McLean, John (Redwood City, CA); Thurston, O. Gavin (San Francisco, CA); Baluk, Peter (San Francisco, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Date of First Priority Issue: Wednesday March 12th, 1997
Patent Number: 7094601
This patent is useful for cryopreservation of extremely sensitive cells such as oocytes and stem cells. Particularly, the patent deals with microinjection of various agents that protect cells during cryopreservation. The patent has 2 independent claims. The first covers the culture of oocytes (the concept that "culture" will be frozen) such that a cryopreservation agent is injected into... Inventors: Toner, Mehmet (Wellesley, MA); Eroglu, Ali (Augusta, GA); Toth, Thomas (Sudbury, MA)
Assignee: The General Hospital Corporation (Boston, MA)
Date of First Priority Issue: Tuesday May 16th, 2000
Patent Number: 7094569
This patent is useful for induction of hair growth through use of hair follicle growth factor (HFGF) proteins. Essentially, the HFGF proteins described in the application appear to be allelic variants of keratinocyte growth factor-2 (also known as FGF-10). There are both composition of matter, use, and delivery claims issued. One of the authors of the patent published a paper describing... Inventors: Kim, Soogyun (Seoul, KR); Jang, Hyun-Jun (Seoul, KR
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Thursday May 24th, 2001
Patent Number: 7091319
This patent covers fusion proteins of IL-3, that are useful for the growth, expansion, and in vivo expansion of stem cells. Although IL-3 and its fused partners are primarily important for hematopoietic stem cell expansion, the fusion proteins may have numerous other uses, including expanding hematopoietic-like stem cells that may be used for regenerative applications. The patent has numerous... Inventors: Bauer, S. Christopher (New Haven, MO); Abrams, Mark Allen (St. Louis, MO); Braford-Goldberg, Sarah Ruth (St. Louis, MO); Caparon, Marie Helena (Chesterfield, MO); Easton, Alan Michael (Maryland Heights, MO); Klein, Barbara Kure (St. Louis, MO); McKearn, J
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Tuesday November 24th, 1992
Patent Number: 7,091,310
This patent is useful for stem cell mobilization, stem cell homing, as well as a variety of other applications involving various chemokines. Specifically, the invention covers peptides that antagonize or agonize receptors for IL-8, IP-10, MIP-1 alpha., MCP-1, RANTES, I-309, and CCL28. IL-8 is known to be associated with inflammation and in terms of stem cells is known to be associated with... Inventors: Merzouk, Ahmed (Richmond, CA); Wong, Donald (Vancouver, CA); Salari, Hassan (Delta, CA)
Assignee: Chemokine Therapeutics Corporation (Vancouver, CA)
Date of First Priority Issue: Friday September 13th, 2002
Patent Number: 7091191
This patent is useful for making scaffolds onto which stem cells, progenitor cells, or other type of cells can be seeded, and the scaffold together with the seeded cells are implanted in vivo. Previous scaffold technologies using hyaluronic acid have the drawback of very rapid resorption in the body, not giving the cells enough time to integrate and function properly. This patent uses a novel... Inventors: Laredo, Walter R. (Hillsborough, NJ); Rezania, Alireza (Hillsborough, NJ)
Assignee: Ethicon, Inc. (Somerville, NJ)
Date of First Priority Issue: Friday December 19th, 2003
1 Comment
Patent Number: 7056687
This patent is useful for drug development. It teaches ways of inducing gene expression in cells (including stem cells) and using the specifically modified cells for screening of drug libraries. The invention itself is not specific to stem cells, so therefore we will not describe it in detail. The patent has 3 independent claims. Specifically:
"A method of screening for cells having an... Inventors: Lorens, James (Portola Valley, CA); Kinsella, Todd M. (Fayetteville, NC); Masuda, Esteban (Menlo Park, CA); Hitoshi, Yasumichi (Mountain View, CA); Liao, X. Charlene (Palo Alto, CA); Pearsall, Denise (Belmont, CA); Freiro, Annabelle (South San Francisco,
Assignee: Rigel Pharmaceuticals, Inc. (South San Francisco, CA)
Date of First Priority Issue: Tuesday May 12th, 1998
Patent Number: 7091035
This invention is important for entities looking to expand various stem cells in vitro. The inventors noted that stem cells can differentiated into various types of other cells, and that a "dynamic" method of growing stem cells is relevant to what type of cells can be produced. The invention essentially covers ways of watching and manipulating stem cells and their progeny in culture as... Inventors: Ravin, Rea (Rockville, MD); Sullivan, James V. (Bowie, MD); McKay, Ronald D. (Bethesda, MD)
Assignee: The United States of America as represented by the Department of Health and Human Services (Washington, DC)
Date of First Priority Issue: Monday December 30th, 2002
Patent Number: 7078232
Repair of articular cartilage is a substantial problem. The patent is useful for entities interested in providing a solution to this problem through the administration of cellular therapy containing adipose-derived stem cells in a biocompatible matrix or delivery system. The patent specifically has 4 independent claims. The first claim covers a composition of matter that is useful for treatment... Inventors: Konkle, Jon (Durham, NC); Gimble, Jeffrey M. (Baton Rouge, LA)
Assignee: Artecel, Inc.
Date of First Priority Issue: Thursday August 19th, 1999
Patent Number: 7078231
This patent deals with the problem that the majority of pancreatic progenitor cells known at the time of filing are only capable of differentiating into islets but not other cells in the pancreas. Specifically, the patent cites patents 5,888,705 (Compositions and method of stimulating the proliferation and differentiation of human fetal and adult pancreatic cells ex vivo) and 5,834,308 (In vitro... Inventors: Roberts, Penelope E (Millbrae, CA); Mather, Jennie Powell (Millbrae, CA)
Assignee: Raven biothechnologies, inc. (South San Francisco, CA)
Date of First Priority Issue: Wednesday October 4th, 2000
Patent Number: 7078230
This patent is useful for entities interested in neurodegeneration and sources of neural-like cells. The patent is a composition of matter patent on adipose tissue derived cells that are endowed with neural characteristics. The patent has 2 independent claims, the first covers an adipose tissue derived stromal cell that is differentiated to express neuronal phenotypic markers. The second claim... Inventors: Wilkison, William O. (Bahama, NC); Gimble, Jeffrey (Chapel Hill, NC)
Assignee: Artecel, Inc. (Baltimore, MD)
Date of First Priority Issue: Saturday February 26th, 2000
Patent Number: 7074397
This patent is useful for treatment of neutropenias and other conditions where expansion of bone marrow is required. The patent teaches the use of WSX ligands in stimulation of hematopoiesis. One such ligand is leptin. The patent has 2 independent claims. The first covers enhancing proliferation or differentiation a cell of the hematopoietic lineage through administration of the OB protein... Inventor: Matthews, William (Woodside, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Date of First Priority Issue: Thursday August 1st, 1996
Patent Number: 7074239
This invention is useful for entities interested in inducing spinal fusion, primarily for patients with lower back pain. The invention covers a medical implant that can be used to deliver various stem cell and progenitor cell chemoattractants, as well as morphogens, in order to accelerate healing and efficient fusion of vertebrae. Inventors: Cornwall, G. Bryan (San Diego, CA); Sohngen, Gary (San Pedro, CA); Lane, Joseph M. (New York, NY); Tomin, Emre A. (New York, NY)
Assignee: Cytori Therapeutics, Inc. (San Diego, CA)
Date of First Priority Issue: Wednesday April 25th, 2001
Patent Number: 7070996
This is a patent covering the use of CD34+ generated mast cells for drug screening. Since technologies for generating mast cells existed in the prior art (for example, as early as 1991 it was known that CD34+ cells can differentiate into mast cells: Kirshenbaum AS, et al. Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. J Immunol. 1991 Mar 1;146(5):1410-5... Inventor: Rossi, Alexander B. (San Francisco, CA)
Assignee: Rigel Pharmaceuticals, Inc. (South San Francisco, CA)
Date of First Priority Issue: Friday August 31st, 2001
Patent Number: 7071372
Although numerous technologies exist for cloning of animals, it appears from the current patent, that one of the limitations is that the donor cell usually has to be freshly isolated, or cultured for a short period of time. This does not allow for manipulation of the donor cell at a genetic level before nuclear transfer. The current patent teaches methods of long-term culture of donor cells so... Inventors: Yang, Xiangzhong (Storrs, CT); Kubota, Chikara (Kagoshima, JP)
Assignee: University of Connecticut (Farmington, CT); The Governor of Kagoshima Prefecture (JP)
Date of First Priority Issue: Saturday April 1st, 2000
Patent Number: 7070989
This patent is important for entities seeking to use the hematopoietic stem cell stimulatory/differentiation factor, granulocyte colony stimulating factor (G-CSF) that is produced in E. coli. The patent has 2 independent claims, the first to a vector encoding human G-CSF, and the second to a method of producing human G-CSF. Inventors: Lee, Sang-Yup (Taejon, KR); Jeong, Ki-Jun (Taejon, KR)
Assignee: Korea Advanced Institute of Science and Technology (KR)
Date of First Priority Issue: Friday March 31st, 2000
Patent Number: 7070582
This patent is a medical device useful for administration of therapeutic agents into a host, through a unique 2 catheter approach that can simultaneously deliver various agents including stem cells. The device if very interesting since it does not require a needle, but includes alternative delivery methods for implatnation of therapeutic solutions and cells into tissue in a localized area. Inventors: Freyman, Toby (Watertown, MA); Naimark, Wendy (Cambridge, MA); Mickley, Tim (Elk River, MN); Epstein, Samuel J. (Newton, MA)
Assignee: Boston Scientific Scimed, Inc. (Maple Grove, MN)
Date of First Priority Issue: Sunday September 8th, 2002
Patent Number: 7067489
The invention is useful for stimulating hematopoiesis, preventing low levels of hematopoietic cells and producing increased numbers of hematopoietic and mature blood cells which can be used both in vivo and in vitro. It appears that CD26 is a peptidase that cleaves certain proteins, including hematopoietic growth factors. Additionally, CD26 cleaves SDF-1 the chemotactic signal that calls in... Inventors: Wallner, Barbara P. (Cohasset, MA); Jones, Barry (Cambridge, MA); Miller, Glenn T. (Merrimac, MA); Adams, Sharlene (Waltham, MA)
Assignee: Point Therapeutics, Inc. (Boston, MA)
Date of First Priority Issue: Monday May 4th, 1998
Patent Number: 7067316
This patent is useful for the long term, in vitroculture of hematopoietic progenitor cells in the absence of exogenously added hematopoietic growth factors. It appears that the inventors developed a system that replicates the bone marrow structure but does not require addition of cytokines or other growth factors, or serum. The invention has 2 independent claims. The first covers a porous... Inventors: Pykett, Mark J. (Boxford, MA); Rosenzweig, Michael (Boston, MA); Kaplan, Richard B. (Beverly Hills, CA)
Assignee: Cytomatrix, LLC (Woburn, MA)
Date of First Priority Issue: Thursday September 25th, 1997
Patent Number: 7067307
This invention is useful for generating artificial tissue, particularly, but not limited to hepatocytes using a flow-through bioreactor that has the following advantages over the existing technologies: a) Cells can be cultivated; b) Cell growth is under extremely low shear forces and turbulences; c) A continuous supply of oxygen-saturated nutrient medium is provided; and d) Continuous assessment... Inventors: Hochleitner, Boris-Wolfgang (Graz, AT); Hengster, Paul (Innsbruck, AT)
Assignee: Raimung Margreiter (Seefeld, AT)
Date of First Priority Issue: Saturday November 2nd, 2002
Patent Number: 7067118
This invention teaches ways of generating active portions of the stem cell expanding protein flt-3L and using these active portions. The assignee is the same company, (Immunex) that developed the original flt-3L. The patent has 4 independent claims. The first covers expanding stem cells, the second covers in vivo expansion, the third covers transplanting cells and expanding them in vivo, the... Inventors: Graddis, Thomas J. (Cupertino, CA); McGrew, Jeffrey T. (Seattle, WA)
Assignee: Immunex Corporation (Seattle, WA)
Date of First Priority Issue: Saturday February 7th, 1998
Patent Number: 7064245
One of the issues associated with cloning of animals is that the donor nucleus has to be reprogrammed by the recipient oocyte. Reprogramming involves unraveling of the densely packed DNA chromatin structures which is performed by the oocyte cytoplasmic machinery. In this invention, heat treatment of donor cell or constituents thereof us used to increase the rate of proper reprogramming. The... Inventors: Loi, Pasqualino (Sassari, IT); Cappai, Pietro (Sassari, IT)
Assignee: Istituto Zootecnico E Caseario per La Sardegna (Sasari, IT)
Date of First Priority Issue: Friday June 4th, 1999
Patent Number: 7064186
This is a composition of matter patent covering the cytokine zcytor17 ligand, which is involved in various immune and stem cell activities. The patent has 3 independent claims, all covering composition of matter. The email of the senior author is dillons@zgi.com Inventors: Sprecher, Cindy A. (Sierra Vista, AZ); Kuijper, Joseph L. (Kenmore, WA); Dasovich, Maria M. (Seattle, WA); Grant, Francis J. (Seattle, WA); Hammond, Angela K. (Kirkland, WA); Novak, Julia E. (Suquamish, WA); Gross, Jane A. (Seattle, WA); Dillon, Stacey R.
Assignee: ZymoGenetics, Inc. (Seattle, WA)
Date of First Priority Issue: Friday January 18th, 2002
Patent Number: 7063842
The catenins are involved in numerous cell to cell interactions. This patent covers ways of inhibiting alpha and beta catenin interactions using a chemical composition. Specifically, the patent has 3 independent claims. The first is for modulating the interaction between alpha and beta catenin with specific peptides and antibodies. The second is for a pharmaceutical composition. The third... Inventors: Blaschuk, Orest W (Westmount, CA); Gour, Barbara J (Kemptville, CA)
Assignee: McGill University (Montreal, CA)
Date of First Priority Issue: Saturday October 4th, 1997
Patent Number: 7060494
This patent is useful for expansion and maintaining mesenchymal stem cells through the uniquely discovered property of cord blood serum to be able to substitute for other sources of serum such as fetal calf serum. The patent has 3 independent claims. The first is directed towards growing mesenchymal stem cells, and the second at third are directed towards isolating mesenchymal stem cells by... Inventor: Bhat, Aravind Venkatrao (Mumnai, IN)
Assignee: Reliance Life Sciences Pvt. Ltd. (Maharashtra, IN)
Date of First Priority Issue: Wednesday September 4th, 2002
Patent Number: 7056885
The invention covers a novel type of fibroblast growth factor called FGF-CX, which is useful for differentiation and expansion of various stem cells. The patent has 2 independent claims: 1 for the composition of matter itself, and the second for the composition of matter together with a pharmaceutically applicable carrier. Inventors: Jeffers, Michael (Branford, CT); Shimkets, Richard A. (West Haven, CT); Prayaga, Sudhirdas K. (East Haven, CT); Boldog, Ferenc L. (North Haven, CT); Yang, Meijia (East Lyme, CT); Burgess, Catherine (Wethersfield, CT); Fernandes, Elma (Branford, CT); Herrm
Assignee: CuraGen Corporation (Branford, CT)
Date of First Priority Issue: Tuesday July 27th, 1999
Patent Number: 7056738
This is a composition of matter patent on a type of bone marrow derived stem cell. The authors state that marrow stromal cells (MSCS) are adult stem cells from bone marrow that can differentiate into multiple non-hematopoietic cell lineages. The authors identified that colonies of human MSCs contain both small, rapidly self-renewing stem cells (RS cells) and large, more mature cells (mMSCs... Inventors: Prockop, Darwin J. (New Orleans, LA); Colter, David C. (Philadelphia, PA); Sekiya, Ichiro (New Orleans, LA)
Assignee: Tulane University (New Orleans, LA); Philadelphia Heath and Education Corporation (Philadelphia, PA)
Date of First Priority Issue: Friday March 23rd, 2001
Patent Number: 7056734
This patent is useful for entities seeking to treat diabetes or other pancreatic abnormalities. The patent has very broad claims, all centered around the ability of GLP and Exendin-4 to induce differentiation of cells into insulin produce or amylase producing cells. The patent has 8 independent claims. The first four claims are directed towards use of GLP-1 or related molecules to make either... Inventors: Egan, Josephine (Baltimore, MD); Perfetti, Riccardo (Washington, DC); Passaniti, Antonino (White Hall, MD); Greig, Nigel (Silver Spring, MD); Holloway, Harold (Middle River, MD); Habener, Joel (Newton Centre, MA); Stoffers, Doris (Moorestown, NJ)
Assignee: The United States of America as represented by the Department of Health and Human Services, NIH
Date of First Priority Issue: Friday October 8th, 1999
Patent Number: 7053264
This patent is useful for parties seeking to perform cloning or generate stem cells through cloning. During nuclear transfer mediated cloning, one of the difficulties is that the donor nucleus has DNA packed tightly into chromatin. During usual nuclear transfer it is the role of the recipient oocyte to unravel the DNA and to perform the necessary "cleaning of the slate" so that the... Inventors: Wolffe, legal representative, Elizabeth (Orinda, CA); Wolffe, deceased, Alan P. (Orinda, CA)
Assignee: Sangamo Biosciences, Inc. (Richmond, CA)
Date of First Priority Issue: Thursday September 28th, 2000
Patent Number: 7053050
This patent is useful for treatment of proliferative diseases, including cancer. It is known that erythropoietin has functions on numerous stem cells in addition to hematopoietic ones. In this patent the inventors demonstrated that inhibition of EPO receptor signalling can have a useful anti-proliferative effect. The 2 independent claims cover use of the receptor antagonist and use of the... Inventors: Yasuda, Yoshiko (Kyoto, JP); Nakamura, Yukio (Higashimurayama, JP); Fujita, Yoshihiko (Sakai, JP)
Assignee: Yoshiko Yasuda (Kyoto, JP)
Date of First Priority Issue: Sunday February 11th, 2001
Patent Number: 7052907
This patent covers a new type of stem cell derived from the dental pulp, it is useful for entities seeking to generate articial teeth, or dendin/pulp tissue. However, given that the patent actually claims a tooth stem cell, it may also be considered a composition of matter patent (although phenotype is somewhat ill defined in the claims). The patent has 3 independent claims. The first covers... Inventors: Shi, Songtao (Gaithersburg, MD); Gronthos, Stan (Rockville, MD); Robey, Pamela Gehron (Bethesda, MD)
Assignee: The United States of America as represented by the Department of Health and Human Services (Washington, DC)
Date of First Priority Issue: Friday July 21st, 2000
1 Comment
Patent Number: 7049348
Porous medical implants are covered by this patent that can be used to administer either stem cells, stem cell activating compositions of matter, or also just administered directly to allow for tissue re-growth on an injured area. The patent has one independent claim that covers the "porous polymeric device". The assignee, Kensey Nash corporation has a variety of implants/medical... Inventors: Evans, Douglas G (Downingtown, PA); Kelly, Jeffrey C (Wilmington, DE); DeWitt, Todd M (Pottstown, PA)
Assignee: Kensey Nash Corporation (Exton, PA)
Date of First Priority Issue: Friday June 7th, 2002
Patent Number: 7049141
When growing neural stem cell cultures, at a certain point in culture they need to be passaged. According to the background in the patent, before the invention, scientists would dissociate neurospheres by mechanical means, which as one could expect causes a loss in cell viability. This patent covers the use of collagenase in dissociating neurospheres when passaging them. This patent is... Inventor: Uchida, Nobuko (Palo Alto, CA)
Assignee: StemCells California, Inc. (Palo Alto, CA)
Date of First Priority Issue: Friday February 26th, 1999
Patent Number: 7049139
There are two types of stem cells associated with the outside part of the eye…the limbal stem cells and the conjunctival stem cells. This patent teaches ways of culturing conjunctival stem cells, using various ex vivo tissue culture scenarious, including specialized culture conditions. There is one independent claim, which covers the basic aspects of these conditions. The patent is useful for... Inventors: Tan, Donald (Singapore, SG); Ang, Leonard (Singapore, SG); Beuerman, Roger (New Orleans, LA)
Assignee: Singapore Eye Research Institute (Singapore, SG)
Date of First Priority Issue: Friday March 29th, 2002
Patent Number: 7049057
This invention teaches methods of generating an in vitro uterus using various scaffolds and cell compositions. The patent has 1 independent claim which covers a multilayered implantable uterus comprising of a biologically compatible matrix holding together uterine epithelial cell population that are attached to smooth muscle cell populations. This is an artificial organ patent, from the same... Inventors: Atala, Anthony (Weston, MA); Yoo, James J. (Brookline, MA)
Assignee: Children's Medical Center Corporation (Boston, MA)
Date of First Priority Issue: Saturday November 16th, 2002
Patent Number: 7049072
It is known from the literature that the non-tumor stroma surrounding the tumor plays an important role in the growth of the tumor by facilitating angiogenesis, providing growth factors, etc. In hematological malignancies, the fact that donor-derived leukemic relapse occurs in some individuals suggests that stromal elements may be responsible, or associated with leukemic transformation. This... Inventor: Seshi, Beerelli (Torrance, CA)
Assignee: University of South Florida (Tampa, unknown)
Date of First Priority Issue: Monday June 5th, 2000
Patent Number: 7048934
This patent teaches ways of treating neurological disease such as Alzheimer's disease, multiple sclerosis (MS), Huntington's disease, amyotrophic lateral sclerosis, and Parkinson's disease through administration of several compounds that are already in the clinic such as prolactin and EPO. The patent applies to selectively producing neural cells, including neurons or glial cells (cells that... Inventors: Thompson, Bradley G. (Calgary, CA); Weiss, Samuel (Calgary, CA); Shingo, Tetsuro (Aoe, JP)
Assignee: Stem Cell Therapeutics Inc. (Calgary, unknown)
Date of First Priority Issue: Thursday August 30th, 2001
Patent Number: 7048922
This patent covers a clinically applicable method of increasing hematopoiesis through administration of activated peripheral blood mononuclear cells. The ability of these cells to secrete hematopoietic stimulatory cytokines is well established, however the inventor is actually claiming a method of using such ex vivo activated cells for treatment of a patient. The patent has 1 independent claim... Inventor: Yang, Demao (Mountain View, CA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Wednesday May 29th, 2002
Patent Number: 7048921
This patent covers ways of treating neurological deficiencies or damage through transplantation of specific types of stem cells, or progenitor cells. Specifically, the patent has 3 independent claims. The first independent claim covers the intracerebrally transplantation of pluripotent, nestin-positive, neuroepithelial cells that have been conditionally immortalized through genetic manipulation... Inventors: Sinden, John (London, GB); Gray, Jeffrey A. (London, GB); Hodges, Helen (London, GB); Kershaw, Timothy (London, GB); Rashid-Doubell, Fiza (Oxford, GB)
Assignee: ReNeuron Limited (GB)
Date of First Priority Issue: Saturday December 9th, 1995
Patent Number: 7045353
This is basically the patent that covers how to generate neurons from embryonic stem cells. Of course the various composition of matter patents on embryonic stem cells (5,843,780, 6,200,806, 7,029,913) have to be in-licensed to use this invention. The invention has one broad independent claim which covers a method of differentiating human embryonic stem cells into neurons. The method basically... Inventor: Benvenisty, Nissim (Jerusalem, IL)
Assignee: Yissum Research Development Company of The Hebrew University of Jerusalem (Jerusalem, IL)
Date of First Priority Issue: Saturday January 8th, 2000
Patent Number: 7045148
This patent is useful for entities seeking to extract additional CD34 stem cells from placenta than can be normally gathered by just letting the blood drip and collecting cord blood. This patent has one independent claim that covers, essentially perfusing the placenta with an anticoagulated solution after the cord blood has dripped out. Inventor: Hariri, Robert J. (Florham Park, NJ)
Assignee: Anthrogenesis Corporation (Cedar Knolls, NJ)
Date of First Priority Issue: Monday June 12th, 2000
Patent Number: 7044965
This patent covers a type of stent that contains cells and is useful not only for maintaining open a blood vessel, but also for delivery of cells that secrete various agents useful for the body. The patent has two independent claims, the first covering a stent containing cells, the second covering a method of administering cells into an organism. Stents have been covered with many agents in... Inventor: Spielberg, Theodore E. (Wellesley, MA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday December 13th, 2002
Patent Number: 7041507
This invention teaches how to generate neurons from skin. Essentially, the inventors found that through the process of isolating epidermal stem cells (basal cells), transfected said basal cells with genes encoding neurogenic transcription factors, suppressing transcription factors that maintain a differentiated phenotype (by for example antisense), and then culturing the cells with exogenous... Inventors: Levesque, Michel F. (Beverly Hills, CA); Neuman, Toomas (Santa Monica, CA)
Assignee: Cedars-Sinai Medical Center (Los Angeles, CA)
Date of First Priority Issue: Wednesday January 20th, 1999
Patent Number: 7041438
This is a very broad patent that essentially covers all drug screening using a specific type of stem cells. The inventors describe these stem cells as "primate Pluripotent Stem cells" (pPS cells), thus including pre-embryonic, embryonic, or fetal tissue-derived cells that can be induced to differentiated into progeny of the three germinal layers: endoderm, mesoderm, and ectoderm. This of... Inventors: Carpenter, Melissa K. (London, CA); Inokuma, Margaret S. (San Jose, CA); Xu, Chunhui (Palo Alto, CA)
Assignee: Geron Corporation (Menlo Park, CA)
Date of First Priority Issue: Thursday June 22nd, 2000
Patent Number: 7041309
HMG-CoA reductase inhibitors ("Statins" for the purpose of our discussion) have been known to increase endothelial stem cell mobilization, as well as possess other interesting functions such as suppressing disease in the mouse model of multiple sclerosis. In this patent, the use of statins for promoting spinal fusion is thought. Specifically, the patent claims that it is not anticipated... Inventors: Remington, Benjamin J. (Modesto, CA); Bearss, David J. (Tucson, AZ); Shahi, Kavian (Granite Bay, CA)
Assignee: NeuroPro Technologies, Inc. (Modesto, CA)
Date of First Priority Issue: Monday May 13th, 2002
Patent Number: 7041283
This patent teaches the use of immunophilin binding agents for culturing of neuronal cells so as to use for cellular therapy. The patent has 2 independent claims, both covering a method of treatment of a neurodegenerative illness by administration of cells that have been cultured with immunophilin binding agents. This patent is very interesting, not from the perspective of cell therapy per se... Inventors: Achim, Cristian L. (Allison Park, PA); Avramut, Mihaela (Pittsburgh, PA); Zeevi, Adriana (Pittsburgh, PA)
Assignee: University of Pittsburgh-Of the Commonwealth System of Higher Education (Pittsburgh, PA)
Date of First Priority Issue: Friday February 16th, 2001
Patent Number: 7037892
Stimulation of hematopoiesis in patients who are neutropenic after chemo, or radiation is a major goal of medicine. This is particularly important due to infectious disease complications that arise in patients that have been myeloablated. This patent teaches the use of insulin like growth factor as an adjuvant to several of the major stimulators of hematopoiesis that are already in the... Inventors: Saito, Yoshimasa (Kawanishi, JP); Ueda, Yoshiko (Osaka, JP); Tamura, Kouichi (Kobe, JP); Takata, Yoko (Osaka, JP); Yamada, Hisashi (Sanda, JP); Yamashita, Tatsuo (Kobe, JP); Kobayashi, Masakazu (Takarazuka, JP)
Assignee: Astellas Pharma Inc. (Tokyo, JP)
Date of First Priority Issue: Monday December 8th, 1997
Patent Number: 7037720
This patent appears to cover a progenitor cell of neuronal lineage. Specifically the patent has 2 independent claims. The first covers a population of neuroepithelial stem cells derived from embryonic sources which are dependent of FGF for proliferation and can differentiate into CNS neuronal cells and CNS glial cells, The second covers a population restricted to the glial lineage but can... Inventors: Rao, Mahendra S. (Salt Lake City, UT); Mayer-Proschel, Margot (Sandy, UT)
Assignee: University of Utah Reseach Foundation (Salt Lake City, UT)
Date of First Priority Issue: Saturday July 5th, 1997
Patent Number: 7037719
This patent teaches how to isolate neuronal stem cells from human fetal brain. The stem cells, or I guess more appropriately, "progenitor cells", are isolated based on positive expression of AC133, binding to the antibody 5E12 (don’t know what that is), and negative for CD34 and CD45. The patent has 6 independent claims which cover the population of CD34-, CD45-, AC133+, 5E12+ cells. In... Inventors: Buck, David W. (Heathfield, GB); Uchida, Nobuko (Palo Alto, CA); Weissman, Irving (Redwood City, CA)
)
Assignee: StemCells California, Inc. (Palo Alto, CA
Date of First Priority Issue: Thursday December 2nd, 1999
Patent Number: 7037493
This patent has 2 independent claims. The first covers a method of addition of medium spiny neurons in an adult brain through local lateral wall administration of a nucleotide expressing BDNF, as well as noggin. The second independent claim covers generation of medium spiny neurons in a patient with Huntington's disease. Medium spiny neurons are inhibitory neurons that comprise about 75% of the... Inventors: Goldman, Steven A. (South Salem, NY); Benraiss, Abdellatif (Astoria, NY)
Assignee: Cornell Research Foundation, Inc. (Ithaca, NY)
Date of First Priority Issue: Wednesday January 5th, 2000
Patent Number: 7033831
This patent covers a method of generating insulin producing cells from human embryonic stem cells through the process of first incubating the human embryonic stem cells with Activin A, and then subsequently incubating the cells with nicotinamide. Activin is a peptide involved in wound healing and morphogenesis, wherease nicotinamide is a type of vitamine B3 and improves beta cell functions... Inventors: Fisk, Gregory J. (Fremont, CA); Inokuma, Margaret S. (San Jose, CA)
Assignee: Geron Corporation (Menlo Park, CA
Date of First Priority Issue: Thursday July 12th, 2001
Patent Number: 7033603
This patent relates to ways of delivering drugs (for example stem cell stimulating agents) to specific anatomical areas using an implantable, biodegradible approach. Specifically, the patent has 4 independent claims, the first 3 cover a delivery composition, and the 4th covers a scaffold. Inventors: Nelson, Kevin D. (Arlington, TX); Crow, Brent B. (Fort Worth, TX)
Assignee: Board of Regents The University of Texas (Austin, TX)
Date of First Priority Issue: Tuesday June 8th, 1999
Patent Number: 7033587
This patent teaches ways to make artificial cartilage patches using adipose stem cells as starting material. These patches may be useful for people having injuries in which cartilage is damaged. The patent has 1 independent claim which essentially covers producing such an artifical patch through taking out adipose stem cells, culturing the cells to become chondrocytes, allowing the... Inventors: Halvorsen, Yuan-Di C. (Holly Springs, NC); Wilkison, William O. (Bahama, NC); Gimble, Jeffrey Martin (Chapel Hill, NC)
Assignee: Artecel Sciences, Inc. (Durham, NC)
Date of First Priority Issue: Thursday August 19th, 1999
Patent Number: 7033345
This invention covers a medical device that can be used for administration of a variety of drugs and/or cellular therapeutics. The patent essentially describes a "deflectable microimplant delivery system" that can be used for relatively non-invasive introduction of cells or agents into areas of need. The patent has numerous independent claims covering the various mechanical aspects of... Inventors: Lee, Michael J. (Santa Rosa, CA); Kristoffersen, Kristian P. (Santa Rosa, CA)
Assignee: Advanced Cardiovascular Systems, Inc. (Santa Clara, CA)
Date of First Priority Issue: Tuesday May 21st, 2002
Patent Number: 7031775
This patent covers and implantable system made of cells, genes, other agents, together wtih a device that elecronically stimulates the cells. Specifically, the patent has 1 independent claim which covers a method of repairing the patient's myocardium through administration of a "cell repopulating source" and an "electrical stimulation device". Inventors: Soykan, Orhan (Shoreview, MN); Donovan, Maura G. (St. Paul, MN)
Assignee: Medtronic, Inc. (Minneapolis, MN)
Date of First Priority Issue: Friday July 11th, 1997
Patent Number: 7030292
This invention teaches how to generate a "cell bank" of embryonic stem cells that are homozygous at HLA. Theoretically, the inventors suggest..."that a few hundred stem cell lines that are homozygous for different haplotypes will be sufficient to match a majority of the human population. This number is tremendously smaller in contrast to the number of haplotypes needed to maintain a... Inventors: Yan, Wen Liang (Potomac, MD); Huang, Steve Chien-Wen (Germantown, MD); Nguyen, Minh-Thanh (Rockville, MD); Lin, Huan (Helen) (N. Potomac, MD); Lei, Jingqi (Gaithersburg, MD); Khanna, Ruchi (Germantown, MD)
Assignee: Stemron, Inc. (Myersville, MD)
Date of First Priority Issue: Thursday February 1st, 2001
Patent Number: 7029915
The invention teaches how to make liver stem cells into cells that resemble pancreatic endocrine cells (ie islets). The patent has 1 independent claim, basically covering a method of endowing hepatic stem cells with an endocrine pancreatic characteristic by first isolating hepatic stem cells from 2-acetylamino-fluorene-treated adult rats and then growing the cells in a medium made of >5.5 mM... Inventor: Yang, Lijun (Gainesville, FL)
Assignee: University of Florida Research Foundation, Inc. (Gainesville, FL)
Date of First Priority Issue: Friday February 22nd, 2002
Patent Number: 7029666
This patent teaches therapeutic uses of mesenchymal stem cells that are NOT MHC matched. Two specific uses seem to be covered: connective tissue regeneration, and muscle regeneration. The patent has two independent claims, the first covers a method of promoting muscle growth in a human by administration of non-MHC matched mesenchymal stem cells, whereas the second covers a method of promoting... Inventors: Bruder, Scott P. (Waltham, MA); McIntosh, Kevin R. (Ellicott City, MD); Marshak, Daniel R. (Lutherville, MD); Mosca, Joseph D. (Ellicott City, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Friday March 13th, 1998
Patent Number: 7022666
This patent seems to cover the preservation of a kidney, despite its title. It may be that preservation is achieved through endogenous stem cell differentiation of kidney epithelium. The patent has one claim covering a method of preserving a kidney by contacting the kidney with a ligand for gp130 receptor (ie LIF, a cardiotrophin, a ciliary neuronotrophic factor, an interleukin-6), and a... Inventors: Barasch, Jonathan M. (New York, NY); Oliver, Juan A. (New York, NY); Yang, Jun (New York, NY)
Assignee: The Trustees of Columbia University in the City of New York (New York, NY)
Date of First Priority Issue: Tuesday May 4th, 1999
Patent Number: 7022321
This patent capitalizes on the ability of bone marrow cells to migrate into the brain and cause repairative function. The patent uses bone marrow cells as a "vector" in order to deliver glial cell line-derived neurotrophic factor (GDNF) to the area of need. The patent has 2 independent claims both covering "A method of treating Parkinson's disease, ". The first covers administration of bone... Inventors: Eglitis, Martin A. (Indianapolis, IN); Mezey, Eva (Rockville, MD); Mouradian, Mary Maral (Bethesda, MD)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Saturday October 4th, 1997
Patent Number: RE39,006
This patent appears to cover a new method of detecting hematopoietic stem cells, without needing to use stem cell-specific markers. The patent seems to use some light and physical properties of the cells to distinguish between stem cells and non-stem cells. The patent has one issued claim which is:
"A method for detecting or counting or both detecting and counting hematopoietic progenitor... Inventors: Houwen, Berend (Redlands, CA); Tsujino, Yukio (Hyogo-ken, JP); Morikawa, Takashi (Hyogo-ken, JP); Ikeuchi, Yoshiro (Hyogo-ken, JP); Hamaguchi, Yukio (Hyogo-ken, JP); Wang, Fu-sheng (Hyogo, JP); Hirai, Kojiro (Hyogo, JP)
Assignee: Sysmex Corporation (Kobe, JP)
Date of First Priority Issue: Saturday March 1st, 1997
Patent Number: 7015037
This patent describes a bone marrow stem cell population that is multipotent and capable of differentiating into various lineages besides hematopoietic ones. Specifically, the patent has 5 independent claims, all covering a stem cell isolated from bone marrow. The first covers a CD49c and CD90 postive cell that doubles around every 36 hours. The second covers a cell of similar phenotype that... Inventors: Furcht, Leo T. (Minneapolis, MN); Verfaillie, Catherine M. (St. Paul, MN); Reyes, Morayma (Minneapolis, MN)
Assignee: Regents of the University of Minnesota (Minneapolis, MN); MCL/LLC (Minneapolis, MN)
Date of First Priority Issue: Saturday May 8th, 1999
Patent Number: 7011828
This patent is a owned by the embryonic stem cell powerhouse, ES International from Singapore. The patent covers a method of administration of embryonic stem cells that have been differentiated into neuron-like cells. The invention contains one independent claim, specifically covering: "a method of administration of stem cell derived neural progenitors" but the neural progenitors are... Inventors: Reubinoff, Benjamin Eithan (Elsternwick, AU); Pera, Martin Frederick (Prahran, AU); Ben-Hur, Tamir (Jerusalem, IL)
Assignee: ES Cell International Pte. Ltd. (Singapore, SG)
Date of First Priority Issue: Wednesday March 14th, 2001
Patent Number: 7011827
This patent covers the use of the human NT2N neurons for treatment of brain injury. Essentially, the NT2N cells are a cell line derived from a human teratocarcinoma which have neuronal properties., specifically, the cells are post-mitotic since the original teratocarcinoma cell is induced to differentiate into neurons which retinoic acid...this way tumors are not suppose to form in the... Inventors: Lee, Virginia M.-Y. (Philadelphia, PA); Trojanowski, John Q. (Philadelphia, PA)
Assignee: Trustees of the University of Pennsylvania (Philadelphia, PA)
Date of First Priority Issue: Saturday September 11th, 1993
Patent Number: 7008394
Bone marrow transplants, as well as other bone marrow applications represent by far the largest use of stem cells in medicine. The process of harvesting bone marrow may be complicated and prone to contamination. Since bone marrow harvest is a painful and almost traumatic procedure, contamination of a bone marrow graft during harvest could be disasterous. The current invention teaches the use of... Inventors: Geise, Russell D. (Allentown, PA); Chapolini, Robert J. (Phoenix, MD)
Assignee: BioAccess, Inc. (Baltimore, MD)
Date of First Priority Issue: Thursday March 29th, 2001
Patent Number: 7005252
The use of serum in stem cell cultures impedes clinical translation since serum has batch to batch variability, as well as possibility of eliciting allergic responses, especially when fetal calf serum is used. The invention teaches how to grow embryonic stem cells without serum. Essentially the claims of the invention all cover compositions of albumin, amino acids, vitamins, minerals, at least... Inventor: Thomson, James A (Madison, WI)
Assignee: Wisconsin Alumni Research Foundation (Madison, WI)
Date of First Priority Issue: Sunday September 3rd, 2000
Patent Number: 6998266
This patent is directed towards the culture of avian embryonic stem cells. The patent has two independent claims. The first is a culture medium for avian embryonic stem cells comprising of FGF-2, IGF-1; at least one cytokine selected from LIF, IL-11, IL-6, CNTF, and oncostatin M (OSM)) and c-kit ligand (either mouse or avian. The second independent claim covers a method of culturing the avian... Inventors: Samarut, Jacques (Lyons, FR); Pain, Bertrand (Lyons, FR)
Assignee: Institute National de la Recherche Agronomique (Paris, FR); Centre National de la Recherche Scientifique (CNRS) (Paris, FR); Ecole Normale Superieur de Lyon (Lyons, FR)
Date of First Priority Issue: Friday October 21st, 1994
Patent Number: 6998125
Despite its title, the patent doesn't really deal with stimulation of hematopoiesis. It covers a method of immunizing a cancer pateint with tumor antigens and concurrenly inhibiting TGF-beta. It is known that TGF-beta is an immunosuppressive agent released by cancer cells. It may be that since TGF-b inhibits hematopoiesis, the inhibition of TGF-b would not only derepress the immune system in... Inventors: Hanna, Nabil (Olivenhain, CA); Braslawsky, Gary R. (San Diego, CA); Hariharan, Kandasamy (San Diego, CA)
Assignee: Biogen IDEC Inc. (Cambridge, MA)
Date of First Priority Issue: Thursday September 18th, 1997
Patent Number: 6995299
This patent teaches ways of growing human hepatocytes in xenogenic hosts. This patent would be useful for using animals as "bioincubators" in order to grow organs or cells for human use. Specifically the patent has two independent claims. The first covers a model of hepatitis C in which a mammal is injected with human hepatocytes when it is in the fetal stage, thus becoming tolerized... Inventors: Wu, George Y. (Avon, CT); Wu, Catherine H. (Avon, CT)
Assignee: University of Connecticut (Farmington, CT)
Date of First Priority Issue: Thursday February 11th, 1999
Patent Number: 6995013
This invention is a 5-layer scaffold that is useful for growing cells in a bioreactor, or in vivo to produce functional vascularized organ tissue. The invention primarily deals with generation of bone tissue, but other types of tissues and organs can be generated using this scaffold. The patent has 1 independent claim which covers the composition of the scaffold. The assignee, Biomed... Inventors: Connelly, Patrick R. (Rochester, NY); Babalola, Omotunde M. (Long Island, NY)
Assignee: BioMed Solutions, LLC (West Henrietta, NY)
Date of First Priority Issue: Wednesday August 7th, 2002
Patent Number: 6991897
This and patent #5,876,956 are licensed to the company Aldagen (2810 Meridian Parkway Suite 148 Durham, NC 27713 919-484-2571) that is actually purifying stem cells using this method for clinical trials (for example: Intramyocardial Injection of Autologous Aldehyde Dehydrogenase-Bright Stem Cells for Therapeutic Angiogenesis at Texas Heart: Oct 5, 2006). The patent covers purifying stem cells... Inventors: Smith, Clayton A. (Tampa, FL); Colvin, Michael (Chapel Hill, NC); Storms, Robert W. (Durham, NC); Ludeman, Susan M. (Durham, NC)
Assignee: Duke University (Durham, NC)
Date of First Priority Issue: Sunday July 12th, 1998
Patent Number: 6991813
This patent covers a way of stimulating healing by treatment with a neutraceutical. Specifically the patent has 1 independent claim covering a method for regenerating skin through administration of a composition on a wound having beeswax a fatty acid-containing oil and a sterol compound. The patent claim is directed toward stimulation of proliferation of keratinocytes that express... Inventor: Xu, Rongxiang (Arcadia, CA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Sunday January 28th, 2001
Patent Number: 6991794
This patent is directed to the stimulation of hematopoietic stem cell proliferation by use of a lectin called FRIL. The patent has 2 independent claims. The first is directed towards a pharmaceutical composition claiming some distinct sequences that bind glycosylated flt-3. The second is directed towards treatment, using the same sequences. There is a paper published by the authors that... Inventors: Colucci, M. Gabriella (La Jolla, CA); Chrispeels, Maarten J. (La Jolla, CA); Moore, Jeffrey G. (Kennebunkport, ME)
Assignee: ImClone Systems Incorporated (New York, NY); The Regents of the University of California (La Jolla, CA)
Date of First Priority Issue: Tuesday June 24th, 1997
Patent Number: 6991787
This patent involves using gene-transfected bone marrow cells as a way of delivering the gene of interest to a tissue that needs it. For example, lets take stroke patients. Conceptually one could administer a therapeutic gene directly into the area of cell death, or in proximity to it, in order to prevent further cell death or to induce regeneration of neurons. This approach is complex since... Inventors: Greenberger, Joel S. (Sewickley, PA); Hurwitz, David R. (Acton, MA)
Assignee: ALG Company (Marlborough, MA)
Date of First Priority Issue: Friday December 29th, 1995
Patent Number: 6989271
Schwann cells generate myelin (insulates neuronal electrical signals [amognst other things]) and are essential for the proper function of neuronal tissue. Various neurological diseases would benefit from the ability to introduce Schwann Cells that are properly functioning. The current patent teaches ways of using bone marrow stromal cells as a source of Schwann Cells. Specifically the patent... Inventors: Dezawa, Mari (Yokosuka, JP); Sawada, Hajime (Yokohama, JP); Takano, Masahiko (Yokohama, JP)
Assignee: Sanbio, Inc. (Mountain View, CA)
Assignee: Sanbio, Inc. (Mountain View, CA)
Date of First Priority Issue: Friday June 22nd, 2001
Patent Number: 6987102
Hematopoietic stem cells stay in the bone marrow due in part to secretion of SDF-1 by bone marrow stromal cells. The chemotactic gradient of SDF-1 is also what causes hematopoietic stem cells to home to the bone marrow of the recipient after a bone marrow transplant. This invention covers some antagonists of the receptor for SDF-1, CXCR-4 which when administered cause the stem cell cells to... Inventors: Bridger, Gary J. (Bellingham, WA); Abrams, Michael J. (Custer, WA); Henson, Geoffrey W. (Ferndale, WA); MacFarland, Ronald Trevor (Vancouver, CA); Calandra, Gary B. (Cresco, PA); Broxmeyer, Hal E. (Indianapolis, IN); Dale, David C. (Seattle, WA)
Assignee: Anormed, Inc. (Langley, CA)
Date of First Priority Issue: Tuesday July 31st, 2001
Patent Number: 6987024
This patent covers a new type of ovarian progenitor cell. Specifically, the patent has 1 independent claim covering a cell population that can differentiate into overian epithelium or granulosa cells. Two other claims that appear to be of high importance are the use of this cell for production of proteins, and the use of this cell for bioassays. Inventors: Li, Rong-hao (La Jolla, CA); Bald, Laura (Los Altos, CA); Mather, Jennie Powell (Millbrae, CA)
Assignee: Raven Biotechnologies, Inc. (South San Francisco, CA)
Date of First Priority Issue: Wednesday October 4th, 2000
Patent Number: 6986887
This patent teaches how to make stem cells less immunogenic by modification of the human leukocyte antigen content. Specifically the patent has 2 independent claims. The first covers modification of HLA-B and HLA-C, whereas the second covers modification of HLA-DR. Essentially the generation of "universal donor" stem cells can be made in such a manner by making the cells more compatible... Inventors: Lawman, Patricia (Chipley, FL); Lawman, Michael J. P. (Chipley, FL)
Assignee: Morphogenesis, Inc. (Oldsmar, FL)
Date of First Priority Issue: Tuesday March 25th, 1997
Patent Number: 6984522
In the cancer patient it is believed that tumors are actually a heterogeneous population of cells, and that not all the tumor cells have equal proliferative capability. This concept of the "tumor stem cell" maintaining the bulk of the tumor population is very important since many believe that the cells targeted by conventional therapies are not the actual tumor stem cell but derivatives thereof... Inventors: Clarke, Michael F. (Ann Arbor, MI); Morrison, Sean J. (Ann Arbor, MI); Wicha, Max S. (Ann Arbor, MI); Al-Hajj, Muhammad (Ann Arbor, MI)
Assignee: Regents of the University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Wednesday March 8th, 2000
Patent Number: 6984379
This patent covers the use of autologous cord blood CD34 cells transfected with the adenosine deaminase gene for the treatment of severe combined immunodeficiency (SCID). The patent has 3 independent claims, the first covering a method of expressing a therapeutic agent in a human (but specifically restricted to adenosine deaminase), the second a method of treating a human with SCID, and the... Inventors: Kohn, Donald B. (Tarzana, CA); Blaese, R. Michael (Rockville, MD); Mullen, Craig A. (Sugar Land, TX); Moen, Robert C. (Mountain View, CA)
Assignee: Children's Hospital of LosAngeles (LosAngeles, CA); The United States of America as represented by the Department of Health and Human Services
Date of First Priority Issue: Thursday August 4th, 1994
Patent Number: 6981948
As mentioned in our discussion about patent # 7008394, bone marrow harvesting is a relatively invasive procedure. This is also very relavant for regenerative uses of bone marrow where patients with a heart attack or stroke are harvested. Accordingly there is a need to develop less invasive and increasingly sterile means of harvesting. The current patent has two independent claims covering a... Inventors: Pellegrino, Richard C. (Mendon, MA); Voellmicke, John C. (Cumberland, RI)
Assignee: DePuy Spine, Inc. (Raynham, MA)
Date of First Priority Issue: Monday November 18th, 2002
Patent Number: 6974571
The invention covers a way of introducing stem cells into a host in such a manner that the cells can be killed off if desired through administration of an agent that induces expression of a suicide gene. This is important since in some situations it is desired to have the exogenous stem cells in the body only for a limited period of time. Specifically, the invention has 2 independent claims... Inventors: Prockop, Darwin J. (Philadelphia, PA); Pereira, Ruth F. (Lansdowne, PA); Leeper, Dennis B. (Wynnewood, PA); O'Hara, Michael D. (Wyncote, PA); Kulkosky, Joseph (Philadelphia, PA); Phinney, Donald (Maple Glen, PA); Laptev, Alexey (Philadelphia, PA)
Assignee: Thomas Jefferson University (Philadelphia, PA)
Date of First Priority Issue: Tuesday March 28th, 1995
Patent Number: 6972195
This patent teaches the composition of a culture media that is shown in the EXAMPLES section useful for growing: Human Intestinal Cells, Mouse Intestinal Mucosal Villi, Mouse Bone Marrow Tissue , Rat Nerve Tissue, Mouse Pancreatic Cells, Mouse Renal Cells, Human Hair Follicles, Rat Cardiomuscular Cells, Rat Thymocytes , and Rat Hepatocytes. The examples also show activity of the media in... Inventor: Xu, Rongxiang (Arcadia, CA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Tuesday December 31st, 2002
Patent Number: 6972168
This patent teaches ways of generating an plethora of compounds which are useful for regeneration of damaged nervous system tissue. Specifically, the patent has 2 independent claims. The first covers growing nerves in conditions that are not associated with degeneration, then killing the nerves, harvesting the material, and introducing the material into an area where damaged neurons are present... Inventor: Muir, David F. (Gainesville, FL)
)
Assignee: University of Florida Research Foundation, Incorporated (Gainesville, FL
Date of First Priority Issue: Monday August 13th, 2001
Patent Number: 6969702
This patent deals with administration of compounds, some which I believe are already in the clinic, for stimulation of neurogenesis in a patient suffering from a neurodegenerative condition. The patent has 2 independent claims, the first covers the administration of calcitonin, or exendin or analogues thereof that intracellular cAMP levels. The second independent claim covers administration of... Inventors: Bertilsson, Goran (Vasterhaninge, SE); Erlandsson, Rikard (Sundyberg, SE); Frisen, Jonas (Stockholm, SE); Haegerstrand, Anders (Danderyd, SE); Heidrich, Jessica (.ANG.rsta, SE); Hellstrom, Nina (Sodertalje, SE); Haggblad, Johan (Vastgotagrand, SE); Jansso
Assignee: NeuroNova AB (Stockholm, SE)
Date of First Priority Issue: Wednesday November 20th, 2002
1 Comment
Patent Number: 6969608
This patent covers the use of a type of stem cell composition derived from tissues having sensory receptors such as olfactor epithelium. The patent contains 1 independent claims. The first covers a composition of neural stem cells and a carrier, the neural stem cells being isolated from tissue containing sensory receptors, expressing nestin, proliferate in absence of EGF, can differentiate... Inventors: Miller, Freda (Montreal, CA); Gloster, Andrew (Saskatoon, CA)
Assignee: McGill University (Montreal, CA)
Date of First Priority Issue: Monday August 26th, 1996
Patent Number: 6967102
This patent sounds (from its title) like it covers use of nitric oxide for activation of muscle stem cells. Given the inventor described a role for nitric oxide in this context (Anderson JE A role for nitric oxide in muscle repair: nitric oxide-mediated activation of muscle satellite cells. Mol Biol Cell. 2000 May;11(5):1859-74 janders@ms.umanitoba.ca), one would anticipate the claims to... Inventor: Anderson, Judy E. (Winnipeg, CA)
Assignee: University of Manitoba (Winnipeg, CA)
Date of First Priority Issue: Wednesday November 3rd, 1999
Patent Number: 6967100
This patent teaches how to generate islet-like cells from fetal progenitors by culturing in the presence of one of the bone morphogenic proteins together with laminin or a laminin-like extracellular matrix. The patent has 3 independent claims all covering essentially the same process. The first one covers induction of growth and proliferation of "mammalian pancreatic epithelial cells into... Inventors: Harrison, Leonard C. (St Kilda West, AU); Jiang, Fang-Xu (North Melbourne, AU); Stanley, Edouard Guy (Ascot Vale, AU); Gonez, Leonel Jorge (Chadstone, AU)
Assignee: The Walter and Eliza Hall Institute of Medical Research (Victoria, AU)
Date of First Priority Issue: Friday February 18th, 2000
Patent Number: 6967029
This patent has 2 independent claims both covering the use of stem cell factor for stimulation of hematopoiesis. The first independent claim covers its use in vivo, whereas the second covers its use ex vivo. Inventors: Zsebo, Krisztina M. (Thousand Oaks, CA); Bosselman, Robert A. (Thousand Oaks, CA); Suggs, Sidney V. (Newbury Parks, CA); Martin, Francis H. (Thousand Oaks, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Date of First Priority Issue: Monday October 16th, 1989
Patent Number: 6967019
This patent teaches ways of making gastrointestinal organ cells and pancreatic cells express insulin in vitro, conceptually for introduction in vivo. The patent essentially teaches that introduction of a neuroendocrine class B basic helix-loop-helix (bHLH) transcription factor gene or the neurogenin3 (Ngn3) gene into gastrointestinal organ cells or pancreatic cells, respectively, endows ability... Inventor: German, Michael S. (Daly City, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Date of First Priority Issue: Friday June 4th, 1999
Patent Number: 6962698
This patent essentially teaches that reducing the copper content in a hematopoietic culture increases efficiency of the culture. The patent has 2 independent claims, the first covering "A method of transplanting expanded undifferentiated hematopoietic cells " and the second covering "A method of adoptive immunotherapy ". The idea that reducing copper content expands ability of... Inventor:
Assignee: Gamida Cell Ltd. (Jerusalem, IL)
Hadasit Medical Research Services and Development, Ltd. (Jerusalem, IL)
Assignee: Peled, Tony (Mevaseret Zion, IL); Fibach, Eitan (Mevaseret Zion, IL); Treves, Avi (Mevaseret Zion, IL)
Date of First Priority Issue: Tuesday February 17th, 1998
Patent Number: 6960473
This patent teaches how to generate large quantities of erythroid cells in vitro. This is useful for nuclear disasters or situations where large quantities of red blood cells are needed for transfusion purposes. This is a very interesting invention since it uses as the starting population blood cells and not bone marrow. The invention has 1 independent claim covering the method of generating... Inventors: Migliaccio, Giovanni (Rome, IT); Franco, Anna Rita (Rome, IT)
Assignee: Istituto Superiore di Sanita (Rome, IT)
Date of First Priority Issue: Saturday February 26th, 2005
Patent Number: 6960446
fetal liver kinase 2 (flk-2) is expressed on numerous types of stem cells. This patent covers isolation of cells expressing this marker using either a monoclonal or polyclonal antibody. The patent has 1 independent claim which essentially covers the subject matter previously mentioned. The importance of flk-2 on hematopoietic stem cells was published by the author (Matthews W, et al. A receptor... Inventor: Lemischka, Ihor R. (Princeton, NJ)
Assignee: The Trustees of Princeton University (Princeton, NJ)
Date of First Priority Issue: Monday February 4th, 1991
Patent Number: 6960427
At face value this patent seems to be extremely broad. The issued claims, which have one independent claim, cover pretty much any type of vascularized bioengineered tissue. The claim is not restricted to type of tissue or method of generating the tissue. It covers the introduction of at least one blood vessel into either a tissue or a matrix which has cells in it, growing of the tissue in... Inventors: Haverich, Axel (Isernhagen, DE); Kofidis, Theo (Hannover, DE)
Assignee: Artiss GmbH (Hannover, DE)
Date of First Priority Issue: Monday April 3rd, 2000
Patent Number: 6960351
One of the main drawbacks of stem cell therapy, or any cell therapy for that matter is that it is important to avoid the issue of immunological rejection. This is why numerous scientists are using autologous stem cells. Unfortunately, there is no such thing as autologous embryonic stem cells. Additionally, the ability to use allogeneic stem cells without rejection would allow for the widespread... Inventors: Dionne, Keith E. (Rehoboth, MA); Emerich, Dwaine F. (Providence, RI); Hoffman, Diane (Cambridge, MA); Sanberg, Paul R. (Spring Hill, FL); Christenson, Lisa (New Haven, CT); Hegre, Orion D. (Green Valley, AZ); Scharp, David W. (St. Louis, MO); Lacy, Paul E
Assignee: Brown University Research Foundation (Providence, RI)
Date of First Priority Issue: Thursday April 25th, 1991
Patent Number: 6956022
This patent teaches the use of an existing pharmaceutical, parathyroid hormone (or agonists of the parathyroid hormone receptor) for stimulation of platelet production. The patent has one issued claim which covers essentially what was just mentioned. This is an interesting patent because in a publication it states that "Between 1958 and the late 1970s it was learned that PTH (the parathyroid... Inventors: Tamura, Masahiko (Shizuoka-ken, JP); Oda, Yasuhiro (Nagano-ken, JP)
Assignee: Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP)
Date of First Priority Issue: Tuesday January 2nd, 1996
Patent Number: 6955898
This patent teaches was of targeting damaged tissue with genes that stimulate angiogenesis. Conceptually the technology could be modified to introduce agents which actually stimulate stem cell proliferation at the site of injury. The patent has one issued claim that covers a fusion polypeptide, with one end having a collagen binding domain which binds exposed vascular collagen (ie during... Inventors: Hall, Frederick L. (Glendale, CA); Gordon, Erlinda M. (Glendale, CA); Starnes, Vaughn A. (Pasadena, CA); Anderson, W. French (San Marino, CA)
Assignee: University of Southern California (Los Angeles, CA)
Date of First Priority Issue: Friday July 31st, 1998
Patent Number: 6953799
This patent teaches ways of modulating "stress" in cells through administration of "therapeutically effective amount of a phthalazine dione" in its one independent claim. The Assignee company, Bach Pharma, Inc is currently practicing the patent in the form of a registered drug (in Russia), Galavit® whose chemically active substance is Monosodium 5-Amino... Inventors: Henry, Mark O. (North Andover, MA); Lynn, William S. (Hillsborough, NC)
Assignee: Bach Pharma, Inc. (North Andover, MA)
Date of First Priority Issue: Wednesday October 30th, 2002
Patent Number: 6953778
This patent is a demonstration of creative patent writing, with positive results of claim issuance. Essentially, the inventors found a novel gene called 2777 which is significantly expressed in erythroid cells both in vitro and in vivo. 2777 is also expressed in erythroid progenitor (BFU-E) cells and Glycophorin A positive-lo (GPA-lo) cells in vivo. Since 2777 appears at a structural level to... Inventor: Carroll, Joseph M. (Cambridge, MA)
Assignee: Millennium Pharmaceuticals, Inc. (Cambridge, MA)
Date of First Priority Issue: Wednesday October 31st, 2001
Patent Number: 6953482
Essentially the invention is a scaffold with a tube-like feature in which cells may be grown outside of the body to form an organ or tissue, and then will be used for implantation into the host. The tube-like features of the scaffold allow for growth of neurons, blood vessels, trachea, and other bodily parts. The patent has 2 independent claims. The first covers general features of the scaffold... Inventors: Doi, Nobutoshi (Osaka, JP); Matsuda, Kazuhisa (Osaka, JP); Hata, Ken-ichiro (Kariya, JP); Sakai, Kensuke (Aichi, JP)
Assignee: Nipro Corporation (Osaka, JP); Ueda, Minoru (Nisshin, JP)
Date of First Priority Issue: Thursday April 26th, 2001
Patent Number: 6949590
Hydrogels are very useful for adminstration of cells into localized tissues. One of the problems is that polymerization of hydrogels often uses catalysts, which add problems to medical implimentation due to adverse effects of catalysts. This invention teaches ways of making hydrogels so that they do not require catalysts. The invention has 3 independent claims. The first covers "... Inventors: Ratner, Buddy D. (Seattle, WA); Nair, Prabha D. (Kerala, IN); Boeckl, Maximiliane Silvia (Seattle, WA); Leber, Elizabeth Reeves (Seattle, WA)
Assignee: University of Washington (Seattle, WA)
Date of First Priority Issue: Tuesday October 1st, 2002
Patent Number: 6949380
This invention is similar to patent 7041507, which was filed by the same inventors. The current invention teaches generation of neuronal-like cells through the transdifferentiation of epidermal basal cells. The invention has 3 independent claims covering, "An in vitro method of transdifferentiating an epidermal basal cell ", "A kit for transdifferentiating, in vitro, an epidermal... Inventors: Levesque, Michel F. (Beverly Hills, CA); Neuman, Toomas (Santa Monica, CA)
Assignee: Cedars-Sinai Medical Center (Los Angeles, CA)
Date of First Priority Issue: Wednesday January 20th, 1999
Patent Number: 6949251
The invention is a composition of matter useful for treatment of bone defects and regeneration of bone. The composition is a porous ceramic material (beta.-tricalcium phosphate) of various pore sizes, porosity and granule size which is biocompatible with human tissue and supports the development of new bone throughout its structural form. The composition may be admixed with cells, cytokines... Inventors: Dalal, Paresh S. (Shrewsbury, MA); Dimaano, Godofredo R. (Edison, NJ); Toth, Carol Ann (Sharon, MA); Kulkarni, Shailesh C. (Natick, MA)
Assignee: Stryker Corporation (Kalamazoo, MI)
Date of First Priority Issue: Saturday February 3rd, 2001
Patent Number: 6946293
This patent teachs ways of expanding a certain type of pancreatic progenitor cell through the steps of first extracting pancreatic or ductal cells; second, treating the cells with a preparation comprising epidermal growth factor, a cAMP elevating agent, and a steroid or corticosteroid; and , third harvesting a non-adherent population. The first and second independent claims essentially cover the... Inventors: Lu, Kuanghui (Brookline, MA); Pang, Kevin (Belmont, MA); Rubin, Lee (Wellesley, MA)
Assignee: ES Cell International Pte Ltd. (
Date of First Priority Issue: Saturday October 2nd, 1999
Patent Number: 6943016
This invention teaches how to obtain a population of astrocytes that is free of microglial cells from a fresh biopsy specimen. The invention has one independent claim covering the process of explanting a tissue that contains both astrocytes and microglial cells, culturing the cells in vitro under conditions that selectively promote adherence of the astrocytes to the culture vessel, and after about... Inventors: Ridet, Jean-Luc (Lausanne, CH); Mallet, Jacques (Paris, FR)
Assignee: Aventis Pharma S.A. (Antony, FR)
Date of First Priority Issue: Saturday May 1st, 1999
Patent Number: 6942995
This invention relates to the generation of knock-out animals Through genetically ablating a specific gene sequence in embryonic stem cells of an animal, it is possible to develop animals, called"knock-outs" which lack the specific sequences throughout all cells of the body. The patent has two independent claims directed towards unique gene-targeting constructs that through homologous... Inventors: Klein, Robert D. (Palo Alto, CA); Brennan, Thomas J. (South San Francisco, CA)
Assignee: Deltagen, Inc. (San Carlos, CA)
Date of First Priority Issue: Monday November 17th, 1997
Patent Number: 6942879
This patent is for a bioartificial kidney suitable for a variety of uses, including in patients with renal failure. The patent has one independent claim covering a filtration device which contains a layer of non-immortalized renal endothelial cells, non-immortalized renal epithelial cells, or a mixture thereof, and (ii) pericytes, vascular smooth muscle cells. This approach is currently in Phase... Inventor: Humes, H. David (Ann Arbor, MI)
Assignee: The Regents of the University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Monday September 30th, 1996
Patent Number: 6939955
This is a composition of matter patent for a receptor that seems to be involved in hematopoietic stem cell expansion. The invention discloses a novel gene, HGFIN, which encodes a protein receptor that is involved in the regulation of hematopoietic proliferation and differentiation, and may act as a negative regulator of the Id2 protein. The invention has 2 independent claims. The first covers... Inventor: Rameshwar, Pranela (Maplewood, NJ)
Assignee: University of Medicine and Dentistry of New Jersey (New Brunswick, NJ)
Date of First Priority Issue: Friday October 20th, 2000
Patent Number: 6936281
This is a composition of matter patent for mesenchymal stem cell progenitors. The first three independent claims of this patent are restricted to generation of these cells from a Dexter type culture system (a specific type of long term culture in which adherent cells are allowed to form a layer and the hematopoietic cells rely on their support). The forth independent claim is not restricted... Inventor: Seshi, Beerelli (Tampa, FL)
Assignee: University of South Florida (Tampa, FL)
Date of First Priority Issue: Wednesday March 21st, 2001
Patent Number: 6936254
This patent covers induction of fetal hemoglobin gene expression by treatment of cells with specific polypeptides. The utility of inducing fetal hemoglobin is for diseases in which adult hemoglobin is defective in carrying oxygen. This invention is useful for the treatment of diseases like sickle cell anemia. The patent has 2 independent claims that essentially cover: a) Induction of adult to... Inventors: Baker, Kevin P. (Darnestown, MD); Botstein, David (Belmont, CA); Eaton, Dan L. (San Rafael, CA); Ferrara, Napoleone (San Francisco, CA); Filvaroff, Ellen (San Francisco, CA); Gerritsen, Mary E. (San Mateo, CA); Goddard, Audrey (San Francisco, CA); Godowsk
Assignee: Genentech, Inc. (South San Francisco, CA)
Date of First Priority Issue: Wednesday December 3rd, 1997
Patent Number: 6933286
The introduction of nucleic acids into cells is a difficult task that has significantly hampered gene therapy. This patent discloses a novel method of getting nucleic acids into cells. The patent has 2 independent claims. The first covers a composition of nucleic acid sequences or one or more triplex DNA compounds, and a nonionic block copolymer. The second covers the method of introducing a... Inventors: Emanuele, R. Martin (Alpharetta, GA); Newman, Mark (Carlsbad, CA); Kousoulas, Konstantin G. (Baton Rouge, LA); Allaudeen, Hameedsulthan S. (Durham, NC)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Tuesday March 19th, 1991
Patent Number: 6933281
This patent teaches the use of peptides that have the ability to home to specific tissues. Such homing peptides may be used to deliver drugs or therapeutic agents, as well as (conceptually) to administer activators of stem cells.
The patent has 4 independent claims:
- A lymph node homing peptide which is PTCAYGWCA (SEQ ID NO: 336).
- A conjugate, comprising the peptide which is... Inventors: Ruoslahti, Erkki (Rancho Santa Fe, CA); Pasqualini, Renata (Solana Beach, CA)
Assignee: The Burnham Institute (San Diego, CA)
Date of First Priority Issue: Friday March 13th, 1998
Patent Number: 6933150
This patent seems to cover methods of purifying and expanding hematopoietic stem cells by transfecting said stem cells with a drug efflux pump. It is not clear if the patent calls for administration of a cytotoxic agent to selectively kill non-stem cells, or if it is inherently the property of the efflux pumps to increase stem cell viability.
The patent has 2 independent claims:
A method of... Inventors: Sorrentino, Brian (Memphis, TN); Bunting, Kevin (Columbus, MD); Schuetz, John (Memphis, TN); Nakauchi, Hiromitsu (Kukizaki-machi, JP)
Assignee: St. Jude Children's Research Hospital (Memphis, TN)
Date of First Priority Issue: Thursday May 28th, 1998
Patent Number: 6929948
This patent teaches ways of extracting cells with a neural phenotype from a population of stem cells that are differentiated along the neural lineage through selecting cells that express a marker under control of a promoter which is active only in neural cells. Specifically, the patent claims the use the Sox gene promoter. One way to use this patent would be to insert GFP under control of Sox... Inventors: Smith, Austin G. (Edinburgh, GB); Li, Meng (Edinburgh, GB)
Assignee: The University Court of the University of Edinburgh (GB)
Date of First Priority Issue: Wednesday April 14th, 1999
Patent Number: 6924142
This patent teaches the induction of differentiation of neural stem cells, the use of hypoxia for enhancing function, and the subsequent use of the cells obtained for drug screening. The patent has one independent claim that covers:
A method for screening the effects of drugs or other agents on neuronal cells, comprising:
a) preparing a cell culture comprising a cell population enriched in... Inventors: Weiss, Samuel (Calgary, CA); Sorokan, S. Todd (Victoria, CA)
Assignee: Neuro Spheres Holdings Ltd. (Calgary, CA)
Date of First Priority Issue: Friday October 24th, 1997
Patent Number: 6927061
This paper teaches the isolation of bi-potent overian stem cells that can differentiate either into overian epithelium, or granulosa cells. The cell type claimed can be used for many purposes, including: a) generation of antibodies; b) cell therapy; c) bioassays; d) drug screening.
The patent has two independent claims that cover:
A method of isolating a substantially pure population of... Inventors: Li, Rong-hao (Millbrae, CA); Bald, Laura (Los Altos, CA); Mather, Jennie Powell (Millbrae, CA)
Assignee: Raven Biotechnologies, Inc. (South San Francisco, CA)
Date of First Priority Issue: Monday April 10th, 2000
Patent Number: 6927060
This is a method of isolating stem cells by dye exclusion and applying the principle to epidermal stem cells. It is well known in the art that stem cells are the property to exclude various dyes. This is what causes the existance of the "side population cells" which were known since 1996 (Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine... Inventors: Bickenbach, Jackie R. (Iowa City, IA); Dunnwald, Martine (Iowa City, IA)
Assignee: University of Iowa Research Foundation (Iowa City, IA)
Date of First Priority Issue: Tuesday March 28th, 2000
Patent Number: 6921632
This patent covers a new way of extracting embryonic stem cells from human blastocyst embryos that have been frozed. The patent is assigned to a Korean Infertility Clinic. It appears that some of the ES cell lines made by this clinic are on the NIH list.
The patent has 2 independent claims:
A process for making undifferentiated human embryonic stem cells, comprising the steps of: (a... Inventors: Lim, Jin-Ho (Seoul, KR); Park, Se-Pill (Seoul, KR); Kim, Eun-Young (Seoul, KR)
Assignee: Maria Biotech Co., Ltd. (Seoul, KR)
Date of First Priority Issue: Sunday April 30th, 2000
Patent Number: 6919209
Gene therapy is limited by ability to transfect quiescent cells. Since the very primitive hematopoietic stem cells reside in a quiescent state, it is difficult to transfect them. This patent demonstrates transfection of early hematopoietic stem cells using an adeno-associated vector. The patent has one independent claim that covers:
A method for stably transferring DNA into multi-potential... Inventors: Chatterjee, Saswati (Sierra Madre, CA); Wong, Jr., Kamehameha K. (Sierra Madre, CA); Wong, Christie (Pasadena, CA); Fisher-Adams, Grace (La Canada, CA)
Assignee: City of Hope (Duarte, CA)
Date of First Priority Issue: Friday December 4th, 1998
Patent Number: 6919206
This patent covers the use of flt-3 ligand for expanding hematopoietic stem cells in vitro. The importance of expansion techniques is seen in that numerous groups have tried and are still trying to identify ways of generating large populations of autologous stem cells. The patent is pretty straight-forward and has 2 independent claims:
A hematopoietic cell expansion medium, comprising a... Inventors: Lyman, Stewart D. (Seattle, WA); Beckmann, M. Patricia (Poulsbo, WA)
Assignee: Immunex Corporation (Thousand Oaks, CA)
Date of First Priority Issue: Monday March 7th, 1994
Patent Number: 6919183
This patent teaches ways of extracting cells from a population based on expression of markers that were either introduced or naturally expressed in the cell. The patent may be useful for pulling out differentiated cells from stem cell heterogenous populations.
A method of detecting and/or isolating a eukaryotic cell that produces a secreted protein of interest (POI), comprising: (a... Inventors: Fandl, James P. (LaGrangeville, NY); Stahl, Neil (Carmel, NY); Chen, Gang (Yorktown Heights, NY); Yancopoulos, George D. (Yorktown Heights, NY)
Assignee: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
Date of First Priority Issue: Tuesday January 16th, 2001
Patent Number: 6918869
This patent teaches ways of administering agents into the lumen of a body, agents including stem cell therapy. The patent seems to cover methods of administering agents in a manner that does not induce restenosis. The patent has 3 independent claims, which are:
A system for delivering a biologically active material to a surface of a body lumen exposed to a radioactive source comprising: (a... Inventors: Shaw, William J. (Cambridge, MA); Barry, James (Marlborough, MA); Goll, Paul J. (Woodinville, WA); Palasis, Maria (Wellesley, MA)
Assignee: SciMed Life Systems (Maple Grove, MN)
Date of First Priority Issue: Monday December 2nd, 2002
Patent Number: 6918396
This invention is useful for repairing injuries to head and neck tissue through use of vertebrate-derived submucosa or basement membrane matrices as a graft for the regeneration and repair of said head and neck soft tissues.
Specifically, it is known that
a) The naturally-occurring extracellular matrix (ECM) of the small intestinal submucosa, as well as other vertebrate sources of... Inventors: Badylak, Stephen F. (West Lafayette, IN); Spievack, Alan R. (Cambridge, MA)
Assignee: Purdue Research Foundation (West Lafayette, IN); Clarian Health Partners, Inc. (Indianapolis, IN)
Date of First Priority Issue: Tuesday December 1st, 1998
Patent Number: 6916655
This patent is useful for generation of skin cells and skin-like cells from umbilical cords. Since cord blood is extracted from the cord and the cord is usually disposed of, this patent may be of particular importance. The only disadvantage of this patent is that its 1 issued claim seems to cover only a certain method of culturing the cells in a specific media.
A method of culturing umbilical... Inventors: Yasumoto, Shigeru (Kanazawa-ken, JP); Takeuchi, Masakatsu (Osaka, JP)
Assignee: Nipro Corporation (Osaka, JP)
Date of First Priority Issue: Thursday November 22nd, 2001
Patent Number: 6916654
This patent covers the modification of cells to make them "universal donors" and thus not be rejected by the immune system. Not only is it next to impossible to completely inhibit expression of all immunogenic MHC molecules, but even if this is accomplished, the influence of the NK cells which kill tissue not expressing MHC must also be overcome. This patent is an interesting idea but of very... Inventors: Sims, Peter J. (Mequon, WI); Bothwell, Alfred L. M. (Guilford, CT); Elliot, Eileen A. (New Haven, CT); Flavell, Richard A. (Killingworth, CT); Madri, Joseph (North Branford, CT); Rollins, Scott (Monroe, CT); Bell, Leonard (Woodbridge, CT); Squinto, Stephe
Assignee: Oklahoma Medical Research Foundation (Oklahoma City, OK); Yale University (New Haven, CT)
Date of First Priority Issue: Monday June 29th, 1992
Patent Number: 6916470
The mpl ligand, also known as thrombopoietin, is important for stimulation of platelet production from hematopoietic stem cells. Thrombopoietin, in addition to shifting differentiation towards the megakaryocytic lineage, also has some ability to induce proliferation of early hematopoietic stem cells.
This patent uses the ability of thrombopoietin to stimulate stem cell proliferation in order... Inventors: Murray, Lesley J. (San Jose, CA); Young, Judy C. (Mountain View, CA)
Assignee: Novartis AG (Basel, CH)
Date of First Priority Issue: Monday October 30th, 1995
Patent Number: 6911533
PP1 is a protein marker of a type of tissue stem cells or progenitor cells. The PP1 protein is made of 221 amino acids and contains two cysteine-rich domains. PP1 is expressed in the ducts of the regenerating pancreas in regions where new islets are developing. In addition, PP1 is expressed in embryonic foregut, stomach and duodenum, but not in developing pancreas or mature pancreas, The PP1... Inventors: Sarvetnick, Nora (San Diego, CA); Fox, Howard (San Diego, CA)
Assignee: The Scripps Research Institute (La Jolla, CA)
Date of First Priority Issue: Wednesday April 26th, 2000
Patent Number: 6911435
Lack of leukocyte production, leukopenia, is a major morbidity and mortality factor in patients recieving high dose chemotherapy, as well as after bone marrow transplant. This patent is very useful since it teaches how to expand hematopoietic stem cell production of leukocytes through administration of adenosine, a compound that is already clinically used.
The patent has two independent... Inventors: Cohn, Ilan (Herzlia, IL); Fishman, Pnina (Herzlia, IL)
Assignee: Can-Fite Biopharma Ltd. (Petach Tikva, IL)
Date of First Priority Issue: Thursday July 10th, 1997
Patent Number: 6911429
Tissue injury is associated with increased concentrations of hyaluronan (hyaluronic acid, HA). HA modifies cell behavior, including causing fibrosis and inflammation through interaction with cell-associated receptors such as receptor for HA-mediated motility (RHAMM, CD168).
The present invention provides compounds that bind to HA and thereby inhibit the binding of HA to RHAMM
Thus this... Inventors: Cruz, Tony (Toronto, CA); Pastrak, Aleksandra (Tornto, CA); Turley, Eva A. (Toronto, CA)
Assignee: Transition Therapeutics Inc. (Toronto, CA)
Date of First Priority Issue: Thursday April 1st, 1999
Patent Number: 6911220
This patent is for a very interesting idea. The induction of tolerance by ablating recipient T cells and recipient thymus, introducting a donor fetal or neonatal thymus, and allowing recipient T cells to mature with the donor thymus. This is based on the whole concept of inducing negative selection so that the recipient T cells will not kill the donor graft...but instead recognize it as... Inventor: Sachs, David H. (Newton, MA)
Assignee: The General Hospital Corporation (Boston, MA)
Date of First Priority Issue: Wednesday February 19th, 1992
Patent Number: 6911201
One of the limiting factors to clinical use of autologous hematopoietic stem cells, as well as cord blood cells, is the limited ways of expanding them. This patent addresses this issue by providing a novel system for such expansion that appears to be more "in vivo-like". Essentially, the patent has 2 independent claims covering:
A method of expanding undifferentiated hemopoietic stem... Inventors: Merchav, Shoshana (Haifa, IL); Meretzki, Shai (Nesher, IL)
Assignee: Technion Research & Development Foundation Ltd. (Haifa, IL)
Date of First Priority Issue: Thursday February 4th, 1999
Patent Number: 6906181
The Methuselah gene mutation is associated with enhanced longevity. Specifically, flies with methuselah (mth) have approximately a 35 percent increase in average life-span and enhanced resistance to various forms of stress, including starvation, high temperature, and dietary paraquat, a free-radical generator (Lin YJ, et al. Extended life-span and stress resistance in the Drosophila mutant... Inventors: Lin, Yi-Jyun (Arcadia, CA); Benzer, Seymour (San Marino, CA)
Assignee: California Institute of Technology (Pasadena, CA)
Date of First Priority Issue: Tuesday July 7th, 1998
Patent Number: 6908763
The stem cell identified in this patent is a type of progenitor cell that can differentiate only along the lymphoid, but not myeloid lineage. These cells are useful for situations in which lymphopoiesis is desired, for example, after lymphodepletion of a cancer patient in protocols used for homeostatic induced antitumor immunity.
The patent essentially covers a cell type that expresses... Inventors: Akashi, Koichi (Chestnut Hill, MA); Kondo, Motonari (Redwood City, CA); Weissman, Irving L. (Redwood City, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University (Palo Alto, CA)
Date of First Priority Issue: Friday August 22nd, 1997
Patent Number: 6908732
The use of various bile extracts for treatment of cancer is known in the art. The Canadian company Lorus Therapeutics developed a drug called Virulizing from cow bile extracts.
This patent teaches the use of bilins for treatment of cancer through induction of cellular differentiation. The advantage of inducing cancer cell differentiation is the possibility of a less toxic approach in contrast... Inventor: Falchuk, Kenneth H. (Newton, MA)
Assignee: President & Fellows of Harvard College (Cambridge, MA)
Date of First Priority Issue: Friday October 13th, 2000
Patent Number: 6905738
This patent was included the 3d culture/scaffold section since it doesnt really seem to fit anywhere else. Essentially the patent teachs how to write on cells (including stem cells) using laser light. The patent has 1 independent claim, which is:
A method for laser deposition comprising the steps of;
providing one or more sources of laser energy that produce laser energy;
providing... Inventors: Ringeisen, Bradley R. (Alexandria, VA); Chrisey, Douglas B. (Bowie, MD); Pique, Alberto (Crofton, MD); McGill, R. Andrew (Lorton, VA)
Assignee: The United States of America as represented by the Secretary of the Navy (Washington, DC)
Date of First Priority Issue: Tuesday May 25th, 1999
Patent Number: 6903073
Hedgehog proteins are involved in development and other biological functions through activation of their receptor called "patched". Hedgehog signalling is inhibited by cyclopamine. Since the authors of the patent originally found that inhibiting hedgehog signalling reduces insulin production, and transfection with hedgehog increases insulin production, (Thomas MK, Rastalsky N, Lee JH, Habener... Inventors: Habener, Joel F. (Newton Centre, MA); Thomas, Melissa K. (Boston, MA)
Assignee: The General Hospital Corporation (Boston, MA)
Date of First Priority Issue: Friday December 10th, 1999
Patent Number: 6902881
This patent teaches the use of a bilin for treating cancer through induction of differentiation. It is a very promising idea since differentiation therapy is relatively non-toxic. The question is what concentrations of these bilins are needed to actually see an in vivo effect.
The 2 independent claims of the patent are:
A method for promoting cell differentiation, comprising treating a... Inventor: Falchuk, Kenneth H. (Newton, MA)
Assignee: President and Fellows of Harvard College (Cambridge, MA)
Date of First Priority Issue: Friday October 13th, 2000
Patent Number: 6902721
This patent teaches that proteosome inhibitors stimulate the growth of bone, in part through inhibition of the inflammatory-associated transcription factor NF-kB. It is unclear if the stimulation of bone growth works via activation of stem cells, or other mechanisms. The patent also discloses use for stimulation of hair growth, but that is not in the claims. The one independent claim is:
A... Inventors: Mundy, Gregory R. (San Antonio, TX); Garrett, I. Ross (San Antonio, TX); Rossini, Jorge G. (San Antonio, TX)
Assignee: OsteoScreen, Inc. (San Antonio, TX)
Date of First Priority Issue: Friday July 10th, 1998
Patent Number: 6900054
Glial cells performed numerous functions in the nervous system including providing support, nutrition, and form myelin for neurons. They represent 90% of the cells in the central nervous system. The ability to generate glial cells ex vivo is critical not only for the potential of administering such cells to damaged areas, but also for using these cells are vectors to carry genes in order to... Inventors: Rao, Mahendra S. (Salt Lake City, UT); Noble, Mark (Brighton, NY); Mayer-Proschel, Margot (Pittsford, NY)
Assignee: University of Utah Research Foundation (Salt Lake City, UT)
Date of First Priority Issue: Saturday November 29th, 1997
Patent Number: 6900017
HIWI is the human homologue of PIWI a gene found in fruitfly embryonic germline stem cells. HIWI is found in CD34 hematopoietic cells and appears to act as a negative regulator in that its transfection causes apoptosis in hematopoietic cell lines (Sharma AK, et al. Human CD34 stem cells express the hiwi gene, a human homologue of the Drosophila gene piwi. Blood. 2001 Jan 15;97(2):426-34... Inventors: Sharma, Arun (Oak Park, IL); Hoffman, Ronald (Chicago, IL)
Assignee: The Board of Trustees of the University of Illinois (Urbana, IL)
Date of First Priority Issue: Thursday January 10th, 2002
Patent Number: 6899915
Inventors: Yelick, Pamela C. (Concord, MA); Bartlett, John D. (Acton, MA); Vacanti, Joseph P. (Winchester, MA); Olsen, Bjorn R. (Milton, MA); Stashenko, Phillip (Medfield, MA)
Assignee: President and Fellows of Harvard College (Cambridge, MA); General Hospital Corporation (Boston, MA); Forsyth Dental Infirmary for Children, Inc. (Boston, MA)
Date of First Priority Issue: Wednesday November 29th, 2000
Patent Number: 6897061
This patent teaches how to make astrocytes into neurons and/or oligodendrocytes. The ability to perform this in large scale would allow for cell replacement therapy for a variety of neural degenerative conditions. The independent claims are:
An in vitro method to produce a population that includes neurons and/or oligodendrocytes, the method comprising: (a) obtaining and/or isolating a... Inventor: Salin-Nordstrom, Tuija Helina (Santa Monica, CA)
Assignee: Spinal Cord Society (Fergus Falls, MN)
Date of First Priority Issue: Friday June 16th, 2000
Patent Number: 6897060
Inventors: Bjornson, Christopher R. (Seattle, WA); Rietze, Rod L. (Brunswick, AU); Reynolds, Brent A. (Saltspring, CA); Vescovi, Angelo L. (Milan, IT)
Assignee: NeuroSpheres Holdings, Ltd. (Calgary, CA)
Date of First Priority Issue: Monday September 29th, 1997
Patent Number: 6893871
This is a patent covering an ovarian stem cell that can become either overian epithelial tissue, as well as granulosa tissue. The three independent claims are:
A method of providing a source of immunogen to a heterologous recipient, comprising administering a plurality of ovarian mesothelial cells in an amount effective to induce an immune response in said recipient, wherein said ovarian... Inventors: Li, Rong-hao (Millbrae, CA); Bald, Laura (Los Altos, CA); Mather, Jennie Powell (Millbrae, CA)
Assignee: Raven Biotechnologies, Inc. (South San Francisco, CA)
Date of First Priority Issue: Tuesday April 10th, 2001
Patent Number: 6890897
This patent teaches the novel use of melanoma inhibitory factor to induce stem cell differentiation into bone and cartilage. It may be used for in vitro generation of stem cells or for acceleration of in vivo healing. The independent claims of the patent are:
A method for inducing chondro-/ostrogenic lineage and promoting of cartilage or bone formation in a person comprising administering a... Inventors: Dony, Carola (Munchen, DE); Proetzel, Gabriele (Schwanfeld, DE); Leser-Reiff, Ulrike (Penzberg, DE)
Assignee: Scil Technology GmbH (Martinsried, DE)
Date of First Priority Issue: Thursday January 28th, 1999
Patent Number: 6890724
This patent teaches how to extract neural precursor cells by expression of a protein called RET. RET is orphan receptor tyrosine kinase essential for enteric neurogenesis
The patent has two independent claims. That are:
A method for the enrichment of neural progenitor cells comprising RET protein, said method comprising: a) combining a mixed population of cells comprising neural-crest... Inventors: Anderson, David J. (Altadena, CA); Lo, Li-Ching (Arcadia, CA)
Assignee: California Institute of Technology (Pasadena, CA)
Date of First Priority Issue: Friday September 6th, 1996
Patent Number: 6887706
This patent is from the same group that originally patented embryonic stem cells of human. In the current patent there is one independent claim that covers the differentiation of human embryonic stem cells into neural progenitor cells. The method claims involves culturing so that embryoid bodies are formed from the embryonic stem cells through incubation with FGF-2, as well as standard culture... Inventors: Zhang, Su-Chun (Middleton, WI); Thomson, James A. (Madison, WI); Duncan, Ian David (Madison, WI)
Assignee: Wisconsin Alumni Research Foundation (Madison, WI)
Date of First Priority Issue: Wednesday October 3rd, 2001
Patent Number: 6887704
This patent teaches the ex vivo expansion of stem cells of the hematopoietic lineage through culture in conditions having reduced copper content. The patent is useful for expanding CD34 stem cells for treatment of a variety of diseases and conditions in which CD34 numbers and/or activity may be beneficial. The fact that copper chelation is practiced as alternative medicine may have something... Inventors: Peled, Tony (Mevaseret Zion, IL); Fibach, Eitan (Mevaseret Zion, IL); Treves, Avi (Mevaseret Zion, IL)
Assignee: Gamida Cell Ltd. (Jerusalem, IL)
Date of First Priority Issue: Tuesday February 17th, 1998
Patent Number: 6886568
This patent teaches the generation of cells with implantable biodegradable material through culture in vitro with materials of various compositions. The patent may be used for generation of artificial tissue, or for creating clusters of cells that may be implantable for treatment of disease.
The patent is particularly aimed at inducing generation of chondrocytes ex vivo or in vitro for... Inventors: Frondoza, Carmelita G. (Woodstock, MD); Fink, David J. (Baltimore, MD); Hungerford, David S. (Cockeysville, MD); Shikani, Alan H. (Ruxton, MD)
Assignee: The Johns Hopkins University (Baltimore, MD); Chrondros, Inc. (Baltimore, MD)
Date of First Priority Issue: Thursday April 9th, 1998
Patent Number: 6884769
Proteosomes are becoming important biological targets in drug discovery. For example pathways associated with numerous diseases, such as NF-kB are dependent on proteosomal activation. In the case of NF-kB the proteosomal degradation of phosphorylated IKB is what allows translocation of NF-kB into the nucleus.
In this patent inhibition of the chymotrypsin-like activity proteasomes is claimed... Inventors: Mundy, Gregory R. (San Antonio, TX); Garrett, I. Ross (San Antonio, TX); Rossini, Jorge Gianny (San Antonio, TX) )
Assignee: OsteoScreen, Inc. (San Antonio, TX
Date of First Priority Issue: Friday July 10th, 1998
Patent Number: 6884428
This patent covers scaffolds that may be administered in vivo so that stem cells and progenitor cells attach to the scaffold and form functional tissue. Alternatively, the patent teaches that such scaffolds may be used in vitro so that cells form a functional tissue in vitro, which is then administered in vivo. Specific tissues that are described for use in the context of the current scaffold... Inventors: Binette, Francois (Weymouth, MA); Bowman, Steven M. (Sherborn, MA); Bruker, Izi (Wayland, MA); Hwang, Julia (Wayland, MA); Melican, Mora Carolynne (Bridgewater, NJ); Rezania, Alireza (Hillsborough, NJ)
Assignee: DePuy Mitek, Inc. (Norwood, MA)
Date of First Priority Issue: Thursday December 21st, 2000
Patent Number: 6884427
This patent teaches a method of administering cells, including stem cells, through use of a filament-type object. The object has a solid core and an outside sheath that is porous and to which cells can be attached to before administration.
The invention teaches that hair follicle cells, cells that have been encapsulated, and cells that have been genetically engineered can be administered... Inventor: Barrows, Thomas H. (Austell, GA)
Assignee: Aderans Research Institute, Inc. (Beverly Hills, CA)
Date of First Priority Issue: Monday February 8th, 1999
Patent Number: 6881226
This patent covers a breast implant that eventually resorbs and is replaced by endogenous tissue. The patent has claims covering not only the use for cosmetic reasons, but also for administration of therapeutic agents. Inventors: Corbitt, Jr., John D. (Palm Springs, FL); Leonetti, Lori A. (Delray Beach, FL)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Wednesday March 11th, 1998
Patent Number: 6878543
Generation and expansion of neuronal cells is described in this patent through inducting proliferation of GFAP+, nestin+ stem cells of neuronal origin through treatment with EGF, amphiregulin, aFGF, bFGF, TGF.alpha. and then inducing differentiation through serum free culture.
The cells generated by this means can be made into neurons or glial cells depending on culture conditions. Inventors: Wahlberg, Lars (Asnaes, DK); Campbell, Kenneth (Cincinnati, OH); Skogh, Charlotta (Malmo, SE); Eriksson, Cecilia (Falsterbo, SE); Wictorin, Klas (Lund, SE)
Assignee: NsGene SA (Ballerup, DK)
Date of First Priority Issue: Monday October 25th, 1999
Patent Number: 6878542
This patent appears to be a really unique way of expanding stem cells. Essentially the patent teaches to connect a growth factor receptor to a promoter that is only expressed on stem cells, such as the promoter for Oct-4. This way stem cells will express the growth factor receptor. This way if you add the ligand for the receptor the stem cells will proliferate selectively.
Theoretically, the... Inventors: Smith, Austin Gerard (Edinburgh, GB); Mountford, Peter Scott (Elsdenwid, AU)
Assignee: The University of Edinburgh (GB)
Date of First Priority Issue: Thursday April 21st, 1994
Patent Number: 6878371
This is a very important patent for the clinical trials ongoing right now that are administering bone marrow autolous stem cells into the heart of patients in order to stimulate angiogenesis.
This paten is definately worthy of detailed reading and understanding in light of existing clinical research in this area. Inventors: Ueno, Takafumi (Decatur, GA); Murohara, Toyoaki (Fukuoka, JP); Robinson, Keith Allen (Norcross, GA); Chronos, Nicolas A. F. (Atlanta, GA); Baldwin, Sam (Newton, MA); Palasis, Maria (Wellesley, MA)
Assignee: Boston Scientific Scimed, Inc. (Maple Grove, MN)
Date of First Priority Issue: Wednesday July 26th, 2000
Patent Number: 6877514
This patent teaches how to induce allogeneic tolerance to transplanted grafts through making the recipient a chimera in terms of blood composition. In other words, donor hematopoietic stem cells are administered in order to make the recipient have both donor blood cells circulating, as well as some left over recipient cells.
This system has been shown effective in several animal models. Inventor: Sykes, Megan (Charlestown, MA)
Assignee: The General Hospital Corporation (Boston, MA)
Date of First Priority Issue: Thursday May 9th, 1996
Patent Number: 6875608
This patent discloses compounds that can be added to a culture of embryonic stem cells so as to selectively kill non-embryonic stem cells. Inventors: Smith, Austin Gerard (Edinburgh, GB); Burdon, Thomas Grant (Edinburgh, GB)
Assignee: University of Edinburgh (Edinburgh, GB)
Date of First Priority Issue: Friday September 11th, 1998
Patent Number: 6875607
Despite its appealing title, the claims of this patent appear only to cover the alteration of differentiation of embryonic stem cells, in part through providing the use of feeder cell layers. Inventors: Reubinoff, Benjamin Eithan (Elsternwick, AU); Pera, Martin Frederick (Prahran, AU); Fong, Chui-Yee (Singapore, SG); Trounson, Alan Osborne (Asburton, AU); Bongso, Ariffeen (Singapore, SG)
Assignee: ES Cell International Pte Ltd (Singapore, SG)
Date of First Priority Issue: Monday November 9th, 1998
Patent Number: 6875441
This patent teaches ways of formulating G-CSF so as to have better pharmacological properties. Specifically the patent is trying to address the problem of: "...administration of hematopoietic growth factors such as G-CSF, GM-CSF, SCF and Flt3-L, requires multiple daily injections. This, in turn leads to another common disadvantage of current injectable therapies such as these, that being the... Inventors: Rosenthal, Gary J. (Louisville, CO); Etter, Jeffrey B. (Boulder, CO)
Assignee: RxKinetix, Inc. (Louisville, CO)
Date of First Priority Issue: Friday May 26th, 2000
Patent Number: 6875430
Xenotransplantation is limited primarily by antibody mediated rejection. Accordingly while this patent covers the use of mesenchymal stem cells for preventing xenograft rejection, the actual applicability of this patent seems unlikely since mesenchymal stem cells do not strongly protect against antibody mediated immune rejection in xenotransplantation. Inventors: McIntosh, Kevin R. (Ellicott City, MD); Mosca, Joseph D. (Ellicott City, MD); Klyushnenkova, Elena (Baltimore, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Wednesday March 18th, 1998
Patent Number: 6872819
This patent describes biomaterials that can be administered in an area of tissue injury to allow for stem cells to expand locally and produce new functional tissue. The biomaterials covered appear to be hyaluronic acid based. Inventors: Pavesio, Alessandra (Padua, IT); Dona' , Massimo (Due Carrare, IT); Callegaro, Lanfranco (Thiene, IT)
Assignee: Fidia Advanced Biopolymers S.r.l. (Brindisi, IT)
Date of First Priority Issue: Wednesday May 27th, 1998
Patent Number: 6872812
HEPP is a gene that appears to be found in certain stem cell populations involved in differentiation, although its function remains unclear. This patent is a composition of matter patent on the gene.
If there are some interesting properties found with this protein, it may be a really good patent to license since not too much work has been performed on it. Inventors: Jurecic, Roland (Key Biscayne, FL); Nachtman, Ronald G. (Miami, FL)
Assignee: University of Miami (Miami, FL)
Date of First Priority Issue: Friday February 16th, 2001
Patent Number: 6872569
This patent teaches how to generate sperm in vitro through the use of sertoli cells and undifferentiated diploid germ cells. It is useful not only for infertility applications, but also for various veterinary purposes. Inventors: Lee, Dong Ryul (Seoul, KR); Kaproth, Michael T. (Ithaca, NY); Parks, John E. (Ithaca, NY)
Assignee: Cornell Research Foundation, Inc. (Ithaca, NY)
Date of First Priority Issue: Friday May 18th, 2001
Patent Number: 6872389
This patent covers a liver stem cell that is isolated based on expression of the marker OV6. These cells could be used for a variety of therapeutic purposes including hepatitis. Liver cell therapy can be performed by administration of single cell suspensions, additionally attractive with this patent is that liver cells are generally more tolerogenic and less likely to rejection than other... Inventor: Faris, Ronald A. (Providence, RI)
Assignee: Rhode Island Hospital (Providence, RI)
Date of First Priority Issue: Friday July 10th, 1998
Patent Number: 6866991
This patent describes the use of zvegf3, a platelet derived growth factor homologue for expansion of various stem cells, including bone marrow stem cells. Inventors: Gilbertson, Debra G. (Seattle, WA); Hart, Charles E. (Woodinville, WA)
Assignee: ZymoGenetics, Inc. (Seattle, WA)
Date of First Priority Issue: Monday May 3rd, 1999
Patent Number: 6866843
This patent teaches extraction of pancreatic stem cells based on expression of nestin...expansion of the cells into islet-like cells...and transplantation of the cells for treatment of diabetes.
The problem is how much expansion can one achieve? Since there is a SEVERE shortage of donor pancreas'. The other problem, of course, is the need for immune suppression. Inventors: Habener, Joel F. (Newton Centre, MA); Zulewski, Henryk (Basel, CH); Abraham, Elizabeth (Quincy, MA); Vallejo, Mario (Madrid, ES); Faustman, Denise L. (Weston, MA); Thomas, Melissa K. (Boston, MA)
Assignee: Viacell, Inc. (Charlestown, MA
Date of First Priority Issue: Monday December 6th, 1999
Patent Number: 6866842
This patent teaches the use of skeletal myoblast, muscle stem cells, for treating urinary incontinence. The cells may be used without modification, or may be genetically engineered to express therapeutic genes. Examples of therapeutic genes include nerve growth factor, nitric oxide, etc. Inventors: Chancellor, Michael B. (Pittsburgh, PA); Huard, Johnny (Wexford, PA)
Assignee: University of Pittsburgh (Pittsburgh, PA)
Date of First Priority Issue: Friday May 1st, 1998
Patent Number: 6864235
The ability of cells to respond to danger signals is associated with how the host will respond to injury in general. This patent is based around observations that cellular injury is associated with upregulation of certain danger signal associated molecules, which the inventors call "transition molecules". This is most likely why the name of one of the companies that the inventors established... Inventors: Turley, Eva A. (Toronto, CA); Cruz, Tony F. (Etobicoke, CA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Thursday April 1st, 1999
Patent Number: 6863900
Inventors: Kadiyala, Sudhakar (Baltimore, MD); Bruder, Scott P. (Owings Mills, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Friday April 19th, 1996
Patent Number: 6858646
Oxidative stress plays a very important role in the ability of stem cells to survive. Specifically, stem cells prefer to reside in areas of relative hypoxia, and are particularly senstive to oxidative stress. This patent teaches that use of pyruvate, and other antioxidants in order to protect neurons, and stem cells of neurons, from damage.
This patent may be used to treat, for example... Inventors: Paquin, Joanne (Montreal, CA); Mateescu, Mircea-Alexandru (Montreal, CA); De Grandpre , Eric (Joliette, CA)
Assignee: Universite du Quebec a Montreal (Montreal, CA)
Date of First Priority Issue: Wednesday May 5th, 1999
Patent Number: 6852534
At first glance this patent seems extremely simple and maybe even obvious. Essentially it teaches the use of counting of leukocytes from a hematopoietic stem cell graft so has to know how many cells to transplant for hematopoietic reconstitution.
The invention is however very important in areas like cord blood stem cell transplants where it is very difficult to actually quantify the number... Inventors: Wernet, Peter (Dusseldorf, DE); Kogler, Gesine (Dusseldorf, DE); Fischer, Johannes (Neuss, DE)
Assignee: Kourion Therapeutics GmbH (Duesseldorf, DE)
Date of First Priority Issue: Friday November 3rd, 2000
Patent Number: 6858583
Hematopoietic stem cells are sensitive to chemotherapy and radiation therapy. Accordingly, hematopoietic stem cells are one of the first cell types to be negatively affected by cancer therapy.
One of the reasons that hematopoietic stem cells are destroyed is due to the fact that at some level, they are proliferating constantly. Now, the early primitive hematopoietic stem cells usually are... Inventors: Tsyrlova, Irena (Gaithersburg, MD); Wolpe, Stephen D. (Rockville, MD)
Assignee: Wellstat Therapeutics Corporation (Gaithersburg, MD)
Date of First Priority Issue: Wednesday March 31st, 1993
Patent Number: 6852706
This patent teaches activation of cardiac healing processes through reducing levels of thyroid hormone. This patent seems to depart substantially from the common notion that thyroid hormone is actually beneficial for the heart. For example, it is published that reducing thyroid hormone by administration of propylthiouracil actually leads to cardiac atrophy, angina and general deterioration (Tang... Inventor: Heber-Katz, Ellen (Philadelphia, PA)
Assignee: The Wistar Institute (Philadelphia, PA)
Date of First Priority Issue: Wednesday March 22nd, 2000
Patent Number: 6852537
This patent covers the expansion of endothelial cells by growing on collagen-1 coated plates in the combination of various growth factors such as FGF, VEGF, and IGF. Additionally, numerous culture conditions for endothelial expansion are disclosed.
The abstract of the patent discribes the use of endothelial cells for gene therapy, but not the claims. The disclosure also describes how... Inventors: Hebbel, Robert P. (North Oaks, MN); Lin, Yi (St. Paul, MN); Lollar, John S. (Decatur, GA)
Assignee: Regents of the University of Minnesota Emory University (Atlanta, GA)
Date of First Priority Issue: Tuesday November 24th, 1998
Patent Number: 6852533
This is a powerful patent that covers essentially the endothelial precursor cell. The importance of endothelial precursors is their ability to induce angiogenesis.
The patent has claims on any CD34 + VEGF R+ cell, as well as CD133+, VEGF R+ endothelial stem cell.
Sources of these cells covered in the claims include circulating blood, cord blood, mobilized blood, and bone marrow.
The... Inventors: Rafii, Shahin (Great Neck, NY); Witte, Larry (Stormville, NY); Moore, Malcolm A. S. (New York, NY)
Assignee: Cornell Research Foundation, Inc. (Ithaca, NY); Sloan-Kettering Institute for Cancer Research (New York, NY); ImClone System Incorporated (New York, NY)
Date of First Priority Issue: Friday January 23rd, 1998
Patent Number: 6852532
This patent teaches methods of extracting and purifying neuroepithelial precursor cells that can differentiate into a variety of neurological tissue and be useful for regenerative medicine. The patent essentially teaches to deplete cells expressing the markers A2B5, NG2 and eNCAM, so that approximately half of the purified cells are positive for AC133/2.
The cells are extracted at the time... Inventors: Mayer-Proschel, Margot (Pittsford, NY); Rao, Mahendra S. (Salt Lake City, UT); Tresco, Patrick A. (Sandy, UT); Messina, Darin J. (Salt Lake City, UT)
Assignee: University of Utah Research Foundation (Salt Lake City, UT)
Date of First Priority Issue: Thursday March 1st, 2001
Patent Number: 6852321
This patent teaches that certain lectins (sugar binding proteins) may be used for the preservation of progenitor cells and stem cells. It is not clear which property of the lectins is involved in the preservation.
The concept that lectins may be used in stem cell preservation brings to mind old experiments in which the preferentially affinity of lectins to cancer cell membranes was reported... Inventors: Colucci, M. Gabriella (Dugenta, IT); Chrispeels, Maarten J. (La Jolla, CA); Moore, Jeffrey G. (Kennebunkport, ME)
Assignee: ImClone Systems Incorporated (New York, NY); Regents of the University of California (La Jolla, CA)
Date of First Priority Issue: Tuesday June 24th, 1997
Patent Number: 6852313
Melanocyte proliferation may be desired in a variety of pathological conditions. Melanocytes are important, for example in burn patients where it is desireble to obtain a sufficient layer of skin so as to avoid scepticemia. Melanocytic proliferation is demonstrated in this patent by treatment with stem cell factor (kit-ligand), as well as combinations of stem cell factor with other cytokines. Inventors: Zsebo, Krisztina M. (Thousand Oaks, CA); Bosselman, Robert A. (Thousand Oaks, CA); Suggs, Sidney V. (Newbury Park, CA); Martin, Francis H. (Thousand Oaks, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Date of First Priority Issue: Friday October 16th, 1998
Patent Number: 6844312
Neurons that express tyrosine hydroxylase (TH) are subfunctional in diseases such as Alzheimer's and Parkinson's. This patent teachs how to generate TH expressing neurons through contacting stem cells with FGF-1, an agent that activates protein kinase A, as well as a phorbol ester and dopamine.
The ability to generate TH neurons in this manner may lead not only to in vitro generation... Inventors: Weiss, Samuel (Calgary, CA); Shingo, Tetsuro (Okayama, JP)
Assignee: Stem Cell Therapeutics Inc. (Calgary, CA)
Date of First Priority Issue: Wednesday April 11th, 2001
Patent Number: 6841542
This patent claims ex vivo inhibition of TGF beta in hematopoietic stem cells in order to increase speed of engraftment post recipient marrow ablation.
Since TGF beta is an endogenous inhibitor of stem cell proliferation, the inhibition of the inhibitor should lead to enhanced proliferation.
The technology described in this patent would definately benefit from RNA... Inventors: Bartelmez, Stephen H. (Seattle, WA); Iversen, Patrick L. (Corvallis, OR)
Assignee: AVI BioPharma, Inc. (Corvallis, OR)
Date of First Priority Issue: Thursday July 6th, 2000
Patent Number: 6841531
This is a composition of matter patent on some endogenous factors that stimulate repair and regeneration of motor neurons. The authors have demonstrated some significant biological activities of the "motoneuronotrophic" factors in nerve injury, including ability to accelerating healing after cutting of the sciatic nerve in rats. Inventor: Chau, Raymond Ming Wah (Hong Kong, HK)
Assignee: Genervon Biopharmaceuticals LLC (Montebello, CA)
Date of First Priority Issue: Friday September 27th, 1996
Patent Number: 6841386
Insulin like growth factor (IGF) is involved in numerous biological activities. The basis of this patent is that IGF possesses some differentiation inducing activity for CD34+ CD38- hematopoietic stem cells. The ability of stem cells to be expanded ex vivo depends on not allowing said cells to differentiate.
This patent teaches that blocking IGF signalling can inhibit hematopoietic stem... Inventors: Kraus, Morey (Jefferson, MA); Deng, Hongkui (Framingham, MA); Liu, Liqin (Framingham, MA)
Assignee: Viacell, Inc. (Worcester, MA)
Date of First Priority Issue: Tuesday April 10th, 2001
Patent Number: 6841150
This appears to be a very important patent in that it teaches the use of adipose stem cells for generating chondrocytes and using the chondrocytes to heal cartilage.
This patent should be compared to ones by Osiris that use adipose derived mesenchymal stem cells for cartilage repair, as well as by Cytori which uses adipose derived stem cells for a variety of indications. Inventors: Halvorsen, Yuan-Di C. (Holly Springs, NC); Wilkison, William O. (Bahama, NC); Gimble, Jeffrey Martin (Chapel Hill, NC)
Assignee: Artecal, Sciences, Inc. (Durham, NC)
Date of First Priority Issue: Thursday August 19th, 1999
Patent Number: 6841147
This is a composition of matter patent on the kit-ligand, otherwise known as stem cell factor. Stem cell factor is involved in regulation of a variety of stem cells in addition to hematopoietic stem cells. This patent is particularly important for when novel methods of inducing stem cell differentation in vivo are discovered and stem cell factor may be added to these methods to either induce... Inventors: Zsebo, Krisztina M. (Thousand Oaks, CA); Bosselman, Robert A. (Thousand Oaks, CA); Suggs, Sidney V. (Newbury Park, CA); Martin, Francis H. (Thousand Oaks, CA)
Assignee: Amgen, Inc. (Thousand Oaks, CA)
Date of First Priority Issue: Monday October 16th, 1989
Patent Number: 6838549
This is a patent for a hematopoietic stimulatory cytokine that the inventors named pluripoietin alpha. This cytokine is described in several papers including (Gabrilove et al. Pluripoietin : A Second Human Hematopoietic Colony-Stimulating Factor Produced by the Human Bladder Carcinoma Cell Line 5637, PNAS | April 15, 1986 | vol. 83 | no. 8 | 2478-2482).
This factor is produced by several cell... Inventors: Welte, Karl (New York, NY); Platzer, Erich (Spardorf, DE); Gabrilove, Janice L. (New York, NY); Mertelsmann, Roland (Mainz, DE); Moore, Malcolm A. S. (Larchmont, NY)
Assignee: Sloan-Kettering Institute for Cancer Research (New York, NY)
Date of First Priority Issue: Thursday March 28th, 1985
Patent Number: 6838284
This is a patent for a specific type of tissue culture media that may be used for growth and expansion of various stem cells.
The media contains combinations of various factors such as anti-oxidants, nutrients, and growth factors.
This patent may be useful not only for laboratory reagents but as a basis for developing cellular therapy media for ex vivo expansion in a GMP setting. Inventors: de Bruijn, Joost Dick (Amersfoort, NL); Tibbe, Gerhardus Johannes M. (Amersfoort, NL); da Silva Madureira Mendes, Sandra Claudia (Gouda, NL)
Assignee: IsoTis N.V. (Bilthoven, NL)
Date of First Priority Issue: Tuesday December 28th, 1999
Patent Number: 6838282
This is a patent for a unique stem cell marker that is recognized by the antibody MG-1. There are numerous stem cell markers in existence which are used for isolation of stem cell subtypes. The value of new stem cell markers is relatively high since the field is very populated. A patent such as the present one, if MG-1 has not been commercialized, can be used to position a new biotech... Inventors: Lawman, Michael J. P. (Chipley, FL); Lawman, Patricia (Chipley, FL)
Assignee: Morphogenesis, Inc. (Chipley, FL)
Date of First Priority Issue: Wednesday November 13th, 1996
Patent Number: 6838079
Leptin is a natural inhibitor of fat. When you knock out leptin gene, mice are extremely obese. Interestingly, leptin has numerous other functions in the body, including stimulation of inflammatory responses, as well as immunologically predisposing to Th1.
In this patent the inventors identified that leptin stimulates hematopoiesis. This patent may be useful for treatment of... Inventors: Snodgrass, H. Ralph (Powell, OH); Cioffi, Joseph (New Albany, OH); Zupancic, Thomas Joel (Worthington, OH); Shafer, Alan Wayne (Lancaster, OH)
Assignee: Indevus Pharmaceuticals, Inc. (Lexington, MA)
Date of First Priority Issue: Wednesday September 14th, 1994
Patent Number: 6838056
This patent covers a medical device that is useful for purifying hematopoietic stem cells. The medical device selects stem cells but not contaminating cancer cells, and is therefore useful for treatment of cancer patients by purifying autologous stem cells before high dose chemotherapy so that the stem cells can be re-introduced in order to accelerate reconstitution of hematopoiesis. Inventor: Foster, John Stuart (Santa Barbara, CA)
Assignee: Innovative Micro Technology (Goleta, CA)
Date of First Priority Issue: Saturday June 8th, 2002
Patent Number: 6835809
This patent covers a peptide that stimulates stem cells to differentiate into the megakaryocytic lineage. This patent is useful for acceleration of platelet recovery after chemotherapy, radiation therapy, or bone marrow transplant. Since thrombopoietin stimulates early stem cells to self-renew, it may be interesting to see if this peptide also has similar activities. Inventors: Liu, Chuan-Fa (Longmont, CO); Feige, Ulrich (Newbury Park, CA); Cheetham, Janet C. (Montecito, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Date of First Priority Issue: Friday October 23rd, 1998
Patent Number: 6835566
This patent teaches the generation of lineage-committed dendritic cell progenitors. This is important since the dendritic cell is a master controller of the immune response, being able to both stimulate responses as well as inhibit them. Dendritic cells can be made to stimulate responses through activation with various cytokines or toll like receptors, whereas they can also suppress responses... Inventors: Smith, Alan K. (Saline, MI); Smith, Douglas M. (Ann Arbor, MI); Mandalam, Ramkumar K. (Westland, MI)
Assignee: Aastrom Biosciences, Inc. (Ann Arbor, MI)
Date of First Priority Issue: Monday February 23rd, 1998
Patent Number: 6833269
Despite all the publicity of embryonic stem cell therapy, the fact that embryonic stem cells turn into cancer cells when inserted into a living organism suggests the very import need to understand and develop ways of manipulating them to differentiate into the tissue that is needed to be repaired.
This patent teaches conditions for generating neural cells from embryonic stem cells through... Inventor: Carpenter, Melissa K. (Castro Valley, CA)
Assignee: Geron Corporation (Menlo Park, CA)
Date of First Priority Issue: Wednesday May 17th, 2000
Patent Number: 6830927
This patent teaches how to generate neuronal stem cells that are bipotent into differentiating into central nervous system neurons as well as peripheral nervous system neurons. The patent uses neuronal stem cells that are extracted from specific parts of the embryo and cultured in fibroblast growth factor and chicken embryo extract.
Besides the intrinsic value of composition of matter on... Inventors: Rao, Mahendra S. (Salt Lake City, UT); Mujtaba, Tahmina (Sandy, UT)
Assignee: University of Utah Research Foundation (Salt Lake City, UT
Date of First Priority Issue: Wednesday May 7th, 1997
Patent Number: 6828145
Classically hematopoietic stem cells are purified based on expression of markers such CD34 or c-kit. This patent teaches that hematopoietic stem cells can also be further purified by selecting cells that lack expression of MHC I. The lack of expression of class I may have to do with the presumed weaker immunogenecity of hematopoietic stem cells.
Currently this invention doesnt seem to be... Inventors: Avital, Itzhak (Los Angeles, CA); Arnaout, Walid (Calabasas, CA); Inderbitzin, Daniel (Zurich, CH)
Assignee: Cedars-Sinai Medical Center (Los Angeles, CA)
Date of First Priority Issue: Wednesday May 10th, 2000
Patent Number: 6825007
This patent covers composition of matter of Jagged 1, as well as its use in stem cell expansion. This patent is useful not only for classical regenerative applications, but also for stimulating production of special immune system cells. Inventors: Zimrin, Ann B. (Marriottsville, MD); Maciag, Thomas (Freeport, ME); Pepper, Michael S. (Geneva, CH); Montesano, Roberto (Geneva, CH); Wong, Michael (Derwood, MD)
Assignee: Maine Medical Center Research Institute (Scarborough, ME)
Date of First Priority Issue: Friday May 31st, 1996
Patent Number: 6821779
This patent covers methods of storing neural stem cells and neural cells that have been differentiated from stem cells. This patent covers not only human but also porcine cells. The assignee company was at one time performing clinical trials with encapsulated porcine neural cells in patients. Inventors: Koopmans, Jan (Groningen, NL); Jacoby, Douglas B. (Wellesley, MA); Dinsmore, Jonathan (Brookline, MA)
Assignee: University Hospital Groningen, Inc. (Groningen, NL); Diacrin, Inc. (Charlestown, MA)
Date of First Priority Issue: Monday July 6th, 1998
Patent Number: 6821513
Inventor: Fleming, William H. (Portland, OR)
Assignee: Oregon Health & Science University (Portland, OR)
Date of First Priority Issue: Wednesday June 23rd, 1999
Patent Number: 6815185
This patent provides methods and vectors for transfection of embryonic stem cells. This patent is useful for generation of various animal research models that have a genetic modification introduced into the whole animal. Additionally, transfection of embryonic stem cells could be useful for a variety of different things, including using the embryonic stem cells as a vector...or in another... Inventors: Klein, Robert D. (Palo Alto, CA); Brennan, Thomas J. (South San Francisco, CA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Monday November 17th, 1997
Patent Number: 6818210
This patent teaches how to generate a myocardial graft using embryonic stem cells that have been induced to differentiate into the cardiac lineage. This patent is especially useful for post myocardial infarction in which scar tissue replaces functional myocardium resulting in decreased cardiac output. Numerous methods have been previously described for generation of myocardial cells from... Inventor: Field, Loren J. (Indianapolis, IN)
Assignee: Advanced Research & Technology Institute (Indianapolis, IN)
Date of First Priority Issue: Tuesday November 16th, 1993
Patent Number: 6815203
This patent teaches ways of dedifferentiating pancreatic duct or exocrine cells and then redifferentiating the cells to generate functional islet cells. This patent is especially relevant in light of the Edmonton Protocol that provides methods of transplanting allogeneic pancreatic islets. The problem with the Edmonton Protocol is that it takes up to 2, sometimes even more pancreas's for 1... Inventors: Bonner-Weir, Susan (Cambridge, MA); Taneja, Monica (Bronx, NY)
Assignee: Joslin Diabetes Center, Inc. (Boston, MA)
Date of First Priority Issue: Wednesday June 23rd, 1999
Patent Number: 6814961
This patent teaches the use of a naturopathic remedy for actually mobilizing stem cells into systemic circulation. The naturopathic remedy is blue green algae. This patent may be used for treating anything that benefits from mobilized stem cells ranging from stroke to myocardial infarction. Inventors: Jensen, Gitte S. (Port Dover, Ontario, CA); Drapeau, Christian (Keno, OR)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Monday May 14th, 2001
Patent Number: 6811776
This patent teaches how to use bone stem cells, or bone precursor cells in order to generate in vitro bones that can be subsequently introduced in vivo. The invention is of use to any biotech interested in entering the regenerative market in the area of osteogenesis. Inventors: Kale, Sujata (Boston, MA); Long, Michael W. (Northville, MI)
Assignee: The Regents of the University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Wednesday December 27th, 2000
Patent Number: 6808704
This patent teaches methods of generating stem cells using cloning that match the potential recipient according to HLA phenotype. This patent could be very useful since in essence it describes a method of making stem cells that will not be rejected by the immune system. Inventors: Lanza, Robert (Clinton, MA); West, Michael D. (Boston, MA); Cibelli, Jose (Holden, MA)
Assignee: Advance Cell Technology, Inc. (Worcester, MA)
Date of First Priority Issue: Tuesday September 7th, 1999
Patent Number: 6808702
This patent is very interesting in that it provides a source of nitric oxide through the use of fetal and embryonically derived neural stem cells. The neural stem cells can be administered by various means in order to correct gastrointestinal deficiencies. Inventors: Pasricha, Pankaj J. (Houston, TX); Micci, Maria A. (Dickinson, TX)
Assignee: Board of Regents, the University of Texas System (Austin, TX)
Date of First Priority Issue: Thursday April 13th, 2000
Patent Number: 6805860
This patent appears to cover the tempory occlusion of a vessel so that stem cells can be administered for repair of the injured organ. This patent has the potential to cover various clinical applications of stem cell therapies, especially for myocardial infarction that use a balloon stent to localize the stem cells into the infarct related artery. Inventor: Alt, Eckhard (D-85521 Ottobrunn, DE)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Sunday September 30th, 2001
Patent Number: 6800790
This patent teaches how to increase the number of germline stem cells in a fruitfly through overexpression of Dpp locally using certain promoters that are specific to germline stem cells. Since the patent is only covering the fruitfly species, clinical applications seem to be limited. Inventors: Spradling, Allan C. (Baltimore, MD); Xie, Ting (Baltimore, MD)
Assignee: Carnegie Institution of Washington (Washington, DC)
Date of First Priority Issue: Friday July 24th, 1998
Patent Number: 6800480
This patent teaches how to grow embryonic stem cells in absence of feeder cells. This is a useful "base patent" that is essential to generation of therapeutics from embryonic stem cells, since it is usually not desired to use feeder cell layers in culture of embryonic stem cells for clinical use. Inventors: Bodnar, Andrea G. (Oshawa, CA); Chiu, Choy-Pik (Cupertino, CA); Gold, Joseph D. (San Francisco, CA); Inokuma, Margaret (San Jose, CA); Murai, James T. (San Bruno, CA); West, Michael D. (Boston, MA)
Assignee: Geron Corporation (Menlo Park, CA)
Date of First Priority Issue: Thursday October 23rd, 1997
Patent Number: 6797269
This patent covers mesenchymal stem cells that are treated with interferon gamma for suppression of an immune response. Mesenchymal stem cells are naturally immunosuppressive...it may be that the interferon gamma treatment is activating the expression of the immune suppressive enzyme 2,3-indolamine-dehydrogenase (IDO), which selectively depletes tryptophan, thus stopping T cell activation. Inventors: Mosca, Joseph D. (Ellicott City, MD); McIntosh, Kevin R. (Ellicott City, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Friday April 3rd, 1998
Patent Number: 6797264
This patent covers the use of neural stem cells together with a growth hormone for treatment of neurological conditions. This covers various hormones including growth hormone itself, as well as fibroblast growth factor. Inventor: Eriksson, Peter (Goteborg, SE)
Assignee: Cellartis AB (Goteborg, SE)
Date of First Priority Issue: Wednesday November 25th, 1998
Patent Number: 6793939
This patent covers the use of liver tissue derived basement membrane material for the stimulation of endogenous or exogenous stem cells. One interesting use of this patent would be the combination of cord blood stem cells with liver tissue extract for stimulation of various regenerative applications. Inventor: Badylak, Stephen F. (West Lafayette, IN)
Assignee: Purdue Research Foundation (West Lafayette, IN)
Date of First Priority Issue: Tuesday December 10th, 1996
Patent Number: 6793677
This patent teaches ways of using cells and stem cells from the nucleus pulposus for the treatment of degenerative back diseases. Since lower back pain is a major medical concern, various stem cell therapeutics are being considered for stimulation of the nucleus pulposus cellular content, so as to regenerate degenerate discs.
The cells used in this patent do not necessarily have to be... Inventor: Ferree, Bret A. (Cincinnati, OH
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday August 13th, 1999
Patent Number: 6790838
This patent teaches ways of improving the transfection of liver cells with genes in vivo. Transfection of liver cells is performed through the administration of the thyroid hormone T3, as well as keratinocyte growth factor. The transfection of liver cells may be performed not only for treatment of genetic disorders, but also for induction of islet differentiation. Inventors: Alison, Malcolm R. (London, GB); Coutelle, Charles (London, GB); Forbes, Stuart J. (London, GB); Hodgson, Humphrey J. F. (London, GB); Sarosi, Ildiko (Newbury Park, CA); Themis, Michael (Oxfordshire, GB)
Assignee: Amgen, Inc. (Thousand Oaks, CA); Imperial College Innovations LTD (London, GB)
Date of First Priority Issue: Tuesday February 23rd, 1999
Patent Number: 6790826
This patent covers composition of matter on a factor, which seems to be not clearly stated, that can induce both proliferation and differentiation of hematopoietic stem cells, as well as stem cells that have been committed to the lymphoid lineage. This patent is particularly useful for treatment of patients after bone marrow transplantation, or chemotherapy, or radiation therapy. Inventors: Kirkness, Ewen F. (Olney, MD); Adams, Mark D. (Rockville, MD); Olsen, Henrik (Gaithersburg, MD); Rosen, Craig A. (Laytonsville, MD)
Assignee: Human Genome Sciences, Inc. (Rockville, MD)
Date of First Priority Issue: Tuesday May 16th, 1995
Patent Number: 6790455
This patent teachs cell delivery matrices that can be used for localized administration of stem cells into an area of need. The matrices disclosed are biocompatible and biodegradable. The patent is owned by a non-for-profit entity and appears to be available for licensing. Inventors: Chu, Benjamin (Setauket, NY); Hsiao, Benjamin S. (Setauket, NY); Hadjiargyrou, Michael (Coram, NY); Fang, Dufei (Painted Post, NY); Zong, Xinhua (Centereach, NY); Kim, Kwangsok (Setauket, NY)
Assignee: The Research Foundation at State University of New York (Stony Brook, NY)
Date of First Priority Issue: Friday September 14th, 2001
Patent Number: 6787357
This patent provides matrices that can be generated easily in GMP conditions, and can be administered in combination with various stem cells for therapeutic benefits. Cytokines and other growth factors may also be administered with the stem cells into the matrix to either induce local proliferation, or to chemoattract endogenous stem cells. Inventors: Bowlin, Gary L. (Mechanicsville, VA); Wnek, Gary (Midlothian, VA); Simpson, David G. (Mechanicsville, VA); Lam, Philippe (Richmond, VA); Carr, Marcus E. (Midlothian, VA); Fillmore, Helen (Richmond, VA)
Assignee: Virginia Commonwealth University (Richmond, VA)
Date of First Priority Issue: Friday September 1st, 2000
Patent Number: 6787356
This patent teaches methods of generating and expanding dopaminergic neurons that can be used for treatment of a variety of neurological conditions. The system uses, amongst other things, fibroblast growth factor for expansion. Inventors: Studer, Lorenz (New York, NY); McKay, Ron D. (Bethesda, MD)
Assignee: The United States of America as represented by the Department of Health and Human Services
Date of First Priority Issue: Friday July 24th, 1998
Patent Number: 6787355
This patent covers multipotent stem cells that are generated from skin or from tongue tissue. This stem cell type is particularly useful for generation of neural stem cells and neurons. Inventors: Miller, Freda D. (Montreal, CA); Gloster, Andrew (Saskatoon, CA); Toma, Jean (Montreal, CA)
Assignee: McGill University (Montreal, CA)
Date of First Priority Issue: Monday August 26th, 1996
Patent Number: 6787353
This patent teaches ways of generating a new type of neuronal precursor cell from embryonic tissue. The cells are negative for the marker A2B5 and positive for expression of NCAM. Inventors: Rao, Mahendra S. (Salt Lake City, UT); Mayer-Proschel, Margot (Sandy, UT); Kalyani, Anjali J. (Salt Lake City, UT)
Assignee: University of Utah Research Foundation (Salt Lake City, UT)
Date of First Priority Issue: Friday July 4th, 1997
Patent Number: 6784155
The connection between the brain and the immune system is well-known, such as the experiments of Pavlovian conditioning of immune responses. Here the inventor covers the use of opiates and certain peptides for stimulation of bone marrow stem cell proliferation.
Specific peptide sequences of hematopoietic stem cell stimulators are disclosed including peptide fractions of hemoglobin chains... Inventors: Wolpe, Stephen D. (Rockville, MD); Tsyrlova, Irena (Gaithersburg, MD)
Assignee: Wellstat Therapeutics Corporation (Gaithersburg, MD)
Date of First Priority Issue: Wednesday April 3rd, 1996
Patent Number: 6783982
This patent teaches that neural stem cells can be expanded through the use of a novel protein called Neural Plakophilin Related Armadillo Protein (hNPRAP). Additionally the patent claims the induction of cellular extensions ushing hNPRAP. Inventors: St. George-Hyslop, Peter H. (Toronto, CA); Fraser, Paul E. (Toronto, CA)
Assignee: The Governing Council of The University of Toronto (Toronto, CA)
Date of First Priority Issue: Friday February 12th, 1999
Patent Number: 6783775
This patent teaches ways of inducing differentiation in stem cells. Specifically it claims a composition of matter that can induce not only differentiation of hematopoietic stem cells, but also of leukemic cells. The composition contains the enzyme ceruloplasmin, together with a specific serum derived component. This patent is ripe for commercialization. Inventors: Peled, Tony (Mevaseret Zion, IL); Fibach, Eitan (Mevaseret Zion, IL); Rachmilewitz, Eliezer A. (Jerusalem, IL)
Assignee: Hadasit Medical Research Services and Development Ltd. (Jerusalem, IL)
Date of First Priority Issue: Tuesday December 10th, 1996
Patent Number: 6781030
This patent teaches a new way of cloning, including for the generation of embryonic stem cells, by selecting oocytes at a specific cell stage called telophase. Inventors: Baguisi, Alexander (Grafton, MA); Overstrom, Eric W. (Grafton, MA)
Assignee: Trustee of Tufts College, Ballou Hall (Medford, MA)
Date of First Priority Issue: Monday November 2nd, 1998
Patent Number: 6777233
This patent provides a tissue culture media and systems that can be used to expand nestin positive neural stem cells. The neural stem cells that are expanded in this patent have more potency and appear to be more undifferentiated than neural stem cells that are covered in the prior art. Inventor: Carpenter, Melissa (Foster City, CA)
Assignee: StemCells California, Inc. (Palo Alto, CA)
Date of First Priority Issue: Friday September 5th, 1997
Patent Number: 6777231
This is one of the founding patents covering work performed by Cytori, formerly Macropore. The patent covers an adipose derived stem cell that can diffentiate into bone, cartilage cell, nerve, or muscle cells. Inventors: Katz, Adam J. (Charlottesville, VA); Llull, Ramon (Mallorca, ES); Futrell, William J. (Pittsburgh, PA); Hedrick, Marc H. (Encino, CA); Benhaim, Prosper (Los Angeles, CA); Lorenz, Hermann Peter (Los Angeles, CA); Zhu, Min (Los Angeles, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Date of First Priority Issue: Wednesday March 10th, 1999
Patent Number: 6777217
This patent appears to be a composition of matter patent on various histone deacetylases. These proteins, histone deacetylases, are very important in controlling gene expression. Typically histone deacetylases suppress gene expression by deacetylazing histones, which control large parts of the DNA. Since histone deacetylase inhibitors actually stimulate expression of genes that are normally... Inventors: Schreiber, Stuart L. (Boston, MA); Taunton, Jack (Somerville, MA); Hassig, Christian A. (Somerville, MA); Jamison, Timothy F. (Cambridge, MA)
Assignee: President and Fellows of Harvard College (Cambridge, MA)
Date of First Priority Issue: Tuesday March 26th, 1996
Patent Number: 6775574
This patent covers the implantation of a stem cell source, or genes associated with stem cells and regeneration, together with a pace-maker type device, into a patient whose heart is in need of regeneration. The advantage of this patent is that numerous times the implanted cells do not beat in synchronism with the host cardiac cells, this patent tries to overcome this problem. Inventors: Soykan, Orhan (New Brighton, MN); Donovan, Maura G. (St. Paul, MN)
Assignee: Medtronic, Inc. (Minneapolis, MN)
Date of First Priority Issue: Friday November 7th, 1997
Patent Number: 6774120
This patent teaches how to make liver cells behave like pancreatic cells and even offers the possibility of treating type 1 diabetes. Essentially the patent claims that by transfecting liver cells with the pancreatic stem cell transcription factor PDX-1, the liver cells will start producing insulin (besides other things). Inventor: Ferber, Sarah (Ramat Hasharon, IL)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Wednesday April 19th, 2000
Patent Number: 6773713
This patent teaches how to combine computer engineering design tools together with stem cell technologies for the formation of 3 dimensional tissues that may subsequently be implanted. Inventors: Bonassar, Lawrence J. (Acton, MA); Rowley, Jon A. (Chapel Hill, NC); Mooney, David J. (Ann Arbor, MI)
Assignee: University of Massachusetts (Boston, MA)
Date of First Priority Issue: Friday February 23rd, 2001
Patent Number: 6773425
This patent discloses various vessels and uses thereof that can be used to store stem cells and other biological products during transportation. Inventor: Tamari, Yehuda (Oyster Bay, NY)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday December 29th, 2000
Patent Number: 6770628
This patent takes a new twist on stimulation of hematopoietic stem cells. It uses inhibitors of Dipeptidyl Peptidase IV, an enzyme that destroys hematopoietic growth factors, in order to "suppress the suppressor". Inventors: Wallner, Barbara P. (Weston, MA); Jones, Barry (Cambridge, MA); Miller, Glenn T. (Haverhill, MA); Adams, Sharlene (Watertown, MA)
Assignee: Point Therapeutics, Inc. (Boston, MA)
Date of First Priority Issue: Monday May 4th, 1998
Patent Number: 6770478
This patent covers methods of preserving red blood cells through cryopreservation. The method involves depletion of cholesterol and loading of the cells with an oligosaccharide. Cryopreservation according to this method may be performed in stem cell derived erythrocytes for use in emergency situations. Inventors: Crowe, John H. (Davis, CA); Crowe, Lois M. (Davis, CA); Tablin, Fern (Davis, CA); Wolkers, Willem F (Davis, CA); Tsvetkova, Nelly M. (Davis, CA); Oliver, Ann F. (Davis, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Date of First Priority Issue: Thursday February 10th, 2000
Patent Number: 6770260
This patent teaches depletion or inactivation of recipient macrophages using dichloromethylene diphosphonate in order to allow allogeneic or xenogeneic stem cell transplants and progeny of the stem cell transplants not to be rejected.
The patent is very interesting since the inactivation of macrophages theoretically may also allow for inactivation of dendritic cells. If this occurs, then the... Inventors: Chen, Ben (Fremont, CA); Fraser, Chris (Los Altos, CA); Weissman, Irv (Redwood City, CA)
Assignee: Novartis AG (Basel, CH)
Date of First Priority Issue: Friday December 17th, 1993
Patent Number: 6767928
This patent covers ways of altering biomaterials so that bone may be grown around them. Specifically useful is the application of such biomaterials as scaffolds around which stem cells can be grown in order to generate tissues that can be implanted. Inventors: Murphy, William L. (Ann Arbor, MI); Peters, Martin C. (Ann Arbor, MI); Mooney, David J. (Ann Arbor, MI); Kohn, David H. (Ann Arbor, MI)
Assignee: The Regents of the University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Friday March 19th, 1999
Patent Number: 6767740
Teeth are known to contain various cellular populations in the pulp, including stem cells. The idea of banking tooth stem cells is limited by the ease of extraction. This patent discloses various apparatus' that are easily used for the extraction of tooth stem cells. Inventors: Sramek, Roger Anton (Sausalito, CA); Javid, Bahram (El Cerrito, CA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Tuesday October 9th, 2001
Patent Number: 6767738
This patent teaches ways of using gradient centrifugation (separation based on weight) to purify stem cells of the neural lineage from adults. This is specifically useful since it is a relatively easy way to purify cells and is commonly used in the purification of hematopoietic stem cells. Inventors: Gage, Fred H. (La Jolla, CA); Palmer, Theo (San Carlos, CA); Safar, Francis G. (Irvine, CA); Takahashi, Jun (Kyoto, JP); Takahashi, Masayo (Kyoto, JP)
Assignee: The Salk Institute for Biological Studies (La Jolla, CA)
Date of First Priority Issue: Friday September 24th, 1999
Patent Number: 6767737
This patent is on a type of stem cell that expresses the fibroblast growth factor receptor. This is a composition of matter patent on a stem cell and could be very useful for strategic positioning of companies in the area of stem cell therapeutics. Inventors: Wilson, E. Lynette (New York, NY); Burger, Patricia E. (Cape Town, ZA)
Assignee: New York University (New York, NY)
Date of First Priority Issue: Monday August 31st, 1998
Patent Number: 6764683
Mucositis is a big problem in cancer patients taking chemotherapy and radiation therapy, in part due to the effect of these therapies on the epithelial stem cell pool. This patent teaches the usefulness of transforming growth factor alpha on preventing this condition by its ability to protect the stem cell compartment and to enhance their expansion. Inventors: Twardzik, Daniel R. (Bainbridge Island, WA); Paskell, Stefan (Bainbridge Island, WA); Felker, Thomas S. (Vashon, WA)
Assignee: Kaleidos Pharma, Inc. (Seattle, WA)
Date of First Priority Issue: Monday April 26th, 1999
Patent Number: 6762167
This patent teaches that angiotensin I and/or angiotensin II can be used for stimulation of hematopoiesis. Inventors: Rodgers, Kathleen E. (Long Beach, CA); DiZerega, Gere S. (Los Angeles, CA)
Assignee: University of Southern California (Los Angeles, CA)
Date of First Priority Issue: Wednesday March 11th, 1998
Patent Number: 6761887
Mesenchymal stem cells can be used as "universal donors" since they do not elicit rejection in certain situations. This patent teaches methods of differentiating mesenchymal stem cells into cartilage through growth on alginate layers. Inventors: Kavalkovich, Karl (Baltimore, MD); Boynton, Raymond (Watertown, MA); Murphy, Mary (Baltimore, MD); Barry, Frank (Baltimore, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Monday November 16th, 1998
Patent Number: 6761883
This is a composition of matter patent on stem cells of the hematopoietic lineage that differentiate specifically into myeloid cells under the appropriate culture and/or in vivo conditions. These stem cells may be used as a "boost" for patients in which the myeloid compartment is not repopulating after bone marrow transplant, or chemotherapy, or radiation therapy. Inventors: Weissman, Irving L. (Redwood City, CA); Traver, David Jeffrey (West Roxbury, MA); Akashi, Koichi (Palo Alto, CA); Manz, Markus Gabriel (Palo Alto, CA); Miyamoto, Toshihiro (Menlo Park, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University (Palo Alto, CA)
Date of First Priority Issue: Tuesday June 29th, 1999
Patent Number: 6759512
This patent covers a protein called F-spondin that is involved in regulation of development and stem cell function. It is published that F-spondin induces differentiation of neural stem cells into neurons (Schubert D et al. F-spondin promotes nerve precursor differentiation. J Neurochem. 2006 Jan;96(2):444-53). Inventors: Hastings, Gregg (Newberry Park, CA); Dillon, Patrick J. (Gaithersburg, MD)
Assignee: Human Genome Sciences, Inc. (Rockville, MD)
Date of First Priority Issue: Monday February 12th, 1996
Patent Number: 6759245
Ex vivo culture of stem cells is important for the generation of artificial organs. This patent teaches culture of stem cells and precursor cells using a unique culture set up that allows for proper differentiation of cells in an in vivo like setting. The patent is primarily targeted towards the generation of hepatocytes. Inventors: Toner, Mehmet (Wellesley, MA); Tilles, Arno W. (Cambridge, MA); Balis, Ulysses J. (Peabody, MA); Yarmush, Martin L. (Newton, MA); Cosman, Maury D. (Woburn, MA); Dimilla, Paul A. (Dover, MA)
Assignee: The General Hospital Corporation (Boston, MA); Organogenesis Inc. (Canton, MA)
Date of First Priority Issue: Monday June 21st, 1999
Patent Number: 6759244
This patent teaches methods of generating a composite blastocyst from non-viable embryos. The invention is useful for generation of stem cells of embryonic origin through a novel method. Inventors: Alikani, Mina (New York, NY); Willadsen, Steen Malte (Windermere, FL)
Assignee: Art Institute of New York and New Jersey, Inc. (New York, NY)
Date of First Priority Issue: Thursday November 8th, 2001
Patent Number: 6759242
This patent teaches that neural stem cells, specifically neural crest stem cells, can be expanded preferentially by growing in low oxygen conditions. Inventors: Csete, Marie (S. Pasadena, CA); Morrison, Sean J. (Ann Arbor, MI); Wold, Barbara (San Marino, CA); Anderson, David J. (Altadena, CA)
Assignee: California Institute of Technology (Pasadena, CA)
Date of First Priority Issue: Wednesday November 18th, 1998
Patent Number: 6759215
This patent is part of the huge wall Amgen put around the IP for stem cell factor. This patent specifically encompasses the cells that are transformed with SCF genes in order to generate SCF protein. SCR is the same as kit ligand. Inventors: Zsebo, Krisztina M. (Thousand Oaks, CA); Bosselman, Robert A. (Thousand Oaks, CA); Suggs, Sidney V. (Newbury Park, CA); Martin, Francis H. (Thousand Oaks, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Date of First Priority Issue: Monday October 16th, 1989
Patent Number: 6759201
This patent covers a new marker for neural stem cells called Daedalos. It provides methods of using this marker for identifying and extracting neural stem cells. The neural stem cells can be used for treatment of a variety of neurological disorders such as Parkinsons, Alzheimers, etc. Inventor: Morgan, Bruce A. (Lexington, MA)
Assignee: The General Hospital Corporation (Boston, MA)
Date of First Priority Issue: Wednesday October 25th, 2000
Patent Number: 6759039
This patent covers methods of culturing and expanding pancreatic stem cells. These cells may be used for the treatment of diabetes through encapsulation or administration into the liver such as thought by the Edmonton Protocol. Inventors: Tsang, Wen-Ghih (Sherman Oaks, CA); Zheng, Tianli (Culver City, CA); Huang, Chang Jiang (Los Angeles, CA)
Assignee: AmCyte, Inc. (Santa Monica, CA)
Date of First Priority Issue: Friday June 30th, 2000
Patent Number: 6758828
This patent is for a medical device that can be utilized for administration of stem cells into tissues. This medical device is unique in that it contains several safety parameters that are important for regulatory approval of such administration devices. Inventors: Hammer, Bruce E. (Minnetonka, MN); Conroy, Mark J. (St. Louis Park, MN)
Assignee: Regents of the University of Minnesota (Minneapolis, MN)
Date of First Priority Issue: Monday December 10th, 2001
Patent Number: 6753153
This patent discloses protein markers that can be used for purification of pancreatic stem cells. The markers are agents that are capable of binding the protein ErbB2.
This patent may be used for purification and ex vivo expantion of islets from tissue, or may be used for characterization of islet stem cells generated via embryonic or other type of stem cell culture. Inventors: Sarvetnick, Nora (San Diego, CA); Kritzik, Marcie (La Jolla, CA)
Assignee: The Scripps Research Institute (La Jolla, CA)
Date of First Priority Issue: Monday December 13th, 1999
Patent Number: 6752834
Disclosed is a matrix that is useful for administration of living stem cells particularly for treatment of bone or cartilage injuries. The matrix is comprised primarily of collagen II and is compatible with a variety of stem cell technologies. This patent is useful for numerous applications. Inventors: Geistlich, Peter (Stanstaad, CH); Eckmayer, Zdenek (Weinheim, DE); Schlosser, Lothar (Darmstadt, DE)
Assignee: Ed Geistlich Soehne AG Fuer Chemische Industrie (CH)
Date of First Priority Issue: Friday October 10th, 1997
Patent Number: 6750196
This patent teaches expansion of retinal cells, and stem cells thereof, through the administration of proteins called neuroregulins. The patent is useful for treatment of a variety of ocular degenerative diseases. Inventors: Reh, Thomas A. (Seattle, WA); Marchionni, Mark A. (Arlington, MA); McCabe, Kathryn L. (Seattle, WA); Bermingham-McDonogh, Olivia (Watertown, MA); Mahanthappa, Nagesh K. (Cambridge, MA); Gwynne, David I. (Beverly, MA)
Assignee: Acorda Therapeutics (Hawthorne, NY)
Date of First Priority Issue: Monday March 27th, 1995
Patent Number: 6750194
This patent covers expansion of muscle mass through the use of vasoactive intestinal peptide receptors (VPAC)agonists.
The activity of such agonists on stem cells are only beginning to be identified, and I am sure this area is ripe for expansion...for example, what do such agonists do on neural stem cells? Inventors: Isfort, Robert Joseph (Fairfield, OH); Sheldon, Russell James (Fairfield, OH)
Assignee: The Procter & Gamble Company (Cincinnati, OH)
Date of First Priority Issue: Monday October 23rd, 2000
Patent Number: 6750055
This patent covers an implantable culture system that uses islet cells and/or stem cells for treatment of diabetes. What is interesting about this patent is that it actually involves a mechanism of detecting insulin so that the culture system and other additions to the body can be perform in order to maintain homeostatic insulin concentrations.
This patent is useful for small biotechs... Inventors: Connelly, Patrick R. (Rochester, NY); Weiner, Michael L. (Webster, NY)
Assignee: Biomed Solutions LLC (West Henrietta, NY)
Date of First Priority Issue: Wednesday March 7th, 2001
Patent Number: 6743628
This patent teaches how to expand neuronal stem cells through administration of the protein neurturin. The patent seems to be restricted to in vitro use. Inventors: Johnson, Jr., Eugene M. (St. Louis, MO); Milbrandt, Jeffrey D. (St. Louis, MO); Kotzbauer, Paul T. (St. Louis, MO); Lampe, Patricia A. (St. Louis, MO)
Assignee: Washington University (St. Louis, MO)
Date of First Priority Issue: Monday August 28th, 1995
Patent Number: 6740493
This patent teaches how to diagnose, or to predict a bone disease through identifying the bone stem cell content and activity of the patient. Inventors: Long, Michael W. (Northville, MI); Mann, Kenneth G. (Grand Isle, VT)
Assignee: The Regents of the University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Friday August 12th, 1994
Patent Number: 6737073
This is an implantable matrix that can be used for growing stem cells in vitro for the regeneration of cartilage. The implant has several advantages over the prior art including the fact that it is compartamentalized in structure to provide a more "in vivo" like function. Inventors: Mahmood, Tahir (Cambridge, MA); Riesle, Jens Uwe (Amsterdam, NL); van Blitterswijk, Clemens Antoni (Hekendorp, NL)
Assignee: IsoTis N.V. (Bilthoven, NL)
Date of First Priority Issue: Wednesday February 10th, 1999
Patent Number: 6737072
This patent covers a matrix that is made of hyaluronic acid and hydrolyzed collagen, that can be used as a scaffold for in vitro three dimensional tissue generation, or can be seeded with stem cells and implanted in vivo. Inventors: Angele, Peter (Regensburg, DE); Kujat, Richard (Pettendorf, DE)
Assignee: Nerlich, Michael (Pentling, DE)
Date of First Priority Issue: Saturday December 3rd, 1988
Patent Number: 6737054
This patent teaches administration of stem cells, or cardiomyocytes, into areas of the heart that have been injured, including by infarction. Inventor: Field, Loren J. (Indianapolis, IN)
Assignee: Advanced Research and Technology Institute (Indianapolis, IN)
Date of First Priority Issue: Thursday December 16th, 1993
Patent Number: 6736799
This patent covers a device for administration of biological matrices that can be co-implanted with stem cells for regenerative purposes. Inventors: Erbe, Erik M. (Berwyn, PA); Marx, Jeffrey G. (Downington, PA); Bagga, Charanpreet S. (Phoenixville, PA)
Assignee: Vita Licensing, Inc. (Wilmington, DE)
Date of First Priority Issue: Tuesday October 24th, 2000
Patent Number: 6734338
This patent teaches how to transfect male germ stem cells in non-human mammals. This technology is useful for generation of a variety of animal models for laboratory experimentation. It is also useful for research companies who want to circumvent some of the transgenic patents today. Inventors: Readhead, Carol W. (Pasadena, CA); Winston, Robert (London, GB)
Assignee: Cedars-Sinai Medical Center (Los Angeles, CA); IMPEL, Imperial College of Science, Technology and Medicine (London, GB)
Date of First Priority Issue: Friday November 14th, 1997
Patent Number: 6734015
This patent covers a type of neuronal stem cell that is restricted in its differentiation ability to the neuronal, but not astrocyte or glial lineage. The patent covers a cell that is E-NCAM positive, FGF-dependent, and derived from embryonic sources. Inventors: Rao, Mahendra S. (Salt Lake City, UT); Mayer-Proschel, Margot (Sandy, UT)
Assignee: University of Utah Research Foundation (Salt Lake City, UT)
Date of First Priority Issue: Friday July 4th, 1997
Patent Number: 6733746
This patent covers a tissue culture media useful for the expansion of CD34+ hematopoietic stem cells that does not require the use of serum, and thus is easier for clinical implimentation. The patent is owned by Invitrogen which sells various laboratory and tissue culture reagents. Inventors: Daley, John P. (Buffalo, NY); Dadey, Barbara M. (East Aurora, NY); Biddle, William C. (Buffalo, NY); Wysocki, Michelle G. (Cheektowaga, NY)
Assignee: Invitrogen Corporation (Carlsbad, CA)
Date of First Priority Issue: Tuesday March 12th, 1996
Patent Number: 6733433
This patent covers a medical device that is useful for the concentration of stem cells, especially hematopoietic stem cells, from peripheral blood and other fluids. Inventor: Fell, Claude (Nyon, CH)
Assignee: Biosafe S.A. (Eysins, CH)
Date of First Priority Issue: Thursday December 24th, 1998
Patent Number: 6730315
This patent covers a hydrogel mixture that is useful for storage and/or expansion of cells, especially useful for stem cell applications. This technology may be used to form an in vivo depot of stem cells, or may be embedded with stem cell chemoattractants to call in endogenous stem cells into an area of need. Inventors: Usala, Anton-Lewis (Winterville, NC); Klann, Richard Chris (Washington, NC)
Assignee: Encelle, Inc. (Greenville, NC)
Date of First Priority Issue: Monday February 24th, 1992
Patent Number: 6730252
This patent covers generation of filaments that are useful for forming three dimensional scaffolds for tissue engineering using stem cells or precursor cells. Inventors: Teoh, Swee Hin (Singapore 596504, SG); Hutmacher, Dietmar Werner (Singapore, SG); Tan, Kim Cheng (Singapore 524856, SG); Tam, Kock Fye (Singapore 730659, SG); Zein, Iwan (Singapore 448909, SG)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Wednesday September 20th, 2000
Patent Number: 6723561
The early hematopoietic stem cells are usually non-proliferating, additionally, intermediately developed hematopoietic stem cells treated with stem cell inhibitors such as TGF-beta, also do not proliferate. This causes a problem for gene therapy since most gene therapy vectors require the cells to be proliferating for appropriate transfection. This patent teaches methods of transfecting cells... Inventors: Russell, Stephen James (Cambridge, GB); Fielding, Adele Kay (Cambridge, GB); Casimir, Colin Maurice (London, GB)
Assignee: Mayo Foundation for Medical Education and Research (Rochester, MN)
Date of First Priority Issue: Thursday September 28th, 1995
Patent Number: 6727224
This patent teaches the use of bone morphogenic proteins together with stem cells for repair of articular cartilage injury. In some embodiments the stem cells may be endogenous. Inventors: Zhang, Renwen (Rutherford, NJ); Peluso, Diane (Marshfield, MA); Morris, Elisabeth (Sherborn, MA)
Assignee: Genetics Institute, LLC. (Cambridge, MA)
Date of First Priority Issue: Monday February 1st, 1999
Patent Number: 6723696
This patent covers a novel factor that on the one hand is involved in leukocyte activation, and on the other hand inhibits bone resorption. This factor is useful in conjunction with stem cell therapies that stimulate bone formation. Inventors: Suzuki, Kazuo (Misaki-machi, JP); Yamagoe, Satoshi (Kashiwa, JP); Yamakawa, Tooru (Tokyo, JP)
Assignee: Japan as represented by Secretary of National Institute of Infectious Diseases (Tokyo, JP)
Date of First Priority Issue: Tuesday December 22nd, 1998
Patent Number: 6723335
This patent covers the use of a fluid matrix together with stem cells, specifically mesenchymal stem cells, for the regeneration of the nucleus pulposus. This invention is suitable for treatment of patients with lower back pain due to disc degeneration. Inventors: Moehlenbruck, Jeffrey William (Austin, TX); Ranieri, John Paul (Austin, TX)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday April 7th, 2000
Patent Number: 6723131
This patent teaches how to administer bone marrow in vivo, so that administration is performed not only of hematopoietic stem cells, but also stromal elements. This combination should be useful in patients whose stroma has been destroyed for one reason or another. The invention may also be useful for prevention of donor-derived leukemic relapse. Inventor: Muschler, George F. (Cleveland Heights, OH)
Assignee: The Cleveland Clinic Foundation (Cleveland, OH)
Date of First Priority Issue: Saturday April 28th, 2001
Patent Number: 6720340
This patent teaches that nicotine may be used for mobilization of stem cells. It covers endothelial precursor cells as well. Inventors: Cooke, John (Palo Alto, CA); Johnson, Frances Lauri (Portola Valley, CA); Pathak, Anjali (Campbell, CA); Jang, James (San Bruno, CA); Tsao, Phillip (San Jose, CA); Heeschen, Christopher (Menlo Park, CA)
Assignee: The Board of Trustees of the Leland Stanford, Jr. Unversity (Palo Alto, CA)
Date of First Priority Issue: Wednesday July 28th, 1999
Patent Number: 6719970
This patent discloses chondrocytes and suitable biocompatible polymers that may be administered in vivo for the regeneration, or de novo generation of cartilage tissue. Inventors: Costantino, Henry R. (Grantham, NH); Bonassar, Lawrence J. (Acton, MA); Tracy, Mark A. (Arlington, MA)
Assignee: Alkermes Controlled Therapeutics, Inc. (Cambridge, MA); University of Massachusetts (Boston, MA)
Date of First Priority Issue: Monday July 10th, 2000
Patent Number: 6719969
This patent teaches that CXC chemokines are potent stimulators of hepatic stem cells and hepatic regeneration. Chemokines covered include MIP-2, ENA-78 and IL-8. Inventors: Hogaboam, Cory M. (Ann Arbor, MI); Bone-Larson, Cynthia L. (Petersburg, MI); Simpson, Kenneth J. (Edinburgh, GB); Lukacs, Nicholas W. (Brighton, MI); Kunkel, Steven L. (Ann Arbor, MI); Colletti, Lisa M. (Webberville, MI); Strieter, Robert M. (Sherman Oaks
Assignee: The Regents of The University of Michigan (Ann Arbor, MI); University Court of The University of Edinburgh (GB)
Date of First Priority Issue: Monday August 9th, 1999
2 Comments
Patent Number: 6719805
This patent seems to cover the use of angiogenic stimuli, together with stem cells for treatment of muscle disorders including disorders associated with the myocardium. This patent may influence the current trials ongoing for treatment of myocardial dysfunction with stem cells and angiogenic stimuli. Inventor: Ahern, John E. (Melrose, MA)
Assignee: C. R. Bard, Inc. (Murray Hill, NJ)
Date of First Priority Issue: Wednesday June 9th, 1999
Patent Number: 6713247
This patent covers neuronal cell and neuronal stem cell lines that are conditionally immortal. These may be used for therapeutic purposes, and also for in vitro drug discovery. Inventors: Sah, Dinah W. Y. (San Diego, CA); Gage, Fred H. (La Jolla, CA); Ray, Jasodhara (San Diego, CA) )
Assignee: Signal Pharmaceuticials, Inc. (San Diego, CA
Date of First Priority Issue: Tuesday September 3rd, 1996
Patent Number: 6713245
This patent covers methods of preserving neural stem cells and various types of neuronal cells so that they may be transported for use in treatment of neurological disorders. One of the drawbacks of such cell therapy is the issue of rejection by the allogeneic immune system, this has been addressed in studies using encapsulation, or using stereotactic implantation into the brain, since the... Inventors: Koopmans, Jan (University of Groningen, NL); Jacoby, Douglas B. (Wellesley, MA); Dinsmore, Jonathan (Brookline, MA)
Assignee: Diacrin, Inc. (Charlestown, MA); University Hospital Groningen (NL)
Date of First Priority Issue: Monday July 6th, 1998
Patent Number: 6713084
This patent covers methods of healing skin after a laser wound through the application of stem cells, or various epithelial cells that may be either allogeneic or xenogeneic. Inventors: Kuri-Harcuch, Walid (Brookline, MA); Bolivar-Flores, Yesid (Delegacion Tlalpan, MX)
Assignee: Celadon Science, LLC (Wellesley, MA)
Date of First Priority Issue: Friday January 17th, 1997
Patent Number: 6713065
This patent covers the use of hedgehog proteins for stimulation of hematopoiesis and angiogenesis. The hedgehog proteins are critically involved in embryogenesis and developmental biology. Given the numerous similarities between stem cells and embryonic cells in general, the notion that hematopoietic stem cells still respond to embryonic signals is intriguing. Inventors: Baron, Margaret H. (New York, NY); Farrington, Sarah M. (Cambridge, MA); Belaoussoff, Maria (Gottingen, DE)
Assignee: President and Fellows of Harvard College (Cambridge, MA)
Date of First Priority Issue: Monday February 10th, 1997
Patent Number: 6713052
This patent teaches ways of mobilizing hematopoietic stem cells using the chemokine know as beta-8. Mobilization may be performed for harvesting of stem cells from peripheral blood by leukopheresis, or it may be performed for the purposes of expanding the number of stem cells in circulation when there is a wound in the body that is attracting stem cells. Such a wound could be the lesion of a... Inventors: White, John R. (Coatsville, PA); Pelus, Louis (Richboro, PA); Li, Haodong (Germantown, MD); Kreider, Brendt L. (Germantown, MD)
Assignee: Human Genome Sciences, Inc. (Rockville, MD); SmithKline Beecham Corporation (Philadelphia, PA)
Date of First Priority Issue: Tuesday October 24th, 1995
Patent Number: 6709864
This patent covers the generation of mesenchymal stem cells from adipose tissue. This is an interesting situation since Cytori and others have patents on stem cells from the adipose tissue, and Osiris has patents on mesenchymal stem cells from any tissue. It will be interesting to watch if there is litigation coming out of this patent in light of other patents and clinical trials. For... Inventors: Pittenger, Mark F. (Severna Park, MD); Beck, Stephen C. (Reistertown, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Tuesday July 30th, 1996
Patent Number: 6703017
This patent covers the treatment of diabetes using islets and/or islet-like cells that are generated from stem cells residing in the pancreatic duct. Inventors: Peck, Ammon B. (Gainesville, FL); Cornelius, Janet (Gainesville, FL); Ramiya, Vijayakumar K. (Gainesville, FL)
Assignee: Ixion Biotechnology, Inc. (Alachua, FL); University of Florida (Gainesville, FL)
Date of First Priority Issue: Thursday April 28th, 1994
Patent Number: 6699471
This patent teaches various forms of hyaloronic acid that may be administered in combination with stem cells for localization and better function of the stem cell. This patent is interesting in light of US patent application # 20060069064 which teaches "Methods for facilitating recovery of functions of endogenous or implanted or transplanted stem cells using hyaluronic acid" Inventors: Radice, Marco (Modena, IT); Pastorello, Andrea (Abano Terme, IT); Pavesio, Alessandra (Padua, IT); Callegaro, Lanfranco (Thiene, IT)
Assignee: Fidia Advanced Biopolymers, SRL (Abano Terme, IT)
Date of First Priority Issue: Tuesday December 21st, 1999
Patent Number: 6696074
This patent teaches how to make scaffolds that are useful for subsequent seeding with stem cells and generating tissues. The scaffolds seem to be made from decellularized tissues, including fetal and xenogeneic (in some cases) sources. Inventors: Dai, Jianwu (Boston, MA); Bell, Eugene (Boston, MA); Russakovsky, Vladimir (Boston, MA)
Assignee: TEI Biosciences, Inc. (Boston, MA)
Date of First Priority Issue: Monday December 4th, 2000
Patent Number: 6695879
This patent provides compositions of matter useful for the treatment of cardiac valve dysfunctions. The compositions may be seeded with stem cells, or may be implanted as scaffolds that naturally become cellularized. Inventor: Bell, Eugene (Boston, MA)
Assignee: TEI Biosciences, Inc. (Boston, MA)
Date of First Priority Issue: Tuesday October 20th, 1998
Patent Number: 6692958
This patent provides methods of expanding cord blood cells to generate T cells in vitro, and the subsequent use of the T cells for immunotherapy. The patent also covers other types of lymphocytes such as B cells, and NK cells. Inventors: Sekine, Teruaki (Tokyo, JP); Ito, Kiminari (Hokkaido, JP); Shimizu, Norio (Yamanashi, JP); Bamba, Kenzo (Ibaraki, JP); Yamaguchi, Tomohiro (Saitama, JP); Kuroiwa, Yasuyuki (Ibaragi, JP)
Assignee: Humantec Ltd. (Ibaraki-ken, JP)
Date of First Priority Issue: Monday December 4th, 2000
Patent Number: 6692761
This patent covers scaffolds that can be seeded with cells and/or growth factors so as to promote regeneration of cartilage. Inventors: Mahmood, Tahir (Cambridge, MA); Riesle, Jens Uwe (Amsterdam, NL); van Blitterswijk, Clemens Antoni (Hekendorp, NL)
Assignee: IsoTis N.V. (Bilthoven, NL)
Date of First Priority Issue: Wednesday February 10th, 1999
Patent Number: 6692738
This patent covers compositions of matter that can be used to deliver proteins to tissue. The matrices described in this patent can be seeded with cells for delivery of stem cells together with the therapeutic protein. In some embodiements of the patent the therapeutic protein can be an antibody, a growth factor, or a cytokine. Inventors: MacLaughlin, David T. (Saugus, MA); Vacanti, Joseph P. (Winchester, MA); Donahoe, Patricia K. (Boston, MA); Masiakos, Peter T. (Boston, MA)
Assignee: The General Hospital Corporation (Boston, MA)
Date of First Priority Issue: Thursday January 27th, 2000
Patent Number: 6690970
This patent covers the use of stem cells and products of stem cells as "biological pacemakers" so as to ensure that the electrical pulses of the heart are appropriately coordinated. Inventors: Taheri, Syde A. (Buffalo, NY); Leonhardt, Howard J. (Weston, FL)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday October 6th, 2000
Patent Number: 6689351
This patent teaches that the hematopoietic stem cell stimulatory cytokine GM-CSF, which is clinically used today, can also be used for acceleration of wound healing when applied topically. This brings the question of what other stem cell stimulatory cytokines may be used to stimulate regeneration or healing of other tissues? The sky is the limit !! Inventors: Pierce, Glenn (Thousand Oaks, CA); Altrock, Bruce W. (Newbury Park, CA) )
Assignee: Amgen Inc. (Thousand Oaks, CA
Date of First Priority Issue: Friday February 22nd, 1991
Patent Number: 6689165
This patent teaches how to accelerate healing of epithelial cells of the cornea through administration of an optical polymer that consists, in part of a hydrogel. The devices and compositions thought are useful for stimulation of stem cells associated with production of corneal epithelial cells. Inventors: Jacob, Jean T. (New Orleans, LA); Bi, Jingjing (River Ridge, LA)
Assignee: Board of Supervisors of Louisana State University and Agricultural and Mechanical College (Baton Rouge, LA)
Date of First Priority Issue: Wednesday May 31st, 2000
Patent Number: 6686388
Like many biological pathways activated in stem cells, the pathways associated with hedgehog signalling are also associated with cancer. In this invention methods of modulating the hedgehog signalling pathway are provided that can be useful for controlling normal stem cells, as well as cancer cells. Inventors: Dudek, Henryk (Wellesley, MA); Ji, Benxiu (Sharon, MA)
Assignee: Curis, Inc. (Cambridge, MA)
Date of First Priority Issue: Wednesday January 13th, 1999
Patent Number: 6686198
This patent teachs how to induce neural differentiation of stem cells through activation of the activin receptor associated pathways. One wonders if this patent is also applicable to bone marrow stem cells, or bone marrow stem cells induced to dedifferentiated by epigenetic modification. Inventors: Melton, Douglas A. (Lexington, MA); Hemmati-Brivanlou, Ali (New York, NY)
Assignee: President and Fellows of Harvard College (Cambridge, MA)
Date of First Priority Issue: Thursday October 14th, 1993
Patent Number: 6686159
Telomerase induces cellular escape from sensence and is important for stem cell activity, as well as for cancer to becoming immortal. In this patent agents are identified that suppress the suppressor of telomerase, therapy allowing various types of cells to express telomerase and thereby escape senescence. Inventors: Andrews, William H. (Reno, NV); Foster, Christopher A. (Carmichael, CA); Fraser, Stephanie (Sparks, NV); Mohammadpour, Hamid (Reno, NV)
Assignee: Sierra Sciences, Inc. (Reno, NV)
Date of First Priority Issue: Friday September 1st, 2000
Patent Number: 6685971
This patent teaches methods of increasing activity of stem cells in the gastrointestinal tract through administration of a beeswax based composition. This patent is useful for treatment of various gastrointestinal disorders. Inventor: Xu, Rongxiang (Arcadia, CA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Thursday June 28th, 2001
Patent Number: 6685936
In an effort to solidify its IP wall, Osiris decided not only to cover immune suppression by mesenchymal stem cells, but also the ability of mesenchymal stem cells to elicit other immunosuppressive cells. In this patent to ability of mesenchymal stem cells to activate/expand suppressor T cells, and other types of immune suppressor cells is covered. Inventors: McIntosh, Kevin (Ellicott City, MD); Klyushnenkova, Elena (Baltimore, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Tuesday October 12th, 1999
Patent Number: 6680199
This is one of the patents that teaches how to activate oocytes into parthenogenesis (ie without the male side). This patent is useful for generation of pathenogenically-derived embryonic stem cells. Inventors: Susko-Parrish, Joan L. (Monona, WI); Northey, David L. (Madison, WI); Leibfried-Rutledge, M. Lorraine (Madison, WI); Stice, Steven L. (DeForest, WI)
Assignee: Infigen, Inc. (Deforest, WI)
Date of First Priority Issue: Wednesday February 10th, 1993
Patent Number: 6680198
This patent teaches a type of neuronal stem cell that can be used for cell therapy of neurological disorders. Characterization of the cell is provided and includes expression of EGF and FGF receptors. Inventors: Snyder, Evan Y. (Jamaica Plain, MA); Wolfe, John H. (Philadelphia, PA); Kim, Seung U. (Vancouver, CA)
Assignee: The Children's Medical Center Corporation (Boston, MA); University of British Columbia (Vancouver, GB); University of Pennsylvania (Philadelphia, PA)
Date of First Priority Issue: Friday August 14th, 1998
Patent Number: 6679898
This patent provides a medical device and ways to use the device to extract corneal tissue and limbal stem cells from the eye of a donor. Inventor: Chuck, Roy S. (Irvine, CA)
Assignee: The Regents of the University of California (Oakland, CA
Date of First Priority Issue: Wednesday September 27th, 2000
Patent Number: 6678556
This patent covers ways of in vivo transfecting cells by means of electroporation without inducing inflammatory or tissue damaging changes. I have included this in the "expansion" section of the StemCellPatents.Com database since electroporation can be used for cytoplasmic transfect of cytoplasm from embryonic stem cells into various tissues, so as to endow the tissues with stem cell like... Inventors: Nolan, Edward (San Diego, CA); Rabussay, Dietmar P. (Solana Beach, CA); Widera, Georg (Del Mar, CA); Zhang, Lei (San Diego, CA) A)
Assignee: Genetronics, Inc. (San Diego, C
Date of First Priority Issue: Monday July 13th, 1998
Patent Number: 6677307
This patent discloses compositions of transforming growth factor alpha peptides and pharmaceutical preparations thereof. The patent is useful for expanding certain stem cells that respond to this cytokine. One potential use is for treatment of mucositis. Inventors: Twardzik, Daniel R. (Bainbridge Island, WA); Pernet, Andre (Lake Forest, IL); Felker, Thomas S. (Vashon, WA); Paskell, Stefan (Bainbridge Island, WA); Reno, John M. (Brier, WA)
Assignee: Kaleidos Pharma, Inc. (Seattle, WA)
Date of First Priority Issue: Thursday August 19th, 1999
Patent Number: 6676675
This patent provides biocompatible surfaces which can be used for growing nerve cells on that are derived from stem cells. This type of technology will be critical for generation of neural networks in vitro and in vivo, and eventually for the ability to expand central nervous system function. Inventors: Mallapragada, Surya K. (Ames, IA); Heath, Carole (Seattle, WA); Shanks, Howard (Ames, IA); Miller, Cheryl A. (Irvine, CA); Jeftinija, Srdija (Ames, IA)
Assignee: Iowa State University Research Foundation, Inc. (Ames, IA)
Date of First Priority Issue: Wednesday April 19th, 2000
Patent Number: 6676655
This patent provides frequencies of light that effect extracellular and cellular components. This patent is useful for regulation of stem cells after implantation into a host through non-pharmacological means. Inventor: McDaniel, David H. (Virginia Beach, VA)
Assignee: Light BioScience L.L.C. (Virginia Beach, VA)
Date of First Priority Issue: Monday November 30th, 1998
Patent Number: 6673904
This is a composition of matter patent that can be used for developing into a pharmaceutical for stem cell stimulation and differentiation. The composition provided is a stimulator of stem cells, both of hematopoietic and non-hematopoietic lineages. Inventors: Nishikawa, Mitsuo (Gunma, JP); Labat, Ivan (Mountain View, CA); Drmanac, Radoje T. (Palo Alto, CA); Tang, Y. Tom (San Jose, CA); Chao, Cheng-Chi (Cupertino, CA); Mize, Nancy (Mountain View, CA); Childs, John (Sunnyvale, CA)
Assignee: Kirin Beer Kabushiki Kaisha (Tokyo, JP); Hyseq, Inc. (Sunnyvale, CA)
Date of First Priority Issue: Saturday December 23rd, 2000
Patent Number: 6673606
This patent teaches how to induce the differentiation of mesenchymal stem cells into oligodendrocyte cells. These oligodendrocytes may be used for treatment of various metabolic and nervous system disorders. Inventors: Tennekoon, Gihan (Wynnewood, PA); Coyle, Andrew J. (Philadelphia, PA); Grinspan, Judith (Ardmore, PA); Beesley, Jackie S. (West Sussex, GB)
Assignee: The Children's Hospital of Philadelphia (Philadelphia, PA
Date of First Priority Issue: Wednesday April 12th, 2000
Patent Number: 6673604
This is a composition patent covering myocardial and fibroblast cell preparations that are useful for administration in the post-infarct myocardium. This approach is interesting and a similar approach seems to have been used clinically by the company Bioheart. Inventor: Edge, Albert (Cambridge, MA)
Assignee: Diacrin, Inc. (Charlestown, MA)
Date of First Priority Issue: Friday July 23rd, 1999
Patent Number: 6673587
This is a composition of matter patent on several proteins that function as histone deacetylases. Histone deacetylases act at an epigenetic level through modifying histones and controlling gene transcription. Manipulation of histone deacetylase activity can be used to change cellular fate. Inventors: Evans, Ronald M. (La Jolla, CA); Kao, Hung-Ying (San Diego, CA); Downes, Michael (San Diego, CA); Ordentlich, Peter (San Diego, CA)
Assignee: The Salk Institute for Biological Studies (La Jolla, CA)
Date of First Priority Issue: Friday August 11th, 2000
Patent Number: 6670123
This patent teaches the identification of stem cells by virtue of expression of the gene known as KIAA0918. Specifically, the claims are aimed at hematopoietic stem cells and detection by hybridization.
It will be interesting to identify the protein and function of the protein encoded by the gene KIAA0918. Inventors: Belyavsky, Alexander (New York, NY); Shmelkov, Sergey (Union City, NJ); Visser, Jan (New York, NY)
Assignee: New York Blood Center, Inc. (New York, NY)
Date of First Priority Issue: Friday November 3rd, 2000
Patent Number: 6671558
This patent covers a method of preventing heart failure after a myocardial infarction through the administration of stem cells, together with a device that induces electrical signals. In some embodiments the stem cells are transfected with genetic material to modify functions (ie increased contractility: transfect with SERCA-2, increase angiogenesis: transfect with FGF, etc). Inventors: Soykan, Orhan (Shoreview, MN); Donovan, Maura G. (St. Paul, MN)
Assignee: Medtronic, Inc. (Minneapolis, MN)
Date of First Priority Issue: Friday November 7th, 1997
Patent Number: 6670397
This patent has some pretty broad claims. It teaches to repair tissue by inducing de-differentiation of cells, and then stimulating redifferentiation into another histological cell type. This patent may be very strong ammunition against companies active in the area of stem cell therapy that have not licensed it. Inventor: Baranowitz, Steven (Apt. 519 Wyncote, PA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Sunday August 29th, 1999
Patent Number: 6667391
This patent provides peptides and various compositions of matter that are useful for stimulation of stem cell proliferation. It is unclear what the biological analogues of these peptides are, but they seem very useful for anyone seeking to enter the area of stem cell therapeutics. Inventors: Drmanac, Radoje T. (Palo Alto, CA); Labat, Ivan (Mountain View, CA); Tang, Y. Tom (San Jose, CA); Chao, Cheng-Chi (Cupertino, CA); Mize, Nancy K. (Mountain View, CA); Childs, John (Sunnyvale, CA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday January 21st, 2000
Patent Number: 6667034
This patent covers ways of ex vivo stimulation of bone marrow and other hematopoietic cells so that after transplantation they may engraft faster. Some of the methods thought in the patent include ways of stimulating production of specific blood cell lineages that may be more important for the specific condition being treated by hematopoietic stem cell transplantation. Inventors: Palsson, Bernhard O. (La Jolla, CA); Armstrong, R. Douglas (Ann Arbor, MI); Clarke, Michael F. (Ann Arbor, MI); Emerson, Stephen G. (Ann Arbor, MI)
Assignee: The Regents of the University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Thursday June 15th, 1989
Patent Number: 6666878
This patent provides various frequencies of light, and ways of administering light so as to stimulate proliferation and differentiation of the stem cell that is responsible for hair growth. It will be interesting to see if these methods and devices provided can also stimulate other types of stem cells. The use of light may also be beneficial for stimulating proliferation of cancer stem cells... Inventor: Carlgren, Stefan (Stockholm, SE)
Assignee: Inca Asset Management S.A. (Geneva, CH)
Date of First Priority Issue: Wednesday June 6th, 2001
Patent Number: 6664039
This patent provides a peptide sequence composition of matter that is useful for treatment of neurodegeneration, in part through the stimulation of neural stem cell proliferation. Agents involved in stimulation of neural stem cells are important not only for obvious reasons, but also because they may also stimulate hematopoiesis. The specific peptide claimed in this patent is called "very long... Inventors: Benzer, Seymour (San Marino, CA); Min, Kyung-Tai (Pasadena, CA)
Assignee: California Institute of Technology (Pasadena, CA)
Date of First Priority Issue: Monday December 14th, 1998
Patent Number: 6660260
This patent coves a heart valve that secretes nitric oxide. This patent is useful for treatment of various diseases associated with valvular dysfunction such as aortic insufficiency and mitral stenosis. The roles of nitric oxide in the cardiovascular system range from vasodilation, to inhibition of apoptosis. Inventor: Rajamannan, Nalini M. (Rochester, MN)
Assignee: Mayo Foundation for Medical Education and Research (Rochester, MN)
Date of First Priority Issue: Tuesday September 21st, 1999
Patent Number: 6659950
As stem cell therapy advances, it becomes more and more important to develop methods of administering the stem cells. In this particular invention a medical device is provided that can inject stem cells, as well as growth factors and other cells, into the epicardium. This of course is useful for many cardiac conditions. Inventor: Taheri, Syde (Buffalo, NY)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday March 2nd, 2001
Patent Number: 6653113
This patent teaches ways of generating knockout mice through targeting of the mouse embryonic stem cell with the various targeting constructs and approaches that are disclosed. Inventors: Berns, Anton (Spaarndam, NL); Robanus Maandag, Els (Haarlem, NL); te Riele, Hein (Amsterdam, NL)
Assignee: Genpharm International, Inc. (Mountain View, CA)
Date of First Priority Issue: Tuesday August 20th, 1991
Patent Number: 6656708
This patent provides a novel protein that is capable of stimulating stem cell proliferation and differentiation. The protein is called human growth differentiation factor (hGDF3-2). This patent is useful for generation of novel stem cell activating therapeutics. Additionally, it may be used to generate competition to the currently used stem cell stimulatory cytokines. Inventors: Yu, Long (Shanghai, CN); Zhang, Honglai (Shanghai, CN); Fu, Qiang (Shanghai, CN); Dai, Fangyan (Shanghai, CN); Zhao, Shouyuan (Shanghai, CN)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Tuesday September 22nd, 1998
Patent Number: 6649352
After chemotherapy or radiation therapy, the myeloid compartment of the immune response is suppressed, due to destruction of the myeloid stem cell compartment. This patent provides a kit that allows the determination of myelosuppression, and therefore can be used to guide the amount of myelo-stimulatory therapy (ie G-CSF) that should be administered. The kit measures alone or in combination... Inventors: Blumenthal, Rosalyn D. (Belleville, NJ); Lew, Walter (Caldwell, NJ); Juweid, Malik (Bloomfield, NJ); Alisauskas, Rita (Hopatcong, NJ); Ying, Zhiliang (East Brunswick, NJ); Goldenberg, David M. (Mendham, NJ)
Assignee: Center for Molecular Medicine and Immunology (Belleville, NJ)
Date of First Priority Issue: Friday January 29th, 1999
Patent Number: 6653134
This patent teaches that one can induce the differentiation of stromal stem cells into neural cells, through the culture of the stromal cells with differentiated neural cells. This patent is useful not only for generating cells for treatment of neurological conditions, but also may be used to begin elucidating what the specific signals are that the neural cells use to teach the stromal stem cells... Inventors: Prockop, Darwin J. (Philadelphia, PA); Stokes, David G. (Willow Grove, PA); Azizi, S. Ausim (Philadelphia, PA)
Assignee: CP Hahnemann University (Philadelphia, PA)
Date of First Priority Issue: Sunday March 28th, 1999
Patent Number: 6652583
This patent teaches how to use stem cells and other differentiated cells in order to generate a heart valve that can be used for replacement of defective valves in patients suffering from various valvular abnormalities. The advantage of this biological valve is that it conceptually is longer lasting than completely artificial or xenogeneic valves. Inventors: Hopkins, Richard A. (Providence, RI); Hoffman-Kim, Diane (Providence, RI)
Assignee: Rhode Island Hospital (Providence, RI)
Date of First Priority Issue: Tuesday April 4th, 2000
Patent Number: 6649189
This patent covers a method of administering a hematopoeitic stem cell activatory factor into a host using a depot-like formulation. One of the problems of protien administration into humans is that many proteins have a short half live and therefore the pharmacokinetic profiles may not be adequate for stimulation of the biological response needed. This patent seems to overcome this problem. Inventors: Talmadge, James E. (Bellevue, NE); Rosenthal, Gary J. (Louisville, CO); Etter, Jeffrey B. (Boulder, CO)
Assignee: RxKinetix, Inc. (Louisville, CO)
Date of First Priority Issue: Monday June 26th, 2000
Patent Number: 6648849
This patent covers a medical device that can be used for administering stem cells together with various polymers and depot-like formulations into a host. The administration of stem cells together with growth factors is useful since this can allow the stem cells to remain in an "activated" state and accelerate their process of interacting with the host cells. Inventors: Tenhuisen, Kevor S. (Clinton, NJ); Rosenblatt, Joel (Watchung, NJ); McAllen, III, John (Point Pleasant, NJ)
Assignee: Ethicon, Inc. (Somerville, NJ)
Date of First Priority Issue: Wednesday June 27th, 2001
Patent Number: 6645763
This patent has one claim that covers a specific mesenchymal stem cell population that is immortalized and appears to contain a gene associated with immortalization. Inventors: Kobayashi, Naoya (Okayama 703-8261, JP); Leboulch, Philippe (Charlestown, MA); Tanaka, Noriaki (Okayama 719-0252, JP); Fujiwara, Toshiyoshi (Okayama 703-8281, JP)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Monday November 12th, 2001
Patent Number: 6645727
This patent covers the antibody kit that can be used for negatively depleting non-mesenchymal stem cell populations from a population of cells in order to obtain a substantially purified population of mesenchymal stem cells. Inventors: Thomas, Terry (Vancouver, CA); Clarke, Emer (Vancouver, CA)
Assignee: StemCell Technologies Inc. (Vancouver, CA)
Date of First Priority Issue: Friday May 26th, 2000
Patent Number: 6645489
This patent covers ways for the in vivo culture and expansion of hematopoietic stem cells. The advantage of expanding such hematopoietic stem cells in vivo is that they are subjected to more "biological" conditions and at least theoretically should work better than other in vitro systems. Inventors: Pykett, Mark J. (Boxford, MA); Rosenzweig, Michael (Boston, MA); Kaplan, Richard B. (Beverly Hills, CA)
Assignee: Cytomatrix, LLC (Woburn, MA)
Date of First Priority Issue: Thursday September 25th, 1997
Patent Number: 6642216
This patent covers inhibitors of the isoprenoid pathway which can be used for stimulation of osteoblast and other bone stem cells in order to stimulate growth of bone. Inventors: Gasper, Shirley R. (Seattle, WA); West, Robert R. (Seattle, WA); Martinez, Theresa (Greenback, WA); Robbins, Kirk G. (Renton, WA); McKernan, Patricia A. (Woodinville, WA); Baindur, Nand (Edmonds, WA); Labroo, Virender M. (Bangalore, IN); Mundy, Gregory R.
Assignee: ZymoGenetics Corporation (Seattle, WA); OsteoScreen, Inc. (San Antonio, TX)
Date of First Priority Issue: Friday December 13th, 1996
Patent Number: 6642049
This patent covers culture techniques and cells that are useful for the growth and expansion of primitive hematopoietic stem cells. One of the interesting aspects of this patent is that it uses human endothelial cells that are derived from the brain as feeder cells. Given all of the interesting correlations between brain cells and bone marrow hematopoietic stem cells, this patent is particularly... Inventors: Chute, John P. (San Francisco, CA); Saini, Abha A. (Collegeville, PA); Chute, Dennis J. (Los Angeles, CA); Davis, Thomas A. (Newton, PA)
Assignee: The United States of America as represented by the Secretary of the Navy
Date of First Priority Issue: Friday December 4th, 1998
Patent Number: 6642048
This patent is part of Geron's armamentarium of patents covering not only embryonic stem cells (licensed from WARF), but also ways of growing them in absence of undefined materials. In this particular patent feeder-free culture methods for maintaining embryonic stem cells, as well as "pluripotent stem cells" are covered. Inventors: Xu, Chunhui (Cupertino, CA); Gold, Joseph D. (San Francisco, CA)
Assignee: Geron Corporation (Menlo Park, CA)
Date of First Priority Issue: Tuesday January 11th, 2000
Patent Number: 6638765
This patent covers methods of dedifferentiating cells, and redifferentiating them in order to produce islet-like cells for the treatment of diabetes. Inventor: Rosenberg, Lawrence (Cote St-Luc, CA)
Assignee: McGill University (Montreal, CA)
Date of First Priority Issue: Thursday February 4th, 1999
Patent Number: 6638763
This patent covers a specific type of early neuronal stem cell that is viable for a sigificant period of time after the host dies. These cells are transplantable and possess some properties of other neural stem cells, however in the patent, unique phenotypic and functional characteristics are provided. Inventors: Steindler, Dennis A. (Memphis, TN); Laywell, Eric D. (Memphis, TN); Kukekou, Valery G. (Memphis, TN); Thomas, L. Brannon (Johnson City, TN)
Assignee: University of Tennessee Research Foundation
Date of First Priority Issue: Tuesday January 7th, 1997
Patent Number: 6638501
This patent covers the use of neural stem cells for enhancing activity of hematopoietic stem cells. This patent attests to the similarity, if not synergy, between the neural stem cell system and the hematopoietic stem cells system. Inventors: Bjornson, Christopher R. (Calgary, CA); Rietze, Rod L. (Calgary, CA); Reynolds, Brent A. (Saltspring, CA); Vescovi, Angelo L. (Milan, IT)
Assignee: Neurospheres Holdings Ltd. (Alberta, CA)
Date of First Priority Issue: Friday June 19th, 1998
Patent Number: 6637437
This patent provides novel cellular "fillers" that are generated in culture specifically for the patient, and administered during head and neck surgery in order to "fill the gap". Inventors: Hungerford, David S. (Cockeysville, MD); Frondoza, Carmelita G. (Woodstock, MD); Shikani, Alan H. (Ruxton, MD); Domb, Abraham J. (Efrat, IL)
Assignee: Johns Hopkins University (Baltimore, MD); Chondros, Inc. (Baltimore, MD)
Date of First Priority Issue: Wednesday April 8th, 1998
Patent Number: 6635802
This patent teaches the use of antiapoptotic agents, and serum starvation, of the recipient cells for nuclear transfer. This can be used to generate autologous embryonic stem cells. Inventors: Piedrahita, Jorge A. (College Station, TX); Lee, Chang-Kyu (Suwon, KR); Weaks, Regina (Richardson, TX); Bazer, Fuller (College Station, TX)
Assignee: The Texas A&M University System (College Station, TX)
Date of First Priority Issue: Friday October 10th, 1997
Patent Number: 6632666
This patent provides novel cellular and tissue storage compositions that are useful for not only stem cells but other cellular therapies. Inventors: Baust, John M. (Vestal, NY); Van Buskirk, Robert (Apalachin, NY); Baust, John G. (Candor, NY)
Assignee: BioLife Solutions, Inc. (Binghamton, NY)
Date of First Priority Issue: Friday January 14th, 2000
Patent Number: 6632620
This patent provides an antibody that recognizes both epidermal stem cells, as well as prostate cancer cells. Inventor: Makarovskiy, Andrew N. (Mendon, MA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Thursday June 22nd, 2000
Patent Number: 6632424
This patent is part of Immunex's wall of IP surrounding the stem cell stimulatory cytokine flt3 ligand. Inventors: Lyman, Stewart D. (Seattle, WA); Beckmann, Patricia M. (Poulsbo, WA)
Assignee: Immunex Corporation (Seattle, WA)
Date of First Priority Issue: Monday May 24th, 1993
Patent Number: 6630470
G-CSF has many properties associated with stimulation of stem cells. In this patent compositions of matter for mimetics of G-CSF are provided. This patent can be used for treatment of neutropenia and other conditions that G-CSF is currently used for. Inventors: Luengo, Juan I (Audubon, PA); Duffy, Kevin J (Norristown, PA)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Date of First Priority Issue: Friday May 22nd, 1998
Patent Number: 6630457
This patent teaches new compositions of matter based on hyaluronic acid that are useful for the administration of stem cells. Inventors: Aeschlimann, Daniel (Madison, WI); Bulpitt, Paul (Madison, WI)
Assignee: Orthogene LLC (Sausalito, CA)
Date of First Priority Issue: Friday September 18th, 1998
Patent Number: 6630349
This patent provides trophoblast cell lines that are of murine origin. Since the trophoblast is similar to cancer cells in terms of immune suppression and metastizing ability, this patent is useful for the generation of a xenogeneic cancer vaccine, similar to XenoVax. The fact that trophoblast stem cells are provided is useful since this can be a good off the shelf starting population for... Inventors: Rossant, Janet (Toronto, CA); Tanaka, Satoshi (Tokyo, JP); Kunath, Tilo (Toronto, CA)
Assignee: Mount Sinai Hospital (Toronto, CA)
Date of First Priority Issue: Wednesday September 23rd, 1998
Patent Number: 6627759
This patent provides ways of extracting stem cells based on their expression of aldehyde dehydrogenase. This patent is in clinical trials by the company Aldegen. Inventors: Smith, Clayton A. (Tampa, FL); Colvin, Michael (Chapel Hill, NC); Storms, Robert W. (Durham, NC); Ludeman, Susan M. (Durham, NC)
Assignee: Duke University (Durham, NC)
Date of First Priority Issue: Thursday December 17th, 1998
Patent Number: 6627191
This patent teaches the use of antibodies to TGF beta in order to stimulate hematopoietic stem cell renewal. Hematopoietic stem cells generation secrete autocrine TGF beta which inhibits their proliferation. This patent inhibits the inhibitor thus attaining stem cell expansion. Inventors: Bartelmez, Stephen H. (Seattle, WA); Sitnicka, Ewa (Lund, SE); Ruscetti, Frank (New Market, MD)
Assignee: Seattle Biomedical Research Institute (Seattle, WA)
Date of First Priority Issue: Monday January 25th, 1999
Patent Number: 6623733
While some patents use cell supernatant for induction of biological activities, this patent goes all out and uses cell lysates! This patent covers the use of various cell lysates, including of stem cells, in order to augment stem cell proliferation as well as angiogenesis. Inventors: Hossainy, Syed F. A. (Fremont, CA); Steward, Jeffrey A. (Lakewood, CO); Consigny, Paul M. (Sunnyvale, CA) )
Assignee: Advanced Cardiovascular Systems, Inc. (Santa Clara, CA)
Date of First Priority Issue: Wednesday June 27th, 2001
Patent Number: 6613568
This patent teaches the generation of human hematopoietic stem cells from human embryonic stem cells by the simple culture of the embryonic stem cells on human bone amrrow stromal cells. Inventors: Kaufman, Dan S. (Madison, WI); Thomson, James A. (Madison, WI)
Assignee: Wisconsin Alumni Research Foundation (Madison, WI)
Date of First Priority Issue: Monday November 8th, 1999
Patent Number: 6613565
This patent covers the inhibition of hematopoietic stem cell differentiation through administration of the protein called "delta-like protein" (dlk).
The patent teaches not only the use for expansion, but also for protecting the stem cell compartment from the effects of chemotherapy or radiotherapy. Inventors: Witte, Larry (Stormville, NY); Pytowski, Bronislaw (New York, NY); Moore, Kateri A. (Princeton, NJ); Lemischka, Ihor R. (Princeton, NJ)
Assignee: ImClone Systems Incorporated (New York, NY); Trustees of Princeton University (Princeton, NJ)
Date of First Priority Issue: Friday March 1st, 1996
Patent Number: 6610656
This patent teaches the use of hedgehog proteins for inducing stem cells to differentiate into the chondocytic lineage (useful for repairing of cartilage). Inventors: Ingham, Philip W. (Summertown, GB); McMahon, Andrew P. (Lexington, MA); Tabin, Clifford J. (Cambridge, MA)
Assignee: President and Fellows of Harvard College (Cambridge, MA); Imperial Cancer Research Technology, Ltd. (London, GB)
Date of First Priority Issue: Thursday December 30th, 1993
Patent Number: 6610654
This patent provides peptides that inhibit stem cell proliferation, specific inhibition of hematopoietic stem cell proliferation is covered. These peptides are originally derived from bone marrow, but here are generated synthetically. They are useful for protection of the bone marrow stem cell compartment from agents that kill mitotically active cells. Inventors: Tsyrlova, Irena (Gaithersburg, MD); Wolfe, Stephen D. (Rockville, MD)
Assignee: Wellstat Therapeutics Corporation (Gaithersburg, MD)
Date of First Priority Issue: Wednesday March 31st, 1993
Patent Number: 6610651
This patent covers peptides that specifically home to the lung. This patent is useful for delivering compounds that activate pulmonary stem cells to the lung. Since injected stem cells generally go to the lung, the administration of stem cell factors targeted to the lung using these peptides in combination with exogenous stem cells may be a new therapeutic approach. Inventors: Ruoslahti, Erkki (Rancho Santa Fe, CA); Pasqualini, Renata (Solana Beach, CA)
Assignee: The Burnham Institute (La Jolla, CA)
Date of First Priority Issue: Friday March 13th, 1998
Patent Number: 6610540
This patent teaches that low oxygen conditions may be used in the expansion and differentiation of undifferentiated mesencephalic stem cells. This is interesting since in the hematopoietic system the early stem cells also prefer growth in the relatively hypoxic niches of the marrow. Inventors: Csete, Marie (Ann Arbor, MI); Doyle, John (South Pasadena, CA); Wold, Barbara J. (San Marino, CA); McKay, Ron (Bethesda, MD); Studer, Lorenz (New York, NY)
Assignee: California Institute of Technology (Pasadena, CA); National Institutes of Health (Bethesda, MD)
Date of First Priority Issue: Wednesday November 18th, 1998
Patent Number: 6610538
This patent teaches how to generate corneal epithelium in vitro from stem cell sources. Inventors: De Luca, Michele (Ardea, IT); Pellegrini, Graziella (Ardea, IT)
Assignee: Provincia Italiana Della Congregazione Dei Figli Dell' Immacolata Concezione - Istituto Dermopatico Dell' Immacolata (Rome, IT)
Date of First Priority Issue: Tuesday September 25th, 2001
Patent Number: 6610535
This patent teaches the generation of islet like cells from pancreatic stem cells. It is useful for the treatment of diabetes.
One source of stem cells used in this patent is pancreatic duct stem cells. Inventors: Lu, Kuanghui (Brookline, MA); Pang, Kevin (Canton, MA); Rubin, Lee (Wellesley, MA)
Assignee: ES Cell International Pte Ltd. (SG)
Date of First Priority Issue: Thursday February 10th, 2000
Patent Number: 6610285
This patent covers a composition of matter that is a little similar to G-CSF in structure. The composition is useful for expansion of hematopoietic stem cells and several other types of cells. Inventor: Hirata, Yuichi (Niihari-mura, JP)
Assignee: Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP)
Date of First Priority Issue: Tuesday April 14th, 1998
Patent Number: 6607913
This is a composition of matter patent on molecules associated with embryonic differentiation of the hedgehog family. These molecules can provide a wealth of possibilities in regenerative medicine, especially given that they have receptors in numerous types of embryonic stem cells. Inventors: Ingham, Philip W. (Summertown, Oxford OX27L, GB); McMahon, Andrew P. (Lexington, MA); Tabin, Clifford J. (Cambridge, MA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Thursday December 30th, 1993
Patent Number: 6607720
This patent covers the use of embryonic stem cells as a source of stem cells for myocardial regeneration. Specifically, this patent covers genetically manipulated cells that are useful for these purposes. Inventors: Xiao, Yong-Fu (Wayland, MA); Morgan, James P. (Newton Centre, MA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Tuesday September 5th, 2000
Patent Number: 6607501
This patent teaches ways to continously perfuse a cell culture with plasma from a patient by performing a specialized "in vivo" plasmapheresis. Inventor: Gorsuch, Reynolds G. (Yountville, CA)
Assignee: Transvivo, Inc. (Napa, CA)
Date of First Priority Issue: Monday May 14th, 2001
Patent Number: 6605275
This patent covers preservation of cord blood cells. It is one of the patents that is actually generating revenue and has stood the test of litigation. Anyone doing cord blood banking in the US has to license this patent. Inventors: Boyse, Edward A. (Tucson, AZ); Broxmeyer, Hal E. (Indianapolis, IN); Douglas, Gordon W. (New York, NY)
Assignee: PharmaStem Therapeutics, Inc. (Wayne, PA)
Date of First Priority Issue: Thursday November 12th, 1987
Patent Number: 6602711
This is a patent for forming what is called "embryoid bodies" which are cellular aggregated generated from embryonic stem cells. Embryoid bodies can be subsequently dissociated in order to form various histological tissues useful for regenerative purposes. Inventors: Thomson, James A (Madison, WI); Marshall, Vivienne S. (Madison, WI); Swiergiel, Jennifer J. (Roscoe, IL)
Assignee: Wisconsin Alumni Research Foundation (Madison, WI)
Date of First Priority Issue: Monday February 21st, 2000
Patent Number: 6602680
This patent teaches that transfection of neuronal stem cells with dlx induces their differentiation into neurons that express GABA. This is useful for generation of cell therapies of neurodegenerative diseases. Inventors: Rubenstein, John L. (San Francisco, CA); Mione, Marina (London, GB); Anderson, Stewart (San Francisco, CA); Stuehmer, Thorsten (San Francisco, CA); Yun, Kyuson (San Francisco, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Date of First Priority Issue: Friday July 14th, 2000
Patent Number: 6599520
This patent provides matrices that are useful for treatment of bone disorders. The matrices may be seeded with stem cells to accelerate regeneration of bone. Inventors: Scarborough, Nelson L. (Andover, MA); Russell, James (Little Silver, NJ)
Assignee: Osteotech, Inc. (Eatontown, NJ)
Date of First Priority Issue: Friday October 13th, 2000
Patent Number: 6599274
This patent provides a medical device that can be utilized for administration of stem cells to localized areas of need using a catheter-based system. Inventors: Kucharczyk, John (Bishop, GA); Gillies, George T., N/A (Charlottesville, VA); Broaddus, William C., Fillmore, Helen L.
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Saturday January 1st, 2000
Patent Number: 6596690
This patent covers the new use of vasostatin in inhibiting the killing of stem cells from agents that are cytotoxic the mitotic cells such as radiation and chemotherapy. Inventors: Tosato, Giovanna (Bethesda, MD); Pike, Sandra E. (North Bethesda, MD); Yao, Lei (Rockville, MD)
Assignee: The United States of America as represented by the Department of Health and Human Services
Date of First Priority Issue: Tuesday October 6th, 1998
Patent Number: 6596688
This patent teaches that administration of the pregnancy associated compound human chorionic gonadotropin can stimulate hematopoietic stem cells. This patent is interesting in light of clinical trials that are ongoing by Stem Cell Therapeutics Inc that use hCG in combination with other compounds for post-stroke regeneration of neurons. Inventors: Gallo, Robert C. (Bethesda, MD); Bryant, Joseph (Rockville, MD); Lunardi-Iskandar, Yanto (Gaithersburg, MD)
Assignee: University of Maryland Biotechnology Institute (Baltimore, MD)
Date of First Priority Issue: Monday September 9th, 1996
Patent Number: 6596274
This patent provides materials that are biologically compatible, combined with bone marrow stem cells and/or progeny, for regenerative uses. Inventors: Abatangelo, Giovanni (Saccolongo, IT); Callegaro, Lanfranco (Thiene, IT)
Assignee: Fidia Advanced Biopolymers S.r.l. (Brindisi, IT)
Date of First Priority Issue: Monday November 20th, 1995
Patent Number: 6593309
This patent provides methods of increasing viability of cells used for the generation of embryonic stem cells. The patent is also useful for in vitro fertilization, where viability of oocytes is an issue. Inventors: Ellington, Joanna E. (Valleyford, WA); Oliver, Sylvia Adams (Spokane, WA)
Assignee: Bio-Origyn LLC (Spokane, WA
Date of First Priority Issue: Thursday October 19th, 1995
Patent Number: 6593290
This patent teaches that IGF-1 and/or FGF-2 are useful for the stimulation of ear hair stem cell expansion. This invention may be used for preventing hearing loss. FGF2 is approved in Japan for certain indications, including some associated with the ear. Inventor: Gao, Wei-Qiang (Foster City, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Date of First Priority Issue: Friday November 1st, 1996
Patent Number: 6592864
When cells are administered into the lung, many times they get stuck there. This invention takes advantage of this and claims the use of various cells, including stem cells, as vectors for genes that are beneficial for lung function. I believe that this inventor actually performed clinical trials by administration of iNOS transfected fibroblasts into patients with pulmonary hypertension. Inventor: Stewart, Duncan John (Toronto, Ontario, CA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday March 27th, 1998
Patent Number: 6592862
This patent essentially covers the induction of angiogenesis using the chemokine MCP-1. This patent would most likely synergize by combining administration of MCP-1 with hematopoietic stem cells and/or endothelial precursor cells. Inventors: Schaper, Wolfgang (Bad Nauheim/Rodgen, DE); Ito, Wulf D. (Luneburg, DE)
Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V. (Berlin, DE)
Date of First Priority Issue: Friday April 4th, 1997
Patent Number: 6589786
This patent teaches how to utilize distinct electromagnetic properties of stem cells for their isolation. Additionally it teaches how to purge a population of stem cells from contaminating cancer cells. Inventors: Mangano, Joseph A. (Vienna, VA); Eppich, Henry M. (Andover, MA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Thursday September 4th, 1997
Patent Number: 6589728
This patent is directed primarily at muscle stem cells and methods of expanding and isolating them by culturing at low oxygen tension. It seems like muscle stem cells are similar to hematopoietic and neuronal stem cells in the fact that they prefer conditions of low oxygen tension. Inventors: Csete, Marie (South Pasadena, CA); Doyle, John (South Pasadena, CA); Wold, Barbara (San Marino, CA)
Assignee: California Institute Of Technology (Pasadena, CA)
Date of First Priority Issue: Wednesday November 18th, 1998
Patent Number: 6589525
This patent teaches how to use various cells, including stem cells, for generation of a dental implant. Inventor: Gault, Philippe (Orleans, FR)
Assignee: Societe Anonyme Natural Implant (Brest, FR)
Date of First Priority Issue: Tuesday October 13th, 1998
Patent Number: 6583121
Gene therapy would greatly benefit from the ability to use stem cells as vectors. This patent addresses the problem of transfecting stem cells through the use of alpha viruses. Some clinical trials are already underway using alpha viruses. Inventors: Johnston, Robert E. (Chapel Hill, NC); Davis, Nancy L. (Chapel Hill, NC); Simpson, Dennis A. (Chapel Hill, NC)
Assignee: University of North Carolina at Chapel Hill (Chapel Hill, NC)
Date of First Priority Issue: Wednesday February 19th, 1997
Patent Number: 6586243
This patent teaches ways of generating dendritic cells from human hematopoietic stem cells and furthermore teaches how to pulse these dendritic cells with tumor antigens for use as cancer vaccines. This approach is similar in some ways to work performed by Eli Gilboa and the company Argos Therapeutics. Inventors: Cezayirli, Cem (Birmingham, AL); Silvers, Mel (North Miami Beach, FL)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Wednesday July 2nd, 1997
Patent Number: 6586192
This patent seems to cover a type of hematopoietic stem cell that is positive for expression of the marker KDR-1. Inventors: Peschle, Cesare (Rome, IT); Ziegler, Benedikt L. (Tuebingen, DE)
Assignee: Thomas Jefferson University (Philadelphia, PA); Instituto Superiore di Sanita (Rome, IT)
Date of First Priority Issue: Friday May 29th, 1998
Patent Number: 6583109
This patent covers derivatives of the human chorionic gonadotrophin, as well as hCG itself, for the stimulation of hematopoiesis, reduction of cancer, and reduction of HIV. Inventors: Gallo, Robert C. (Bethesda, MD); Bryant, Joseph (Rockville, MD); Lunardi-Iskandar, Yanto (Gaithersburg, MD)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Monday September 9th, 1996
Patent Number: 6582960
This patent teaches that FGF-2 can actually de-differentiate certain cells, and be used for the formation of chondrocytes. This would be useful for cartilage repair, as well as for various tissue regenerative purposes. Inventors: Martin, Ivan (Basel, CH); Freed, Lisa E. (Belmont, MA); Langer, Robert (Newton, MA); Vunjak-Novakovic, Gordana (Belmont, MA)
Assignee: Massachusetts Institute of Technology (Cambridge, MA)
Date of First Priority Issue: Friday September 18th, 1998
Patent Number: 6579313
The problem with various grafts and prosthesis is that the body starts reacting to them, either through restenosis, or complement activation, or thrombosis. This patent teaches unique ways to generate grafts and prosthetics through the implantation of stem cells and/or other cellular components in the structure to be introduced into the body. Inventors: Dzau, Victor J. (Newton, MA); Pratt, Richard E. (Newton, MA); Mann, Michael J. (Newton, MA); Ehsan, Afshin (Boston, MA); Griese, Daniel P. (Boston, MA)
Assignee: The Bringham and Women's Hospital (Boston, MA)
Date of First Priority Issue: Friday July 10th, 1998
Patent Number: 6576433
This patent teaches the use of HOX11 cell populations for identifying genes that control stem cell proliferation and differentiation. Inventors: Keller, Gordon M. (Denver, CO); Hawley, Robert G. (Toronto, CA); Choi, Kyunghee (Baltimore, MD)
Assignee: National Jewish Medical & Research Center (Denver, CO)
Date of First Priority Issue: Monday November 21st, 1994
Patent Number: 6569995
This patent covers an antibody that binds to GPCR involved in stem cell expansion and differentiation. Inventors: Weng, Zhigang (Los Angeles, CA); Witte, Owen N. (Sherman Oaks, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Date of First Priority Issue: Thursday November 13th, 1997
Patent Number: 6576465
This patent covers a type of stem cell, or actually a cell that helps bone generating stem cells to perform their function. Therapeutic applications of this cell range from in vitro expansion of bone stem cells, to in vivo induction of bone regeneration. Inventor: Long, Michael W. (Northville, MI)
Assignee: The Regents of the University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Monday November 10th, 1997
Patent Number: 6576464
It is well known that embryonic stem cells can cause cancers called teratomas. This patent teaches the transfection of embryonic stem cells with suicide genes so that after the embryonic stem cell or its differentiated progeny are introduced into the body, they can be induced to kill themselves after having performed their effects. Of course we all know that cells mutate and even one small... Inventors: Gold, Joseph D. (San Francisco, CA); Lebkowski, Jane S. (Portola Valley, CA)
Assignee: Geron Corporation (Menlo Park, CA)
Date of First Priority Issue: Monday November 27th, 2000
Patent Number: 6569654
This patent teaches ways of stimulating virtually all possible biological activities from mesenchymal stem cells through the contact with electroactive materials. Inventors: Shastri, Venkatram (Lower Gwynedd, PA); Martin, Ivan (Oberwil, CH); Langer, Robert (Newton, MA); Rahman, Nahid (Boston, MA)
Assignee: Massachusetts Institute of Technology (Cambridge, MA)
Date of First Priority Issue: Friday September 18th, 1998
Patent Number: 6569428
This patent provides the endothelial stem cell together with endothelial stem cell activatory genes as a pharmaceutical preparation for the stimulation of angiogenesis. This patent is useful for the treatment of ischemic disorders ranging from angina, to cerebral palsy, to peripheral vascular disease. Inventors: Isner, Jeffrey M. (Weston, MA); Asahara, Takayuki (Arlington, MA)
Assignee: St. Elizabeth's Medical Center of Boston, Inc. (Boston, MA)
Date of First Priority Issue: Friday November 8th, 1996
Patent Number: 6569427
This patent covers the use of cord blood cells. Any cord blood bank in the US has to license this patent or else Pharmastem will litigate as they have in the past. Inventors: Boyse, Edward A. (Tucson, AZ); Broxmeyer, Hal E. (Indianapolis, IN); Douglas, Gordon W. (New York, NY)
Assignee: PharmaStem Therapeutics, Inc. (Del Mar, CA)
Date of First Priority Issue: Thursday November 12th, 1987
Patent Number: 6569423
This patent teaches how to induce neuronal stimulation and production of new neurons through administration of Schwann cells that express the protein DELTA.SCIP. Inventor: Weinstein, David E. (Dobbs Ferry, NY)
Assignee: Albert Einstein College of Medicine of Yeshiva University (Bronx, NY)
Date of First Priority Issue: Monday April 19th, 1999
Patent Number: 6566579
This patent teaches ways of generating knockout mice through a new targeting vector. Alternatively, knockout human embryonic stem cells can be made by this approach for generation of new tissues. Inventors: Jaisser, Frederic (Malakoff, FR); Cohen-Tannoudji, Michel (Paris, FR); Robine, Sylvie (Vanves, FR); Choulika, Andre (Paris, FR); Louvard, Daniel (Sceaux, FR); Babinet, Charles (Paris, FR)
Assignee: Institut Pasteur (Paris, FR); Institut Curie (Paris, FR); Centre Nationale de la Recherche Scientifique (Paris, FR)
Date of First Priority Issue: Thursday April 18th, 1996
Patent Number: 6569421
This patent teaches how to treat neurological damage through administration of stem cells into the contralateral hemisphere of the brain. Inventor: Hodges, Helen (London, GB)
Assignee: Reneuron Limited (GB)
Date of First Priority Issue: Wednesday March 29th, 2000
Patent Number: 6569147
This patent teaches methods of administering cells and fluids in order to prevent inflammation and induce regeneration in areas of stent placement. Inventors: Evans, Douglas G. (Downingtown, PA); Nash, John E. (Chester Springs, PA)
Assignee: Kensey Nash Corporation (Exton, PA)
Date of First Priority Issue: Friday July 26th, 1996
Patent Number: 6566335
This patent teaches ways of mobilizing hematopoietic stem cells by administration of angiotensin I and/or II and/or analogues thereof. Inventors: Rodgers, Kathleen E. (Long Beach, CA); DiZerega, Gere (Pasadena, CA)
Assignee: University of Southern California (Los Angeles, CA
Date of First Priority Issue: Monday May 11th, 1998
Patent Number: 6565843
This patent teaches the use of the protein osteogenic protien-1 (OP-1) for the induction of tissue differentiation from stem cells. The invention is aimed primarily at induction of bone formation from osteogenic precursor cells. Inventors: Cohen, Charles M. (Medway, MA); Kuberasampath, Thangavel (Medway, MA); Pang, Roy H. L. (Medway, MA); Oppermann, Hermann (Medway, MA); Rueger, David C. (West Roxbury, MA)
Assignee: Curis, Inc. (Cambridge, MA)
Date of First Priority Issue: Sunday March 11th, 2001
Patent Number: 6562619
This patent teaches the utilization of ligands that activate gp130 for the induction of differentiation of embryonic germ stem cells. Inventors: Gearhart, John D. (Baltimore, MD); Shamblott, Michael Joseph (Baltimore, MD)
Assignee: The Johns Hopkins University School of Medicine (Baltimore, MD)
Date of First Priority Issue: Monday March 31st, 1997
Patent Number: 6558952
This patent teaches how to induce endogenous islet stem cells to multiply through administration of gastrin together with a ligand of the EGF receptor such as TGF alpha. One of the principles behind the current company doing clinical trials with this, Dr Tony Cruz, is also involved in the company Stem Cell Therapeutics, which is performing clinical trials with exogenous agents that stimulate... Inventors: Parikh, Indu (Chapel Hill, NC); Lane, Anne (Westmount, CA); Nardi, Ronald V. (Mahwah, NJ); Brand, Stephen J. (Lincoln, MA)
Assignee: Waratah Pharmaceuticals, Inc. (Quebec, CA); The General Hospital Corporation (Boston, MA)
Date of First Priority Issue: Thursday July 30th, 1998
Patent Number: 6558925
This invention covers a composition of matter consisting of polypeptides that inhibit stem cell proliferation. This invention is useful for protecting stem cells during administration of chemotherapy or radiotherapy. Inventors: Graham, Gerard (Glasgow, GB); Pragnell, Ian (Glasgow, GB)
Assignee: Wyeth (Madison, NJ)
Date of First Priority Issue: Tuesday March 9th, 1993
Patent Number: 6555374
This patent seems to cover a composition of cells that is made of adipose tissue and hematopoietic tissue. The composition is useful for regeneration of a hematopoietic system after ablation. Additionally, this composition may have uses for the induction of angiogenesis. In some papers, the induction of angiogenesis by bone marrow stem cells requires large amounts of stem cells to be... Inventors: Gimble, Jeffrey Martin (Chapel Hill, NC); Halvorsen, Juan-Di Chang (Holly Springs, NC); Wilkison, William O. (Bahama, NC)
Assignee: Artecel Sciences, Inc. (Durham, NC)
Date of First Priority Issue: Thursday August 19th, 1999
Patent Number: 6555324
This patent covers methods for identifying hematopoietic stem cells based on expression of markers such as CD34, CD38, and various growth factor receptors. Inventors: Olweus, Johanna (Fremont, CA); Lund-Johansen, Fridtjof (Fremont, CA); Terstappen, Leon Wmm (Palo Alto, CA)
Assignee: Becton Dickinson & Company (Franklin Lakes, NJ)
Date of First Priority Issue: Thursday November 4th, 1993
Patent Number: 6555118
This patent covers extracts from certain plants for the regeneration of skin tissue after wounding. The patent is useful not only for generation of a new topical product, but also for identification of potentially novel stem cell stimulators found in the concoction. Inventor: Niazi, Sarfaraz K (Deerfield, IL)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Thursday February 22nd, 2001
Patent Number: 6551782
This patent covers ways of identifying expression of the gene patched inside cells. This is important since various stem cells, embryonic tissues, and cancer cells express this gene in its wildtype or mutated form. The manipulation of the patched pathway can be used for stem cell differentiation and/or expansion. Inventors: Scott, Matthew P. (Stanford, CA); Goodrich, Lisa V. (Palo Alto, CA); Johnson, Ronald L. (Redwood City, CA); Epstein, Jr., Ervin (Orinda, CA)
Assignee: Stanford University (Stanford, CA); University of California (Oakland, CA)
Date of First Priority Issue: Friday October 7th, 1994
Patent Number: 6551618
This patent covers a matrix that is embedded with genes that stimulate stem cell expansion and/or differentiation. The matrix can be administered alone or in combination with stem cells. Inventors: Baird, Andrew (San Diego, CA); Gonzalez, Ana Maria (San Diego, CA); Logan, Ann (Worcester, GB); Berry, Martin (Birmingham, GB)
Assignee: University of Birmingham (Birmingham, GB); King's College (London, GB); Selective Genetics, Inc. (San Diego, CA
Date of First Priority Issue: Tuesday March 15th, 1994
Patent Number: 6551355
This patent covers various biocompatible coating compositions that in one embodiment are used to decrease immunogenecity of bone grafts. Inventors: Lewandrowski, Kai-Uwe (Brookline, MA); Bondre, Shrikar (Malden, MA); Trantolo, Debra J. (Princeton, MA); Cattaneo, Maurice V. (Quincy, MA); Gresser, Joseph D. (Brookline, MA); Wise, Donald L. (Belmont, MA)
Assignee: Cambridge Scientific, Inc. (Cambridge, MA)
Date of First Priority Issue: Friday August 14th, 1998
Patent Number: 6551338
This patent covers ways of entering the myocardium through transthoracic means in order to administer angiogenic stimuli, which may include stem cells, or activators of stem cells that are associated with angiogenesis. The patent also discloses various administration devices. Inventors: Chiu, Ray Chu-Jeng (Montreal, CA); Lachapelle, Kevin (Westmount, CA)
Assignee: McGill University (Montreal, CA)
Date of First Priority Issue: Wednesday September 1st, 1999
Patent Number: 6548299
This patent teaches how to generate cells of the lymphoid lineage in vitro through a variety of devices and culture techniques. This patent could be used for generating T suppressor cells in order to antigen-specifically inhibit autoimmunity. Inventors: Pykett, Mark J. (Newton, MA); Rosenzweig, Michael (Boston, MA); Scadden, David T. (Weston, MA); Poznansky, Mark C. (Charlestown, MA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Thursday November 12th, 1998
Patent Number: 6545199
This patent teaches ways of culturing various pluripotent embryonic germ stem cells. Methods are disclosed, as well as specific culture reagents. In one particular embodiment emphasis is placed on embryonic germ cells from pigs. Inventors: Anderson, Gary B. (Davis, CA); Shim, Hosup (Davis, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Date of First Priority Issue: Tuesday January 9th, 1996
Patent Number: 6545005
This patent provides compositions of matter that target signalling through the hedgehog pathway. This is important for inhibition of cancer cells since in many cases they have constitutive activation of the hedgehog pathway. Inventors: Baxter, Anthony David (Abingdon, GB); Boyd, Edward Andrew (Didcot, GB); Guicherit, Oivin M. (Belmont, MA); Price, Stephen (Aylesbury, GB); Rubin, Lee D. (Wellesley, MA)
Assignee: Curtis, Inc. (Cambridge, MA)
Date of First Priority Issue: Thursday September 16th, 1999
Patent Number: 6544787
This patent provides methods of performing hematopoietic transplants without having to wipe out the recipient's myelopoietic system. Specifically the patent teaches ways of inducing tolerance. This can be used not only for stem cell transplants, but also to induce donor-specific tolerance in a variety of solid organ transplant settings. Inventor: Slavin, Shimon (Jerusalem, IL)
Assignee: Hadash Medical Research Services and Development Ltd. (Jerusalem, IL); Baxter International Inc. (Deerfield, IL)
Date of First Priority Issue: Friday November 15th, 1996
Patent Number: 6541251
This patent teaches ways of identifying pancreatic stem cells by assessing expression of the gene which encodes pancreatic progenitor-1. Inventors: Sarvetnick, Nora (San Diego, CA); Fox, Howard (San Diego, CA)
Assignee: The Scripps Research Institute (La Jolla, CA)
Date of First Priority Issue: Thursday April 26th, 2001
Patent Number: 6544290
This patent provides cell scaffolds made of a variety of materials, including ceramic. These scaffolds are useful for the growth of various tissues both in vitro and in vivo. Inventors: Lee, Dosuk D. (Brookline, MA); Rey, Christian (Castanet, FR); Aiolova, Maria (Brookline, MA)
Assignee: Etex Corporation (Cambridge, MA)
Date of First Priority Issue: Friday May 19th, 1995
Patent Number: 6541255
These are stem cells that are isolated from human fetal telencephalon and are useful for engrafting and generating various neuronal structures. Inventors: Snyder, Evan Y. (Jamaica Plain, MA); Wolfe, John H. (Philadelphia, PA); Kim, Seung U. (Vancouver, CA)
Assignee: The Children's Medical Center Corporation (Boston, MA); The University of British Columbia (CA); The University of Pennsylvania (Philadelphia, PA)
Date of First Priority Issue: Friday August 14th, 1998
Patent Number: 6541249
This patent covers some stromal cell lines that have been deposited with ATCC. These cell lines are useful for expansion of hematopoietic stem cells since they secrete a variety of different cytokines. I would be interesting to see if they support expansion of other types of stem cells such as neuronal stem cells. Inventors: Wager, Ruth E. (Rockville, MD); Ourmanova, Maria (Boyds, MD)
Assignee: Human Genome Sciences, Inc. (Rockville, MD)
Date of First Priority Issue: Wednesday December 22nd, 1999
Patent Number: 6541247
This patent covers stem cells of the ependymal CNS type from an animal that is non-embryonic. These neuronal stem cells can be isolated based on expression of Notch-1 receptor. Inventors: Frisen, Jonas (Stockholm, SE); Janson, Ann Marie (Stockholm, SE); Johansson, Clas (Stockholm, SE); Momma, Stefan (Sp.ang.nga, SE); Clarke, Diana (Stockholm, SE); Zhao, Ming (Solna, SE); Lendahl, Urban (Sundbyberg, SE); Delfani, Kioumars (Solna, SE)
Assignee: Neuronova AB (Stockholm, SE)
Date of First Priority Issue: Monday May 25th, 1998
Patent Number: 6541217
This patent covers a cytokine that is able to stimulate proliferation of hematopoietic stem cells. It is unclear what the modern name of this cytokine is. This patent may be very useful for development of a stem cell pharmaceutical. Inventors: Hiraoka, Atsunobu (Kyoto-shi, Kyoto 616-8428, JP); Sugimura, Atsushi (Hokkaido, JP); Mio, Hiroyuki (Shizuoka, JP)
Assignee: Kyowa Hakko Kogyo Co., Ltd. (Tokyo, JP); Hiraoka, Atsunobu (Kyoto, JP)
Date of First Priority Issue: Tuesday August 27th, 1996
Patent Number: 6541024
This patent teaches ways of generating bone tissue using mesenchymal stem cells that are placed into a special matrix. In one embodiment, the matrix and the mesenchymal stem cells are administered into an area of bone injury. Inventors: Kadiyala, Sudhakar (Baltimore, MD); Bruder, Scott P. (Owings Mills, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Monday October 28th, 1996
Patent Number: 6537808
This patent covers the use of NGF for storing corneal samples, but also for use as a topical solution for the treatment of diseases associated with corneal dysfunction. Inventor: Lambiase, Alessandro (Rome, IT)
Assignee: Anabasis S.R.L. (Rome, IT)
Date of First Priority Issue: Thursday April 24th, 1997
Patent Number: 6537807
This patent is in competition with other composition of matter patents that cover hematopoietic stem cells. Specific phenotypes are covered by this patent, which may be the reason why it issued in light of several other patents that also cover similar phenotypes and activities. Inventors: Smith, Clayton A. (Durham, NC); Storms, Robert W. (Durham, NC); Gilboa, Eli (Durham, NC)
Assignee: Duke university
Date of First Priority Issue: Thursday December 4th, 1997
Patent Number: 6534084
The importance of scaffolds in tissue engineering can not be understated. In this patent, various composition of matter, included foam-based and biodegradable scaffolds are provided. Inventors: Vyakarnam, Murty N. (Edison, NJ); Zimmerman, Mark C. (East Brunswick, NJ); Scopelianos, Angelo George (Whitehouse Station, NJ); Roller, Mark B. (North Brunswick, NJ); Gorky, David V. (Flemington, NJ)
Assignee: Ethicon, Inc. (Somerville, NJ)
Date of First Priority Issue: Wednesday June 30th, 1999
Patent Number: 6534052
This patent teaches how to administer embryonic stem cells, and differentiated cells thereof, into the area of infarcted myocardium so as to prevent future heart failure. Inventors: Xiao, Yong-Fu (Wayland, MA); Morgan, James P. (Newton Centre, MA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Tuesday September 5th, 2000
Patent Number: 6531445
This patent teaches the use of proteins such as osteogenic protein-1 (OP-1) for stimulation of liver regeneration. Inventors: Cohen, Charles M. (Medway, MA); Kuberasampath, Thangavel (Medway, MA); Pang, Roy H. L. (Medway, MA); Oppermann, Hermann (Medway, MA); Rueger, David C. (Hopkinton, MA)
Assignee: Curis, Inc. (Cambridge, MA)
Date of First Priority Issue: Monday March 11th, 1991
Patent Number: 6530956
This patent teaches how to make scaffolds that can be implanted in order to promote healing and regeneration of injured cartilage. Chondrocytes and/or mesenchymal stem cells may be used along with this invention. Inventor: Mansmann, Kevin A. (Paoli, PA
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Thursday September 10th, 1998
Patent Number: 6528306
This patent uses human fetal telencephalon as a source of stem cells that can be implanted and subsequent to implantation actually interdigitate and function in unison with host neurons. Inventors: Snyder, Evan Y. (Jamaica Plain, MA); Wolfe, John H. (Philadelphia, PA); Kim, Seung U. (Vancouver, CA)
Assignee: The Children's of Medical Center Corporation (Boston, MA); The University of British Columbia (CA); The University of Pennsylvania (Philadelphia, PA)
Date of First Priority Issue: Tuesday April 14th, 1998
Patent Number: 6528245
This patent teaches that bone marrow stromal cells may be used as a source of neurons or to assist in neuronal regeneration. One wonders if these bone marrow stromal cells are similar to the mesenchymal stem cells that are patented by Osiris Therapeutics. Inventors: Sanchez-Ramos, Juan (Tampa, FL); Song, Shijie (Tampa, FL); Janssen, William (Tampa, FL); Sanberg, Paul (Spring Hill, FL); Freeman, Thomas (Tampa, FL)
Assignee: University of South Florida (Tampa, FL)
Date of First Priority Issue: Thursday May 7th, 1998
Patent Number: 6528052
This patent discloses frequencies and methods of culturing stem cells in order to generate a source of bioartificial cartilage. Inventors: Smith, R. Lane (Palo Alto, CA); Carter, Dennis R. (Stanford, CA); Schurman, David J. (Stanford, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University (Stanford, CA)
Date of First Priority Issue: Friday October 1st, 1999
Patent Number: 6525243
This patent teaches ways of improving efficacy of cloning through nuclear transfer into oocytes that are in specific stages of proliferation. The use of cloning for generation of autologous embryonic stem cells offers incredible potential for regenerative medicine. Inventors: Stockman Campbell, Keith Henry (Midlothian, GB); Wilmut, Ian (Midlothian, GB) Assignee: Roslin Institute (Edinburgh, GB)
Assignee: The Minister of Agricultural, Fisheries and Food (GB); Biotechnology & Biological Sciences Research Council (GB)
Date of First Priority Issue: Thursday August 31st, 1995
Patent Number: 6525030
The periosteum is a dense layer of connective tissue that wraps around bone. This patent teaches ways of transfecting this layer with various genes that are capable of stimulating stem cells and other cells to proliferate and/or differentiate. Inventor: Eriksson, Elof (Wellesley Hills, MA)
Assignee: Applied Tissue Technologies, LLC (Wellesley Hills, MA)
Date of First Priority Issue: Thursday December 14th, 1989
Patent Number: 6517872
This patent teaches ways of extracting mesenchymal stem cells that act as progenitors for various types of bone. The expression of the receptor for fibroblast growth factor-3 is used as the identifying marker. Inventors: Yayon, Avner (Moshav Sitria, IL); Nevo, Zvi (Herzlia, IL)
Assignee: Yeda Research and Development Co., Ltd. (Rehovot, IL); Ramdt University Authority for Applied Research and Industrial Development Ltd. (Tel Aviv, IL)
Date of First Priority Issue: Thursday January 12th, 1995
Patent Number: 6517833
This patent teaches the use of pig retinal cells and a variety of stem cells associated with retinal development, as a source of cellular material for transplantation into humans that suffer from various ocular diseases. Inventor: Edge, Albert (Cambridge, MA)
Assignee: Diacrin, Inc. (Charlestown, MA)
Date of First Priority Issue: Tuesday August 25th, 1998
Patent Number: 6514752
This patent discloses a stem cell theat has been modified so as to lack expression of MHC genes. The modification involves homologous recombination in a manner similar to which knockout mice are made. The cells are then used for transplantation since they are presumed to be less immunogeneic. If it was possible to generate liver cells through this method, then the therapy may actually be... Inventors: Kucherlapati, Raju (Darien, CT); Koller, Beverly H. (Carrboro, NC); Smithies, Oliver (Chapel Hill, NC); Dubridge, Robert B. (Belmont, CA); Greenburg, Gary (San Carlos, CA); Capon, Daniel J. (Hillsborough, CA); Williams, Steven R. (San Francisco, CA); Arbo
Assignee: cell genesys
Date of First Priority Issue: Tuesday July 25th, 1989
Patent Number: 6514522
This patent provides compositions of matter for administration of cells and cytokines into a host. The compositions are various polymers that are biodegradable, but can serve as delivery systems. Inventor: Domb, Abraham J. (Efrat, IL)
Assignee: Chondros, Inc. (Towson, MD)
Date of First Priority Issue: Wednesday April 8th, 1998
Patent Number: 6514514
This patent covers a matrix that can be used for cartilage repair comprising of biodegradable materials, as well as cytokines and growth factors. Inventors: Atkinson, Brent (Lakewood, CO); Benedict, James J. (Arvada, CO)
Assignee: Sulzer Biologics Inc. (Austin, TX)
Date of First Priority Issue: Thursday August 14th, 1997
Patent Number: 6506801
This patent teaches the use of retinoids to stimulate olfactory stem cells in order to restore the sense of smell to an animal in need thereof.
The use of retinoids for stimulation of stem cell differentiation is well known and is actually therapeutic in various types of cancer, in which the malignant cell is subjected to "differentiation therapy" such that it loses its malignancy. Inventors: Yee, Karen K. (Philadelphia, PA); Rawson, Nancy E. (Marlton, NJ)
Assignee: Monell Chemical Senses Center (Philadelphia, PA)
Date of First Priority Issue: Wednesday October 4th, 2000
Patent Number: 6506599
This patent teaches how to expand autologous or allogeneic islet stem cells and to generate from them islets useful for the treatment of diabetes. The culture techniques disclosed involve cytokine, matrix and antibody cocktails. This invention may be useful in conjunction with the various embryonic stem cell technologies that are currently being studied. Inventor: Yoon, Tai-Wook (Seodaemoon-Ku Seoul, KR)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday October 15th, 1999
Patent Number: 6506576
This patent covers a method of growing neurons in a media that is free from serum and feeder cells. This media will be important in clinical trials since there are high regulatory hurdles if cells are used that are grown in the presence of xenogenic feeders or with serum containing media. Inventor: Belcher, Scott M. (Little Rock, AR)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Wednesday March 14th, 2001
Patent Number: 6506574
This patent teaches how to generate hepatocytes by the differentiation of embryonic stem cells. Methods of using the newly generated hepatocytes for drug screening are also provided.
The patent describes uses of histone decetylase inhibitors in the culture and differentiation process. Inventors: Rambhatla, Lakshmi (Redwood City, CA); Carpenter, Melissa K. (Castro Valley, CA)
Assignee: Geron Corporation (Menlo Park, CA)
Date of First Priority Issue: Thursday April 27th, 2000
Patent Number: 6500421
This patent teaches ways of using tranfection of hematopoietic stem cells in order to select for primitive cells in vivo. This patent is useful for treatment of a variety of hematological disorders in which stem cell transplants are indicated. Inventors: Sorrentino, Brian P. (Memphis, TN); Blakely, Raymond L. (Germantown, TN); Allay, James (Cordova, TN); Spencer, H. Trent (Columbia, SC)
Assignee: St. Jude Children's Research Hospital (Nashville, TN)
Date of First Priority Issue: Monday November 4th, 1996
Patent Number: 6498150
This patent covers the composition of matter for several aminocarboxylic acid amide derivatives that are both immunostimulatory, as well as augment hematopoietic activity of stem cells. This seems very interesting a combination since many cytokines that stimulate the immune system, at least the Th1 arm of the immune system, are also suppressive to the hematopoietic compartment.
For... Inventors: Taub, Floyd (Silver Spring, MD); Perun, Thomas J. (Round Lake, IL); Murray, Christopher K. (Longmont, CO); Daughenbaugh, Randall J. (Longmont, CO); Lednicer, Daniel (Rockville, MD)
Assignee: Dovetail Technologies, Inc. (College Park, MD)
Date of First Priority Issue: Tuesday October 17th, 1995
Patent Number: 6498138
This patent covers the use of angiotensinogen I and II and fragments thereof for promoting viability of tissues. This could be used form maintaining the viability of stem cells during organ storage. Inventors: Rodgers, Kathleen E. (Long Beach, CA); DiZerega, Gere (Pasadena, CA)
Assignee: University of Southern California (Los Angeles, CA)
Date of First Priority Issue: Wednesday March 11th, 1998
Patent Number: 6498018
This patent appears to cover a method of screening for compounds that have ability to induce expension of neuronal stem cells. In one of the dependent claims the patent covers forebrain derived neural stem cells in the culture for screening. Inventor: Carpenter, Melissa (Foster City, CA)
Assignee: Cytotherapeutics, Inc. (Lincoln, RI)
Date of First Priority Issue: Friday September 5th, 1997
Patent Number: 6497875
This patent covers the generation of an artificial skin that has a keratinocyte layer and a dermis-forming layer. The second layer can be generated by use of mesenchymal stem cells. This patent could be useful not only for covering of burn patients or sufferers of wounds that take a long time to heal, but it could also be useful for generation of in vitro systems for assessing ability of topical... Inventors: Sorrell, J. Michael (Cleveland Heights, OH); Caplan, Arnold I. (Cleveland Heights, OH)
Assignee: Case Western Reserve University (Cleveland, OH)
Date of First Priority Issue: Friday April 26th, 1996
Patent Number: 6497872
This patent covers the use of a multipotent neural stem cell for transplantation into patients suffering from various neurodegenerative disorders. Markers of the cells suitable for transplantation, as well as culture conditions, and genes which the stem cells can be transfected with are provided. Inventors: Weiss, Samuel (Alberta, CA); Reynolds, Brent (Alberta, CA); Hammang, Joseph P. (Barrington, RI); Baetge, E. Edward (Barrington, RI)
Assignee: NeuroSpheres Holdings Ltd. (Calgary, CA)
Date of First Priority Issue: Monday July 8th, 1991
Patent Number: 6495513
This patent provides certain morphogen proteins that are capable of regenerating neural stem cells, as well as protecting neurons from apoptosis or other types of cell death. The claims cover specific polypeptides for neurite extension, as well as for repairing the gap between neurons. Inventors: Rueger, David C. (Hopkinton, MA); Kuberasampath, Thangavel (Medway, MA); Oppermann, Hermann (Medway, MA); Ozkaynak, Engin (Milford, MA); Pang, Roy H. L. (Etna, NH); Cohen, Charles M. (Medway, MA)
Assignee: Curis, Inc. (Cambridge, MA)
Date of First Priority Issue: Monday March 11th, 1991
Patent Number: 6495365
This patent covers the use of IGF-1 (a protein that is already in the clinic) in combination with a protein selected from the group comprising of: G-CSF, M-CSF, or stem cell factor, for the stimulation of hematopoiesis.
This patent should be examined for the possibility of extending this technology to the area of other uses of hematopoietic stem cells. For example, will these combinations... Inventors: Saito, Yoshimasa (Kawanishi, JP); Ueda, Yoshiko (Osaka, JP); Tamura, Kouichi (Kobe, JP); Takata, Yoko (Osaka, JP); Yamada, Hisashi (Sanda, JP); Yamashita, Tatsuo (Kobe, JP); Kobayashi, Masakazu (Takarazuka, JP)
Assignee: Fujisawa Pharmaceutical Co., Ltd. (Osaka, JP)
Date of First Priority Issue: Tuesday August 12th, 1997
Patent Number: 6485971
This patent covers a type of stem cell that gives rise to keratinocytes. These cells can be purified from skin biopsy and used for amplification and generation of numerous other cell types and tissue. One interesting possibility is the use of such keratinocyte stem cells for generation of artificial thymus. Inventors: Kaur, Pritinder (East Melbourne, AU); Simmons, Paul J. (East Melbourne, AU)
Assignee: Peter MacCallum Cancer Institute (Victoria, AU)
Date of First Priority Issue: Wednesday March 18th, 1998
Patent Number: 6485480
The process of ultradiluting a compound in order to magically "potentiate" various effects has been used for hundreds of years in the area of homeopathic medicine. Homeopathy is based on the principle of "like cures like", in the sense that if you are allergic to a specific compound, the ultradilution of that compound, prepared through a magical shaking during the dilution process, will result in... Inventor: Brewitt, Barbara A. (Seattle, WA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Thursday March 31st, 1994
Patent Number: 6482645
The fascia is a layer of connective tissue that surrounds muscles, bones, and joints. This patent teaches ways of generating artificial fascia's through the use of various stem cells and biological matrices. Inventor: Atala, Anthony (Weston, MA)
Assignee: Children's Medical Center Corporation (Boston, MA)
Date of First Priority Issue: Wednesday December 29th, 1999
Patent Number: 6482406
This patent covers the transfection of various cells and their administration in order to heal various pulmonary lesions or disorders. In one utilization, cells are transfected with iNOS and used to administer nitric oxide directly into the lung of patients with pulmonary hypertension. Inventor: Stewart, Duncan J. (Toronto, Ontario, CA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday March 26th, 1999
Patent Number: 6479283
This patent covers a method of administering beta cells in a matrix that allows for enhanced viability, as well as insulin production. Inventors: M.ang.nsson, Per (Sollentuna, SE); Lundin, Tomas (Enkoping, SE); Busch, Christer (Troms.o slashed., SE)
Assignee: Ascendia AB (Sollentuna, SE)
Date of First Priority Issue: Tuesday March 18th, 1997
Patent Number: 6479066
This patent covers an implantable 3 dimensional matrix that takes the shape of the cavity it is administered in. This matrix is a great delivery system for introduction of various cell types into the host.
In some ways this patent is useful for generation of compositions useful for the treatment of bone defects, livers, and other bodily structures. Inventor: Harpstead, Stanley D. (Arden Hills, MN)
Assignee: RST Implanted Cell Technology, LLC (Arden Hills, MN)
Date of First Priority Issue: Thursday December 16th, 1999
Patent Number: 6475481
This patent covers ways of purging tumor cells from bone marrow stem cell grafts. Specifically, the patent teachs ways of selectively protecting the bone marrow through gene transfection, while allowing tumor cells to die.
This patent is particularly suited for situations of autolous bone marrow transplants in cancer patients in order to allow for high levels of chemotherapy and/or... Inventor: Talmadge, James E. (Bellevue, NE)
Assignee: Canji, Inc. (San Diego, CA)
Date of First Priority Issue: Tuesday November 18th, 1997
Patent Number: 6468794
StemCells Inc is one of the few companies that has actually entered clinical trials. In this patent the extraction of specific neuronal stem cells is disclosed. Cells that bind to the antibodies 5E12 and/or AC133 derived from brain sources are identified as neuronal stem cells capable of inducing production of neurospheres. These cells have also demonstrated ability to integrate into the brains... Inventors: Uchida, Nobuko (Palo Alto, CA); Buck, David W. (Santa Clara, CA); Weissman, Irving (Redwood City, CA)
Assignee: StemCells, Inc. (Palo Alto, CA)
Date of First Priority Issue: Friday February 12th, 1999
Patent Number: 6465249
The various signalling pathways associated with embryogenesis seem to be fundamentally important in controlling a variety of stem cells. In this patent the manipulation of beta catenin signalling is covered for the activation of stem cells to either differentiate or proliferate. Inventors: Reya, Tannishtha (Mountain View, CA); Nusse, Roeland (Stanford, CA); Weissman, Irving L. (Redwood City, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University (Palo Alto, CA)
Date of First Priority Issue: Tuesday January 18th, 2000
Patent Number: 6465248
This patent teaches ways how to culture neurons in order to obtain certain phenotypes. One type of neuron that is obtained by using the culture conditions thought by this invention is a dopamine secreting neuron.
This invention is owned by the company Prescient NeuroPharma which appears to be a Canadian venture-backed company. Inventor: Commissiong, John (Mississauga, CA)
Assignee: Prescient NeuroPharma, Inc. (Toronto, CA)
Date of First Priority Issue: Friday July 16th, 1999
Patent Number: 6465247
This patent covers a type of stem cell that has differentiated and is committed to the myeloid lineage. This stem cell is useful for inducing a rapid production of myeloid cells such as granulocytes and monocytes, which are protective against bacteria.
The cells covered in the patent display the phenotype of c-kit positive, negative for IL-7 receptor (most likely since IL-7 is associated... Inventors: Weissman, Irving L. (Redwood City, CA); Traver, David Jeffrey (West Roxbury, MA); Akashi, Koichi (Palo Alto, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University (Palo Alto, CA)
Date of First Priority Issue: Tuesday June 29th, 1999
Patent Number: 6465215
This patent covers genes that are indicative if cells of the neuronal lineage are suitable for transplantation for regenerative purposes. The genes mentioned in this patent are not named, but sequences are provided. So if one is curious what these are, they have to check genbank. Inventors: Price, Jack (London, GB); Uwanogho, Dafe (London, GB)
Assignee: Reneuron Limited (London, GB)
Date of First Priority Issue: Tuesday December 14th, 1999
Patent Number: 6464983
This patent teaches how to induce mesenchymal stem cells into chondrocytes (to make cartilage) or osteoblasts (to make bone) through the use of the cytokine called Connective Tissue Growth Factor.
This patent is useful for regenerative purposes in the area of injuries, however it is interesting in that the mesenchymal stem cell patents are owned by Osiris and should be licensed in order to... Inventor: Grotendorst, Gary R. (Miami, FL)
Assignee: University of South Florida (Tampa, FL); University of Miami (Miami, FL)
Date of First Priority Issue: Tuesday April 30th, 1991
Patent Number: 6463933
This patent teaches how to perform transplantation of cells directly into the bone or bone marrow. The patent specifically claims the transplantation of hepatocytes or islet cells. It is known that the bone marrow is an immune priviledged environment, at least to some extent, therefore this idea is really novel.
Sakaguchi in Japan was at one time publishing that intra-bone transplant of... Inventors: Laster, Morris (Jerusalem, 97289, IL); Rosenwald, Lindsay (New York, NY)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Tuesday March 25th, 1997
Patent Number: 6458589
This patent covers methods of generating and isolating hepatocytes from embryonic stem cells. The hepatocytes are designated by specific phenotypic and functional characteristics that are described in the patent.
This invention could be useful for treatment of a wide variety of disorders ranging from hepatitis to cirrhosis. Inventors: Rambhatla, Lakshmi (Redwood City, CA); Carpenter, Melissa K. (Castro Valley, CA)
Assignee: geron
Date of First Priority Issue: Thursday April 27th, 2000
Patent Number: 6458588
This patent covers a renal stem cell that is identified based on expression of the markers flk-1 and Sca-1.
It is interesting how some many stem cells of different tissues all express similar markers and in some situations similar properties. Examples of such similarities include expression of Sca-1 (which appropriately stands for "stem cell antigen") on stem cells ranging from... Inventors: Arnaout, M. Amin (Chestnut Hill, MA); Linde, Peter G. (Dedham, MA)
Assignee: The General Hospital Corporation (Boston, MA)
Date of First Priority Issue: Wednesday January 31st, 2001
Patent Number: 6455678
This patent appears to cover the stem cell antigen AC133, otherwise known as CD133. This antigen is found not only on hematopoietic stem cells, but also on stem cells capable of inducing angiogenesis.
This patent may be useful for people who do not want to licence CD34. Inventors: Yin, Amy H. (San Jose, CA); Miraglia, Sheri (Palo Alto, CA); Godfry, Wayne G. (Atherton, CA); Buck, David W. (Santa Clara, CA)
Assignee: AmCell Corporation (Burlingame, CA)
Date of First Priority Issue: Friday April 26th, 1996
Patent Number: 6451558
This patent covers some genes whose function is not really described in the application. In order to understant the relevance of this patent, one should take the sequence and blast it in genbank to see what the real name of this gene is. Inventors: Cooke, Michael Paul (Del Mar, CA); Holness, Claire Louise (Palo Alto, CA); Sirenko, Oksana Ivanivna (Belmont, CA)
Assignee: Novartis AG (Basel, CH)
Date of First Priority Issue: Monday August 3rd, 1998
Patent Number: 6454811
This patent provides various engineering techniques and devices for generation of artificial tissue from biological sources in vitro and in vivo.
Specific material and ways of manipulating the materials to design cellular substrates and shape inducing structures are disclosed. Inventors: Sherwood, Jill K. (Princeton, NJ); Griffith, Linda G. (Cambridge, MA); Brown, Scott (Princeton, NJ)
Assignee: Massachusetts Institute of Technology (Cambridge, MA); Therics, Inc. (Princeton, NJ)
Date of First Priority Issue: Monday October 12th, 1998
Patent Number: 6451306
This patent covers a method of treating a neurodegenerative condition through administration of neuronal stem cells into the cholinergic basal forebrain that have been transfected with nerve growth factor or a neurotropin.
This patent uses the natural ability of neural stem cells to migrate to the place where they are needed, in order to deliver the protein that is produced from the gene that... Inventors: Tuszynski, Mark H. (La Jolla, CA); Gage, Fred (La Jolla, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Date of First Priority Issue: Wednesday April 15th, 1998
Patent Number: 6451303
There are more than 20 members of the fibroblast growth factor family. Many of the FGF proteins are involved in activation of stem cell proliferation, as well as induction of angiogenesis. This patent covers the treatment of coronary artery disease, for example ischemia induced by it...through the stimulation of angiogenesis by administration of FGF.
There is at least one trial ongoing with... Inventors: Whitehouse, Martha J. (San Francisco, CA); Kavanaugh, W. Michael (Marin, CA)
Assignee: Chiron Corporation (Emeryville, CA)
Date of First Priority Issue: Tuesday October 13th, 1998
Patent Number: 6447766
Inventors: Pelus, Louis Martin (Richboro, PA); King, Andrew Garrison (Blue Bell, PA); Qian, Yanqiu (King of Prussia, PA)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Date of First Priority Issue: Tuesday June 8th, 1993
Patent Number: 6444205
This patent covers administration of GABA producing neurons or neural stem cells from a fetus into a patient with chronic pain or spasticity. This patent covers not only human donor sources but also porcine.
The ability to generate different types of pigs through genetic engineering may allow for some of these approaches to enter the clinic. One such particular strain of pig is the alpha... Inventors: Dinsmore, Jonathan (Brookline, MA); Siegan, Julie (Boston, MA)
Assignee: Diacrin, Inc. (Charlestown, MA)
Date of First Priority Issue: Wednesday September 30th, 1998
Patent Number: 6440934
This patent covers specific doses of FGF-2 that may be used for the stimulation of angiogenesis.
Angiogenesis stimulation should not be thought of as important only for disease such as angina, but for other disease associated with ischemia such as cerebral palsy, and peripheral vascular disease. Inventor: Whitehouse, Martha Jo (San Francisco, CA)
Assignee: Chiron Corporation (Emeryville, CA)
Date of First Priority Issue: Tuesday October 13th, 1998
Patent Number: 6440734
This patent discloses various three dimensional biomaterials that resemble the actual bone marrow microenvironment and are useful for stimulating expansion of hematopoietic stem cells.
This patent may be used for expanding autologous stem cells for patients that lack a suitable bone marrow or stem cell donor.
Additionally, the ability to expand and grow hematopoietic stem cells can also... Inventors: Pykett, Mark J. (Newton, MA); Rosenzweig, Michael (Boston, MA); Kaplan, Richard B. (Beverly Hills, CA)
Assignee: Cytomatrix, LLC (Woburn, MA)
Date of First Priority Issue: Friday September 25th, 1998
Patent Number: 6440407
This patent covers IL-3 and various forms of it for the expansion of hematopoietic stem cells outside of the body. Inventors: Bauer, S. Christopher (New Haven, MO); Abrams, Mark Allen (St. Louis, MO); Braford-Goldberg, Sarah Ruth (St. Louis, MO); Caparon, Maire Helena (Chesterfield, MO); Easton, Alan Michael (Maryland Heights, MO); Klein, Barbara Kure (St. Louis, MO); McKearn, J
Assignee: Searle, G. D. (Chicago, IL)
Date of First Priority Issue: Tuesday November 24th, 1992
Patent Number: 6436704
This patent covers a type of pancreatic stem cell that can be grown and expanded outside of the body. The cells are defined as expressing the following markers: cytokeratin-19, CEA, carbonic anhydrase II, and CFTCR. Inventors: Roberts, Penelope E. (Millbrae, CA); Mather, Jennie Powell (Millbrae, CA)
Assignee: Raven Biotechnologies, Inc. (South San Francisco, CA)
Date of First Priority Issue: Monday April 10th, 2000
Patent Number: 6436701
This patent covers methods of generating stem cells, embryonic stem cells from ungulate species. This technology may be useful not only for veterinary applications, but also for generating large quantities of cytoplasm with "dedifferentiating" ability that may be used for various regenerative purposes in humans...many of the cytoplasmic factors in embryonic stem cells that induce... Inventors: Evans, Martin John (Cambridge, GB); Moor, Robert Michael (Babraham, GB); Notaranni, Elena (Cambridge, GB)
Assignee: Babraham Institute (Cambridge, GB)
Date of First Priority Issue: Monday September 12th, 1988
Patent Number: 6436387
This patent covers chimeric proteins that are based on the cytokine interleukin-3. The specific use of these proteins for expanding stem cells of the hematopoeitic lineage outside the body are disclosed. Inventors: Bauer, S. Christopher (New Haven, MO); Abrams, Mark Allen (St. Louis, MO); Braford-Goldberg, Sarah Ruth (St. Louis, MO); Caparon, Maire Helena (Chesterfield, MO); Easton, Alan Michael (Maryland Heights, MO); Klein, Barbara Kure (St. Louis, MO); McKearn, J
Assignee: G.D. Searle & Co. (Chicago, IL)
Date of First Priority Issue: Tuesday November 24th, 1992
Patent Number: 6435190
This patent teaches what appears to be a surgical method for producing an autograft that can cover lesions in the heart. This is important since after a heart attack, there is scar tissue formation, and the heart starts to lose function. The patent also covers ways in which autologous stem cells may be administered. Inventors: Taheri, Syde A. (Buffalo, NY); Leonhardt, Howard J. (Weston, FL)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Wednesday June 14th, 2000
Patent Number: 6432917
This patent covers a strange composition generated from bone marrow by various chemical and physical procedures that seems to inhibit leukemic stem cell proliferation.
This patent is similar to a composition published previously called Reptimed that was also bone marrow derived and inhibited leukemic cell activity. Inventors: Kozlov, Vladimir (Novosibirisk, RU); Tsyrlova, Irena (Gaithersburg, MD)
Assignee: Pro-Neuron, Inc. (Gaithersburg, MD)
Date of First Priority Issue: Wednesday March 31st, 1993
Patent Number: 6432711
This patent covers the generation of neurons and muscle cells from embryonic stem cells. The patent uses fetal calf serum which can be a drawback to clinical implimentation. Inventors: Dinsmore, Jonathan H. (Brookline, MA); Ratliff, Judson (Stoneham, MA)
Assignee: Diacrin, Inc. (Charlestown, MA)
Date of First Priority Issue: Wednesday November 3rd, 1993
Patent Number: 6429013
This patent teaches how to generate cartilage and chondrocytes from stromal cells that are derived from adipose tissues.
Another company working heavily in this area is Cytori, formerly called Macropore. Inventors: Halvorsen, Yuan-Di C. (Holly Springs, NC); Wilkison, William O. (Bahama, NC); Gimble, Jeffrey Martin (Chapel Hill, NC)
Assignee: Artecel Science, Inc. (Durham, NC)
Date of First Priority Issue: Thursday August 19th, 1999
Patent Number: 6429012
This is a patent for a cell population that can differentiate into both the hematopoietic lineage and the endothelial lineage. Inventors: Kraus, Morey (Worcester, MA); Wilder, Paul (Worcester, MA)
Assignee: Viacell, Inc. (Worcester, MA)
Date of First Priority Issue: Tuesday June 10th, 1997
Patent Number: 6423681
This patent teaches how to induce formation of new kidney cells in vivo through the administration of ligands of gp130 such as LIF.
This is one of the few patents that covers administration of therapies systemically that induce generation of new cells by stimulation of endogenous stem cells.
This patent is in line with the approach of Transition Therapeutics for generation of new islets, and... Inventors: Barasch, Jonathan M. (New York, NY); Oliver, Juan A. (New York, NY); Yang, Jun (New York, NY)
Assignee: The Trustees of Columbia University in the City of New York (New York, NY)
Date of First Priority Issue: Tuesday May 4th, 1999
Patent Number: 6419918
This patent covers the pluripotent colony stimulating factor, a type of cytokine that is not really described in terms of modern nomenclature in this patent.
The use of such stem cell stimulatory cytokines that come from the hematopoietic system should be explored for other types of stem cells...this is especially since there is so much similarity between stem cells of various tissues not... Inventors: Welte, Karl (New York, NY); Platzer, Erich (Spardorf, DE); Gabrilove, Janice L. (New York, NY); Mertelsman, Roland (Mainz, DE); Moore, Malcolm A. S. (Larchmont, NY)
Assignee: Sloan-Kettering Institute for Cancer Research (New York, NY)
Date of First Priority Issue: Thursday March 28th, 1985
Patent Number: 6413773
This patent teaches that if one inhibits the PI3 kinase pathway, it is possible to induce differentiation of pancreatic stem cells into islet-like cells.
PI3k has activity in a variety of stem cells, including hematopoietic stem cells. It will be interesting to see what modification of this enzyme does in other types of stem cells. Inventors: Ptasznik, Andrezej (Philadelphia, PA); Hayek, Alberti (La Jolla, CA); Beattie, Gillian M. (Poway, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Date of First Priority Issue: Monday June 1st, 1998
Patent Number: 6413772
This patent teaches methods of expanding hepatic stem cells, and hepatocytes in culture through a specialized type of serum free media.
This media is useful for clinical applications and may be an important part in cellular therapy of hepatic disorders. Inventor: Block, Geoffrey D. (Pittsburgh, PA)
Assignee: University of Pittsburgh (Pittsburgh, PA)
Date of First Priority Issue: Monday March 18th, 1996
Patent Number: 6413509
This patent provides variants of interleukin 3 that are useful for the expansion of stem cells in general, and specifically hematopoietic stem cells.
These stem cells may be expanded for a variety of uses including for autologous stem cell transplantation.
When methods of inducing hematopoietic stem cell differentiation into other types of tissues are figured out, this patent will be... Inventors: Bauer, S. Christopher (New Haven, MO); Abrams, Mark Allen (St. Louis, MO); Braford-Goldberg, Sarah Ruth (St. Louis, MO); Caparon, Maire Helena (Chesterfield, MO); Easton, Alan Michael (Maryland Heights, MO); Klein, Barbara Kure (St. Louis, MO); McKearn, J
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Tuesday November 24th, 1992
Patent Number: 6410320
This patent covers a type of renal stem cell that is useful for generation of artificial nephrons and eventually artificial kidneys. Inventor: Humes, H. David (Ann Arbor, MI)
Assignee: The University of Michigan (Ann Arbor, MI
Date of First Priority Issue: Monday March 2nd, 1992
Patent Number: 6410015
This patent covers hematopoietic stem cells that are gene transfected with various clotting factors. In some embodiments the stem cells have a preferntially affinity towards injured tissue. Inventors: Gordon, Erlinda Maria (Glendale, CA); Hall, Frederick L. (Glendale, CA); Anderson, W. French (San Marino, CA)
Assignee: University of Southern California (Los Angeles, CA)
Date of First Priority Issue: Tuesday November 12th, 1996
Patent Number: 6409764
This patent provides methods of using stem cells to generate an artificial bone. Various stem cells are able to be used in the context of this invention, including mesenchymal stem cells. This invention also uses members of the TGF beta family in combination with specialized artificial matrices. Inventors: White, Charles F. (Camp Verde, AZ); Flynn, Charles (Cottonwood, AZ); Cook, Alonzo D. (Flagstaff, AZ); Hardwick, William R. (Flagstaff, AZ); Wikesjo, Ulf M. E. (Bryn Mawr, PA); Thomson, Robert C. (Flagstaff, AZ)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Thursday December 3rd, 1998
Patent Number: 6399369
This patent provides the genes that are expressed in various neuronal cells and stem cells. These genes are useful for identifying markers of stem cells that can be used for their extraction and isolation. Additionally, knowledge of these genes may enable drug discovery and target identification for ways of expanding and/or differentiating neural stem cells. Inventors: Weiss, Samuel (Calgary, CA); Reynolds, Brent (Saltspring, CA)
Assignee: Neurospheres Holdings Ltd. (Calgary, CA)
Date of First Priority Issue: Monday July 8th, 1991
Patent Number: 6399300
This patent teaches ways of purifying out cells expressing myocardial genes from a heterogeneous population of stem cells.
Specifically the patent teaches the use of cardiac specific promoters driving expression of markers that can be used to take the cells desired out of a heterogeneous population of cells. Inventor: Field, Loren J. (Indianapolis, IN)
Assignee: Indiana University Foundation (Bloomington, IN)
Date of First Priority Issue: Tuesday November 16th, 1993
Patent Number: 6398819
This patent teaches ways of decellularizing tissue, including xenogeneic tissue, so that it may be used as a scaffold to be seeded with human stem cells, and then the stem cells plus tissue scaffold are implanted into the human as an artificial composite tissue. Inventor: Bell, Eugene (Boston, MA)
Assignee: TEI Biosciences, Inc. (Boston, MA)
Date of First Priority Issue: Friday August 7th, 1992
Patent Number: 6398816
This patent teaches the use of mesenchymal stem cells transfected with "bioactive molecules" (ie cytokines, growth factors, etc), so as to induce repair of bone, cartilage, or connective tissue. Inventors: Breitbart, Arnold S. (Great Neck, NY); Grande, Daniel A. (Sea Cliff, NY); Mason, James M. (Bethpage, NY)
Assignee: North Shore-Long Island Jewish Research Institute (Manhasset, NY)
Date of First Priority Issue: Thursday September 4th, 1997
Patent Number: 6387369
This patent covers the use of mesenchymal stem cells for cardiac repair, specifically after myocardial infarction. Mesenchymal stem cells are currently in clinical trials for this application. In fact the same company to which this patent is assigned to, Osiris Therapeutics, has actually published positive double blind data on patients post infarct treated with allogeneic, Inventors: Pittenger, Mark F. (Severna Park, MD); Gordon, Stephen L. (Columbia, MD); Mackay, Alastair Morgan (Towson, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Monday July 14th, 1997
Patent Number: 6387367
This patent covers mesenchymal stem cells and provides a specific phenotype for them which includes CD45+, SH2,3,4+, and in some cases CD14+.
This patent is important for anyone operating in the area of mesenchymal stem cells since it essentially covers the use of this specific cell population.
Patents on cells have been previously upheld by the courts, as was previously illustrated for... Inventors: Davis-Sproul, Janice M. (Towson, MD); Moorman, Mark Aaron (Baltimore, MD); McNeil, Renee Marie (Baltimore, MD); Simonetti, Jr., Donald William (Forest Hill, MD); Hammill, Lora Catherine (Bel Air, MD); Craig, Stewart (Timonium, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Friday May 29th, 1998
Patent Number: 6387366
This patent teaches ways how to overcome some of the negative effects associated with cell therapy in regards to excessive coagulation. It is stated in the specification that in many cases the administration of a cellular therapy results in coagulation of blood due to expression of pro-clotting agents on the surface of the administered blood cells such as tissue factor. The patent teaches ways... Inventors: Hurwitz, David R. (Boston, MA); Cherington, Van (Harvard, MA); Galanopoulos, Theofanis (Arlington, MA); Levine, Peter H. (Worcester, MA); Greenberger, Joel S. (Sewickley, PA)
Assignee: ALG Company (Marlboro, MA)
Date of First Priority Issue: Thursday December 31st, 1998
Patent Number: 6383481
This patent teaches that intraportal administration of bone marrow subsequent to myeloablation can be used as a therapy for the treatment of autoimmune disease.
This approach may be useful since it "reprograms" the immune system, allowing for it to come back into homeostasis.
The problem with this is that several severe toxicities are usually associated with transplantation of bone... Inventors: Ikehara, Susumu (Osaka, JP); Inaba, Muneo (Kyoto, JP); Takeuchi, Kenji (Osaka, JP); Kushida, Taketoshi (Amagasaki, JP)
Assignee: Japan Immunoresearch Laboratories Co., Ltd. (Gunma-Ken, JP)
Date of First Priority Issue: Monday March 30th, 1998
Patent Number: 6383480
This patent covers a cytokine cocktail, that contains midkine, amongst other classical hematopoietic cytokines, useful for the expansion of hematopoietic stem cells.
The cocktail may be used for the in vivo treatment of patients that are neutropenic or cytopenic, or may be used for the ex vivo expansion of hematopoietic stem cells. Inventors: Kikuchi, Makoto (Fukuoka, JP); Ikematsu, Shinya (Kanagawa, JP); Oda, Munehiro (Kanagawa, JP); Sakuma, Sadatoshi (Kanagawa, JP); Muramatsu, Takashi (Aichi, JP)
Assignee: Meiji Milk Products, Co., Ltd. (Tokyo, JP)
Date of First Priority Issue: Wednesday July 10th, 1996
Patent Number: 6379953
This patent teaches the use of the molecule ALCAM for induction of mesenchymal cell differentiation. It is also thought in this patent that ALCAM may be useful for the isolation of certain types of mesenchymal stem cells. Inventors: Bruder, Scott P. (Owings Mills, MD); Jaiswal, Neelam (Ellicott City, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Thursday September 4th, 1997
Patent Number: 6379710
This patent teaches that one can take an organ from an allogeneic or xenogeneic animal, decellularize the organ, and use the matrix components of the organ as a scaffold to be seeded with stem cells either in vitro or in vivo, and used for the generation of a new organ.
In one specific embodiment, livers are generated using this approach. Inventor: Badylak, Stephen F. (West Lafayette, IN)
Assignee: Purdue Research Foundation (West Lafayette, IN)
Date of First Priority Issue: Tuesday December 10th, 1996
Patent Number: 6376238
This patent provides a culture media for the growth of neuronal stem cells, and neurons themselves. The media is made using standard tissue culture components, with the exception that astroglial cells are used to condition it.
The fact that astroglial cells normally produce various compounds that support the nervous system cells is what maybe triggered the inventor to think to condition... Inventor: Watanabe, Yoshiaki (Akita, JP)
Assignee: Sumitomo Bakelite Co., Ltd. (Tokyo, JP)
Date of First Priority Issue: Tuesday June 27th, 1995
Patent Number: 6372494
This patent teaches how to generate cell conditioned media. The unique part about this patent is that the cells used to condition the media are grown in three dimensional culture. Inventors: Naughton, Gail K. (La Jolla, CA); Mansbridge, Jonathan N. (La Jolla, CA); Pinney, R. Emmett (Poway, CA) )
Assignee: Advanced Tissue Sciences, Inc. (La Jolla, CA)
Date of First Priority Issue: Friday May 14th, 1999
Patent Number: 6372262
This patent covers a factor derived from serum by chemical purification techniques that induces stem cell differentiation, and is able to induce differentiation of leukemic cells.
Such factors have great possibilities in cancer therapy. Older work by Laurence Burton at the Immune Augmentative Therapy (IAT) clinic actually clinically used such factors with good results in mesothelioma patients... Inventors: Peled, Tony (Mevaseret, IL); Fibach, Eitan (Mevaseret Zion, IL); Rachmilewitz, Eliezer A. (Jerusalem, IL)
Assignee: Hadasit Medical Research Services & Development Company Ltd. (Jerusalem, IL)
Date of First Priority Issue: Tuesday December 10th, 1996
Patent Number: 6372210
This patent provides tissue culture media and conditions for expansion and growth of hematopoietic cells in vitro. Specifically, this patent is useful for cellular therapy in which the media for growing and maintaining the stem cells has to be chemically defined and effective. Inventor: Brown, Ronald L. (Derwood, MD)
Assignee: Quality Biological, Inc. (Gaithersburg, MD)
Date of First Priority Issue: Friday October 18th, 1996
Patent Number: 6368854
Bone marrow stem cells and other types of stem cells prefer to reside in conditions of hypoxia. In this patent, the use of hypoxia for inducing differentiation of neural stem cells into neurons is disclosed. Inventors: Weiss, Samuel (Calgary, CA); Sorokan, S. Todd (Victoria, CA) )
Assignee: NeuroSpheres Holdings Ltd. (Calgary, CA
Date of First Priority Issue: Friday October 24th, 1997
Patent Number: 6368636
This patent teaches the use of mesenchymal stem cells for preventing allograft rejection through immune modulation.
It is known that bone marrow cells can display a veto-like effect in that they are capable of inducing donor-specific tolerance. The bone marrow cells are one source of mesenchymal stem cells. In this patent purified mesenchymal stem cells are claimed not only for inducing... Inventors: McIntosh, Kevin R. (Ellicott City, MD); Mosca, Joseph D. (Ellicott City, MD); Klyushnenkova, Elena N. (Baltimore, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Wednesday March 18th, 1998
Patent Number: 6368612
This patent covers a device that can be implanted so as to protect the cells inside the device from immune mediated rejection. This is particularly useful for stem cell therapy and therapy with cells that are differentiated from stem cells because it would allow for the use of one cell source in all people.
The device is also useful for transplantation of islet cells that are xenogeneic to the... Inventors: Lanza, Robert P. (Clinton, MA); Chick, William (Wellesley, MA)
Assignee: Biohybrid Technologies LLC (Shrewsbury, MA)
Date of First Priority Issue: Friday December 12th, 1997
Patent Number: 6365404
This patent teaches the treatment of HIV by reconstituting the immuen system with cells that can not be infected since they lack the HIV receptor or co-receptor.
This patent is neat since theoretically it would not need immune suppression since the HIV will perform the task of selecting only for the cells that are resistant...then again the HIV may mutate !! Inventor: O'Donnell, Jr., Francis E. (St. Louis, MO)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Monday August 12th, 1996
Patent Number: 6365153
This patent teaches ways of using physical means to stretch out neuronal cells. These neurons can then be inserted into an animal or human with a nervous system injury.
This patent is useful for stem cells since the neurons could be generated from progenitors in vitro, then mechanically modified, then placed into the nervous system of the patient. Inventor: Smith, Douglas H. (Concord/Boothwyn, PA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Tuesday August 17th, 1999
Patent Number: 6365149
This patent covers the composition of matter and use of a specialized foam that can be embedded with stem cells and inserted in vivo, or can be inserted in vivo with chemoattractants for stem cells so that the endogenous stem cells repopulate it. Inventors: Vyakarnam, Murty N. (Edison, NJ); Zimmerman, Mark C. (East Brunswick, NJ); Scopelianos, Angelo George (Whitehouse Station, NJ); Roller, Mark B. (North Brunswick, NJ); Gorky, David V. (Flemington, NJ)
Assignee: Ethicon, Inc. (Somerville, NJ)
Date of First Priority Issue: Wednesday June 30th, 1999
Patent Number: 6361998
This patent teaches how to generate large amounts of erythrocytes by specifically culturing hematopoietic stem cells with cytokines such as IL-3, Stem Cell Factor, and EPO. Inventors: Bell, David N. (Oakville, CA); Matthews, Kathryn Emma (Toronto, CA); Mueller, Susan G. (Milton, CA)
Assignee: Hemosol Inc. (Mississauga, CA)
Date of First Priority Issue: Friday June 25th, 1999
Patent Number: 6361997
This patent provides stem cells that are mesenchymal-like or lack expression of CD34, for the purpose of transfection with a foreign gene. Inventor: Huss, Ralf (83666 Waakirchen, DE)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday July 24th, 1998
Patent Number: 6361996
This patent provides a type of neural stem cell that is capable of differentiating into neural cells and glial cells. Specific properties of the stem cell are covered such as dependence on FGF. Inventors: Rao, Mahendra S. (Salt Lake City, UT); Mayer-Proschel, Margot (Sandy, UT)
Assignee: University of Utah Research Foundation (Salt Lake City, UT)
Date of First Priority Issue: Wednesday May 7th, 1997
Patent Number: 6361977
IL-3 is an important cytokine not only for hematopoietic stem cell proliferation and differentiation, but also for other immune cells and non-hematopoietic stem cells. This patent provides various compositions of matter relating to proteins that stimulate the IL-3 receptor. Inventors: Bauer, S. Christopher (New Haven, MO); Abrams, Mark Allen (St. Louis, MO); Braford-Goldberg, Sarah Ruth (St. Louis, MO); Caparon, Maire Helena (Chesterfield, MO); Easton, Alan Michael (Maryland Heights, MO); Klein, Barbara Kure (St. Louis, MO); McKearn, J
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Tuesday November 24th, 1992
Patent Number: 6361976
This patent teaches the use of various proteins that activate the IL-3 receptor in combination with other hematopoietic growth factors for the stimulation of hematopoietic stem cell proliferation. Inventors: Bauer, S. Christopher (New Haven, MO); Abrams, Mark Allen (St. Louis, MO); Braford-Goldberg, Sarah Ruth (St. Louis, MO); Caparon, Maire Helena (Chesterfield, MO); Easton, Alan Michael (Maryland Heights, MO); Klein, Barbara Kure (St. Louis, MO); McKearn, J
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Tuesday November 24th, 1992
Patent Number: 6358505
This patent provides various compositions of matters in the form of proteins that are useful for stimulating in an agonistic manner the receptor for granulocyte colony stimulating factor. This patent may be used for treatment of neutropenia as a way of getting around Amgen's G-CSF. Inventors: Zurfluh, Linda (Kirkwood, MO); Klein, Barbara (St. Louis, MO); McWherter, Charles (Wildwood, MO); Feng, Yiping (St. Louis, MO); McKearn, John (Glencoe, MO); Braford-Goldberg, Sarah (St. Louis, MO)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Wednesday September 27th, 1995
Patent Number: 6358252
Usually bone marrow is extracted from the iliac crest of patients. In this patent a new device for extracting bone marrow is disclosed. The patent is useful for, intra alia, taking out bone marrow from the jaw bone of a subject that is undergoing dental surgery. If you thought root canals are painful, imagine this ! Inventor: Shapira, Ira L. (Highland Park, IL)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Tuesday July 1st, 1997
Patent Number: 6355239
This patent covers the use of mesenchymal stem cells that are either allogeneic or xenogeneic for the purposes of regeneration and/or enhancing hematopoietic graft function.
Since mesenchymal stem cells are immunosuppressive (at least locally), the use of immunosuppressants can be avoided. This patent would be interesting to use with islet grafts for the treatment of diabetes. I mean, some... Inventors: Bruder, Scott P. (Waltham, MA); McIntosh, Kevin R. (Ellicott City, MD); Marshak, Daniel R. (Lutherville, MD); Mosca, Joseph D. (Ellicott City, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Friday March 13th, 1998
Patent Number: 6355237
Leptin inhibits obesity. In this patent leptin is used in combination with other hematopoietic cytokines for the stimulation of hematopoietic stem cell function. Given the similarity between hematopoietic stem cells and neuronal stem cells, it would be interesting to assess the effects of leptin on neuronal stem cells. Inventors: Snodgrass, H. Ralph (Powell, OH); Cioffi, Joseph (New Albany, OH); Zupancic, Thomas Joel (Worthington, OH); Shafer, Alan Wayne (Lancaster, OH)
Assignee: Progenitor, Inc. (Columbus, OH)
Date of First Priority Issue: Wednesday September 14th, 1994
Patent Number: 6352555
This patent provides methods and devices for administration of cells, including stem cells, via various prosthetic devices. Inventors: Dzau, Victor J. (Newton, MA); Pratt, Richard E. (Newton, MA); Mann, Michael J. (Newton, MA); Ehsan, Afshin (Boston, MA); Griese, Daniel P. (Boston, MA)
Assignee: The Brigham and Womens Hospital, Inc. (Boston, MA)
Date of First Priority Issue: Friday July 10th, 1998
Patent Number: 6348444
This patent teaches the use of growth hormone to stimulate hematopoiesis. The fact that various hormones have hematopoietic activity suggests that it may be worthwhile to assess their activity on the growth of neural stem cells both in vitro, but also in vivo.
I believe that there is evidence of hormones like testosterone increasing mental acuity in elderly patients...could this have something... Inventor: Chappel, Scott C. (Milton, MA)
Assignee: Applied Research Systems ARS Holding N.V. (Curacao, NL)
Date of First Priority Issue: Thursday December 17th, 1998
Patent Number: 6346531
This patent provides compositions of matter that are useful for stimulating the receptor for granulocyte colony stimulating factor. The fact that G-CSF was the first drug introduced that acted on the level of stem cells suggests that this is an important area for drug development.
This patent may be useful not only for stimulation of neutrophil function, but also for increasing stem cell... Inventors: Luengo, Juan I (Audubon, PA); Duffy, Kevin J (Norristown, PA)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Date of First Priority Issue: Saturday March 20th, 1999
Patent Number: 6342344
This patent provides kits for purifying out of a human-SCID mouse cells of human origin. Inventors: Thomas, Terry E. (Vancouver, CA); Eaves, Connie J. (Vancouver, CA)
Assignee: StemCell Technologies Inc. (Vancouver, CA)
Date of First Priority Issue: Friday July 31st, 1998
Patent Number: 6340674
This patent teaches that inhibition of stem cell proliferation, and induction of differentiation may be achieved by inhibiting expression or function of the protein insulin like growth factor. This patent can also be used with more modern gene silencing techniques such as RNA interference. Inventors: Baserga, Renato (Ardmore, PA); Sell, Christian (Philadelphia, PA); Rubin, Raphael (Penn Valley, PA)
Assignee: Thomas Jefferson University (Philadelphia, PA)
Date of First Priority Issue: Friday March 26th, 1993
Patent Number: 6340668
The bone morphogenic proteins (BMPs) are able to stimulate various regenerative capabilities, including in the hematopoietic system, and especially in cartilage and bone.
This patent teaches that BMP-11 is able to increase survival of neurons both in vitro and in vivo. This patent is useful for stimulation of neuronal stem cells, as well as for culture of neurons generated from stem cells... Inventors: Celeste, Anthony J. (Hudson, MA); Wozney, John M. (Hudson, MA); Thies, R. Scott (Andover, MA)
Assignee: Genetics Institute, Inc. (Cambridge, MA)
Date of First Priority Issue: Wednesday May 12th, 1993
Patent Number: 6338942
This patent seems very interesting. It covers ways of selectively inducing proliferation of certain cell populations while "weeding out" cells that are not desirable. This patent is very useful in selection of stem cells and their progeny. Inventors: Kraus, Morey (Worcester, MA); Wilder, Paul T. (Boylston, MA); Friberg, Jill (Seattle, WA)
Assignee: T. Breeders, Inc. (Worcester, MA)
Date of First Priority Issue: Friday May 19th, 1995
Patent Number: 6337184
This patent claims that expression of the anti-apoptotic gene bcl-2 can be used as a marker for stem cells of the muscle. The problem is that bcl-2 is an intracellular molecule, therefore it is difficult to selectively purify based on its expression. If a colourogenic substrate for bcl-2 can be discovered or already exists, this would greatly increase the value of the current patent. Inventor: Miller, Jeffrey B. (Cambridge, MA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Tuesday April 1st, 1997
Patent Number: 6335195
This patent teaches that angiotensinogen I, II, and analogues thereof, are useful for the stimulation of mesenchymal and/or hematopoietic stem cell proliferation and/differentiation. Inventors: Rodgers, Kathleen E. (Long Beach, CA); DiZerega, Gere S. (Pasadena, CA)
Assignee: Maret Corporation (Newport Beach, CA)
Date of First Priority Issue: Tuesday January 28th, 1997
Patent Number: 6333192
This patent teaches novel ways of generating chicken embryonic stem cells. This patent is useful for veterinary applications, as well, it may be transferrable to other species. Inventors: Petitte, James N. (Raleigh, NC); Chang, Il-Kuk (Raleigh, NC)
Assignee: North Carolina State University (Raleigh, NC)
Date of First Priority Issue: Monday August 9th, 1999
Patent Number: 6333029
This patent provides compositions of matter, and their uses, for generation of foams and various implantable structures that can function as scaffolds for the generation of artificial tissues. Inventors: Vyakarnam, Murty N. (Edison, NJ); Zimmerman, Mark C. (East Brunswick, NJ); Scopelianos, Angelo George (Whitehouse Station, NJ); Roller, Mark B. (North Brunswick, NJ); Gorky, David V. (Flemington, NJ)
Assignee: Ethicon, Inc. (Somerville, NJ)
Date of First Priority Issue: Wednesday June 30th, 1999
Patent Number: 6331659
This patent provides the use of cumulus cells as donors of nuclei for the purpose of cloning animals with the exception of humans. Inventors: Wakayama, Teruhiko (Honolulu, HI); Yanagimachi, Ryuzo (Honolulu, HI)
Assignee: University of Hawaii (Honolulu, HI)
Date of First Priority Issue: Wednesday January 21st, 1998
Patent Number: 6331406
This patent provides a new type of cell that can function as a stem cell, or is useful in the generation of stem cells. The cell population is characterized and is isolated from embryonic gonadal ridges. Inventors: Gearhart, John D. (Baltimore, MD); Shamblott, Michael Joseph (Baltimore, MD)
Assignee: The John Hopkins University School of Medicine (Baltimore, MD)
Date of First Priority Issue: Monday March 31st, 1997
Patent Number: 6328960
This patent teaches the use of mesenchymal stem cells as biological immunosuppressants for prevention of graft rejection. Inventors: McIntosh, Kevin R. (Ellicott City, MD); Mosca, Joseph D. (Ellicott City, MD); Klyushnenkova, Elena N. (Baltimore, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Monday January 19th, 1998
Patent Number: 6328765
This patent teaches how to generate a vascularized tissue in vitro for subsequent implantation in vivo. Inventors: Hardwick, William R. (Flagstaff, AZ); Thomson, Robert C. (Flagstaff, AZ); Cleek, Robert L. (Flagstaff, AZ); Mane, Shrikant M. (Flagstaff, AZ); Cook, Alonzo D. (Flagstaff, AZ)
Assignee: Gore Enterprise Holdings, Inc. (Newark, DE)
Date of First Priority Issue: Thursday December 3rd, 1998
Patent Number: 6326205
Thrombopoietin (TPO) is a stimulatory molecule for early hematopoietic stem cells. In this patent the use of TPO and other ligands of its receptor, called mpl, are disclosed for purposes of expansion, and/or megakaryocytic differentiation of hematopoietic stem cells.
It would be interesting to see if other types of stem cells also respond to mpl ligands in the manner that hematopoietic stem... Inventors: Murray, Lesley J. (San Jose, CA); Young, Judy C. (San Carlos, CA)
Assignee: Systemix, Inc. (Palo Alto, CA)
Date of First Priority Issue: Monday October 30th, 1995
Patent Number: 6326198
This patent provides systems for expanding hematopoietic stem cells, but culturing of these cells on stromal cells which secrete IL-6, and/or GM-CSF. It is important for the stromal cells to be secreting these compounds since stromal cells possess a wide variety of hematopoietic stimulatory signals, some known and others unknown. The synergy of the stromal signals with IL-6 and/or GM-CSF is used... Inventors: Emerson, Stephen G. (Ann Arbor, MI); Clarke, Michael F. (Ann Arbor, MI); Palsson, Bernhard O. (Ann Arbor, MI)
Assignee: Regents of the University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Thursday June 15th, 1989
Patent Number: 6322804
This patent provides methods of encapsulating cells so that they will not be rejected by the recipient immune system. Encapsulation devices such as this should be considered not only for the protection of the cells that are administered, but also for protection of the host from the cells. For example, lets say that embryonic stem cells are administered into a degenerating organ for the... Inventors: Dionne, Keith E. (Rehoboth, MA); Emerich, Dwaine F. (Providence, RI); Hoffman, Diane (Cambridge, MA); Sanberg, Paul R. (Spring Hill, FL); Christenson, Lisa (New Haven, CT); Hegre, Orion D. (Green Valley, AZ); Scharp, David W. (St. Louis, MO); Lacy, Paul E
Assignee: Neurotech S.A. (Evry, FR)
Date of First Priority Issue: Thursday April 25th, 1991
Patent Number: 6322784
Mesenchymal stem cells can differentiate into a variety of cellular lineages. In this patent the ability of mesenchymal stem cells to be induced into the adipocyte lineage is covered. Inventors: Pittenger, Mark F. (Severna Park, MD); Beck, Stephen C. (Reistertown, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD
Date of First Priority Issue: Tuesday July 30th, 1996
Patent Number: 6316254
This patent covers the use of TPO (thrombopoietin) for the stimulation of hematopoietic stem cells to differentiate into red blood cells. Classically, as the name implies, TPO is considered a growth factor that induces differentiation of hematopoietic stem cells into the megakaryocytic lineage (ie to make platelets). Inventor: Kaushansky, Kenneth (Woodinville, WA)
Assignee: University of Washington (Seattle, WA
Date of First Priority Issue: Monday February 14th, 1994
Patent Number: 6303768
Methuselah is a gene, which certain variants of it are associated with life extension. The mechanisms of action are not completely known, however it appears that it acts along the pathway of reducing cellular metabolic stress. Inventors: Lin, Yi-Jyun (Arcadia, CA); Benzer, Seymour (San Marino, CA)
Assignee: California Institute of Technology (Pasadena, CA)
Date of First Priority Issue: Monday September 7th, 1998
Patent Number: 6312957
Hematopoietic stem cells are an ideal vector for gene therapy since they repopulate the whole body, and in some cases can differentiate into various tissues in the body. This patent teaches the use of adeno-associated virus vectors to transfect hematopoietic stem cells so that the hematopoietic stem cells can repopulate the host and deliver the protein product of the gene to where it is... Inventors: Einerhand, Markus Peter Wilhelmus (Amsterdam, NL); Valerio, Domenico (Leiden, NL)
Assignee: Introgene B.V. (NL)
Date of First Priority Issue: Thursday December 5th, 1996
Patent Number: 6306575
This patent provides kits for negatively depleting a population of cells so that what remains is hematopoietic stem cells. Different variants of this kit are sold by the Canadian company StemCell Technologies. Inventors: Thomas, Terry (Vancouver, CA); Lansdorp, Peter (Vancouver, CA)
Assignee: StemCell Technologies, Inc. (Vancouver, CA)
Date of First Priority Issue: Friday June 16th, 1995
Patent Number: 6306424
This patent provides various compositions of matter for making foam implants that can be used to deliver cells into a host. Inventors: Vyakarnam, Murty N. (New York, NY); Zimmerman, Mark C. (East Brunswick, NJ); Scopelianos, Angelo George (Whitehouse Station, NJ); Chun, Iksoo (Flemington, NJ); Melican, Mora C. (Bridgewater, NJ); Bazilio, Clairene A. (Plainfield, NJ); Roller, Mark B. (Nor
Assignee: Ethicon, Inc. (Somerville, NJ)
Date of First Priority Issue: Wednesday June 30th, 1999
Patent Number: 6303136
This teaches novel ways of encapsulating cells so that the immune system of the host does not reject them. Inventors: Li, Rebecca (Needham, MA); Rein, David (Providence, RI)
Assignee: Neurotech S.A. (Evry, FR)
Date of First Priority Issue: Monday April 13th, 1998
Patent Number: 6300314
CD26 is an ectoenzyme that is found on numerous cells including stem cells. The enzyme performs numerous functions that inhibit stem cell proliferation.
This patent provides a composition of matter that potently inhibits the CD26 ectoenzyme activity and thereby stimulates proliferation of hematopoietic stem cells.
This patent would be very useful for stimulation of other types of stem cells... Inventors: Wallner, Barbara P. (Weston, MA); Jones, Barry (Cambridge, MA); Miller, Glenn T. (Haverhill, MA); Adams, Sharlene (Watertown, MA)
Assignee: Point Therapeutics, Inc. (Boston, MA)
Date of First Priority Issue: Monday May 4th, 1998
Patent Number: 6294346
Great advances in combinatorial chemistry and in silico design have fast outpaced the availability of biological systems that can be screened using high-throughput systems.
In this patent various neural stem cells and their progeny are claimed for use as screening targets in drug discovery. Inventors: Weiss, Samuel (Calgary, CA); Reynolds, Brent (Calgary, CA); Hammang, Joseph P. (Barrington, RI); Baetge, E. Edward (Barrington, RI)
Assignee: Neurospheres Holdings, Ltd. (Alberta, CA)
Date of First Priority Issue: Monday July 8th, 1991
Patent Number: 6288301
This patent teaches how to treat diabetes by the activation of endogenous stem cells through administration of gastrin and EGF. This patent is in clinical trials. Inventors: Nardi, Ronald V. (Sudbury, MA); Brand, Stephen J. (Lincoln, MA) )
Assignee: Waratah Pharmaceuticals, Inc. (CA); The General Hospital Corporation (Boston, MA
Date of First Priority Issue: Monday December 14th, 1992
Patent Number: 6281012
This patent covers the use of mesenchymal stem cells to generate T suppressor cells in general. Specifically it mentions that CD8 positive T cells can be turned into suppressor cells by contact with mesenchymal stem cells.
Usually, T suppressor cells are called T regulatory cells and this refers to CD4+ CD25+ cells. CD8+ T suppressor cells were very popular in the 1970s and 1980s but then... Inventors: McIntosh, Kevin (Ellicott City, MD); Klyushnenkova, Elena (Baltimore, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Tuesday October 12th, 1999
Patent Number: 6280718
This patent covers ways of inducing the generation of hematopoietic stem cells from embryonic stem cells. This is very useful since it may be possible to generate allogeneic hematopoietic stem cells for the whole population using such a method. Inventors: Kaufman, Dan S. (Madison, WI); Thomson, James A. (Madison, WI)
Assignee: WARF
Date of First Priority Issue: Sunday November 8th, 1998
Patent Number: 6277369
This patent teaches how to transfect hematopoietic stem cells with various genes, including the gene for Factor IX. Transfection is performed by first treating the stem cells with TGF beta in order to increase rate of DNA incorporation. Inventors: Gordon, Erlinda M. (Glendale, CA); Anderson, W. French (San Marino, CA); Hall, Frederick L. (Glendale, CA)
Assignee: University of Southern California (Los Angeles, CA)
Date of First Priority Issue: Tuesday November 12th, 1996
Patent Number: 6277082
This patent provides a medical device that detects ischemia based on electrical conductivity and other parameters. This invention is useful in combination with stem cell therapy so as to enable the administrator of stem cell angiogenic therapy to decide when and where therapy is needed. Inventor: Gambale, Richard A. (Tyngsboro, MA)
Assignee: C. R. Bard, Inc. (Murray Hill, NJ)
Date of First Priority Issue: Thursday July 22nd, 1999
Patent Number: 6261841
This patent teaches that administration of prolactin may be used for enhancing hematopoiesis. This is interesting since there are other patents, including by Stem Cell Therapeutics, that teach the use of prolactin and other compounds for stimulation of neural stem cells. Inventors: Cohen, Isaac (Wilmette, IL); Lefebvre, Phil (Chicago, IL); Lin, Jiandie (Evanston, IL); Linzer, Daniel (Evanston, IL)
Assignee: The Board of Trustees of Northwestern University (Evanston, IL)
Date of First Priority Issue: Friday June 25th, 1999
Patent Number: 6261549
In the same way that hematopoietic stem cells can be purified from peripheral blood, and in the same way that they can be mobilized, this patent teaches that the concept is also applicable to mesenchymal stem cells. Inventors: Fernandez, Mireya (Santiago, CL); Minguell, Jose J. (Santiago, CL)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Thursday July 3rd, 1997
Patent Number: 6258597
The enzyme dipeptidyl peptidase is expressed on a variety of cells including stem cells. This enyzme inhibits the ability of stem cells to proliferate. This patent provides an "inhibitor of inhibitor" so as to stimulate stem cell proliferation. Inventors: Bachovchin, William (Melrose, MA); Wallner, Barbara (Weston, MA)
Assignee: Point Therapeutics, Inc. (Boston, MA)
Date of First Priority Issue: Monday September 29th, 1997
Patent Number: 6258354
This patent covers the use of gene transfected stromal cells in order to increase engraftment of a hematopoietic stem cell transplant. Inventor: Greenberger, Joel S. (Lincoln, MA
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday September 29th, 1989
Patent Number: 6258353
This patent covers the use of a specialized cell population obtained from xenogeneic sources for the stimulation of recovery of various neurological disorders. Specifically, the patent covers pig lateral ganglionic eminence cells that are treated so as to not elicit immune rejection. Inventors: Isacson, Ole (Cambridge, MA); Dinsmore, Jonathan (Brookline, MA)
Assignee: Diacrin, Inc. (Charlestown, MA)
Date of First Priority Issue: Tuesday November 8th, 1994
Patent Number: 6254865
This patent covers the use of neural terminally differentiated teratocarcinoma cells (hNT) for the treatment of Huntington's disease. This technology has actually been used in clinical trials. Inventors: Freed, Curt R. (Denver, CO); Kaddis, Farida G. (Lakewood, CO)
Assignee: University Technology Corporation (Boulder, CO)
Date of First Priority Issue: Tuesday June 17th, 1997
Patent Number: 6255112
This patent covers the use of mesenchymal stem cells to stimulate hematopoietic stem cells. Mesenchymal stem cells are actually in Phase III trials for prevention of graft versus host after hematopoietic stem cell transplants. This patent ensures that if the mesenchymal stem cells also stimulate hematopoiesis, then Osiris is covered from an IP perspective. Inventors: Thiede, Mark A. (Forest Hill, MD); Mbalaviele, Gabriel (Columbia, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Monday June 8th, 1998
Patent Number: 6252133
This patent covers a method of increasing efficacy of the cloning process. Cloning may be used as a source for the generation of stem cells of the embryonic type. Inventors: Campbell, Keith Henry Stockman (Midlothian, GB); Wilmut, Ian (Midlothian, GB)
Assignee: Roslin Institute (Edinburgh) (Midlothian, GB); The Minister of Agriculture, Fisheries & Food (London, GB); Biotechnology & Biological Sciences Research Council (Swindon, GB)
Date of First Priority Issue: Thursday August 31st, 1995
Patent Number: 6251671
This patent covers methods of generating spermatogonial stem cells. These stem cells may be used for a wide variety of regenerative purposes, as well, they appear similar in some ways to the cells generated by the company Primegen. Inventors: Hogan, Brigid L. M. (Brentwood, TN); Zhao, Guang-Quan (Nashville, TN)
Assignee: Vanderbilt University (Nashville, TN)
Date of First Priority Issue: Wednesday February 28th, 1996
Patent Number: 6251669
This patent covers a type of neural stem cell. In one embodiment the stem cells can be differentiated into gamma aminobutyric acid (GABA) expressing neurons. Inventor: Luskin, Marla B. (Decatur, GA)
Assignee: Emory University (Atlanta, GA)
Date of First Priority Issue: Thursday July 6th, 1995
Patent Number: 6251665
This patent covers the use of hematopoietic stem cells to generate dendritic cells. The dendritic cells disclosed are able to elicit an antitumor immune response. Inventors: Cezayirli, Cem (Birmingham, AL); Silvers, Mel (N. Miami Beach, FL)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday February 7th, 1997
Patent Number: 6251383
This patent covers the use of an extract of the plant called Tinospora cordifolia for stimulation of hematopoietic stem cells. Inventors: Upadhyay, Shakti N. (New Delhi, IN); Madan, Vikas (New Delhi, IN)
Assignee: National Institute of Immunology (New Delhi, IN)
Date of First Priority Issue: Tuesday April 20th, 1999
Patent Number: 6248791
This patent covers ways of inducing the differentiation of cells into adipocytes that are responsive to insulin. This is for the treatment of type II diabetes. Inventors: Ailhaud, Gerard (Nice, FR); Grimaldi, Paul (Nice, FR); Safonova, Irina (Nice, FR); Shroot, Braham (Antibes, FR); Reichert, Uwe (Pont du Loup, FR)
Assignee: Centre International de Recherches Dermatologiques Galderma (Valbonne, FR)
Date of First Priority Issue: Saturday April 2nd, 1994
Patent Number: 6248725
This is an interesting patent that teaches the concurrent administration of the thyroid hormone T3, together with keratinocyte growth factor (KGF) can stimulate proliferation of endogenous hepatic stem cells. Inventors: Alison, Malcom R. (London, GB); Coutelle, Charles (London, GB); Forbes, Stuart J. (Middlesex, GB); Hodgson, Humphrey J. F. (London, GB); Sarosi, Ildiko (Thousand Oaks, CA); Themis, Michael (Buckinghamshire, GB)
Assignee: Amgen, Inc. (Thousand Oaks, CA)
Date of First Priority Issue: Tuesday February 23rd, 1999
Patent Number: 6248588
This patent teaches how to store various biological tissues and cells, including stem cells, through the injection of various cryopreservants into said tissues or cells. Inventors: Crespo, Andre (Ormesson, FR); Soria, Henri Michel (Monts, FR)
Assignee: Aventis Pharms S.A. (Antony, FR)
Date of First Priority Issue: Tuesday March 12th, 1996
Patent Number: 6248587
This patent provides the use of angiotensinogen I, II, and various analogues thereof in order to accelerate proliferation and differentiation of mesenchymal stem cells that are in contact with various types of other cells. Inventors: Rodgers, Kathleen E. (Long Beach, CA); DiZerega, Gere (Pasadena, CA)
Assignee: University of Southern Cailfornia (Los Angeles, CA)
Date of First Priority Issue: Friday January 23rd, 1998
Patent Number: 6245566
This patent covers human primordial germ stem cells. These cells can be used for generating a variety of different stem cell lines, as well as for in vitro generation of various germ cells. Inventors: Gearhart, John D. (Baltimore, MD); Shamblott, Michael Joseph (Baltimore, MD)
Assignee: The Johns Hopkins University School of Medicine (Baltimore, MD)
Date of First Priority Issue: Friday December 12th, 1997
Patent Number: 6242579
This patent covers an antigen that is found on some types of hematopoietic stem cells. This antigen can be used for purification of hematopoietic stem cells by magnetic or flow cytometric means. Inventors: Lawman, Michael J. P. (Key Largo, FL); Lawman, Patricia (Key Largo, FL)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Wednesday November 13th, 1996
Patent Number: 6242252
This patent covers a type of hepatic stem cell that expresses OX-43, OX-44, and/or OC3. Inventors: Reid, Lola M. (Chapel Hill, NC); Sigal, Samuel H. (Riverdale, NY); Brill, Shlomo (Ramat-Gan, IL); Holst, Patricia A. (Ossining, NY)
Assignee: Albert Einstein College of Medicine of Yeshiva University (Bronx, NY)
Date of First Priority Issue: Wednesday August 7th, 1991
Patent Number: 6241984
This patent covers autologous hematopoietic stem cell transplants with ex vivo expansion through an IL-3 + GM-CSF fusion protein, and/or with stem cell factor. Inventors: Hoffman, Ronald (Palo Alto, CA); Brandt, John (Palo Alto, CA)
Assignee: The Indiana University Foundation (Bloomington, IN)
Date of First Priority Issue: Tuesday April 9th, 1991
Patent Number: 6238922
This patent teaches that tissue samples, or neurospheres, may be dissociated with collagenase instead of mechanical means, in order to maintain viability of the stem cell component. Inventor: Uchida, Nobuko (Palo Alto, CA)
Assignee: StemCells, Inc. (Sunnyvale, CA)
Date of First Priority Issue: Friday February 26th, 1999
Patent Number: 6235970
This patent teaches ways of generating stem cells, and inner cell mass cells through nuclear transfer. This patent is important for generation of embryonic stem cells, and offers the possibility of generation of autologous embryonic stem cells by nuclear transfer techniques. Inventors: Stice, Steven L. (Belchertown, MA); Cibelli, Jose (Amherst, MA); Robl, James (Belchertown, MA); Golueke, Paul (Belchertown, MA); Ponce de Leon, F. Abel (Amherst, MA); Jerry, D. Joseph (Shutesbury, MA)
Assignee: University of Massachusetts, Amherst Campus (Amherst, MA)
Date of First Priority Issue: Friday January 10th, 1997
Patent Number: 6228640
Disclosed in this patent are methods of generating antigen-loaded dendritic cells useful for cancer immunotherapy, through the differentiation of hematopoietic stem cells. Inventors: Cezayirli, Cem (Birmingham, AL); Silvers, Mel (North Miami Beach, FL)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday February 7th, 1997
Patent Number: 6225119
This patent teaches that mesenchymal stem cells can be used to support the production of platelets from hematopoietic stem cells. Additionally, the patent covers genetically transformed hematopoietic stem cells in contact with mesenchymal stem cells for the generation of genetically transformed platelets. Inventors: Qasba, Pankaj (Columbia, MD); Thiede, Mark A. (Forest Hill, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Friday May 22nd, 1998
Patent Number: 6224860
This patent provides a culture media that can be used for the expansion of hematopoietic stem cells in vivo for use in transplantation. Inventor: Brown, Ronald L. (Derwood, MD)
Assignee: Quality Biological, Inc. (Gaitersburg, MD)
Date of First Priority Issue: Friday October 18th, 1996
Patent Number: 6221359
This patent covers the use of hepatocyte growth factor (and various combinations) for the stimulation of hematopoietic stem cells. Inventors: Komiyama, Atsushi (Matsumoto, JP); Nakahata, Tatsutoshi (Matsumoto, JP); Kubo, Tetsuo (Matsumoto, JP); Tanaka, Ryuhei (Tsu, JP); Kawano, Genji (Kamakura, JP); Sudo, Tetsuo (Kamakura, JP); Sano, Emiko (Yokohama, JP); Kojima, Katsuaki (Yokohama, JP)
Assignee: Toray Industries, Inc. (Tokyo, JP)
Date of First Priority Issue: Friday July 26th, 1991
Patent Number: 6215039
This patent teaches ways of repopulating the testicles with stem cells and/or other cells so that the resulting animal may have offspring that are genetically different. Inventor: Brinster, Ralph L. (Gladwyne, PA)
Assignee: The Trustees of the University of Pennsylvania (Philadelphia, PA)
Date of First Priority Issue: Friday December 6th, 1991
Patent Number: 6214369
This patent covers the use of mesenchymal stem cells for generation of bone and cartilage. It is interesting that Osiris has patents in this area as well. Inventors: Grande, Daniel A. (Sea Cliff, NY); Lucas, Paul A. (Macon, GA)
Assignee: MorphoGen Pharmaceuticals, Inc. (Downey, CA)
Date of First Priority Issue: Tuesday March 14th, 1995
Patent Number: 6214334
This patent covers a neuronal stem cell line that is useful for treatment of central and peripheral nervous system disorders. Inventors: Lee, Virginia M. -Y. (Philadelphia, PA); Trojanowski, John Q. (Philadelphia, PA)
Assignee: Trustees of the University of Pennsylvania (Philadelphia, PA)
Date of First Priority Issue: Monday October 21st, 1991
Patent Number: 6213127
This patent teaches ways of administering allogeneic lymphocytes that have been treated chemically or with radiation so as to elicit an antitumor effect while at the same time not causing graft versus host. Inventor: Waller, Edmund K. (Atlanta, GA)
Assignee: Emory University (Atlanta, GA)
Date of First Priority Issue: Tuesday September 1st, 1998
Patent Number: 6207802
This is one of the composition of matter patents on the stem cell stimulatory cytokine called "stem cell factor". Since the receptor for this cytokine, c-kit, is present on numerous other types of stem cells (ie cardiac, muscle, kidney stem cells), it is of interest whether this cytokine can also be of use in expanding non-hematopoietic stem cells. Inventors: Zsebo, Krisztina M. (Thousand Oaks, CA); Bosselman, Robert A. (Thousand Oaks, CA); Suggs, Sidney V. (Newbury Park, CA); Martin, Francis H. (Thousand Oaks, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Date of First Priority Issue: Monday October 16th, 1989
Patent Number: 6207658
Disclosed are various formulations and chemicals in which cells and tissue can be stored for prolonged time periods. Inventors: Simpkins, James W. (Gainesville, FL); Green, Pattie S. (Gainesville, FL); Gridley, Kelly E. (Gainesville, FL)
Assignee: University of Florida Research Foundation, Inc. (Gainesville, FL)
Date of First Priority Issue: Thursday January 11th, 1996
Patent Number: 6206914
This patent covers the use of cells, including stem cells and derivatives, for producing certain drugs or proteins specifically upon stimulation. Stimulation may be electrical, mechanical, or chemical. Inventors: Soykan, Orhan (New Brighton, MN); Donovan, Maura G. (St. Paul, MN) )
Assignee: Medtronic, Inc. (Minneapolis, MN
Date of First Priority Issue: Thursday April 30th, 1998
Patent Number: 6204363
This patent covers the composition of matter for a stem cell expansion protein named "stem cell factor", this is the ligand for c-kit. Inventors: Zsebo, Krisztina M. (Thousand Oaks, CA); Bosselman, Robert A. (Thousand Oaks, CA); Suggs, Sidney V. (Newbury Park, CA); Martin, Francis H. (Thousand Oaks, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Date of First Priority Issue: Monday October 16th, 1989
Patent Number: 6200806
This is one of the patents that cover embryonic stem cells. These patents are under much controversy since they cover the composition of matter for all embryonic stem cells. Inventor: Thomson, James A. (Madison, WI)
Assignee: Wisconsin Alumni Research Foundation (Madison, WI)
Date of First Priority Issue: Friday January 20th, 1995
Patent Number: 6200606
This patent covers the use of adipose derived stem cells for the generation of cartilage and bones. Inventors: Peterson, Dale R. (Carmel, IN); Nousek-Goebl, Nancy (Fishers, IN)
Assignee: DePuy Orthopaedics, Inc. (Warsaw, IN)
Date of First Priority Issue: Tuesday January 16th, 1996
Patent Number: 6197751
Thymosin is expressed by the thymus and is associated with immune stimulation. In this patent the ability of thymosin to augment regeneration of tissue, as well as stimulate stem cells is patented.
It is interesting that the production of thymosin actually decreases, as well as general thymic function with age. This patent may be a way to induce longevity by administration of thymosin. Inventors: Malinda, Katherine M. (Millersville, MD); Kleinman, Hynda K. (Kensington, MD); Goldstein, Allan L. (Washington, DC)
Assignee: The United States of America as represented by the Department of Health and Human Services (Washington, DC)
Date of First Priority Issue: Friday November 7th, 1997
Patent Number: 6194635
This patent teaches how to generate embryonic germ cells. These cells may be used for transgenic and knockout experiments, as well as for generation of stem cells with unique properties. Inventors: Anderson, Gary B. (Davis, CA); Shim, Hosup (Davis, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Date of First Priority Issue: Tuesday January 9th, 1996
Patent Number: 6194202
This patent covers the generation of embryonic stem cells through parthenogenesis in cows. Parthenogenesis involves activating the oocyte to differentiate in absence of sperm. Inventors: Susko-Parrish, Joan L. (Monona, WI); Northey, David L. (Madison, WI); Leibfried-Rutledge, M. Lorraine (Madison, WI); Stice, Steven L. (DeForest, WI)
Assignee: Infigen, Inc. (DeForest, WI)
Date of First Priority Issue: Wednesday February 10th, 1993
Patent Number: 6190910
This patent teaches the generation of several embryonic stem cell lines that are useful for creation of knockout mouse models. Inventors: Kusakabe, Moriaki (Ibaragi, JP); Kamon, Toshio (Tokyo, JP)
Assignee: The Institute of Physical and Chemical Research (Saitama, JP)
Date of First Priority Issue: Thursday March 21st, 1996
Patent Number: 6190368
This patent covers a medical device that is useful for extraction of cord blood so as to avoid the need for letting the cord blood drop by gravity into the collection receptacle. Inventors: Kuypers, Franciscus A. (El Cerrito, CA); Cole, Robert B. (Alamo, CA); Meyst, Richard P. (Valley Center, CA); Gorton, Lanny A. (San Diego, CA); Wright, James I. (Villa Park, CA)
Assignee: Children's Hospital Medical Center of Northern California (Oakland, CA)
Date of First Priority Issue: Tuesday May 14th, 1996
Patent Number: 6184035
This patent teaches ways of growing muscle stem cells through exposure to low oxygen tension and other tissue culture media. Inventors: Csete, Marie (South Pasadena, CA); Doyle, John (South Pasadena, CA); Wold, Barbara (San Marino, CA)
Assignee: California Institute of Technology (Pasadena, CA)
Date of First Priority Issue: Wednesday November 18th, 1998
Patent Number: 6184033
This patent teaches the administration of fetal cells, including stem cells, for the treatment of HIV infection. Various stem cells are known to secrete anti-inflammatory compounds such as TGF-beta. One possible mechanism of action is that stem cells secrete these antiinflammatory compounds, which in turn inhibit NF-kappa B, which does not allow for the HIV to replicate. Inventor: Smikodub, Alexandr Ivanovich (Kiev, UA)
Assignee: Centr Embrionalnikh Tkaney "Emcell" (Kiev, UA)
Date of First Priority Issue: Wednesday August 9th, 1995
Patent Number: 6179819
Patented is a medical device that can extract cord blood out of an umbilical cord. Inventor: Haswell, John N. (Sarasota, FL)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday August 30th, 1996
Patent Number: 6177402
This patent teaches how to induce differentiation of neurons, as well as to enhance their survival using a variety of growth factors, including leukemia inhibitory factor. Inventors: Bartlett, Perry (North Carlton, AU); Murphy, Mark (Fitzroy, AU)
Assignee: Amrad Corporation, Ltd. (Victoria, AU)
Date of First Priority Issue: Monday March 19th, 1990
Patent Number: 6176089
It is not good enough to encapsulate stem cells for therapeutic use, since the stem cells will have to be transported to the hospital or institution where they are needed. This patent covers methods of cryopreserving cells that have been encapsulated so that they may be shipped to the region of need. Inventor: Bouche, Nicola (Lausanne, CH)
Assignee: Modex Therapeutics (Lausanne, CH)
Date of First Priority Issue: Tuesday October 27th, 1998
Patent Number: 6174526
This patent teaches the use of circulating mesenchymal stem cells for treatment of wounds. Inventors: Cerami, Anthony (Shelter Island, NY); Bucala, Richard J. (New York, NY)
Assignee: The Picower Institute for Medical Research (Manhaset, NY)
Date of First Priority Issue: Friday February 26th, 1993
Patent Number: 6174333
This patent covers implantable agents that can be administered together with mesenchymal stem cells for the purpose of creating or repairing various tissues. Inventors: Kadiyala, Sudhakar (Baltimore, MD); Caplan, Arnold I. (Cleveland Heights, OH); Fink, David J. (Shaker Heights, OH); Young, Randall G. (Ellicott City, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD); Case Western Reserve University (Cleveland, OH)
Date of First Priority Issue: Monday June 6th, 1994
Patent Number: 6171610
This patent covers hydrogels that may be used in combination with stem cells for the generation of various artificial tissues. Inventors: Vacanti, Charles A. (Uxbridge, MA); Vacanti, Joseph P. (Winchester, MA); Vacanti, Martin P. (Westborough, MA)
Assignee: University of Massachusetts (Boston, MA); The Children's Medical Center Corporation (Boston, MA)
Date of First Priority Issue: Friday April 24th, 1998
Patent Number: 6171340
This patent covers a procedure for repairing articular cartilage through administration of growth factors and/or stem cells. Inventor: McDowell, Charles L. (Richmond, VA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday February 27th, 1998
Patent Number: 6165783
EPO is used clinically for treatment of anemia and is considered generally safe. This patent teaches that administration of EPO can stimulate the differentiation of neurons. Currently this concept is being tested (at least in part) by Stem Cell Therapeutics who are conducting clinical trials using EPO together with hCG for the treatment of stroke. Inventors: Weiss, Samuel (Calgary, CA); Sorokan, S. Todd (Victoria, CA)
Assignee: Neuro Spheres Holdings Ltd. (Calgary, CA)
Date of First Priority Issue: Friday October 24th, 1997
Patent Number: 6165459
This patent teaches that administration of various chemokines, such as, for example MIP-1 alpha or IL-8, inhibits the production of myeloid stem cell derived cells such as granulocytes or monocytes. Inventors: Broxmeyer, Hal E. (Indianapolis, IN); Cooper, Scott (Indianapolis, IN); Mantel, Charles (Indianapolis, IN); Lu, Li (Indianapolis, IN)
Assignee: Indiana University Foundation (Indianapolis, IN)
Date of First Priority Issue: Wednesday December 9th, 1992
Patent Number: 6162643
This is a composition of matter patent on a tissue culture medium that is useful for the growth of various stem cells. Inventor: Wille, Jr., John J. (Trenton, NJ)
Assignee: Hy-Gene Biomedical Corporation (Ventura, CA)
Date of First Priority Issue: Monday January 29th, 1990
Patent Number: 6162427
This patent teaches that a more potent stimulation of hematopoietic stem cell mobilization can be achieved by combining G-CSF with cyclophosphamide, as opposed to administration of either alone. Inventors: Baumann, Matthias (Karl-Ludwig-Strasse, DE); Ochlich, Peter-Paul (Wallonenstrasse, DE)
Assignee: Roche Diagnostics GmbH (Mannheim, DE)
Date of First Priority Issue: Wednesday December 20th, 1995
Patent Number: 6159940
This patent seems ripe for development. It covers a composition of matter that appears, at face value, relatively easy to synthesize and is useful for the stimulation of hematopoietic stem cells. Inventors: Deigin, Vladislav I. (North York, CA); Korotkov, Andrei M. (Moscow, RU)
Assignee: Immunotech Developments Inc. (Toronto, CA)
Date of First Priority Issue: Wednesday February 28th, 1996
Patent Number: 6159934
This patent teaches that Sertoli cells make stem cell factor (which is interesting since people are co-culturing sertoli cells with islets from treating diabetes)...and that production of stem cell factor from sertoli cells may be upregulated by administration of the hormone GHRH-RP. Inventor: Pescovitz, Ora H. (Carmel, IN)
Assignee: Indiana University Foundation (Bloomington, IN)
Date of First Priority Issue: Wednesday December 20th, 1995
Patent Number: 6159462
This patent provides composition of matter for various peptides that are derived frim Wnt that are capable of stimulating stem cell expansion. Inventors: Matthews, William (Woodside, CA); Austin, Timothy W. (Morgan Hill, CA)
Assignee: Genentech, Inc. (So. San Francisco, CA)
Date of First Priority Issue: Friday August 16th, 1996
Patent Number: 6159461
Combinations of cytokines are provided in this patent for expanding the number of hematopoietic stem cells. Cytokines include stem cell factor, tnf-alpha, and pixy. This is somewhat interesting since TNF alpha is usually considered to inhibit hematopoiesis. Inventors: Besmer, Peter (New York, NY); Buck, Jochen (New York, NY); Moore, Malcolm A. S. (New York, NY); Nocka, Karl (Harvard, MA)
Assignee: Sloan-Kettering Institute for Cancer Research (New York, NY)
Date of First Priority Issue: Thursday April 23rd, 1992
Patent Number: 6156733
This patent teaches how to treat heart failure by administration of antagonists to endothelin and LIF. Inventors: Ferrara, Napoleone (San Francisco, CA); King, Kathleen (Pacifica, CA); Luis, Elizabeth (San Francisco, CA); Mather, Jennie P. (Millbrae, CA); Paoni, Nicholas F. (Belmont, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Date of First Priority Issue: Monday April 24th, 1995
Patent Number: 6156572
This patent provides novel compositions of matter that are useful for growing stem cells and neurons derived thereof for the purpose of implantation into the host. Specific matrices are provided. Inventors: Bellamkonda, Ravi (Boston, MA); Ranieri, John P. (Lausanne, CH); Aebischer, Patrick (Lutry, CH)
Assignee: Neurotech S.A. (Evry, FR)
Date of First Priority Issue: Wednesday July 20th, 1994
Patent Number: 6156301
This patent teaches the use of IL-7 for stimulation of hematopoiesis, as well as increasing the output of lymphocytes. IL-7 has several interesting properties, including the ability to support homeostatic expansion of T cells. Inventors: Namen, Anthony E. (Seattle, WA); Goodwin, Raymond G. (Seattle, WA); Lupton, Stephen D. (Seattle, WA); Mochizuki, Diane Y. (Seattle, WA)
Assignee: Sanofi-Synthelabo (Paris, FR)
Date of First Priority Issue: Monday October 26th, 1987
Patent Number: 6150164
This patent teaches how to make a cell-seeded bioreactor so as to grow various types of kidney cells onto a hollow fiber filter for the generation of an "artificial kidney". Inventor: Humes, H. David (Ann Arbor, MI)
Assignee: The Regents of the University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Monday September 30th, 1996
Patent Number: 6149902
This patent teaches how to expand stem cells of ectodermal, endodermal and mesodermal origin without inducing differentiation, by the activation of the notch pathway. This patent could be a very strong base for development of regenerative cell populations either allogeneic or autologous. Inventors: Artavanis-Tsakonas, Spyridon (Hamden, CT); Fortini, Mark Edward (New Haven, CT); Matsuno, Kenji (New Haven, CT)
Assignee: Yale University (New Haven, CT)
Date of First Priority Issue: Monday September 25th, 1995
Patent Number: 6147052
Disclosed is the novel protein "Erythroid Differentiation and Denucleation Factor" (EDDF) which is capable of inducing production of red blood cells from hematopoietic stem cells both in vitro and in vivo. Methods of stimulating hematopoietic stem cells to generate various lineages of cells are important in medicine. It will be interesting to see if the EDDF also has similarity to EPO in terms... Inventor: Chau, Raymond Ming Wah (Hong Kong, CN)
Assignee: KM Biotech, Inc. (Montebello, CA)
Date of First Priority Issue: Thursday December 5th, 1996
Patent Number: 6146889
Disclosed are culture conditions and compositions of matter that are useful for expansion of liver stem cells. This patent is useful not only for the generation of single cell hepatocytes, but may be used with other scaffold patents in order to generate artificial liver lobes. Inventors: Reid, Lola M. (Chapel Hill, NC); Agelli, Maria (New Providence, NJ)
Assignee: Albert Einstein College of Medicine of Yeshiva University, a division of Yeshiva University (Bronx, NY)
Date of First Priority Issue: Wednesday August 7th, 1991
Patent Number: 6146888
In this patent an antibiotic resistance gene is placed under the control of a promoter associated with stem cells. This way only the stem cells will live while the other cells will die when exposed to the antibiotic. Inventors: Smith, Austin Gerard (Edinburgh, GB); Mountford, Peter Scott (Elsfernwid, AU)
Assignee: The University of Edinburgh (GB)
Date of First Priority Issue: Thursday April 21st, 1994
Patent Number: 6146623
This patent covers genetic transfection of stem cells that give rise to neutrophils. Transfection of this cell population may be performed to enhance their ability to proliferate, or may be performed to endow them with increased antibacterial activities. Inventors: Bender, James G. (Lindenhurst, IL); Maples, Phillip B. (Waukegan, IL); Smith, Stephen (Arlington Heights, IL); Unverzagt, Kristen L. (Palatine, IL); Van Epps, Dennis E. (Cary, IL)
Assignee: Nexell Therapeutics Inc. (Irvine, CA)
Date of First Priority Issue: Monday March 23rd, 1992
Patent Number: 6143293
This patent covers a multilayered scaffold that can be seeded with stem cells, other types of cells, and/or growth factors for the generation of three dimensional tissues in culture. Inventors: Weiss, Lee E. (Pittsburgh, PA); Calvert, Jay Wynn (Pittsburgh, PA)
Assignee: Carnegie Mellon (Pittsburgh, PA); University of Pittsburgh (Pittsburgh, PA)
Date of First Priority Issue: Thursday March 26th, 1998
Patent Number: 6143289
Disclosed are methods of inhibiting production of myeloid lineage hematologic cells through the administration of various members of the chemokine family. Chemokines useful for inhibiting myeloid cell production include MIP1 alpha, and beta, IL-8, PF4, and MCAF. Inventors: Broxmeyer, Hal E. (Indianapolis, IN); Cooper, Scott (Indianapolis, IN); Mantel, Charles (Indianapolis, IN); Lu, Li (Indianapolis, IN)
Assignee: Indiana University Foundation (Bloomington, IN)
Date of First Priority Issue: Wednesday December 9th, 1992
Patent Number: 6140121
This patent provides compounds that are capable of increasing the viability of germ cells and embryos both in vitro and in vivo. Inventors: Ellington, Joanna E. (Valleyford, WA); Oliver, Sylvia Adams (Spokane, WA)
Assignee: Advanced Reproduction Technologies, Inc. (Valleyford, WA)
Date of First Priority Issue: Sunday September 10th, 1995
Patent Number: 6140116
This patent covers a type of stem cell, specifically xenogeneic pig cerebral cortical cells. These cells, when treated so as to not elicit immune rejection, are useful for the treatment of various neurodegenerative disorders. Inventor: Dinsmore, Jonathan (Brookline, MA)
Assignee: Diacrin, Inc. (Charlestown, MA)
Date of First Priority Issue: Tuesday November 8th, 1994
Patent Number: 6139578
This patent provides scaffolds and various compositions for their manufacture so that the structures made may be seeded with stem cells and/or other types of cells for tissue engineering purposes. Inventors: Lee, Dosuk D. (Brookline, MA); Rey, Christian (Castanet, FR); Aiolova, Maria (Brookline, MA)
Assignee: Etex Corporation (Cambridge, MA)
Date of First Priority Issue: Friday May 19th, 1995
Patent Number: 6136952
This patent covers the composition of matter of JAGGED and various peptide derivatives. JAGGED is important embryonically for development, as well it has stimulatory activity on a wide variety of stem cells. Inventors: Li, Linheng (Seattle, WA); Hood, Leroy (Seattle, WA)
Assignee: University of Washington (Seattle, WA)
Date of First Priority Issue: Wednesday June 25th, 1997
Patent Number: 6132714
This patent covers the composition of matter for several methyltransferases that are associated with stem cell renewal. These methyltransferases may be associated with activity of numerous cell types in addition to hair follicle stem cells. Inventors: Tang, Y. Tom (San Jose, CA); Yue, Henry (Sunnyvale, CA); Guegler, Karl J. (Menlo Park, CA); Shah, Purvi (Sunnyvale, CA)
Assignee: Incyte Pharmaceuticals, Inc. (Palo Alto, CA)
Date of First Priority Issue: Monday April 13th, 1998
Patent Number: 6132708
While some patents cover the generation of islet like cells from hepatocytes by transfection with PDX-1, this patent covers the generation of live cells through insertion of pancreatic cells into the spleen (in one embodiment). If anything, this patent attests to the plasticity of various cellular populations. Inventor: Grompe, Markus (Portland, OR)
Assignee: Oregon Health Sciences University (Portland, OR)
Date of First Priority Issue: Friday October 10th, 1997
Patent Number: 6132463
This patent covers compositions of matter useful for generation of bone grafts and artificial bones either in vitro or in vivo. Inventors: Lee, Dosuk D. (Brookline, MA); Rey, Christian (Castanet, FR); Aiolova, Maria (Brookline, MA)
Assignee: Etex Corporation (Cambridge, MA)
Date of First Priority Issue: Friday May 19th, 1995
Patent Number: 6130061
This patent covers a new protein that is expressed on various types of stem cells. This protein can be used for purification of stem cells from tissue, or for assessment of stem cell populations in various in vitro culture systems. Inventors: Ni, Jian (Rockville, MD); Yu, Guo-Liang (Darnestown, MD); Gentz, Reiner (Silver Spring, MD); Gocayne, Jeannine D. (Potomac, MD)
Assignee: Human Genome Sciences, Inc. (Rockville, MD)
Date of First Priority Issue: Thursday November 9th, 1995
Patent Number: 6129911
This patent covers the stem cell for livers. Given the strong regenerative capacity of the liver, the characterization of stem cells of this organ is of great interest. Specific markers and methods of expanding liver stem cells are provided. The patent is currently owned by a company called MultiCell. Inventor: Faris, Ronald A. (Providence, RI)
Assignee: Rhode Island Hospital, A LifeSpan Partner (Providence, RI)
Date of First Priority Issue: Friday July 10th, 1998
Patent Number: 6127135
This patent covers a novel marker of stem cells which the inventors call EM10. This patent is useful for identifying the stem cell content of a population of cells. Inventors: Hill, Beth Louise (Mountain View, CA); Rozler, Elen (Mountain View, CA); Chen, Benjamin P. (Fremont, CA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Wednesday June 7th, 1995
Patent Number: 6117850
This patent teaches how to mobilize stem cells through administration of beta glucan and various derivatives of it. The use of other immune stimulants and TLR agonists should be evaluated for mobilization in future. Inventors: Patchen, Myra L. (Framingham, MA); Bleicher, Paul (Newton, MA)
Assignee: The Collaborative Group, Ltd. (Stony Brook, NY)
Date of First Priority Issue: Monday August 28th, 1995
Patent Number: 6117675
This patent covers retinal stem cells. These stem cells are useful for the treatment of a variety of ocular disorders including viral retinitis, blind spots, or loss of color vision. Inventors: van der Kooy, Derek (Toronto, CA); McInnes, Roderick (Ontario, CA); Chiasson, Bernard (York, CA); Tropepe, Vincenzo (Toronto, CA)
Assignee: HSC Research and Development Limited Partnership (Toronto, CA)
Date of First Priority Issue: Wednesday September 25th, 1996
Patent Number: 6117424
This patent covers induction of neural regeneration through administration of monocytes and other immune cells. The immune cells may be administered for the treatment of spinal cord injury. This is actually in clinical trials right now. Inventors: Eisenbach-Schwartz, Michal (Rehovot, IL); Spiegler, Orly (Rehovot, IL); Hirschberg, David L. (Stanford, CA)
Assignee: Yeda Research and Development Co. Ltd. (Rehovot, IL)
Date of First Priority Issue: Friday September 15th, 1995
Patent Number: 6114357
This patent covers unique compositions of matter that stimulate the proliferation of hematopoietic stem cells. Inventors: Bhatnagar, Pradip Kumar (Exton, PA); Heerding, Dirk Andries (Malvern, PA); Hartmann, Michael (Linz, AT); Hiebl, Johann (Linz, AT); Kremminger, Peter (Asten, AT); Rovenszky, Franz (Linz, AT)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA); Nycomed Austria GmbH (Linz, AT)
Date of First Priority Issue: Monday November 13th, 1995
Patent Number: 6114311
This patent covers promoters of smooth muscle cells, as well as promoters found in the stem cells for smooth muscle cells. The invention teaches how to use these promoters to treat various conditions ranging from restenosis to asthma. Inventors: Parmacek, Michael S. (Chicago, IL); Solway, Julian (Glencoe, IL)
Assignee: Arch Development Corporation (Chicago, IL)
Date of First Priority Issue: Monday October 7th, 1996
Patent Number: 6114166
This patent covers a cytokine that stimulates proliferation of hematopoietic stem cells which give rise to all hematopoietic lineages. Inventors: Welte, Karl (New York, NY); Platzer, Erich (Erlangen, DE); Gabrilove, Janice L. (New York, NY); Mertelsmann, Roland (Mainz, DE); Moore, Malcolm A. S. (Larchmont, NY)
Assignee: Sloan-Kettering Institute for Cancer Research (New York, NY)
Date of First Priority Issue: Thursday March 28th, 1985
Patent Number: 6110743
This patent covers islet stem cells and cell lines that generate islet cells. This patent could be useful for the treatment of type 1 diabetes. In some cases, it may be beneficial to encapsulate the cell lines so as to avoid immune mediated rejection. Alternatively these cells would provide a great source of tissue for using the Edmonton Protocol. Inventors: Levine, Fred (Del Mar, CA); Wang, Sijian (Dallas, TX); Beattie, Gillian M. (Poway, CA); Hayek, Alberto (La Jolla, CA)
Assignee: The Regents of the University of California (Oakland, CA); Whittier Institute for Diabetes and Endocrinology (La Jolla, CA)
Date of First Priority Issue: Friday February 10th, 1995
Patent Number: 6110739
This patent covers generation of cells from embryonic stem cells, and subsequent immortalization of the generated cells. The generated cells may be semidifferentiated stem cells or precursor cells. Immortalization may be accomplished by transfection with the gene HOX 11. Inventors: Keller, Gordon M. (Denver, CO); Hawley, Robert G. (Toronto, CA); Choi, Kyunghee (Baltimore, MD)
Assignee: National Jewish Medical and Research Center (Denver, CO)
Date of First Priority Issue: Monday November 21st, 1994
Patent Number: 6110482
This patent teaches how to make artificial joints using stem cells and various devices and systems. Inventors: Khouri, Roger K. (St. Louis, MI); Sampath, Kuber T. (Medway, MA); Rueger, David C. (Hopkinton, MA)
Assignee: Styker Corporation (Kalamazoo, MI)
Date of First Priority Issue: Friday June 3rd, 1994
Patent Number: 6110176
This patent provides procedures and devices useful for harvesting bone marrow. In one embodiment the bone marrow is harvested from the jaw of the patient. Inventor: Shapira, Ira L. (Highland Park, IL)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Tuesday July 1st, 1997
Patent Number: 6107543
This patent is about ways of cloning cows using stem cells harvested form the inner cell mass. Inventors: Sims, Michelle M. (Stoughton, WI); First, Neal L. (Madison, WI)
Assignee: Infigen, Inc. (DeForest, WI)
Date of First Priority Issue: Thursday August 20th, 1992
Patent Number: 6103701
Small molecules are provided that stimulate hematopoietic stem cell proliferation. These molecules may be of interest for stimulation of non-hematopoietic stem cells. Inventors: von Borstel, Reid Warren (Darnestown, MD); Bamat, Michael Kevin (Darnestown, MD)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Wednesday October 28th, 1987
Patent Number: 6103694
This patent teaches how to perform hematopoietic stem cell transplants without myeloablating the recipient. This patent provides specific doses of radiation that can mimic the effects of chemotherapy.
This patent may be useful for other types of stem cell therapy in order to temporarily suppress the recipient immune system so as to allow the transplanted cells to engraft, establish themselves... Inventors: Mardiney, III, Michael (Baltimore, MD); Malech, Harry L. (Bethesda, MD)
Assignee: The United States of America as represented by the Department of Health (Washington, DC)
Date of First Priority Issue: Friday July 21st, 1995
Patent Number: 6103530
This patent provides a tissue culture media that is useful for the growth and expansion of neural stem cells. Inventor: Carpenter, Melissa (Lincoln, RI)
Assignee: Cytotherapeutics, Inc. (Lincoln, RI)
Date of First Priority Issue: Friday September 5th, 1997
Patent Number: 6103528
This patent teaches how to make a tissue culture media which gells upon treatment or exposure to specific conditions. The advantage of this is that cells can be added when the media is liquid, and then the gelling characteristic can be used for the formation of specially shaped structures, structures which can subsequently be implanted. Inventors: An, Yuehuei H. (Charleston, SC); Mironov, Vladimir A. (Mt. Pleasant, SC); Gutowska, Anna (Richland, WA)
Assignee: Battelle Memorial Institute (Richland, WA); Medical University of South Carolina (Charleston, SC)
Date of First Priority Issue: Friday April 17th, 1998
Patent Number: 6103522
Culture of early hematopoietic stem cells (human ones) was previously performed on murine stromal cells, and stromal cells of mouse that are transfected with certain genes. In this patent a human stromal cell line is provided (can be bought at ATCC), which is capable of sustaining expansion of early human hematopoietic stem cells. This cell line allows for growth and generation of human... Inventors: Torok-Storb, Beverly (Seattle, WA); Roecklein, Bryan A. (Seattle, WA); Johnson, Gretchen (Issaquah, WA)
Assignee: Fred Hutchinson Cancer Research Center (Seattle, WA)
Date of First Priority Issue: Wednesday July 20th, 1994
Patent Number: 6100443
This patent covers non-human cells and stem cells that are "de-immunogenized" so that they may be transplanted into humans without rejection. The patent "de-immunogenizes" the cells by inducing expression of human anticomplement proteins, as well as by suppressing the expression of immunogenic proteins such as those of the MHC type. Inventors: Sims, Peter J. (Mequon, WI); Bothwell, Alfred L. M. (Guilford, CT); Elliot, Eileen A. (New Haven, CT); Flavell, Richard A. (Killingworth, CT); Madri, Joseph (North Branford, CT); Rollins, Scott (Monroe, CT); Bell, Leonard (Woodbridge, CT); Squinto, Stephe
Assignee: Oklahoma Medical Research Foundation (Oklahoma City, OK); Yale University (New Haven, CT)
Date of First Priority Issue: Monday June 12th, 1989
Patent Number: 6100070
This patent covers the composition of matter of several polypeptides and compounds that can activate the granulocyte colony stimulating factor receptor. These compounds can be developed into therapeutic agents for similar indications such those treated by Amgen's Neupogen. Inventors: Zurfluh, Linda L. (Kirkwood, MO); Klein, Barbara K. (St. Louis, MO); McWherrter, Charles A. (Wildwood, MO); Feng, Yiqing (St. Louis, MO); McKearn, John P. (Glencoe, MO); Braford-Goldberg, Sarah Ruth (St. Louis, MO)
Assignee: G. D. Searle & Co. (Chicago, IL)
Date of First Priority Issue: Thursday October 5th, 1995
Patent Number: 6096540
This patent teaches various proteins that can be used as discriminatory markers for distinguishing progenitors of the monocytic lineage from progenitors of the granulocytic lineages. Inventors: Olweus, Johanna (Palo Alto, CA); Lund-Johansen, Fridtjof (Palo Alto, CA); Thompson, Peter (Danville, CA)
Assignee: Becton Dickinson and Company (Franklin Lakes, NJ)
Date of First Priority Issue: Monday September 30th, 1996
Patent Number: 6093531
Brain to blood...thats essentially what this patent teaches...the use of neural stem cells as a source of hematopoietic cells. Inventors: Bjornson, Christopher R. (Seattle, WA); Rietze, Rod L. (Brunswick, AU); Reynolds, Brent A. (Saltspring, CA); Vescovi, Angelo L. (Milan, IT)
Assignee: NeuroSpheres Holdings Ltd. (Calgary, CA)
Date of First Priority Issue: Monday September 29th, 1997
Patent Number: 6093395
This patent teaches various forms of IL-3 together with various stem cell stimulatory factors for the expansion of hematopoietic stem cells. Inventors: Bauer, S. Christopher (New Haven, MO); Abrams, Mark Allen (St. Louis, MO); Braford-Goldberg, Sarah Ruth (St. Louis, MO); Caparon, Maire Helena (Chesterfield, MO); Easton, Alan Michael (Maryland Heights, MO); Klein, Barbara Kure (St. Louis, MO); McKearn, J
Assignee: G. D. Searle & Co. (Chicago, IL)
Date of First Priority Issue: Tuesday November 24th, 1992
Patent Number: 6093390
This patent teaches that LIF may be used alone, or in combination with neurotrophic factors for the stimulation of neurogenesis and muscle innervation. This patent may be useful for combining with exogenous stem cell sources such as cord blood. Additionally, the patent may be used for treating patients with multiple sclerosis. Inventors: Bartlett, Perry (North Carlton, AU); Murphy, Mark (Fitzroy, AU); Brown, Melissa (London, GB)
Assignee: Amrad Corporation Limited (Victoria, AU)
Date of First Priority Issue: Tuesday March 20th, 1990
Patent Number: 6090782
This patent covers peptides that inhibit proliferation of hematopoietic stem cells. These peptides may be used for protection form chemotherapy or radiotherapy induced stem cell destruction. Inventors: Tsyrlova, Irena (Gaithersburg, MD); Wolpe, Stephen D. (Rockville, MD)
Assignee: Pro-Neuron, Inc. (Gaithersburg, MD)
Date of First Priority Issue: Wednesday March 31st, 1993
Patent Number: 6090625
This patent teaches that by crosslinking various portions of MHC II on differentiated cells, the cells will dedifferentiate and increase the number of CD34 stem cells. This patent, if the data is reproducible, could revolutionize stem cell therapy. The company currently developing this patent is called TriStem. Inventor: Abuljadayel, Ilham (London, GB)
Assignee: Dhoot, Ghazi Jaswinder (London, GB)
Date of First Priority Issue: Thursday February 2nd, 1995
Patent Number: 6093557
This patent teaches methods of introducing materials into cells. It is useful for introducing genes into cells to cause differentiation, or alternatively introducing cytoplasm of embryonic stem cells into adult cells in order to "rejuvenate" them. Inventors: Pui, David Y. H. (Plymouth, MN); Chen, Da-Ren (Lauderdale, MN)
Assignee: Regents of the University of Minnesota (Minneapolis, MN)
Date of First Priority Issue: Thursday June 12th, 1997
Patent Number: 6090622
This patent teaches a new type of stem cell that is isolated from the gonadal ridge. Inventors: Gearhart, John D. (Baltimore, MD); Shamblott, Michael Joseph (Baltimore, MD)
Assignee: The Johns Hopkins School of Medicine (Baltimore, MD)
Date of First Priority Issue: Monday March 31st, 1997
Patent Number: 6087168
This patent teaches how to induce "trandifferentiation" of epidermal cells into neurons. The neurons are useful for treatment of neurodegenerative diseases. Inventors: Levesque, Michel F. (Beverly Hills, CA); Neuman, Toomas (Santa Monica, CA)
Assignee: Cedars Sinai Medical Center (Los Angeles, CA)
Date of First Priority Issue: Wednesday January 20th, 1999
Patent Number: 6087113
As part of Osiris's territorial stake on the mesenchymal stem cell area, this patent covers antibodies that are publically available from ATCC, that specifically recognize mesenchymal stem cells. Inventors: Caplan, Arnold I. (Cleveland Heights, OH); Haynesworth, Stephen E. (Cleveland Heights, OH)
Assignee: Case Western Reserve University (Cleveland, OH)
Date of First Priority Issue: Tuesday June 18th, 1991
Patent Number: 6084060
This patent discloses lectins and portions of the lectins that are capable of protecting various types of stem cells from death or inactivation. Inventor: Moore, Jeffrey G. (New York, NY)
Assignee: ImClone Systems Incorporated (New York, NY)
Date of First Priority Issue: Monday December 9th, 1996
Patent Number: 6083747
This patent discloses a new marker of hematopoietic stem cells. The marker can be used for isolation, purification, or identification of such stem cells. Inventors: Wong, Peter M. C. (Gladwyne, PA); Chung, Siu-Wah (Gladwyne, PA); Han, Xiaodong (San Francisco, CA)
Assignee: Stemcell Therapeutics LLC (Bala Cynwyd, PA)
Date of First Priority Issue: Tuesday June 6th, 1995
Patent Number: 6083523
This patent covers a device that is implantable, and explantable, that can be used for administration of stem cells so that they will not be rejected by the host immune system. It will be interesting to use such devices with embryonic stem cells so as to allow the embryonic stem cells to secrete soluble factors in vivo that hopefully will possess rejuvenating ability. Inventors: Dionne, Keith E. (Rehoboth, MA); Emerich, Dwaine F. (Providence, RI); Hoffman, Diane (Cambridge, MA); Sanberg, Paul R. (Spring Hill, FL); Christenson, Lisa (New Haven, CT); Hegre, Orion D. (Green Valley, AZ); Scharp, David W. (St. Louis, MO); Lacy, Paul E
Assignee: Brown University Research Foundation (Providence, RI); Brown University (Providence, RI)
Date of First Priority Issue: Thursday April 25th, 1991
Patent Number: 6082364
This patent seems to cover a cell that is very similar to the cell covered by Osiris...that is mesenchymal stem cells. Inventors: Balian, Gary (Charlottesville, VA); Wang, Gwo-Jaw (Charlottesville, VA); Diduch, David (Charlottesville, VA); Hahn, Chang (Charlottesville, VA)
Assignee: Musculoskeletal Development Enterprises, LLC (Charlottesville, VA)
Date of First Priority Issue: Monday December 15th, 1997
Patent Number: 6080581
This patent covers a method of generating three dimensional tissues in culture. The culture system allows for continuous addition of media and growth factors as well as escape of waste products. Inventors: Anderson, Charles Daniel (Houston, TX); Dodd, Charlie W. (Seabrook, TX)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Thursday July 2nd, 1998
Patent Number: 6077987
This patent covers the induction of healing through administration of mesenchymal stem cells alone, or mesenchymal stem cells after transfection with other genes. Inventors: Breitbart, Arnold S. (Great Neck, NY); Grande, Daniel S. (Sea Cliff, NY); Mason, James M. (Bethpage, NY)
Assignee: North Shore-Long Island Jewish Research Institute (Manhasset, NY)
Date of First Priority Issue: Thursday September 4th, 1997
Patent Number: 6077857
This patent provides compositions of matter that stimulate hematopoietic stem cell proliferation. These compounds appear to be small molecules and have an acceptable safety profile in the data provided. Inventors: Bhatnagar, Pradip Kumar (Exton, PA); Heerding, Dirk Andries (Malvern, PA)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Date of First Priority Issue: Tuesday November 12th, 1996
Patent Number: 6077710
This patent covers the generation of embryos through virgin birth or parthenogenesis. Essentially if an oocyte is activated through the induction of calcium flux it can generate an embryo-like structure which can be used to derive stem cells. Inventors: Susko-Parrish, Joan L. (Monona, WI); Northey, David L. (Madison, WI); Leibfried-Rutledge, M. Lorraine (Madison, WI); Stice, Steven L. (DeForest, WI)
Assignee: Infigen, Inc. (Deforest, WI)
Date of First Priority Issue: Wednesday February 10th, 1993
Patent Number: 6077708
This patent teaches how to determine the number of stem cells in a tissue culture situation through assessing various metabolic properties of the tissue culture media. Inventors: Collins, Paul C. (Bridgewater, NJ); Papoutsakis, E. Terry (Glenview, IL); Miller, William M. (Evanston, IL)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday July 18th, 1997
Patent Number: 6069005
This patent discloses methods of purifying hepatic stem cells. These stem cells may be expanded and used for therapeutic purposes. One interesting application of this invention would be to tranfect embryonic stem cell cytoplasm into these hepatocyte stem cells and to see if we can increase their expansion capability.
Theoretically hepatocytes should be easier to tranplant than other tissues... Inventors: Reid, Lola M. (Chapel Hill, NC); Sigal, Samuel H. (Riverdale, NY); Brill, Shlomo (Ramat-Gan, IL); Holst, Patricia A. (Ossining, NY)
Assignee: Albert Einstein College of Medicine of Yeshwa University (Bronx, NY)
Date of First Priority Issue: Saturday September 7th, 1991
Patent Number: 6068836
This patent teaches how to transfect quiescent hematopoietic stem cells. Transfection of these primitive stem cells should be useful for a variety of gene therapy applications including treatment of several metabolic diseases such as Krabbe Disease. Inventor: Quesenberry, Peter J. (Shrewsbury, MA)
Assignee: University of Massachusetts (Boston, MA)
Date of First Priority Issue: Wednesday November 23rd, 1994
Patent Number: 6066451
This patent provides a marker for the identification of specific neural cells. This marker is useful for knowing the quantity and quality of neurons generated from various stem cell populations. Inventors: Avraham, Shalom (Brookline, MA); Avraham, Hava (Brookline, MA); Groopman, Jerome E. (Brookline, MA)
Assignee: Beth Israel Deaconess Medical Center, Inc. (Boston, MA)
Date of First Priority Issue: Monday October 3rd, 1994
Patent Number: 6066318
This patent covers variants of thrombopoietin and the use of these variants in combination with other hematopoietic cytokines for the stimulation of hematopoietic stem cells. Inventors: Feng, Yiqing (St. Louis, MO); Staten, Nicholas R. (St. Louis, MO); Baum, Charles M. (Evanston, IL); Summers, Neena L. (St. Charles, MO); Caparon, Maire Helena (Chesterfield, MO); Bauer, S. Christopher (New Haven, MO); Zurfluh, Linda L. (Kirkwood, MO); McK
Assignee: G.D. Searle & Co. (Chicago, IL)
Date of First Priority Issue: Thursday October 5th, 1995
Patent Number: 6066317
This patent teaches that interleukin 11 can be administered into patients for stimulation of hematopoietic activity. Interleukin 11 is known to upregulate platelet production but not as potently as TPO. Inventors: Yang, Yu-Chung (Indianapolis, IN); Bennett, Frances K. (Melrose, MA); Paul, Stephan R. (Wyncote, PA)
Assignee: Genetics Institute, Inc. (Cambridge, MA)
Date of First Priority Issue: Wednesday November 22nd, 1989
Patent Number: 6063593
This patent teaches that tranforming growth factor beta treatment of hematopoietic stem cells will make them more susceptible to gene transfection. Inventors: Gordon, Erlinda Maria (Glendale, CA); Hall, Frederick L. (Glendale, CA); Anderson, W. French (San Marino, CA)
Assignee: University of Southern California University Park Campus (Los Angeles, CA)
Date of First Priority Issue: Tuesday November 12th, 1996
Patent Number: 6060270
This patent teaches how to grow kidney tubules from renal stem cells, and how to use these for making a hollow fiber filter that resembles an artificial kidney. Inventor: Humes, H. David (Ann Arbor, MI)
Assignee: The University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Monday March 2nd, 1992
Patent Number: 6060052
This patent teaches ways of using thrombopoietin or other ligands of MPL in order to stimulate proliferation of early hematopoietic stem cells. Since thrombopoietin is used in numerous stem cell expansion cocktails, this patent is very important. Inventors: Murray, Lesley J. (San Jose, CA); Young, Judy C. (San Carlos, CA)
Assignee: SyStemix, Inc. (Palo Alto, CA)
Date of First Priority Issue: Monday October 30th, 1995
Patent Number: 6059968
Methods and devices are disclosed that enable efficient collection and storage of cord blood. Inventor: Wolf, Jr., Ludwig (Inverness, IL)
Assignee: Baxter International Inc. (Deerfield, IL)
Date of First Priority Issue: Tuesday January 20th, 1998
Patent Number: 6057123
This patent provides analogues of chemokines that are capable of inhibiting proliferation of hematopoietic stem cells. Inventors: Craig, Stewart (Oxford, GB); Hunter, Michael George (Buckinghamshire, GB); Edwards, Richard Mark (Oxford, GB); Czaplewski, Lloyd George (Oxford, GB); Gilbert, Richard James (Oxford, GB)
Assignee: British Biotech Pharmaceuticals Limited (Oxford, GB)
Date of First Priority Issue: Wednesday December 23rd, 1992
Patent Number: 6056777
This patent provides medical devices useful for the treatment of cartilage injury. Stem cells may be differentiated into cartilage and used in combination with this invention. Inventor: McDowell, Charles L. (Richmond, VA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday February 27th, 1998
Patent Number: 6054465
Small molecule compounds are provided that stimulate hematopoietic stem cell proliferation. It would be interesting to see whether these compounds have selective stimulatory capability towards normal versus leukemic hematopoietic stem cells. Inventors: Bhatnagar, Pradip Kumar (Exton, PA); Heerding, Dirk Andries (Malvern, PA)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Date of First Priority Issue: Monday November 13th, 1995
Patent Number: 6054442
This patent discloses small molecules that modulate activity of telomerase. On the one hand telomerase inhibition is useful for cancer therapy, on the other activation of telomerase is useful for longevity purposes. Inventors: Chen, Shih-Fong (San Antonio, TX); Maine, Ira (San Antonio, TX); Kerwin, Sean M. (Round Rock, TX); Fletcher, Terace M. (San Antonio, TX); Salazar, Miguel (Austin, TX); Mamiya, Blain (Austin, TX); Windle, Bradford E. (San Antonio, TX); Wajima, Makoto (San
Assignee: Board of Regents, University of Texas System (Austin); CTRC Research Foundation (San Antonio, TX)
Date of First Priority Issue: Thursday July 6th, 1995
Patent Number: 6054441
This patent covers small molecule stimulators of hematopoietic stem cell activity. These molecules appear to have a reasonable safety profile and are interesting for clinical development. One area of development may be their use in combination with cord blood transplants in adults...since cord blood transplants usually take a longer time to reconstitute. Inventors: von Borstel, Reid W. (Potomac, MD); Bamat, Michael K. (Potomac, MD); Hiltbrand, Bradley M. (Columbia, MD); Butler, James C. (Gaithersburg, MD); Shirali, Shyam (Gaithersburg, MD)
Assignee: Pro-Neuron, Inc. (Rockville, MD)
Date of First Priority Issue: Monday June 5th, 1995
Patent Number: 6054142
This patent provides scaffolds that can be seeded with stem cells and subsequently inplanted for regeneration of various tissues. Inventors: Li, Rebecca (Canton, MA); Hazlett, Tyrone F. (Coventry, RI)
Assignee: Cyto Therapeutics, Inc. (Lincoln, RI)
Date of First Priority Issue: Thursday August 1st, 1996
Patent Number: 6054121
If I read this currently, this patent seems to cover the use of blood mesenchymal stem cells for stimulation of immune responses to antigens. This is the opposite to what the current knowledge of mesenchymal stem cells is...that being that they are immune suppressive. If these cells were immune stimulatory then the current Phase III trials for graft versus host disease that Osiris is doing would... Inventors: Cerami, Anthony (Shelter Island, NY); Bucala, Richard J. (New York, NY)
Assignee: The Picower Institute for Medical Research (Manhasset, NY)
Date of First Priority Issue: Friday February 26th, 1993
Patent Number: 6051557
This patent covers the use of GLP-2 for stimulation of stem cells in the upper GI tract. This patent is useful for treatment of pathologies associated with malfunction of these cells, such as mucositis, gastritis, or various types of injuries. Inventor: Drucker, Daniel J. (Ontario, CA)
Assignee: 1149336 Ontario Inc. (Toronto, CA)
Date of First Priority Issue: Friday May 16th, 1997
Patent Number: 6051415
C reactive protein is produced by the liver in times of inflammation. This patent discloses various mutants of CRP that are capable of stimulating production of increased platelets. Given that TPO, another agent that stimulates platelet production, can stimulate self renewal of primitive hematopoietic stem cells, it would be interesting to see if these CRP mutants have similar activity. Inventor: Potempa, Lawrence A. (Deerfield, IL)
Assignee: Immtech International, Inc. (Evanston, IL)
Date of First Priority Issue: Wednesday February 23rd, 1994
Patent Number: 6051217
This patent provides compositions of matter for various forms of the cytokine IL-3. Uses of IL-3 such as stimulation of hematopoiesis are described. Since myeloid suppressor cells express the IL-3 receptor, it may be interesting to see if IL-3 can actually mediate immune suppressive functions. Inventors: Bauer, S. Christopher (New Haven, MO); Abrams, Mark Allen (St. Louis, MO); Braford-Goldberg, Sarah Ruth (St. Louis, MO); Caparon, Maire Helena (Chesterfield, MO); Easton, Alan Michael (Maryland Heights, MO); Klein, Barbara Kure (St. Louis, MO); McKearn, J
Assignee: G. D. Searle & Co. (Chicago, IL)
Date of First Priority Issue: Saturday November 14th, 1992
Patent Number: 6049026
This patent provides methods of administering stem cells after differentiating them into bioartificial bone. Inventor: Muschler, George Frederick (Cleveland Heights, OH)
Assignee: The Cleveland Clinic Foundation (Cleveland, OH)
Date of First Priority Issue: Monday June 3rd, 1996
Patent Number: 6048721
This patent provides new devices and culture conditions for expanding stem cells of the hematopoietic lineage ex vivo. This patent has actually been used for development of technologies that were used in clinical trials. Inventors: Armstrong, R. Douglas (Ann Arbor, MI); Maluta, James (Dexter, MI); Roecker, David (Denver, CO)
Assignee: Aastrom Biosciences, Inc. (Ann Arbor, MI)
Date of First Priority Issue: Wednesday June 7th, 1995
Patent Number: 6045807
This patent teaches how to make immortalized neurons through differentiation of neuronal stem cells and then transfection with various genes. These immortalized cell lines can subsequently be used for treatment of neurodegenerative conditions. Inventors: Gage, Fred H. (La Jolla, CA); Ray, Jasodhara (San Diego, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Date of First Priority Issue: Wednesday January 6th, 1993
Patent Number: 6043348
This patent covers a new marker of hematopoietic stem cells. This marker can be used for extraction of these stem cells, as well as for quantification.
The protein marker is called "MG-1" in the specification. Inventors: Lawman, Michael J. P. (Gainesville, FL); Lawman, Patricia (Gainesville, FL)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Wednesday November 13th, 1996
Patent Number: 6043092
This patent covers a specific tissue culture media that is useful for the expansion of hepatocytes. The media is a serum free media and can be used for clinical applications. Inventor: Block, Geoffrey D. (Pittsburgh, PA)
Assignee: University of Pittsburgh (Pittsburgh, PA)
Date of First Priority Issue: Monday March 18th, 1996
Patent Number: 6040180
This patent teaches that by manipulating divalent ion content of a tissue culture media, it is possible to modify the differentiation program of neuronal stem cells. Various methods of inducing differentiation of such neuronal stem cells into neurons, astrocytes, and oligodendrocytes are disclosed. Inventor: Johe, Karl K. (Potomac, MD)
Assignee: NeuralStem Biopharmaceuticals, Ltd. (College Park, MD)
Date of First Priority Issue: Thursday May 23rd, 1996
Patent Number: 6037174
This is a patent on generation of neutrophil precursors and their expansion ex vivo. It may be interesting to use a patent such as this to generate allogeneic neutrophils for short term use after chemotherapy for patients that are immunocompromised so that they do not get infections.
The question is whether administration of such allogeneic neutrophils would cause nephritis by virtue of... Inventors: Smith, Stephen L. (Arlington Heights, IL); Qiao, Xiaoying (Waukegan, IL); Maciukas, Susan M. (El Cerrito, CA); Loudovaris, Maureen F. (Grayslake, IL); Bender, James G. (Lindenhurst, IL); Van Epps, Dennis (Cary, IL)
Assignee: Nexell Therapeutics, Inc. (Irvine, CA)
Date of First Priority Issue: Monday August 23rd, 1993
Patent Number: 6033906
This patent covers ways of generating glial cells in vitro for in vivo use. Several growth factors and culture conditions are provided. Inventor: Anderson, David J. (Altadena, CA)
Assignee: California Institute of Technology (Pasadena, CA)
Date of First Priority Issue: Monday July 26th, 1993
Patent Number: 6030836
This patent covers expansion of hematopoietic stem cells by culturing with allogeneic or autologous mesenchymal stem cells. Inventors: Thiede, Mark A. (Forest Hill, MD); Pittenger, Mark F. (Severna Park, MD); Mbalaviele, Gabriel (Columbia, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Monday June 8th, 1998
Patent Number: 6027744
This patent covers ways generating tissue implants and artificial tissues in vitro for in vivo implantation. Inventors: Vacanti, Charles A. (Worcester, MA); Vacanti, Joseph P. (Worcester, MA)
Assignee: University of Massachusetts Medical Center (Boston, MA); The Children's Medical Center Corporation (Boston, MA)
Date of First Priority Issue: Friday April 24th, 1998
Patent Number: 6022743
This patent teaches the three dimensional generation of artificial pancreatic grafts using a proprietary culture system that is described in detail. Inventors: Naughton, Gail K. (Del Mar, CA); Naughton, Brian A. (El Cajon, CA)
Assignee: Advanced Tissue Sciences, Inc. (La Jolla, CA)
Date of First Priority Issue: Friday April 18th, 1986
Patent Number: 6022540
This patent covers the induction of mesenchymal stem cell differentiation by activation of a ligand called ALCAM. Mesenchymal stem cells can differentiate into a wide variety of non-hematopoietic tissues and are useful for many clinical applications since they can be transplanted across allogeneic barriers, therefore knowing how to modulate their differentiation programs is very useful. Inventors: Bruder, Scott P. (Owings Mills, MD); Jaiswal, Neelam (Ellicott City, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Thursday September 4th, 1997
Patent Number: 6020197
This patent covers the induction of differentiation of neural stem cells into various committed neuronal lineages. The patent provides FGF-2 for expansion of neural cells and stem cells, as well it provides various oncogenes which may be used for their immortalization. Inventors: Gage, Fred H. (La Jolla, CA); Ray, Jasodhara (San Diego, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Date of First Priority Issue: Wednesday January 6th, 1993
Patent Number: 6019965
This patent teaches that the administration of the clinically-used cytokine GM-CSF is useful for the treatment of alveolar proteinosis. This patent would be great to use in combination with systemically administered stem cell therapy since most stem cells given intravenously end up in either the lung or the liver. Inventors: Dunn, Ashley Roger (Parkville, AU); Stanley, Edouard Guy (London, GB); Lieschke, Graham John (Parkville, AU); Grail, Dianne (Parkville, AU); Fowler, Kerry J. (Parkville, AU)
Assignee: Ludwig Institute for Cancer Research (New York, NY)
Date of First Priority Issue: Monday October 24th, 1994
Patent Number: 6015671
This patent teaches how to extract specific cells from a population of stem cells that are differentiating. Inventor: Field, Loren J. (Indianapolis, IN)
Assignee: Indiana University Foundation (Bloomington, IN)
Date of First Priority Issue: Wednesday June 7th, 1995
Patent Number: 6013067
This patent teaches to treat a hematopoietic stem cell donor with thrombopoietic, collect the "activated" stem cells, and infuse them into a recipient. In some situations the recipient may also be given thrombopoietin. Inventors: Fibbe, Willem E. (Lisse, NL); Grossman, Angelika (Seattle, WA)
Assignee: ZymoGenetics, Inc. (Seattle, WA)
Date of First Priority Issue: Wednesday June 7th, 1995
Patent Number: 6012450
This patent teaches the administration of hematopoietic stem cell stimulatory factors through the intrapulmonary route. This patent is interesting in light of the fact that exogenous stem cells generally go to the liver or lung. Inventor: Rubsamen, Reid M. (Berkeley, CA)
Assignee: Aradigm Corporation (Hayward, CA)
Date of First Priority Issue: Tuesday March 5th, 1991
Patent Number: 6011197
This patent teaches methods of cloning cattle. Inventors: Strelchenko, Nikolai S. (DeForest, WI); Betthauser, Jeffrey M. (Windsor, WI); Jurgella, Gail L. (Madison, WI); Pace, Marvin M. (DeForest, WI); Bishop, Michael D. (Rio, WI)
Assignee: Infigen, Inc. (Deforest, WI)
Date of First Priority Issue: Thursday March 6th, 1997
Patent Number: 6010697
This patent teachs ways of overcoming neutropenia by administration of committed stem cells that differentiate into the neutrophil lineage. This work has the potential to be very beneficial in nuclear accidents where a quick supply of neutrophils is needed. The biggest barrier is whether allogeneic neutrophil committed stem cells may be used or whether the stem cells strictly have to be... Inventors: Smith, Stephen L. (Arlington Heights, IL); Qiao, Xiaoying (Waukegan, IL); Maciukas, Susan M. (El Cerrito, CA); Loudovaris, Maureen F. (Grayslake, IL); Bender, James G. (Lindenhurst, IL); Van Epps, Dennis E. (Cary, IL)
Assignee: Nexell Therapeutics, Inc. (Irvine, CA)
Date of First Priority Issue: Monday August 23rd, 1993
Patent Number: 6010696
This patent covers the administration of mesenchymal stem cells as "facilitator cells" such that engraftment of hematopoietic stem cells is accelerated. Mesenchymal stem cells may play this engraftment assisting role due to the wide variety of growth factors that they are known to produce. Inventors: Caplan, Arnold I. (Cleveland Heights, OH); Haynesworth, Stephen E. (Cleveland Heights, OH); Gerson, Stanton L. (Pepper Pike, OH); Lazarus, Hillard M. (Shaker Heights, OH)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Friday November 16th, 1990
Patent Number: 6008035
This patent covers a method of generating viruses that are useful for transfection in living beings. Specifically the viral approaches can be used to target bone marrow stem cells. Inventors: Johnston, Robert E. (Chapel Hill, NC); Davis, Nancy L. (Chapel Hill, NC); Simpson, Dennis A. (Pittsboro, NC)
Assignee: The University of North Carolina at Chapel Hill (Chapel Hill, NC)
Date of First Priority Issue: Wednesday February 19th, 1997
Patent Number: 6007978
This patent covers methods of freeze-drying various cells, including stem cells. Inventors: Goodrich, Jr., Raymond P. (Pasadena, CA); Coker, Samuel O. S. (South Pasadena, CA); Arnaud, Francoise (Pasadena, CA); Hackett, Roger W. (Pasadena, CA)
Assignee: COBE Laboratories, Inc. (Lakewood, CO)
Date of First Priority Issue: Wednesday May 18th, 1988
Patent Number: 6007819
This patent covers a small molecular weight family of compounds that directly stimulate hematopoietic stem cell proliferation but at the same time have immune augmentative effects. Such compounds are especially useful after bone marrow transplantation for leukemias or cancers since post transplantation it is not only enough to have restored hematopoiesis, but augmentation of the immune system... Inventors: Taub, Floyd (Silver Spring, MD); Perun, Thomas J. (Round Lake, IL); Murray, Christopher K. (Longmont, CO); Daughenbaugh, Randall J. (Longmont, CO); Lednicer, Daniel (Rockville, MD)
Assignee: Dovetail Technologies, Inc. (College Park, MD)
Date of First Priority Issue: Tuesday October 17th, 1995
Patent Number: 6004810
This patent covers a type of liver stem cell that is useful for the treatment of various hepatic diseases. It will be interesting to compare this patent to the other ones in this directory that cover liver stem cells. Inventors: Tateno, Chise (Hiroshima, JP); Yoshizato, Katsutoshi (Hiroshima, JP)
Assignee: Research Development Corporation of Japan (Saitama, JP)
Date of First Priority Issue: Tuesday April 11th, 1995
Patent Number: 6004548
This patent covers hematopoietic stem cell stimulatory peptides and proteins that are analogs of pluripotent G-CSF. These compounds are useful for stimulation of hematopoiesis after ablation with radiotherapy or chemotherapy. Inventor: Souza, Lawrence M. (Thousand Oaks, CA)
Assignee: Amgen, Inc. (Thousand Oaks, CA)
Date of First Priority Issue: Friday August 23rd, 1985
Patent Number: 6001654
This patent teaches how to induce the differentiation of neural stem cells into either neurons or smooth muscle cells by treatment with proteins that belong to the transforming growth factor beta superfamily. Inventors: Anderson, David J. (Altadena, CA); Shah, Nirao M. (New York, NY)
Assignee: California Institute of Technology (Pasadena, CA)
Date of First Priority Issue: Monday July 27th, 1992
Patent Number: 6001647
This patent teaches how to expand populations of islet cells in vitro for possible in vivo use in the treatment of type 1 diabetes. This technology seems very exciting, however the patent has some priority claims more than a decade ago and to our knowledge this therapy has yet to be clinically implimented. Inventors: Peck, Ammon B. (Gainesville, FL); Cornelius, Janet G. (Gainesville, FL)
Assignee: Ixion Biotechnology, Inc. (Alachua, FL)
Date of First Priority Issue: Thursday April 28th, 1994
Patent Number: 6001352
This patent teaches the use of platelet derived growth factor for stimulating proliferation of chondrocyte and chondrocyte stem cells along the area of a joint defect, so as to accelerate healing. Inventors: Boyan, Barbara D. (San Antonio, TX); Schwartz, Zvi (Jerusalem, IL)
Assignee: OsteoBiologics, Inc. (San Antonio, TX)
Date of First Priority Issue: Monday March 31st, 1997
Patent Number: 5997860
This patent covers IL-3 and various deviations of it, in combination with other hematopoietic stem cell stimulatory cytokines for acceleration of hematopoietic recovery after stem cell transplantation. This patent is useful in situations in which the stem cell dose administered may be relatively low, such as cord blood transplants given to adult recipients. Inventors: Bauer, S. Christopher (New Haven, MO); Abrams, Mark Allen (St. Louis, MO); Braford-Goldberg, Sarah Ruth (St. Louis, MO); Caparon, Maire Helena (Chesterfield, MO); Easton, Alan Michael (Maryland Heights, MO); Klein, Barbara Kure (St. Louis, MO); McKearn, J
Assignee: G. D. Searle & Co. (Chicago, IL)
Date of First Priority Issue: Tuesday November 24th, 1992
Patent Number: 5994518
This patent covers ways of generating a molecule that has granulocyte colony stimulating activity. It may be that this molecule is similar to G-CSF which is currently sold as "Neupogen" by the company Amgen. Inventors: Kuga, Tetsuro (Yamaguchi, JP); Miyaji, Hiromasa (Tokyo, JP); Sato, Moriyuki (Tokyo, JP); Okabe, Masami (Shizuoka, JP); Morimoto, Makoto (Shizuoka, JP); Itoh, Seiga (Kanagawa, JP); Yamasaki, Motoo (Tokyo, JP); Yokoo, Yoshiharu (Kanagawa, JP); Yamaguchi, Ka
Assignee: Kyowa Hakko Co., Ltd (JP)
Date of First Priority Issue: Tuesday December 22nd, 1987
Patent Number: 5993801
This patent covers transfection of stromal cells with therapeutic genes and administering the transfected cells into a recipient in need of therapy.
It is interesting to see if these stromal cells have a similar phenotype as the mesenchymal stem cells that Osiris has patents on. Inventors: Greenberger, Joel S. (Lincoln, MA); Levine, Peter H. (Worcester, MA)
Assignee: ALG Company (Marlboro, MA)
Date of First Priority Issue: Thursday February 2nd, 1989
Patent Number: 5993429
This patent anticipated the cord blood revolution and therefore claimed various devices and methods of collection of cord blood. Stem cells purified from cord blood are currently used for a variety of hematological and non-hematological disorders. Inventors: Kuypers, Franciscus A. (El Cerrito, CA); Cole, Robert B. (Alamo, CA); Meyst, Richard P. (Valley Center, CA); Gorton, Lanny A. (San Diego, CA); Wright, James I. (Villa Park, CA)
Assignee: Childen's Hospital Medical Center of Northern California (Oakland, CA)
Date of First Priority Issue: Tuesday May 14th, 1996
Patent Number: 5993387
This patent in a way smells like a method of doing business patent. Interestingly it was actually filed before the "State Street v Signature Financial" case.
Essentially this patent covers a computer registry for matching cord blood to donors. I wonder if this patent is actually being enforced today? Inventors: Moore, Thomas Eldon (Los Altos Hills, CA); Harris, David Thomas (Tucson, AZ); Kramer, Jesse O. (San Francisco, CA)
Assignee: Core Blood Registry, Inc. (San Bruno, CA)
Date of First Priority Issue: Thursday August 14th, 1997
Patent Number: 5989537
As the name "thrombopoietin" implies, this cytokine is conventionally viewed as a stimulator of platelet production. In this patent the use of thrombopoietin for stimulation of the granulocytic/monocytic lineage is claimed. Currently numerous companies are developing agonists and agonistic antibodies of the thrombopoietin receptor. Inventors: Holly, Richard D. (Seattle, WA); Lok, Si (Seattle, WA); Foster, Donald C. (Seattle, WA); Hagen, Frederick S. (Seattle, WA); Kaushansky, Kenneth (Woodinville, WA); Kuijper, Joseph L. (Bothell, WA); Lofton-Day, Catherine E. (Brier, WA); Oort, Pieter J. (Sea
Assignee: ZymoGenetics, Inc. (Seattle, WA); University of Washington (Seattle, WA)
Date of First Priority Issue: Monday March 21st, 1994
Patent Number: 5986069
This patent covers peptides that inhibit HELA cell proliferation, but are stimulatory to T cells and hematopoietic stem cells. Inventors: Kirkness, Ewen F. (Olney, MD); Adams, Mark D. (North Potomac, MD); Olsen, Henrick S. (Gaithersburg, MD); Rosen, Craig A. (Laytonsville, MD)
Assignee: Human Genome Sciences, Inc. (Rockville, MD)
Date of First Priority Issue: Tuesday January 25th, 1994
Patent Number: 5985830
This patent teaches that Insulin Like Growth Factor-1 is useful for the treatment of polycystic kidney disease. Given the stimulatory effects of this hormone on stem cells, it is interesting to see if this patent can be used with exogenous stem cell therapy. Inventors: Acott, Philip D. (Halifax, CA); Crocker, John F. S. (Halifax, CA)
Assignee: Dalhousie University (Halifax, CA)
Date of First Priority Issue: Monday September 16th, 1996
Patent Number: 5985659
This patent provides some embryonic stem cell lines derived from mice that are useful for the creation of knockout animals. Inventors: Kusakabe, Moriaki (Ibaragi, JP); Kamon, Toshio (Tokyo, JP)
Assignee: The Institute of Physical and Chemical Research (Saitama, JP)
Date of First Priority Issue: Tuesday May 21st, 1996
Patent Number: 5985656
This patent covers a type of bone marrow immune suppressive cell that appears to be related to what is currently called the NKT cell. This suppressor cell may also be related to the classical "natural suppressor cell" which is a myeloid progenitor with immune suppressive properties.
The cells in this patent are useful for the treatment of autoimmunity and transplant rejection. Inventor: Strober, Samuel S. (Portola Valley, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University (Stanford, CA)
Date of First Priority Issue: Thursday June 12th, 1986
Patent Number: 5981708
This patent covers a cytokine whose modern name is not known from reading the patent. The cytokine is capable of stimulating expansion of CD34+ human hemapoietic stem cells. Inventors: Lawman, Michael J. P. (Gainesville, FL); Lawman, Patricia D. (Gainesville, FL); Denslow, Nancy D. (Gainesville, FL)
Assignee: University of Florida (Gainesville, FL)
Date of First Priority Issue: Thursday October 6th, 1983
Patent Number: 5981220
This patent covers a protein that stimulates stem cell differentiation into epidermal cells. The protein is useful for a variety of regenerative purposes, either alone or in combination with exogenous stem cells. Inventors: Ni, Jian (Rockville, MD); Feng, Ping (Gaithersburg, MD); Dillon, Patrick J. (Gaithersburg, MD); Gentz, Reiner (Silver Spring, MD)
Assignee: Human Genome Sciences, Inc. (Rockville, MD)
Date of First Priority Issue: Wednesday March 27th, 1996
Patent Number: 5981211
This patent teaches how to grow cells outside of the body but in chambers that can be connected to an extracorporeal set up. In one particular embodiment this patent may be used for the generation of an artificial liver. Inventors: Hu, Wei-Shou (Falcon Heights, MN); Cerra, Frank Bernard (Edina, MN); Nyberg, Scott Lyle (St. Louis Park, MN); Scholz, Matthew Thomas (Woodbury, MN); Shatford, Russell A. (Minneapolis, MN)
Assignee: Regents of the University of Minnesota (Minneapolis, MN)
Date of First Priority Issue: Thursday May 18th, 1989
Patent Number: 5981165
This patent teaches how to generate in vitro neurons that produce dopamine. The neurons are generated from stem cells through culture in FGF and TGF beta family members, as well as in the presence of feeder cell layers. Inventors: Weiss, Samuel (Alberta, CA); Reynolds, Brent (Alberta, CA)
Assignee: NeuroSpheres Holdings Ltd. (Calgary, CA)
Date of First Priority Issue: Monday July 8th, 1991
Patent Number: 5980887
This patent covers the use of various endothelial stem cells, and stem cells that resemble hematopoietic stem cells, for the stimulation of angiogenesis.
Cell types covered include: CD34+, Tie+, or flk-1+.
Methods of expanding the cells in vitro prior to implantation are also disclosed. Inventors: Isner, Jeffrey M. (Weston, MA); Asahara, Takayuki (Arlington, MA)
Assignee: St. Elizabeth's Medical Center of Boston (Boston, MA)
Date of First Priority Issue: Friday November 8th, 1996
Patent Number: 5980886
This patent covers ways of transfecting liver cells in vivo through the induction of liver stem cell activation by first transfection with a gene such as tPA or uPA, and then once the cells are proliferating, transfection with another gene that is therapeutic. Inventors: Kay, Mark A. (Seattle, WA); Lieber, Andre (Seattle, WA)
Assignee: University of Washington (Seattle, WA)
Date of First Priority Issue: Wednesday December 14th, 1994
Patent Number: 5980885
This patent teaches the in vivo expansion of neural stem cells through administration of fibroblast growth factor in combination with an agent selected from the group comprising of: EGF, TGF, and amphiregulin.
This patent is useful for the treatment of degenerative nervous system diseases alone, or in combination with exogenously administered stem cells. Inventors: Weiss, Samuel (Alberta, CA); Reynolds, Brent (Alberta, CA)
Assignee: NeuroSpheres Holdings Ltd. (Calgary, CA)
Date of First Priority Issue: Monday July 8th, 1991
Patent Number: 5972703
This patent teaches the isolation, expansion, and use of bone stem cells that are separated from bone marrow cells. Inventors: Long, Michael W. (Northville, MI); Mann, Kenneth G. (Shelburne, VT)
Assignee: The Regents of the University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Friday August 12th, 1994
Patent Number: 5968829
This patent provides a type of neural stem cells, including stem cells derived from the basal forebrain. Disclosed are methods of maintaining the neural stem cells in culture, as well as ways of differentiating them into neurons. Inventor: Carpenter, Melissa (Lincoln, RI)
Assignee: Cytotherapeutics, Inc. (Providence, RI)
Date of First Priority Issue: Friday September 5th, 1997
Patent Number: 5968546
This patent provides compositions for treatment of skin defects, including burn wounds, through culture and diffentiation of keratinocyte stem cells, and subsequent administration of the keratinocyte stem cells in vivo. Inventors: Baur, Marcus (CH-1066 Epalinges, CH); Hunziker, Thomas (CH-3653 Oberhofen, CH); Limat, Alain (CH-1712 Tafers, CH); Riedel, Wolfram (D-869198 Utting, DE); Toloczyki, Christian (D-86919 Utting, DE)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday May 16th, 1997
Patent Number: 5968513
This patent teaches that the pregnancy associated protien hCG is a stimulator of hematopoiesis. This is an interesting concept since numerous cancers actually secrete hCG. I wonder if during pregnancy, or cancer, there is a high enough gradient of hCG to stimulate hematopoiesis.
It is known that pregnant mice have an increase in spleen size, I wonder if the hCG has anything to do with this? Inventors: Gallo, Robert C. (Bethesda, MD); Bryant, Joseph (Rockville, MD); Lunardi-Iskandar, Yanto (Gaithersburg, MD)
Assignee: University of Maryland Biotechnology Institute (College Park, MD)
Date of First Priority Issue: Monday June 24th, 1996
Patent Number: 5968501
This patent covers the use of HGF for stimulation of hematopoietic stem cell proliferation, as well as differentiation along the erythroid lineage. This patent may be useful for the treatment of anemia, as well as post hematopoietic stem cell ablation patients. Inventor: Comoglio, Paolo (Turin, IT)
Assignee: Dompe S.p.A. (IT)
Date of First Priority Issue: Thursday November 24th, 1994
Patent Number: 5965457
This patent covers methods of screening for identifying which compounds bind to purified CD34+ cells. Since CD34+ cells are stem cells of the hematopoietic lineage, by identifying agents that bind to them it is possible to generate novel ways of purifying and identifying them. Inventor: Magnani, John L. (Rockville, MD)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Tuesday June 6th, 1995
Patent Number: 5965437
This patent teaches the in vitro purification of early hematopoietic stem cells by killing of the mature ones. This is performed through addition of a hematopoietic growth factor, together with a cytotoxic agent that only kills dividing cells. The hematopoietic stem cells that are very primitive will not be killed since the primitive hematopoietic stem cells do not undergo division very... Inventor: Scadden, David T. (Weston, MA)
Assignee: Beth Israel Deaconess Medical Center, Inc. (Boston, MA)
Date of First Priority Issue: Thursday September 1st, 1994
Patent Number: 5965436
This patent teaches that mesenchymal stem cells in the bone marrow are sometimes found in attachment to megakaryocytes. The patent teaches that it is possible to extracted megakaryocytes from the bone marrow, using antibodies such as anti-CD41, and then from the megakaryocytes to de-attach the mesenchymal stem cells. Inventors: Thiede, Mark A. (Forest Hills, MD); Marshak, Daniel R. (Lutherville, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Friday November 15th, 1996
Patent Number: 5962325
This patent teaches how to generate three dimensional cultures of stem cells through the use of special metrices and TGF beta. The three dimensional cultures can be generated using a variety of stem cells including mesenchymal stem cells. The mesenchymal stem cells may be extracted from bone marrow, cord blood or other sources. Inventors: Naughton, Gail K. (La Jolla, CA); Naughton, Brian A. (El Cajon, CA)
Assignee: Advanced Tissue Sciences, Inc. (La Jolla, CA)
Date of First Priority Issue: Friday April 18th, 1986
Patent Number: 5962323
This patent teaches how to grow bone marrow stromal cells in vitro. Several types of culture conditions for growing stromal cells are given. For example, the stromal cells may be expanded by treatment with FGF-1 on gelatin-coated plates. If FGF-1 can stimulate stromal cells in vitro, one wonders whether it also has similar in vivo abilities. The reason this is important is that there are... Inventors: Greenberger, Joel S. (Sewickley, PA); Hurwitz, David R. (Acton, MA)
Assignee: ALG Company (Marlboro, MA)
Date of First Priority Issue: Friday December 29th, 1995
Patent Number: 5962321
This patent teaches the use of the cytokine LIF for increasing the rate of implantation of embryos. This patent is useful for generation of knockout and transgenic mice. Inventors: Gough, Nicholas Martin (North Balwyn, AU); Willson, Tracey Ann (North Balwyn, AU); Seamark, Robert Frederick (Beulah Park, AU)
Assignee: Amrad Corporation Limited (Victoria, AU)
Date of First Priority Issue: Thursday December 1st, 1994
Patent Number: 5958767
This patent covers a type of neural stem cells that is isolated from human fetal telencephalon. This stem cell can be propagated in vitro and subsequently implanted for therapeutic benefit in a wide variety of animal models. Inventors: Snyder, Evan Y. (Jamaica Plain, MA); Wolfe, John H. (Philadelphia, PA); Kim, Seung U. (Vancouver, CA)
Assignee: The Children's Medical Center Corp. (Boston, MA)
Date of First Priority Issue: Friday August 14th, 1998
Patent Number: 5955357
This patent covers the differentiation of hematopoietic stem cells into neutrophil stem cells. The neutrophil stem cell is a type of cell that gives rise primarily to neutrophils upon further differentiation. Inventors: Bender, James G. (Lindenhurst, IL); Maples, Phillip B. (Waukegan, IL); Smith, Stephen L. (Arlington Heights, IL); Unverzagt, Kristen L. (Palatine, IL); Van Epps, Dennis E. (Cary, IL)
Assignee: Nexell Therapeutics Inc. (Irvine, CA)
Date of First Priority Issue: Monday March 23rd, 1992
Patent Number: 5948623
This patent covers the use of the transcription factor Pax4 for identifying the number of pancreatic stem cells in an animal. This patent is useful for entities seeking to expand the number of pancreatic stem cells in vivo through administration of various compounds. One such example is the work by Transition Therapeutics utilizing gastrin with EGF for treatment of diabetes through inducing... Inventors: Sosa-Pineda, Beatriz (Memphis, TN); Gruss, Peter (Gottingen, DE)
Assignee: Max-Planck Gesellschaft Zur Forderung der Wissenschaften E.V. (Berlin, DE)
Date of First Priority Issue: Tuesday December 31st, 1996
Patent Number: 5948426
This patent covers a matrix derived from bone that is able to induce the proliferation and expansion of hematopoietic stem cells in vitro. Inventor: Jefferies, Steven R. (York, PA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Saturday May 3rd, 1997
Patent Number: 5945337
This patent covers the composition of matter for several types of tissue culture media that are useful for ex vivo expanding stem cells in absence of various forms of serum. This is useful for clinical purposes since administration of cells grown in serum is not looked upon favorably by regulatory agencies. Inventor: Brown, Ronald L. (Derwood, MD)
Assignee: Quality Biological, Inc. (Gaithersburg, MD)
Date of First Priority Issue: Friday October 18th, 1996
Patent Number: 5945303
This patent provides various pepties that stimulate proliferation of hematopoietic stem cells. It is not clear from the specification what exactly these peptides are stimulating in order to induce hematopoietic stem cell expansion. Inventors: Wei, Ying-Fei (Darnestown, MD); Li, Haodong (Gaithersburg, MD)
Assignee: Human Genome Sciences, Inc. (Rockville, MD)
Date of First Priority Issue: Thursday April 11th, 1996
Patent Number: 5942225
Disclosed are tissue culture conditions that can direct the differentiation of mesenchymal stem cells into the following cell lineages: osteogenic, chondrogenic, tendonogenic, ligamentogenic, myogenic, marrow stromagenic, adipogenic and dermogenic.
This patent is useful for the generation of artificial tissue. Although the mesenchymal stem cells themselves are poorly immunogenic, the tissue... Inventors: Bruder, Scott P. (Owings Mills, MD); Caplan, Arnold I. (Cleveland Heights, OH); Haynesworth, Stephen E. (Cleveland Heights, OH)
Assignee: Case Western Reserve University (Cleveland, OH); Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Tuesday January 24th, 1995
Patent Number: 5942221
This patent covers primate G-CSF. G-CSF is a potent stimulator of granulocyte production and is used clinically under the name Neupogen and more recently Neulasta. Inventors: Clark, Steven C. (Winchester, MA); Kaufman, Randal J. (Boston, MA); Wong, Gordon G. (Cambridge, MA)
Assignee: Novartis Corporation (Basel, CH)
Date of First Priority Issue: Wednesday July 6th, 1994
Patent Number: 5939529
This patent covers the use of various types of C Reactive Protein mutants for the stimulation of platelet production. CRP is actually made naturally by the liver in times of inflammation. I wonder if natural CRP also has hematopoietic effects? Inventor: Potempa, Lawrence A. (Deerfield, IL)
Assignee: Immtech International Inc. (Evanston, IL)
Date of First Priority Issue: Wednesday February 23rd, 1994
Patent Number: 5928947
This patent covers a type of stem cell that gives rise to numerous neural lineages. The stem cell is useful for administration after differentiation, administration in an undifferentiated state, as well as administration after gene transfection.
This stem cell is purified from the fetal neural crest. Inventors: Anderson, David J. (Altadena, CA); Stemple, Derek L. (Newton, MA)
Assignee: California Institute of Technology (Pasadena, CA)
Date of First Priority Issue: Monday July 27th, 1992
Patent Number: 5928945
This patent teaches how to generate cartilage through the growth of chondrocyte stem cells under shear stress. It is believed that the sheer stress activates certain mechanoreceptors which cause appropriate differentiation of the chondrocyte stem cells into cartilage. Inventors: Seliktar, Dror (Atlanta, GA); Dunkelman, Noushin (San Diego, CA); Peterson, Alvin Edward (Jamul, CA); Schreiber, Ronda Elizabeth (Ramona, CA); Willoughby, Jane (Del Mar, CA); Naughton, Gail K. (Del Mar, CA)
Assignee: Advanced Tissue Sciences, Inc. (La Jolla, CA)
Date of First Priority Issue: Wednesday November 20th, 1996
Patent Number: 5928943
This patent covers specific embryonically-derived cells that have stem cell ability to regenerate myocardium after injury. Methods for selecting cells with such potential are disclosed. Inventors: Franz, Wolfgang-Michael (Gross Gronau, DE); Wobus, Anna M. (Gatersleben, DE)
Assignee: Institut fur Pflanzengenetik und Kulturpflanzenforschung (Gatersieben, DE)
Date of First Priority Issue: Tuesday November 22nd, 1994
Patent Number: 5925568
This patent teaches that the chemokines MIP-1 alpha/LD78 are capable of causing the mobilization of stem cells from the bone marrow. This patent is useful for increasing the number of circulating stem cells from a donor so that peripheral blood may be harvested for stem cells for transplantation. Additionally, mobilization may be performed in a patient with a stroke or cardiac infarct so as to... Inventors: Comer, Michael Berisford (Oxford, GB); McCourt, Matthew John (Oxford, GB); Wood, Lars Michael (Oxford, GB); Hunter, Michael George (Oxford, GB); Edwards, Richard Mark (Oxford, GB)
Assignee: British Biotech Pharmaceuticals Limited (Oxford, GB)
Date of First Priority Issue: Tuesday June 15th, 1993
Patent Number: 5922847
This patent teaches ways of purifying hematopoietic stem cells based on their expression of the marker c-kit. This marker is the receptor for the cytokine stem cell factor that was developed by Amgen. Inventors: Broudy, Virginia C. (Seattle, WA); Lin, Nancy (Seattle, WA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Date of First Priority Issue: Friday April 5th, 1991
Patent Number: 5922597
This patent teaches ways of increasing the number of stem cells ex vivo through a specific tissue culture cocktail that contains several cytokines but is serum-free and stromal cell-free. Inventors: Verfaillie, Catherine M. (St. Paul, MN); McGlave, Philip B. (St. Paul, MN); Miller, Jeffrey S. (Little Canada, MN)
Assignee: Regents of the University of Minnesota (Minneapolis, MN)
Date of First Priority Issue: Tuesday November 14th, 1995
Patent Number: 5922572
This patent covers peptide sequences from the "hematopoietic maturation factor", a protein that stimulates differentiation of hematopoietic stem cells. Inventors: Rosen, Craig A. (Laytonsville, MD); Olsen, Henrik (Gaithersburg, MD); Adams, Mark D. (North Potomac, MD); Kirkness, Ewen (Washington, DC)
Assignee: Human Genome Sciences, Inc. (Rockville, MD)
Date of First Priority Issue: Tuesday January 25th, 1994
Patent Number: 5919176
This patent covers a medical device for extraction of cord blood from an umbilical cord after delivery. Inventors: Kuypers, Franciscus A. (El Cerrito, CA); Cole, Robert B. (Alamo, CA); Meyst, Richard P. (Valley Center, CA); Gorton, Lanny A. (San Diego, CA); Wright, James I. (Villa Park, CA)
Assignee: Children's Hospital Medical Center of Northern California (Oakland, CA)
Date of First Priority Issue: Tuesday May 14th, 1996
Patent Number: 5916202
This patent covers a medical device that contains a special pouch for the collection of cord blood from umbilical cords after delivery. Inventor: Haswell, John N. (Sarasota, FL)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday August 30th, 1996
Patent Number: 5914268
This patent covers ways of culturing an embryoid body that is derived from embryonic stem cells, in order to generate a type of cell that gives rise to hematopoietic lineage stem cells and differentiated cells. Inventors: Keller, Gordon M. (Denver, CO); Kennedy, Marion (Denver, CO); Choi, Kyunghee (Denver, CO); Firpo, Meri T. (Denver, CO)
Assignee: National Jewish Center for Immunology & Respiratory Medicine (Denver, CO)
Date of First Priority Issue: Monday November 21st, 1994
Patent Number: 5914121
This patent teaches how to use bone marrow stromal cells (are they similar to mesenchymal stem cells??) for generation of artificial bone. The use of various matrices, including ceramic powder is disclosed for practicing this invention. Inventors: Robey, Pamela Gehron (Bethesda, MD); Bianco, Paolo (Rome, IT); Kuznetsov, Sergei (Bethesda, MD); Rowe, David (West Hartford, CT); Krebsbach, Paul (Bethesda, MD); Mankani, Mahesh H. (Bethesda, MD)
Assignee: The United States of America as represented by the Secretary of the (Washington, DC)
Date of First Priority Issue: Wednesday February 12th, 1997
Patent Number: 5914108
Provided are hematopoietic stem cells that are capable of reconsituting a hematopoietic system. Inventors: Tsukamoto, Ann (Palo Alto, CA); Baum, Charles M. (Mountain View, CA); Aihara, Yukoh (Yokohama, JP); Weissman, Irving (Palo Alto, CA)
Assignee: Systemix, Inc. (Palo Alto, CA)
Date of First Priority Issue: Friday March 30th, 1990
Patent Number: 5913859
This patent teaches methods and discloses devices, that are useful for the extraction of bone marrow stem cells from the jawbone of a patient. Inventor: Shapira, Ira L. (Highland Park, IL)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Tuesday July 1st, 1997
Patent Number: 5912326
This patent discloses a polypeptide that is involved in the formation of various brain structures. This polypeptide is useful for stem cell differentiation and expansion. Inventor: Chang, Han (Mountain View, CA)
Assignee: President and Fellows of Harvard College (Cambridge, MA); Leland S. Stanford University (Palo Alto, CA)
Date of First Priority Issue: Friday September 8th, 1995
Patent Number: 5912177
This patent covers methods of "grabbing" stem cells by virtue of a fibrin matrix together with RGD binding motifs. The attachment of stem cells to various structures may be useful as a means of harvesting stem cells. Inventors: Turner, Marc Leighton (South Queensferry, GB); Murphy, William Gerrard (Edinburgh, GB)
Assignee: Common Services Agency (Edinburgh, GB)
Date of First Priority Issue: Wednesday June 29th, 1994
Patent Number: 5912175
This patent teaches how to grow specialized epithelial structures from stem cells such as cornea, gingiva, and ureters. Specific tissue culture conditions and media are provided for growing the stem cells and inducing their differentiation into the desired tissue. Inventor: Wille, Jr., John J. (Trenton, NJ)
Assignee: Hy-Gene, Inc. (Ventura, CA)
Date of First Priority Issue: Sunday January 21st, 1990
Patent Number: 5912174
This patent provides gelatin-based compounds that allow for the preservation of various cells, including stem cells of the hematopoietic lineage. Inventors: Scheer, David (Guilford, CT); Babior, Bernard M. (San Diego, CA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Thursday June 25th, 1992
Patent Number: 5912133
This patent teaches that cells expressing flk-1 on their surface may be stem cells. It specifically provides methods of using flk-1, alone, or in combination with other markers for the purification of stem cells. Inventor: Lemischka, Ihor R. (Princeton, NJ)
Assignee: The Trustees of Princeton University (Princeton, NJ)
Date of First Priority Issue: Tuesday April 2nd, 1991
Patent Number: 5908784
This patent teaches how to induce differentiation of mesenchymal stem cells into chondrocytes. The tissue culture conditions described may be used for generation of artificial cartilage. This patent is useful in combination with the numerous patents that describe three dimensional matrices and scaffolds useful for making cartilage. Inventors: Johnstone, Brian (Shaker Heights, OH); Yoo, Jung (Shaker Heights, OH)
Assignee: Case Western Reserve University (Cleveland, OH)
Date of First Priority Issue: Thursday November 16th, 1995
Patent Number: 5908782
This patent provides serum free media for the growth, expansion, and differentiation of mesenchymal stem cells. Having media that can be used for expanding mesenchymal stem cells was a critical part of Osiris developing its advanced clinical program. Inventors: Marshak, Daniel R. (Cold Spring Harbor, NY); Holecek, James J. (Solon, OH)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Monday June 5th, 1995
Patent Number: 5908763
This patent covers composition of matter for the hematopoietic cytokine granulocyte monocyte colony stimulating factor. Inventors: Clark, Steven C. (Winchester, MA); Kaufman, Randal J. (Boston, MA); Wong, Gordon G. (Cambridge, MA); Wang, Elizabeth A. (Carlisle, MA)
Assignee: Novartis Corporation (Basel, CH)
Date of First Priority Issue: Friday July 6th, 1984
Patent Number: 5906938
This patent provides antibodies that stimulate the receptor c-kit and allow for enhancement of hematopoiesis.
This patent may be useful not only for stimulation of hematopoiesis, but for stimulating other tissue specific stem cells that also express c-kit...these include endogenous cardiac and other muscle stem cells. Inventors: Broudy, Virginia C. (Seattle, WA); Lin, Nancy (Seattle, WA)
Assignee: Board of Regents of the University of Washington (Seattle, WA)
Date of First Priority Issue: Wednesday May 1st, 1991
Patent Number: 5906934
This patent covers the use of mesenchymal stem cells for generation of artificial bone and cartilage. It is interesting that this patent was issued in light of Osiris's domination of the field of mesenchymal stem cells. This patent should be read in light of the other mesenchymal stem cell patents. Inventors: Grande, Daniel A. (Sea Cliff, NY); Lucas, Paul A. (Macon, GA)
Assignee: Morphogen Pharmaceuticals, Inc. (New York, NY); North Shore University Hospital Research Corporation (Manhasset, NY)
Date of First Priority Issue: Tuesday March 14th, 1995
Patent Number: 5906827
Disclosed are a variety of devices and matrices that are useful for generation of artifical joints through the use of stem cells and differentiated cells. Inventors: Khouri, Roger K. (St. Louis, MO); Sampath, Kuber T. (Medway, MA); Rueger, David C. (Hopkinton, MA)
Assignee: Creative BioMolecules, Inc. (Hopkinton, MA)
Date of First Priority Issue: Friday June 3rd, 1994
Patent Number: 5905042
This patent provides technologies for growing stem cells that are useful for the generation of chimeric cows or pigs. Inventors: Stice, Steven L. (Belchertown, MA); Golueke, Paul J. (Belchertown, MA)
Assignee: University of Massachusetts, A Public Institution of Higher Education of (Amherst, MA)
Date of First Priority Issue: Monday April 1st, 1996
Patent Number: 5905031
This patent covers ways of detecting blast cells from other types of cells using photometric means. Inventors: Kuylen, Nazle (Miami, FL); Crews, Harold R. (Pembroke Pines, FL); Jaffe, Gerald E. (Pembroke Pines, FL); Barcelon, Maria (Ft. Lauderdale, FL); Lucas, Francis J. (Boca Raton, FL); Garcia, Nancy M. (Miami, FL)
Assignee: Coulter International Corp. (Miami, FL)
Date of First Priority Issue: Thursday May 18th, 1995
Patent Number: 5888965
This patent teaches how to enhance hematopoiesis using hepatocyte growth factor alone or in combination with other cytokines. Inventors: Kmiecik, Thomas E. (Frederick, MD); Vande Woude, George F. (Berryville, VA)
Assignee: The United States of America as represented by the Department of Health and Human Services (Washington, DC)
Date of First Priority Issue: Wednesday December 27th, 1989
Patent Number: 5888807
This patent provides bioreactors and specialized culture vessels that are useful for the growth and expansion of human hematopoietic stem cells. Inventors: Palsson, Bernhard O. (Ann Arbor, MI); Emerson, Stephen G. (Ann Arbor, MI); Schwartz, Richard M. (Ann Arbor, MI)
Assignee: The Regents of the University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Thursday June 15th, 1989
Patent Number: 5888499
This patent covers ways of generating neutrophil-committed stem cells. These neutrophil committed stem cells are useful for prevention of infection after myeloablation. Inventors: Bender, James G. (Lindenhurst, IL); Maples, Phillip B. (Waukegan, IL); Smith, Stephen (Arlington Heights, IL); Unverzagt, Kristen L. (Palatine, IL); Van Epps, Dennis E. (Cary, IL)
Assignee: Nexell Therapeutics Inc. (Irvine, CA)
Date of First Priority Issue: Monday March 23rd, 1992
Patent Number: 5879940
This patent covers a "stromal" cell line that supports hematopoiesis in vitro. I wonder how different are these "stromal" cell lines from the mesenchymal stem cells that are described by Osiris? Inventors: Torok-Storb, Beverly (Seattle, WA); Roecklein, Bryan A. (Seattle, WA); Johnson, Gretchen (Issaquah, WA)
Assignee: Fred Hutchinson Cancer Research Center (Seattle, WA)
Date of First Priority Issue: Wednesday July 20th, 1994
Patent Number: 5869463
This patent covers a type of stem cell that is isolated from fetal brain that is useful for the treatment of neurodegenerative disease. Inventors: Major, Eugene O. (Oakton, VA); Tornatore, Carlo S. (University Park, MD)
Assignee: The United States of America as represented by the Department of Health and Human Services (Washington, DC)
Date of First Priority Issue: Tuesday April 13th, 1993
Patent Number: 5866414
This patent describes compositions derived from the submucosa of various mammals that possess growth factors useful for the expansion of stem cells. Inventors: Badylak, Stephen F. (West Lafayette, IN); Voytik, Sherry (Lafayette, Indiana, IN); Boder, George (Martinsville, IN)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday February 10th, 1995
Patent Number: 5861483
This patent describes peptides derived from hemoglobin that inhibit stem cell proliferation. These peptides are useful for protecting stem cells from killing by chemotherapy or radiation therapy. Inventor: Wolpe, Stephen D. (Rockville, MD)
Assignee: Pro-Neuron, Inc. (Rockville, MD)
Date of First Priority Issue: Wednesday April 3rd, 1996
Patent Number: 5861315
This patent covers the use of the c-kit ligand together with stimulators of gp130 for the in vitro and ex vivo expansion of hematopoietic stem cells. Since the c-kit ligand is important for other types of stem cells, it will be interesting to see if this patent can be used for expansion of, say for example, cardiac stem cells. Inventor: Nakahata, Tatsutoshi (Tokyo, JP)
Assignee: Amgen Inc. (Thousand Oaks, CA); Tosoh Corporation (Thousand Oaks, CA)
Date of First Priority Issue: Wednesday November 16th, 1994
Patent Number: 5861313
This patent covers a type of stem cell that is isolated from the bile duct that can be induced to differentiate into various types of pancreatic cells including islets. Inventors: Pang, Kevin K. (Belmont, MA); Homa, Monica W. (Marblehead, MA)
Assignee: Ontogeny, Inc. (Cambridge, MA)
Date of First Priority Issue: Wednesday June 7th, 1995
Patent Number: 5858747
This patent covers several means of growing stem cells and their derivatives, as well as generating scaffolds and implantable means that protect the stem cells from the immunological reaction of the host. Inventors: Schinstine, Malcolm (Ben Salem, PA); Shoichet, Molly S. (Toronto, CA); Gentile, Frank T. (Warwick, RI); Hammang, Joseph P. (Barrington, RI); Holland, Laura M. (Horsham, PA); Cain, Brian M. (Everett, MA); Doherty, Edward J. (Mansfield, MA); Winn, Shelley R
Assignee: CytoTherapeutics, Inc.
Date of First Priority Issue: Wednesday July 20th, 1994
Patent Number: 5856301
This patent covers the inhibition of stem cell proliferation through administration of MIP-1 alpha or LD78. It is interesting to ask whether these compounds also inhibit proliferation of leukemic stem cells. If they do not, the use of these compounds may selectively protect healthy hematopoietic stem cells but allow killing of the leukemic hematopoietic stem cells by chemotherapy. Inventors: Craig, Stewart (Oxford, GB2); Hunter, Michael George (Buckinghamshire, GB2); Edwards, Richard Mark (Oxford, GB2); Czaplewski, Lloyd George (Oxford, GB2); Gilbert, Richard James (Oxford, GB2)
Assignee: British Biotech Pharmaceuticals Limited (Oxford, GB)
Date of First Priority Issue: Wednesday December 23rd, 1992
Patent Number: 5855619
This patent provides various compositions of matter that are useful for the administration of stem cells in order to heal or regenerate soft tissue. Inventors: Caplan, Arnold I. (Cleveland Heights, OH); Fink, David J. (Shaker Heights, OH); Young, Randell G. (Ellicott City, MD)
Assignee: Case Western Reserve University (Cleveland, OH)
Date of First Priority Issue: Monday June 6th, 1994
Patent Number: 5854292
This patent covers the use of the retinoid receptor pathway to induce differentiation of adipocyte stem cells in vivo and therefore make a patient who is insulin resistant, insulinn sensitive. Inventors: Ailhaud, Gerard (Nice, FR); Grimaldi, Paul (Nice, FR); Safonova, Irina (Nice, FR); Shroot, Braham (Antibes, FR); Reichert, Uwe (Pont Du Loup, FR)
Assignee: Centre International De Recherches Dermatologiques Galderma (Valbonne, FR)
Date of First Priority Issue: Wednesday August 2nd, 1995
Patent Number: 5853717
This patent teaches ways of encapsulating stem cells and their derivatives. It provides various means and devices for the generation of artificial organs. Additionally, the patent teaches how to optimize the viability of the stem cells in the artificial organ. Inventors: Schinstine, Malcolm (Ben Salem, PA); Shoichet, Molly S. (Toronto, CA); Gentile, Frank T. (Warwick, RI); Hammang, Joseph P. (Barrington, RI); Holland, Laura M. (Horsham, PA); Cain, Brian M. (Everett, MA); Doherty, Edward J. (Mansfield, MA); Winn, Shelley R
Assignee: CytoTherapeutics, Inc. (Lincoln, RI)
Date of First Priority Issue: Monday June 20th, 1994
Patent Number: 5851984
Wnt peptides are critical in embryonic development and cell fate determination. In this patent Wnt peptides are used for the expansion and differentiation of hematopoietic stem cells. I predict that these peptides would also be useful for expansion of non-hematopoietic stem cells as well. Inventors: Matthews, William (Woodside, CA); Austin, Timothy W. (Morgan Hill, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Date of First Priority Issue: Friday August 16th, 1996
Patent Number: 5851832
This patent covers a type of neural stem cell that can differentiate into neurons and neuron supporting cells.
This patent also teaches ways of expanding and differentiating the neural stem cells. Inventors: Weiss, Samuel (Alberta, CA); Reynolds, Brent (Alberta, CA); Hammang, Joseph P. (Barrington, RI); Baetge, E. Edward (Barrington, RI)
Assignee: Neurospheres, Ltd. (CA)
Date of First Priority Issue: Monday July 8th, 1991
Patent Number: 5851534
Inventors: Raheman, Fazal (Burlington, MA); Istrate, Nicolae (Lexington, MA); Muni, Gita (North Reading, MA); Brauner, Edgard (Brighton, MA)
Assignee: Dynagen, Inc. (Cambridge, MA)
Date of First Priority Issue: Friday May 3rd, 1996
Patent Number: 5849686
This patent provides various morphogens that can be administered in vivo for the induction of liver regeneration. This patent is useful alone, or in combination with exogenous stem cell delivery for treatment of hepatic disorders.
This patent is especially interesting in light of recent work using cord blood stem cells for liver regeneration. Inventors: Kuberasampath, Thangavel (Medway, MA); Rueger, David C. (Hopkinton, MA); Oppermann, Hermann (Medway, MA); Pang, Roy H. L. (Etna, NH); Cohen, Charles M. (Medway, MA)
Assignee: Creative BioMolecules, Inc.
Date of First Priority Issue: Monday March 11th, 1991
Patent Number: 5849553
This patent covers neural stem cells that are transfected with various oncogenes so as to make them immortal. These cells would be highly beneficial for cell therapy of neurodegenerative diseases, if the safety issue of potential oncogenesis can be overcome. Inventors: Anderson, David J. (Altadena, CA); Stemple, Derek L. (Newton, MA)
Assignee: California Institute of Technology (Pasadena, CA)
Date of First Priority Issue: Monday July 27th, 1992
Patent Number: 5849287
This patent covers the use of stromal cells for delivery of genes. Stromal cells can migrate systemically and when transfected with genes can serve as a stable source of protein production in a patient.
I wonder what the difference is between the stromal cells described in this patent and the mesenchymal stem cells covered by Osiris? Inventors: Greenberger, Joel S. (Lincoln, MA); Levine, Peter H. (Worcester, MA)
Assignee: Stromagene Corporation (Lincoln, MA); Gene Therapy Sciences, Inc. (Worcester, MA)
Date of First Priority Issue: Thursday February 2nd, 1989
Patent Number: 5847078
Disclosed is a novel peptide that is useful for terminally differentiating leukemic cells. This peptide could be generally used for luekemia therapy, but should also be considered in combination with some other differentiation inducing agents such as retinoic acid. Inventors: Eto, Yuzuru (Yokohama-shi, Kanagawa-ken, JP); Tsuji, Tomoko (Kawasaki-shi, Kanagawa-ken, JP); Takano, Satoshi (Yokohama-shi, Kanagawa-ken, JP); Takezawa, Misako (Yokohama-shi, Kangawa-ken, JP); Yokogawa, Yasunori (Yamato-shi, Kanagawa-ken, JP); Shibai, Hi
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Wednesday July 2nd, 1986
Patent Number: 5846958
This patent covers a small molecule that is useful for expansion of hematopoietic stem cells in vivo. This small molecule would be interesting to use in a depot formulation and administered together with local cell therapy for the stimulation of angiogenesis. Inventors: Capizzi, Robert L. (Haverford, PA); List, Alan F. (Tucson, AZ)
Assignee: U.S. Bioscience, Inc. (West Conshohocken, PA); Arizona Board of Regents on Behalf of the University of Arizona (Tucson, AZ)
Date of First Priority Issue: Friday February 17th, 1995
Patent Number: 5846937
This patent may be interesting for Amylin from San Diego to look at. Why it is interesting is because, I believe, Amylin actually has taken some of the compounds described in this patent to the clinic.
This patent teaches the use of GLP-1 and/or exendin-4 for modulation of central nervous system activity. Inventor: Drucker, Daniel J. (Toronto, CA)
Assignee: 1149336 Ontario Inc. (Toronto, CA)
Date of First Priority Issue: Monday March 3rd, 1997
Patent Number: 5846807
This patent describes ways of growing tissue in space or under microgravity conditions. This patent could be used not only for generation of medically important implants, but also for production of various artificial meats and foods for astronauts to eat while in space. Inventor: Goodwin, Thomas J. (Friendswood, TX)
Assignee: The United States of America as represented by the Administrator of the National Aeronautics and Space Administration (Washington, DC)
Date of First Priority Issue: Thursday June 30th, 1988
Patent Number: 5846796
This patent covers mesenchymal stem cells that are circulating in the blood. This patent is interesting since the cells covered contain the hematopoietic stem cell marker CD34, which is usually not believed to be expressed on mesenchymal stem cells. Additionally, the marker CD45, is usually a hematopoietic associated marker, but it too is also expressed on the mesenchymal stem cells that are... Inventors: Cerami, Anthony (Shelter Island, NY); Bucala, Richard J. (New York, NY)
Assignee: The Picower Institute for Medical Research (Manhasset, NY)
Date of First Priority Issue: Friday February 26th, 1993
Patent Number: 5846529
This patent covers ways of treating neutropenic patients through administration of stem cells that are committed to differentiating into neutrophils.
This patent is useful for the treatment of patients that are suppressed in terms of white blood cell numbers. Inventors: Smith, Stephen L. (Arlington Heights, IL); Qiao, Xiaoying (Waukegan, IL); Maciukas, Susan M. (El Cerrito, CA); Loudovaris, Maureen F. (Grayslake, IL); Bender, James G. (Lindenhurst, IL); Van Epps, Dennis E. (Cary, IL)
Assignee: Nexell Therapeutics, Inc. (Irvine, CA)
Date of First Priority Issue: Monday August 23rd, 1993
Patent Number: 5844079
This patent covers hedgehog proteins and their derivatives. These compositions of matter are very important for embryonic development and can be used for the expansion and differentiation of a wide variety of stem cells. Inventors: Ingham, Philip W. (Summertown, GB2); McMahon, Andrew P. (Lexington, MA); Tabin, Clifford J. (Cambridge, MA)
Assignee: President and Fellows of Harvard College (Cambridge, MA)
Date of First Priority Issue: Thursday December 30th, 1993
Patent Number: 5843780
This is one of the composition of matter patents on embryonic stem cells. It belongs to what is called the "WARF Patents" covering the use and production of human and primate embryonic stem cells. Inventor: Thomson, James A. (Madison, WI)
Assignee: Wisconsin Alumni Research Foundation (Madison, WI)
Date of First Priority Issue: Friday January 20th, 1995
Patent Number: 5843633
This patent covers the antigen known as AC133 or CD133. This antigen is useful for purification of hematopoietic stem cells, as well as stem cells with angiogenic activity. Inventors: Yin, Amy (San Jose, CA); Miraglia, Sheri (Alameda, CA); Buck, David W. (Half Moon Bay, CA)
Assignee: Amcell Corporation (Sunnyvale, CA)
Date of First Priority Issue: Friday April 26th, 1996
Patent Number: 5843438
This patent covers the use of anti-VLA-4 and anti-VCAM antibodies for mobilizing stem cells from the bone marrow. Stem cell mobilization is induced by the antibodies blocking the binding of the hematopoietic stem cells to the bone marrow stroma. Inventor: Papayannopoulou, Thalia (Seattle, WA)
Assignee: Board of Regents University of Washington (Seattle, WA)
Date of First Priority Issue: Friday November 13th, 1992
Patent Number: 5843431
This patent covers the use of certain compositions of matter for the generation of implantable cells and stem cells. In some embodiments the cells are treated so as to not elicit an immune response. In other embodiments the proliferation of the cells in the encapsulation devices is controlled. Inventors: Schinstine, Malcolm (Ben Salem, PA); Shoichet, Molly S. (Toronto, CA); Gentile, Frank T. (Warwick, RI); Hammang, Joseph P. (Barrington, RI); Holland, Laura M. (Horsham, PA); Cain, Brian M. (Everett, MA); Doherty, Edward J. (Mansfield, MA); Winn, Shelley R
Assignee: CytoTherapeutics, Inc.
Date of First Priority Issue: Wednesday July 20th, 1994
Patent Number: 5843423
This patent covers the stimulation of hematopoietic stem cells with flt-3 ligand. This cytokine is used in many stem cell stimulation/expansion cocktails...additionally flt-3 ligand is one of the few cytokines that can preferentially induce expansion of tissue dendritic cells. Inventors: Lyman, Stewart D. (Seattle, WA); Beckmann, M. Patricia (Poulsbo, WA)
Assignee: Immunex Corporation (Seattle, WA)
Date of First Priority Issue: Monday May 24th, 1993
Patent Number: 5840580
This patent covers the combination of various phenotypic markers for the extraction of hematopoietic stem cells. For example, CD34+, CD38-, HLA-DR- is one phenotype of hematopoietic stem cell described. Inventors: Terstappen, Leon W. (Huntingdon Valley, PA); Loken, Michael R. (Mercer Island, WA); Huang, Shiang (San Ramon, CA); Olweus, Johanna (Fremont, CA); Lund-Johansen, Fridtjof (Fremont, CA)
Assignee: Becton Dickinson and Company (Franklin Lakes, NJ)
Date of First Priority Issue: Tuesday May 1st, 1990
Patent Number: 5837539
This patent covers the use of specific antibodies for the isolation and detection of mesenchymal stem cells. The antibodies are deposited at ATCC and can be purchased publically. Inventors: Caplan, Arnold I. (Cleveland Heights, OH); Haynesworth, Stephen E. (Cleveland Heights, OH)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Friday November 16th, 1990
Patent Number: 5837241
This patent covers antagonizing either or both the endothelin receptor and the LIF receptor. Methods of action by which this combination inhibits heart failure may have to do with modulation of stem cell function. Inventors: Ferrara, Napoleone (San Francisco, CA); King, Kathleen (Pacifica, CA); Luis, Elizabeth (San Francisco, CA); Mather, Jennie P. (Millbrae, CA); Paoni, Nicholas F. (Belmont, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Date of First Priority Issue: Tuesday April 25th, 1995
Patent Number: 5837229
Covered in this patent is the use of the cytokine currently named M-CSF, for the expansion of hematopoietic stem cells and their differentiation along the myeloid lineage. Mice that are knocked out for M-CSF do not have functional macrophages, but also do not have tumor associated angiogenesis. Inventors: Ralph, Peter (Orinda, CA); Chong, Kong T. (Union City, CA)
Assignee: Chiron Corporation (Emeryville, CA)
Date of First Priority Issue: Tuesday November 17th, 1998
Patent Number: 5834312
This patent covers a liquid composition that is useful for the growth of epithelial cells and various stem cells that differentiate along the epithelial lineages. Relevant types of cells generated by this culture could be corneal epithelial or gingival cells. Inventor: Wille, Jr., John J. (Trenton, NJ)
Assignee: Hy-Gene, Inc. (Ventura, CA)
Date of First Priority Issue: Monday January 29th, 1990
Patent Number: 5834308
This the success of the Edmonton Protocol for treating diabetes using allogeneic islets, the need for sources of islet cells has intensified. The patent addresses that need through teaching ways of growing and expanding islet cells from pancreatic stem cells. Inventors: Peck, Ammon B. (Gainesville, FL); Cornelius, Janet G. (Gainesville, FL)
Assignee: University of Florida Research Foundation, Inc. (Gainesville, FL)
Date of First Priority Issue: Thursday April 28th, 1994
Patent Number: 5834029
This patent teaches ways of generating in vitro channels in which nerves can be grown. These channels can then be administered in vivo for the treatment of neurodegenerative diseases. Inventors: Bellamkonda, Ravi (Boston, MA); Ranieri, John P. (Lausanne, CH); Aebischer, Patrick (Lutry, CH)
Assignee: CytoTherapeutics, Inc. (Lincoln, RI)
Date of First Priority Issue: Friday May 20th, 1994
Patent Number: 5834001
This patent teaches ways of generating devices that contain cells or stem cells that can be implanted without fear of immune mediated rejection. Inventors: Dionne, Keith E. (Rehoboth, MA); Emerich, Dwaine F. (Providence, RI); Hoffman, Diane (Cambridge, MA); Sanberg, Paul R. (Spring Hill, FL); Christenson, Lisa (New Haven, CT); Hegre, Orion D. (Green Valley, AZ); Sharp, David W. (St. Louis, MO); Lacy, Paul E.
Assignee: Brown University Research Foundation
Date of First Priority Issue: Thursday April 25th, 1991
Patent Number: 5833979
Lets imagine that one wanted to implant embryonic stem cells into a human. The first concern would be rejection by allogeneic immunity. To overcome this one could immune suppress, which is not desirable, or one could encapsulate the cells. If the cells are encapsulated but start proliferating, then they can either die or break through the encapsulation device. This patent teaches the use of UV... Inventors: Schinstine, Malcolm (Ben Salem, PA); Shoichet, Molly S. (Toronto, CA); Gentile, Frank T. (Warwick, RI); Hammang, Joseph P. (Barrington, RI); Holland, Laura M. (Horsham, PA); Cain, Brian M. (Everett, MA); Doherty, Edward J. (Mansfield, MA); Winn, Shelley R
Assignee: CytoTherapeutics, Inc. (Lincoln, RI)
Date of First Priority Issue: Wednesday July 20th, 1994
Patent Number: 5830705
This is a patent on ways of generating a cytokine called human p-G-CSF. I wonder what the modern name of this cytokine is?
In any case, the invention teaches that this cytokine stimulates hematopoietic stem cells proliferation. Inventor: Souza, Lawrence M. (Witherspoon, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Date of First Priority Issue: Friday August 23rd, 1985
Patent Number: 5830701
This patent provides devices that can quantify hematopoietic stem cell numbers from a pool of cells through non-immunological means. Inventors: Houwen, Berend (Redlands, CA); Tsujino, Yukio (Hyogo-ken, JP); Morikawa, Takashi (Hyogo-ken, JP); Ikeuchi, Yoshiro (Hyogo-ken, JP); Hamaguchi, Yukio (Hyogo-ken, JP)
Assignee: Tao Medical Electronics Co., Ltd. (JP)
Date of First Priority Issue: Friday March 28th, 1997
Patent Number: 5830651
This patent covers a neural stem cell line that can differentiate into neurons, oligodendrocytes, and glial cells. This cell line can be used for drug discovery since it provides a uniform cellular population. These cells may be purchased by the public from ATCC. Inventors: Cauley, Keith (Burlington, VT); Kukekov, Valery (San Diego, CA)
Assignee: Signal Pharmaceuticals, Inc. (San Diego, CA)
Date of First Priority Issue: Monday May 1st, 1995
Patent Number: 5827742
This patent takes advantage of the fact that early hematopoietic stem cells are usually CD34+ and quiescent. By treatment of CD34+ cells with cytotoxic agents that kill proliferating cells, a population of primitive stem cells may be obtained. Inventor: Scadden, David T. (Weston, MA)
Assignee: Beth Israel Deaconess Medical Center, Inc. (Boston, MA)
Date of First Priority Issue: Thursday September 1st, 1994
Patent Number: 5827740
Treatment of mesenchymal stem cells with a glucocorticoid together with an agent that increases intracellular cAMP is disclosed as one of several methods for inducing the differentiation of mesenchymal stem cells into adipocytes. Inventor: Pittenger, Mark F. (Severna Park, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Tuesday July 30th, 1996
Patent Number: 5827735
This patent provides a new type of stem cell that is similar to the mesenchymal stem cells covered by Osiris. It appears that the stem cells disclosed in this patent are derived from muscle cells. If these cells are mesenchymal or express the markers SH2-4 covered by Osiris, this could be an interesting patent to watch out for. Inventors: Young, Henry E. (Macon, GA); Lucas, Paul A. (Poughkeepsie, NY)
Assignee: MorphoGen Pharmaceuticals, Inc. (New York, NY)
Date of First Priority Issue: Monday June 22nd, 1992
Patent Number: 5827670
This patent covers VCAM positive bone marrow stromal cells. These are the cells that support hematopoietic stem cell proliferation. Do mesenchymal stem cells have VCAM on them?? Inventors: Masinovsky, Boris (Bellevue, WA); Gallatin, William Michael (Mercer Island, WA); Simmons, Paul J. (Seattle, WA)
Assignee: Fred Hutchinson Cancer Research Center (Seattle, WA)
Date of First Priority Issue: Tuesday October 27th, 1998
Patent Number: 5824489
Covered is a method of purifying or extracting a type of stem cells from the fetal neural crest. This population of stem cells expresses low-affinity nerve growth factor receptor (LNGFR) and nestin and can differentiate into various cells of the neural lineage. Inventors: Anderson, David J. (Altadena, CA); Stemple, Derek L. (Pasadena, CA)
Assignee: California Institute of Technology (Pasadena, CA)
Date of First Priority Issue: Tuesday July 21st, 1992
Patent Number: 5824304
This patent teaches how to treat HIV by removal of mobilized stem cells (stem cell mobilization by anti-VLA4 antibody), administering chemo or radiotherapy, and then subsequently reinfusing the purified stem cells to reconstitute the hematopoietic system. Inventor: Papayannopoulou, Thalia (Seattle, WA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday November 13th, 1992
Patent Number: 5817773
This patent teaches that members of the FGF family are useful for expansion of hematopoietic stem cells. This is interesting since FGF-2 was actually used in the clinic for treatment of stroke. Although results were impressive in small subsets of patients, the adverse effects of systemic administration of this protein stopped its clinical development. According to this patent the systemic... Inventors: Wilson, Elaine Lynette (New York, NY); Gabrilove, Janice (New York, NY)
Assignee: New York University (New York, NY); Sloan-Kettering Institute for Cancer Research (New York, NY)
Date of First Priority Issue: Friday June 8th, 1990
Patent Number: 5817622
This patent teaches that administration of neurturin can increase survival and induce expansion of neural stem cells. It would be interesting to see if neurturin can also effect hematopoiesis, given the similarity between stem cells of the hematopoietic and neural lineages. Inventors: Johnson, Jr., Eugene M. (St. Louis, MO); Milbrandt, Jeffrey D. (St. Louis, MO); Kotzbauer, Paul T. (St. Louis, MO); Lampe, Patricia A. (St. Louis, MO)
Assignee: Washington University (St. Louis, MO)
Date of First Priority Issue: Monday August 28th, 1995
Patent Number: 5814440
Disclosed are methods of purifying hematopoietic stem cells using the antibody EM10. Inventors: Hill, Beth Louis (Mountain View, CA); Rozler, Elen (Mountain View, CA); Chen, Benjamin P. (Fremont, CA)
Assignee: Systemix, Inc. (Palo Alto, CA)
Date of First Priority Issue: Wednesday June 7th, 1995
Patent Number: 5811407
This patent teaches the transfection of bone marrow stem cells using a new type of vector. The vector disclosed is an alphavirus vector. Transfection by alphavirus has been performed in numerous situations and is actually in clinical trials. Inventors: Johnston, Robert E. (Chapel Hill, NC); Davis, Nancy L. (Chapel Hill, NC); Simpson, Dennis A. (Pittsboro, NC)
Assignee: The University of North Carolina at Chapel Hill (Chapel Hill, NC)
Date of First Priority Issue: Wednesday February 19th, 1997
Patent Number: 5811301
This patent teaches ways of genetically modifying stem cells, and their progeny so as to generate a population of cells that is acceptable by all humanity. Inventor: Cameron, Robert B. (San Francisco, CA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Tuesday November 16th, 1993
Patent Number: 5811094
This is one of the original Osiris patents covering the therapeutic use of mesenchymal stem cells. In this patent mesenchymal stem cells are generated from the bone marrow and used to regenerate connective tissue such as bone or cartilage. Inventors: Caplan, Arnold I. (Cleveland Heights, OH); Haynesworth, Stephen E. (Cleveland Heights, OH)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Friday November 16th, 1990
Patent Number: 5811089
This patent covers the injection of fetal hematopoietic organs, and extracts thereof, for the treatment of HIV. Inventors: Smikodub, Alexandr Ivanovich (Kiev, UA); Markov, Igor Semenovich (Kiev, UA); Pilipchak, Elena Makarovna (Kiev, UA)
Assignee: Centr Embrionainikh Tkaney "Emcell" (Kiev, UA)
Date of First Priority Issue: Tuesday December 14th, 1993
Patent Number: 5808002
This patent covers the use of an antibody to c-kit for the quantification and extraction of hematopoietic stem cells. Since non-hematopoietic stem cells also express c-kit, this antibody may have other uses than originally contemplated. Inventor: Buhring, Hans-Jorg (Tubingen, DE)
Assignee: Eberhard-Karls-Universitat Tubingen (Tubingen, DE)
Date of First Priority Issue: Wednesday January 10th, 1996
Patent Number: 5807744
This patent teaches that the Th1 cytokine interferon gamma inhibits proliferation of hematopoietic stem cells. In one use, this cytokine may be administered to cultures of bone marrow harvested from cancer patients for autologous transplant, the administration of interferon gamma would protect the stem cells from chemotherapy which would kill residual cancer cells. Additionally, the interferon... Inventors: Berneman, Zwi (Antwerp, BE); Van Bockstaele, Dirk (Edegem, BE); Snoeck, Hans-Willem (Antwerp, BE)
Assignee: Boehringer Mannheim GmbH (Mannheim, DE)
Date of First Priority Issue: Saturday August 13th, 1994
Patent Number: 5807686
This patent covers an early hematopoietic stem cell that is identified by unique physical characteristics. It is interesting to see how this patent is read in light of other patents dealing with hematopoietic stem cell populations. Inventors: Wagner, John E. (Plymouth, MN); Lebkowski, Jane S. (Portola Valley, CA)
Assignee: Regents of University of Minnesota (Minneapolis, MN); Rhone-Poulenc Rorer Pharmaceuticals (Collegeville, PA)
Date of First Priority Issue: Monday November 16th, 1992
Patent Number: 5806529
This patent teaches that administration of "mega-dose" hematopoietic stem cell grafts may be useful for circuventing the requirement of completely ablating the recipient immune system. Use of this patent may allow for reduced neutropenic times and increased survival after bone marrow transplantation. Inventors: Reisner, Yair (Old Jaffa, IL); Martelli, Massimo (Perugia, IT)
Assignee: Yeda Research and Development Co. Ltd. (IL)
Date of First Priority Issue: Wednesday November 3rd, 1993
Patent Number: 5804446
This patent covers a type of stem cell that circulates and is mesenchymal in nature. The cell phenotype is CD34+ and CD45+, both being markers of hematopoietic and not classical mesenchymal stem cells. Inventors: Cerami, Anthony (Shelter Island, NY); Bucala, Richard J. (New York, NY)
Assignee: The Picower Institute for Medical Research (Manhasset, NY)
Date of First Priority Issue: Friday February 26th, 1993
Patent Number: 5800829
This patent provides a method of isolating cells from the immune system through encapsulation. Specific means of generating this implantable device, and use with stem cells, as well as other populations of cells is disclosed. Inventors: Dionne, Keith E. (Rehoboth, MA); Emerich, Dwaine F. (Providence, RI); Hoffman, Diane (Cambridge, MA); Sanberg, Paul R. (Spring Hill, FL); Christenson, Lisa (New Haven, CT); Hegre, Orion D. (Green Valley, AZ); Scharp, David W. (St. Louis, MO); Lacy, Paul E
Assignee: Brown University Research Foundation
Date of First Priority Issue: Thursday April 25th, 1991
Patent Number: 5800828
This patent teaches ways of growing cells in vivo in an environment that is protected from immunological attack. Specific ways of encapsulating cells, including stem cells, and their progeny are described. This patent is useful, in one embodiment, for the treatment of diabetes with artificially generated islets. Inventors: Dionne, Keith E. (Rehoboth, MA); Emerich, Dwaine F. (Providence, RI); Hoffman, Diane (Cambridge, MA); Sanberg, Paul R. (Spring Hill, FL); Christenson, Lisa (New Haven, CT); Hegre, Orion D. (Green Valley, AZ); Scharp, David W. (St. Louis, MO); Lacy, Paul E
Assignee: Brown University Research Foundation
Date of First Priority Issue: Thursday April 25th, 1991
Patent Number: 5800537
This patent teaches how to decellularize various tissues and to use the remnants as a scaffold for seeding of stem cells. This patent is useful for tissue engineering of varous organs and anatomical structures. Inventor: Bell, Eugene (Boston, MA)
Assignee: Tissue Engineering, Inc. (Boston, MA)
Date of First Priority Issue: Friday August 7th, 1992
Patent Number: 5795790
This patent teaches the use of UV irradiation in order to render encapsulated cells mitotically inactive, but still metabolically active. This patent is useful for the generation of grafts that are implantable, for example an artificial pancreas. Inventors: Schinstine, Malcolm (Ben Salem, PA); Shoichet, Molly S. (Toronto, CA); Gentile, Frank T. (Warwick, RI); Hammang, Joseph P. (Barrington, RI); Holland, Laura M. (Horsham, PA); Cain, Brian M. (Everett, MA); Doherty, Edward J. (Mansfield, MA); Winn, Shelley R
Assignee: Cytotherapeutics, Inc. (Lincoln, RI)
Date of First Priority Issue: Wednesday July 20th, 1994
Patent Number: 5767092
The composition of matter described in this patent is actually a stimulator of NKT cells. In this patent, the composition, alpha galactosyl ceramide is described for the use of protecting the hematopoietic stem cell compartment from radiation or chemotherapy. It is unknown if these effects are directly mediated on the CD34+ hematopoietic stem cells, or if they are indirect through the activation... Inventors: Koezuka, Yasuhiko (Takasaki, JP); Kabaya, Koji (Takasaki, JP); Motoki, Kazuhiro (Takasaki, JP)
Assignee: Kirin Beer Kabushiki Kaisha (Tokyo-to, JP)
Date of First Priority Issue: Thursday July 15th, 1993
Patent Number: 5766950
This patent teaches that the clinically used cytokine FGF-1 is able to expand bone marrow stromal cells. This bone marrow stromal cell subtype seems to resemble, at least superficially, the mesenchymal stem cell. This is an interesting question that should be examined further. Inventors: Greenberger, Joel S. (Sewickley, PA); Hurwitz, David R. (Acton, MA)
Assignee: ALG Company (Marlborough, MA)
Date of First Priority Issue: Friday December 29th, 1995
Patent Number: 5766948
This patent teaches how to generate a type of multipotential neural stem cell. These stem cells are extracted from embryonic sources. This patent may be useful for the treatment of a variety of neurodegenerative diseases. Inventors: Gage, Fred H. (La Jolla, CA); Ray, Jasodhara (San Diego, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Date of First Priority Issue: Wednesday January 6th, 1993
Patent Number: 5766944
Disclosed are methods of generating T cells in vitro from CD34+ hematopoietic stem cells. Specifically, the use of thymic fragments are provided so as to recapitulate in vivo thymopoiesis. Inventor: Ruiz, Margaret Eileen (Chevy Chase, MD)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Tuesday December 31st, 1996
Patent Number: 5763266
Specific bioreactors and culture conditions are provided for the expansion of hematopoietic stem cells. These cells may be used directly for treatment post marrow ablation, or may be further differentiated into specific hematological cells for treatment of specific diseases. Inventors: Palsson, Bernhard O. (Ann Arbor, MI); Emerson, Stephen G. (Wayne, PA); Schwartz, Richard M. (San Mateo, CA)
Assignee: The Regents of the University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Thursday March 4th, 1993
Patent Number: 5763197
This patent teaches the use of the CD34+, lineage negative hematopoietic stem cell as a target for the in vitro screening and identification of drugs. For example, libraries may be screened for ability to inhibit or stimulate proliferation, or alternatively to induce differentiation into various lineages. Inventors: Tsukamoto, Ann (Palo Alto, CA); Baum, Charles M. (Mountain View, CA); Aihara, Yukoh (Yokohama, JP); Weissman, Irving (Palo Alto, CA)
Assignee: Systemix, Inc. (Palo Alto, CA)
Date of First Priority Issue: Friday March 30th, 1990
Patent Number: 5759765
This patent teaches the use of immortalized human hepatic epithelial cells for testing toxicity of agents in vitro. This is a rapid and easy way to test for potential toxicity of various candidates without having to perform animal testing. Inventors: Harris, Curtis C. (Bethesda, MD); Cole, Katharine H. (Dayton, MD); Lechner, John F. (Albuquerque, NM); Reddel, Roger (St. Ives, AU)
Assignee: The United States of America as represented by the Secretary of the (Washington, DC)
Date of First Priority Issue: Wednesday December 14th, 1988
Patent Number: 5753505
This patent provides a new type of neural stem cell that can be used for screening or therapeutic purposes. Inventor: Luskin, Marla B. (Decatur, GA)
Assignee: Emory University (Atlanta, GA)
Date of First Priority Issue: Thursday July 6th, 1995
Patent Number: 5753491
This patent covers fetally derived neuronal stem cells, alone, and after transfection with therapeutic genes. These stem cells may be transfected in order to secrete trophic factors that would allow endogenous brain stem cells to proliferate. On the other hand, they may be transfected with anti-apoptotic genes such as Xiap. Xiap transfection would allow the cells to maintain viability. Inventors: Major, Eugene O. (Oakton, VA); Tornatore, Carlo S. (University Park, MD); Yadid, Gal (Kfar Saba, IL)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Tuesday April 13th, 1993
Patent Number: 5750397
This is one of the composition of matter patents on hematopoietic stem cells. It covers the phenotype of CD34+ and Thy1+ Inventors: Tsukamoto, Ann (Palo Alto, CA); Baum, Charles M. (Mountain View, CA); Aihara, Yukoh (Yokohama, JP); Weissman, Irving (Palo Alto, CA)
Assignee: Systemix, Inc. (Palo Alto, CA)
Date of First Priority Issue: Friday March 30th, 1990
Patent Number: 5750376
This patent covers neural stem cells of a specific phenotype and their use for delivery of gene products into an area of need. Inventors: Weiss, Samuel (Alberta, CA); Reynolds, Brent (Alberta, CA); Hammang, Joseph P. (Barrington, RI); Baetge, E. Edward (Barrington, RI)
Assignee: NeuroSpheres Holdings Ltd. (Calgary, CA)
Date of First Priority Issue: Monday July 8th, 1991
Patent Number: 5750339
Fetal to maternal trafficking of stem cells is a relatively undiscussed phenomena. This patent covers methods of detecting fetal cells in maternal circulation, in one embodiment through identification of cells expressing the immune suppressive molecule HLA-G Inventor: Smith, J. Bruce (Philadelphia, PA)
Assignee: Thomas Jefferson University (Philadelphia, PA)
Date of First Priority Issue: Wednesday November 30th, 1994
Patent Number: 5744361
This patent provide tissue culture reagents for the expansion of hematopoietic stem cells. Inventors: Hoffman, Ronald (Palo Alto, CA); Brandt, John (Palo Alto, CA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Tuesday April 9th, 1991
Patent Number: 5744347
This patent covers an early hematopoietic stem cell that is derived from the yolk sac. The yolk sac is actually the first site, or one of the first sites of hematopoiesis during development. Inventors: Wagner, Thomas E. (Albany, OH); Antczak, Michael R. (Albany, OH)
Assignee: Ohio University Edison Biotechnology Institute (Athens, OH)
Date of First Priority Issue: Friday January 16th, 1987
Patent Number: 5739110
This patent covers the use of the peptide AcSDKP for inhibiting hematopoietic stem cell proliferation and protecting the stem cells from radiation or chemotherapy. In addition, since the angiotensin-converting enzyme is responsible for degradation of AcSDKP, inhibition of ACE by clinically used inhibitors for the inhibition of hematopoiesis is provided. ACE inhibitors include captopril... Inventors: Bogden, Arthur E. (West Yarmouth, MA); De Paillette, Evelyn Deschamps (Paris, FR)
Assignee: Biomeasure Inc. (Milford, MA); Societe de Conseils de Recherches Et D'Applications Scientifiques (FR)
Date of First Priority Issue: Monday September 12th, 1994
Patent Number: 5736396
This patent teaches ways of inducing the differentiation of mesenchymal stem cells into bone, cartilage and other non-hematopoietic tissues. Inventors: Bruder, Scott P. (Moreland Hills, OH); Caplan, Arnold I. (Cleveland Heights, OH); Haynesworth, Stephen E. (Cleveland Heights, OH)
Assignee: Case Western Reserve University (Cleveland, OH)
Date of First Priority Issue: Tuesday January 24th, 1995
Patent Number: 5733878
This patent provides various morphogens, such as OP-1 for the regeneration of various dendal components, including tooth sockets. Inventors: Kuberasampath, Thangavel (Medway, MA); Rueger, David C. (Hopkinton, MA); Oppermann, Hermann (Medway, MA); Cohen, Charles M. (Medway, MA); Pang, Roy H. L. (Etna, NH)
Assignee: Creative BioMolecules, Inc. (Hopkinton, MA)
Date of First Priority Issue: Friday August 30th, 1991
Patent Number: 5733542
This patent teaches the use of mesenchymal stem cells to promote engraftment of hematopoietic stem cells.
I wonder how this mesenchymal cell population is different that the stromal cell populations that are also used to promote engraftment? Inventors: Haynesworth, Stephen E. (Cleveland Heights, OH); Caplan, Arnold I. (Cleveland Heights, OH); Gerson, Stanton L. (Pepper Pike, OH); Lazarus, Hillard M. (Shaker Heights, OH)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday November 16th, 1990
Patent Number: 5733541
This patent covers the use of osteoblasts to stimulate activity and function of hematopoietic stem cells. I wonder if osteoblasts can also stimulate the activity of other types of stem cells? Inventors: Taichman, Russell S. (Ann Arbor, MI); Emerson, Stephen G. (Wayne, PA)
Assignee: The Regent of the University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Monday November 30th, -0001
Patent Number: 5716827
This is one of the patents on the composition of matter of hematopoietic stem cells, it covers a population of CD34+, Thy-1+ cells. Inventors: Tsukamoto, Ann (Palo Alto, CA); Baum, Charles M. (Mountain View, CA); Aihara, Yukoh (Yokohama, JP); Weissman, Irving (Palo Alto, CA)
Assignee: SyStemix, Inc. (Palo Alto, CA)
Date of First Priority Issue: Friday March 30th, 1990
Patent Number: 5716616
This patent teaches that stromal cells may be used for the treatment of various bone disorders, as well as regeneration of bone. How are these stromal cells related to the mesenchymal stem cells that Osiris is using? Inventors: Prockop, Darwin J. (Philadelphia, PA); Pereira, Ruth F. (Lansdowne, PA); Leeper, Dennis B. (Wynnewood, PA); O'Hara, Michael D. (Wyncote, PA)
Assignee: Thomas Jefferson University (Philadelphia, PA)
Date of First Priority Issue: Tuesday March 28th, 1995
Patent Number: 5705732
This patent covers manipulated cells and stem cells that are not immunogeneic when inplanted into a recipient. Various means of reducing immunogenecity are disclosed such as expression of human complement inhibitors and deletion or suppression of MHC expression. Inventors: Sims, Peter J. (Mequon, WI); Bothwell, Alfred L.M. (Guilford, CT); Elliot, Eileen A. (New Haven, CT); Flavell, Richard A. (Killingworth, CT); Madri, Joseph (North Branford, CT); Rollins, Scott (Monroe, CT); Bell, Leonard (Woodbridge, CT); Squinto, Stephen
Assignee: Oklahoma Medical Research Foundation (Oklahoma City, OK); Yale University (New Haven, CT)
Date of First Priority Issue: Monday June 12th, 1989
Patent Number: 5705149
This patent covers the use of IL-7 to stimulate hematopoiesis. Inventors: Namen, Anthony E. (Seattle, WA); Goodwin, Raymond G. (Seattle, WA); Lupton, Stephen D. (Seattle, WA); Mochizuki, Diane Y. (Seattle, WA)
Assignee: Sterling Winthrop Inc. (New York, NY)
Date of First Priority Issue: Monday October 26th, 1987
Patent Number: 5700691
This patent teaches how to differentiate hematopoietic stem cells into a type of stem cell that is committed to the neutrophil lineage. These "committed" stem cells may be administered into a neutropenic patient until endogenous neutrophils rebound. Inventors: Bender, James G. (Lindenhurst, IL); Maples, Phillip B. (Waukegan, IL); Smith, Stephen (Arlington Heights, IL); Unverzagt, Kristen L. (Palatine, IL); Van Epps, Dennis E. (Cary, IL)
Assignee: Baxter Healthcare Inc. (Irvine, CA)
Date of First Priority Issue: Monday March 23rd, 1992
Patent Number: 5700289
This patent teaches that in some situations, cells from the periosteum can be grown and used as a "stem cell like" population for the treatment of bone defects. Inventors: Breitbart, Arnold S. (Great Neck, NY); Grande, Daniel A. (Sea Cliff, NY)
Assignee: North Shore University Hospital Research Corporation (Manhasset, NY)
Date of First Priority Issue: Friday October 20th, 1995
Patent Number: 5695998
This patent teaches that submucosa matrix proteins are useful for expanding islet cells in vitro. This technology may allow the use of pancreatic stem cells to generate large amounts of islets for treatment of patients with Type 1 diabetes. Inventors: Badylak, Stephen F. (W. Lafayette, IN); Boder, George (Martinsville, IN); Voytik, Sherry (Lafayette, IN); Demeter, Robert J. (Mooresville, IN); Critser, John (Carmel, IN); Liu, Chi (Indianapolis, IN)
Assignee: Purdue Research Foundation (West Lafayette, IN); Methodist Hospital of Indiana, Inc. (Indianapolis, IN)
Date of First Priority Issue: Friday February 10th, 1995
Patent Number: 5695995
This patent teaches specific gene sequences that transcribe proteins which induce differentiation of stem cells into neurons. Inventors: Weintraub, deceased, Harold M. (late of Seattle, WA); Lee, Jacqueline E. (Denver, CO); Hollenberg, Stanley M. (Portland, OR); Tapscott, Stephen J. (Seattle, WA)
Assignee: Fred Hutchinson Cancer Research Center (Seattle, WA)
Date of First Priority Issue: Friday May 6th, 1994
Patent Number: 5695755
This patent covers mobilization of hematopoietic stem cells by administration of antibodies to VCAM or VLA-4. Inventor: Papayannopoulou, Thalia (Seattle, WA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday November 13th, 1992
Patent Number: 5686306
This patent provides compositions of matter, specifically peptide targets for telomerase, which allow for enhanced telomerase activity and longer cellular life span. Inventors: West, Michael D. (San Carlos, CA); Shay, Jerry (Dallas, TX); Wright, Woodring E. (Arlington, TX)
Assignee: Board of Regents, The University of Texas System (Austin, TX)
Date of First Priority Issue: Wednesday May 13th, 1992
Patent Number: 5681587
This patent teaches how to expand islets as much as 1000 fold !! This is performed through culture of islet stem cells in laminin 5, and other substrates derived from cell lines that are provided in the patent. This patent may be useful to stem cell companies that are currently generating islets from of a variety of stem cell sources. Inventors: Halberstadt, Craig (San Diego, CA); Zimber, Michael (Pullman, WA); Grzesiak, John J. (Cardiff, CA)
Assignee: Desmos, Inc. (San Diego, CA)
Date of First Priority Issue: Friday March 29th, 1996
Patent Number: 5681559
This patent teaches the extraction of hematopoietic stem cells from fetal sources. It may be that these stem cells have more potent repopulating activity as compared to stem cells from sources. Inventors: DiGiusto, David (Palo Alto, CA); Galy, Anne (Palo Alto, CA)
Assignee: Systemix, Inc. (Palo Alto, CA)
Date of First Priority Issue: Wednesday August 25th, 1993
Patent Number: 5677139
This patent teaches how to generate T cells from hematopoietic stem cells in vitro. T cells may be used for immune stimulation, or in some other cases may be used for generation of T suppressor cells. If nuclear transfer can be performed in the starting population of cells, then patient-specific T cells may be generated. Inventors: Johnson, R. Paul (Lexington, MA); Rosenzweig, Michael (Boston, MA); Scadden, David T. (Weston, MA)
Assignee: President and Fellows of Harvard College (Cambridge, MA)
Date of First Priority Issue: Friday April 21st, 1995
Patent Number: 5677136
This patent teaches that the protein CD59 may be used as a marker of hematopoietic stem cells both for identification, and also for purification. Inventors: Simmons, Paul J. (Adelaide, AU); Hill, Beth L. (Mountain View, CA); Chen, Benjamin P. (Fremont, CA)
Assignee: Systemix, Inc. (Palo Alto, CA)
Date of First Priority Issue: Monday November 14th, 1994
Patent Number: 5676941
Like other hematopoietic cytokines, this patent teaches that hpG-CSF may be administered for the treatment of burn wounds. Inventor: Souza, Lawrence M. (Thousand Oaks, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Date of First Priority Issue: Friday August 23rd, 1985
Patent Number: 5674843
This patent teaches that the stem cell inhibitory compound TGF-beta may be administered for the purpose of mobilization. Inventor: Carlino, Joseph A. (San Leandro, CA)
Assignee: Celtrix Pharmaceuticals, Inc. (Santa Clara, CA)
Date of First Priority Issue: Thursday September 2nd, 1993
Patent Number: 5674841
Disclosed is a peptide that inhibits stem cell proliferation...it doesnt give a name for the peptide.. Inventors: Pragnell, Ian B. (Glasgow, GB6); Donaldson, Debra D. (Cambridge, MA); Graham, Gerald J. (Glasgow, GB6); Wong, Gordon G. (Jamaica Plain, MA)
Assignee: Genetics Institute, Inc. (Cambridge, MA)
Date of First Priority Issue: Monday September 25th, 1989
Patent Number: 5672361
This patent teaches that laminin-5 is very potent at stimulation of expansion of pancreatic islet cells from stem cells. Inventors: Halberstadt, Craig (San Diego, CA); Grzesiak, John J. (Cardiff, CA)
Assignee: Desmos, Inc. (San Diego, CA)
Date of First Priority Issue: Friday March 29th, 1996
Patent Number: 5672346
This patent covers the CD34+, HLA-DR negative, c-kit positive, hematopoietic stem cell. Inventors: Srour, Edward (Indianapolis, IN); Zanjani, Esmail (Reno, NV); Brandt, John E. (Indianapolis, IN); Hoffman, Ronald (Indianapolis, IN)
Assignee: Indiana University Foundation (Bloomington, IN)
Date of First Priority Issue: Monday July 27th, 1992
Patent Number: 5670372
This patent covers certain types of embryonic stem cells and their use for screening. Note that this patent has priority to the WARF patents... Inventor: Hogan, Brigid L. M. (Brentwood, TN)
Assignee: Vanderbilt University
Date of First Priority Issue: Thursday October 8th, 1992
Patent Number: 5670351
This patent covers methods of expanding human hematopoietic stem cells through ex vivo transfection with various genes. Specific culture conditions are also provided. This patent can be used for post myeloablative reconsitution, but also, theoretically, for stimulation of angiogenesis by administration of the bone marrow stem cells into ischemia areas. Inventors: Emerson, Stephen G. (Ann Arbor, MI); Clarke, Michael F. (Ann Arbor, MI); Palsson, Bernhard O. (Ann Arbor, MI); Schwartz, Richard M. (Ann Arbor, MI)
Assignee: The Regents of the University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Thursday June 15th, 1989
Patent Number: 5670147
This patent teaches ways of expanding stem cell, including culture in IL-6 and GM-CSF. Inventors: Emerson, Stephen G. (Ann Arbor, MI); Clarke, Michael F. (Ann Arbor, MI); Palsson, Bernhard O. (Ann Arbor, MI)
Assignee: Regents of the University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Thursday June 15th, 1989
Patent Number: 5670146
This patent covers the various formulations of human p-CSF. It also covers the factor's use for stimulation of hematopoiesis. I wonder what the modern name for p-CSF is? Inventors: Welte, Karl (New York, NY); Platzer, Erich (Erlangen, DE); Gabrilove, Janice L. (New York, NY); Mertelsm, Roland (Chappaqua, NY); Moore, Malcolm A. S. (Larchmont, NY)
Assignee: Sloan-Kettering Institute (New York, NY)
Date of First Priority Issue: Thursday March 28th, 1985
Patent Number: 5668104
This patent covers a protein that expands hematopoietic stem cells called FDF-3. Inventors: Nakahata, Tatsutoshi (Matsumoto, JP); Kawano, Genji (Kamakura, JP); Sudo, Tetsuo (Kamakura, JP); Kojima, Katsuaki (Yokohama, JP)
Assignee: Toray Industries, Inc. (Tokyo, JP)
Date of First Priority Issue: Tuesday March 31st, 1992
Patent Number: 5665557
This patent covers the use of CDw109 for purification and identification of hematopoietic stem cells. Inventors: Murray, Lesley (San Jose, CA); Sutherland, D. Robert (Oakville, CA)
Assignee: Systemix, Inc. (Palo Alto, CA); The Toronto Hospital Research Institute (Toronto, CA)
Date of First Priority Issue: Monday November 14th, 1994
Patent Number: 5662895
This patent covers the hematopoietic uses of a tumor derived hematopoiesis stimulator called pluripotent colony stimulating factor...what is the modern name of this??? Inventors: Welte, Karl (New York, NY); Platzer, Erich (Spardorf, DE); Gabrilove, Janice L. (New York, NY); Mertelsmann, Roland (Mainz, DE); Moore, Malcolm A. S. (Larchmont, NY)
Assignee: Sloan-Kettering Institute (New York, NY)
Date of First Priority Issue: Thursday March 28th, 1985
Patent Number: 5658761
This patent covers immortalized stromal cells, which can be used for gene therapy. These stromal cells appear to be similar to mesenchymal stem cells in some ways. Inventors: Thalmeier, Karin (Munchen, DE); Dormer, Peter (Gilching, DE)
Assignee: Gsf-Forschungszentrum fur Umwelt und Gesundheit GmbH (OberscheleiBheim, DE)
Date of First Priority Issue: Wednesday July 7th, 1993
Patent Number: 5654189
This patent covers differentiated teratocarinoma cells as a source of neurons. The concepts and subject matter of this patent actually was used in clinical trials for stroke. Inventors: Lee, Virginia (Philadelphia, PA); Pleasure, Samuel (Philadelphia, PA)
Assignee: Trustees of the University of Pennsylvania (Philadelphia, PA)
Date of First Priority Issue: Friday July 10th, 1992
Patent Number: 5654186
This patent covers a special population of stem cells that circulate in peripheral blood. Although the patent uses the word "mesenchymal" to describe the cells, these may not be true mesenchymal cells since they possess hematopoietic markers such as CD34 and CD45. Inventors: Cerami, Anthony (Shelter Island, NY); Bucala, Richard J. (New York, NY)
Assignee: The Picower Institute for Medical Research (Manhasset, NY)
Date of First Priority Issue: Friday February 26th, 1993
Patent Number: 5654183
LNGFR expressing neural stem cells are patented. The use of these cells for targets of gene transfection, and subsequent administration of the transfected stem cells for therapeutic benefit is disclosed. Inventors: Anderson, David J. (Altadena, CA); Stemple, Derek L. (Newton, MA)
Assignee: California Institute of Technology (Pasadena, CA)
Date of First Priority Issue: Thursday July 2nd, 1992
Patent Number: 5650299
This patent covers a cell line that produces a factor associated with inducing proliferation of stem cells. If this factor is not already commercialized, which it appears it is not, this patent is a great tool for starting a biotech company. Inventors: Lawman, Michael J. P. (Orlando, FL); Lawman, Patricia D. (Orlando, FL); Denslow, Nancy D. (Gainesville, FL)
Assignee: The University of Florida (Gainesville, FL)
Date of First Priority Issue: Wednesday October 6th, 1993
Patent Number: 5648248
This patent teaches how to use hematopoietic stem cells as a stem cell source for the generation of dendritic cells. Since the dendritic cell is the most potent stimulator of the immune system, this patent is useful for generating a biological adjuvant for vaccines. The patent teaches that activation of the rel gene through a unique construct can be used for generation of dendritic cells out... Inventors: Zenke, Martin (Schonow, DE); Boehmelt, Guido (North York, CA); Madruga, Jaime (Berlin, DE); Enrietto, Paula (Stony Brook, NY)
Assignee: Boehringer Ingelheim International GmbH (DE)
Date of First Priority Issue: Friday December 30th, 1994
Patent Number: 5643741
This patent covers the identification of human hematopoietic stem cells by seeking out cells that express the markers CD34 and Thy1. Inventors: Tsukamoto, Ann (Palo Alto, CA); Baum, Charles M. (Mountain View, CA); Aihara, Yukoh (Yokohama, JP); Weissman, Irving (Palo Alto, CA)
Assignee: Systemix, Inc. (Palo Alto, CA)
Date of First Priority Issue: Friday March 30th, 1990
Patent Number: 5641622
This patent covers the use of continuous flow centrifuges and various systems for purification of homogeneous cells from a heterogeneous population. This patent may be useful for purifying stem cells from blood based on weight and other physical characteristics. Inventors: Lake, William C. (Laguna Niguel, CA); Giesler, Richard (Deerfield, IL); Epps, Dennis Van (Cary, IL); Chapman, John R. (Lake Villa, IL); Martinson, Jeffrey A. (Mundelein, IL); Ellis, Dale R. (Wonder Lake, IL); Aono, Frederick (Arlington Heights, IL); Bisch
Assignee: Baxter International Inc. (Deerfield, IL)
Date of First Priority Issue: Thursday September 13th, 1990
Patent Number: 5635387
This patent provide conditions and systems for the ex vivo expansion of hematopoietic stem cells. Specific cell concentrations, growth factors, and vessels are provided.
This patent is useful for expansion of cells either in the autologous situation, or in situations where an allogeneic source is not sufficient, such as in cord blood transplants. Inventors: Fei, Rui G. (Seattle, WA); Heimfeld, Shelly (Woodinville, WA); Minshall, Billy W. (Mill Creek, WA); Berenson, Ronald J. (Mercer Island, WA)
Assignee: CellPro, Inc. (Bothell, WA)
Date of First Priority Issue: Monday April 23rd, 1990
Patent Number: 5635386
This patent provides culture conditions for in vitro pushing stem cells of the hematopoietic lineage to differentiate into various blood cells. This patent is useful for generation of "off the shelf" cells if a method is figured out how to "de-immunogenize" the cells. Inventors: Palsson, Bernhard O. (Ann Arbor, MI); Armstrong, R. Douglas (Ann Arbor, MI); Clarke, Michael F. (Ann Arbor, MI); Emerson, Stephen G. (Ann Arbor, MI)
Assignee: The Regents of The University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Thursday June 15th, 1989
Patent Number: 5635156
This patent teaches how to perform bone marrow transplantation, or transplantation of stem cells with hematopoietic potential, without completely ablating the recipient hematopoietic system. The patent uses various antibodies to not-completely deplete the host, but just enough so that the stem cells administered are not completely cleared away. Inventor: Ildstad, Suzanne T. (Pittsburgh, PA)
Assignee: University of Pittsburgh (Pittsburgh, PA)
Date of First Priority Issue: Monday September 13th, 1993
Patent Number: 5633426
This is one of the patents on the human SCID mouse. It teaches methods of introducing human stem cells into a mouse that is immune compromized, so that the behaviour of human stem cells can be studied in a non-human model. Inventors: Namikawa, Reiko (Palo Alto, CA); Kyoizumi, Seishi (Hiroshima, JP); McCune, Joseph M. (San Francisco, CA); Kaneshima, Hideto (Palo Alto, CA)
Assignee: Systemix, Inc. (Palo Alto, CA)
Date of First Priority Issue: Friday May 25th, 1990
Patent Number: 5631219
This patent teaches that hemoglobin itself may have hematopoietic stem cell stimulatory properties. The ability of hemoglobin chains has been described by others for stimulation of stem cell proliferation, and in some cases inhibition.
This patent covers purified hemoglobin, mutant hemoglobin, and various recombinant hemoglobins.
In Feb 25, 1998, Somatogen was bought by Baxter for 189... Inventors: Rosenthal, Gary J. (Boulder, CO); Gerber, Michael J. (Denver, CO)
Assignee: Somatogen, Inc. (Boulder, CO)
Date of First Priority Issue: Tuesday March 8th, 1994
Patent Number: 5629293
This is a composition of matter patent on a peptide that has stimulatory activity to stem cells of the hematopoietic system. This patent can be used for not only stimulating hematopoiesis in a patient, but also for other novel uses such as angiogenesis. Inventors: Undheim, Kjell (Sandvika, NO); Kremminger, Peter (Liuz, AT); Hartmann, Michael (Pettenbach, AT)
Assignee: Nycomed Imaging AS (Oslo, NO)
Date of First Priority Issue: Tuesday June 2nd, 1992
Patent Number: 5629286
This is a patent on using the technique of homeopathy (ultra-dilution with potentiation) in order to generate stem cell stimulants and other growth factors. This patent is very exciting...if the data is reproducible it could revolutionize medicine. Inventor: Brewitt, Barbara (Seattle, WA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Thursday March 31st, 1994
Patent Number: 5626617
This patent teaches that stem cells can be expanded by applying radiofrequencies that correspond with growth factors. This is a very interesting approach since conceptually the radiofrequencies can be used as pharmaceuticals. This patent definately deserves further investigation. Inventor: Brewitt, Barbara (Seattle, WA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Thursday March 31st, 1994
Patent Number: 5620957
This patent provides novel compositions of matter for stimulation of hematopoietic stem cells. This patent is useful for post chemotherapy and post radiation therapy stimulation of blood cell production. It may be useful for stimulation of other stem cells as well, including for stimulation of endothelial precursors and angiogenesis. Inventors: Bhatnagar, Pradip K. (Exton, PA); Huffman, William F. (Malvern, PA); Talmadge, James E. (Bellevue, NE)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Date of First Priority Issue: Friday July 14th, 1989
Patent Number: 5612211
This patent covers the expansion of hematopoietic stem cells, both in vitro and in vivo with fibroblast growth factors. This patent is important not only for stimulation of post-ablation hematopoiesis, but can also be used to cover angiogenesis stimulation by fibroblast growth factors since angiogenesis involves hematopoietic stem cells, at least in some embodiments. Inventors: Wilson, Elaine L. (New York, NY); Gabrilove, Janice (New York, NY)
Assignee: New York University (New York, NY); Sloan-Kettering Institute For Cancer Research (New York, NY)
Date of First Priority Issue: Monday January 8th, 1990
Patent Number: 5612206
This patent covers transfection of primate bone marrow cells with genes that that gene therapy may be used. The patent provides amphotropic retroviral vectors for transfection of the bone marrow. Inventors: Valerio, Domenico (Leiden, NL); van Beusechem, Victor W. (Amsterdam, NL)
Assignee: Introgene B.V. (NL)
Date of First Priority Issue: Friday October 4th, 1991
Patent Number: 5612028
This patent teaches the use of stem cells derived from amniotic tissue for regeneration of cartilage tissue. The stem cells of the amniotic tissue claimed are epithelial and free of mesenchymal tissue. Inventors: Sackier, Jonathan M. (Surrey, GB3); Wood, Christopher B. (Buckinghamshire, GB3); Krishnan, Rajagopallan (Surrey, GB3); Wiggington, Gordon R. (Hampshire, GB3); Butler, Douglas Mitchel H. (Surrey, GB3)
Assignee: Genethics Limited (Surrey, GB)
Date of First Priority Issue: Wednesday February 17th, 1988
Patent Number: 5610141
This patent is a composition of matter patent covering a novel peptide that has ability to stimulate bone marrow proliferation and hematopoiesis.
This is a very useful patent for pharmaceutical development since there is a need in the art for agents with good pharmacokinetics that stimulate hematopoiesis. Inventors: Undheim, Kjell (Sandvika, NO); Solbakken, Magne (Oslo, NO); Agner, Erik (Oslo, NO); Kremminger, Peter (Linz, AT); Lange, Meinolf (Oslo, NO)
Assignee: Nycomed Imaging AS (NO)
Date of First Priority Issue: Tuesday June 2nd, 1992
Patent Number: 5610056
This patent teaches that administration of stem cell factor, IL6, and IL6 soluble receptor, to hematopoietic stem cells, causes the hematopoietic stem cells to differentiate into erythroid precursors, and into erythrocytes.
This patent is useful for parties seeking to generate red blood cells in vitro. Inventor: Nakahata, Tatsutoshi (Tokyo, JP)
Assignee: Amgen Inc. (Thousand Oaks, CA); Tosoh Corporation (Tokyo, JP)
Date of First Priority Issue: Wednesday November 16th, 1994
Patent Number: 5605829
This patent provides a novel composition of matter that is useful for expansion of hematopoietic stem cells in vitro. The composition of matter is a unique proteoglycan that can selectively enhance the numbers of CD34+ stem cells when added to various in vitro culture systems. Inventors: McGlave, Philip B. (St. Paul, MN); Verfaillie, Catherine M. (St. Paul, MN); Gupta, Pankaj (Minneapolis, MN)
Assignee: Regents of the University of Minnesota (Minneapolis, MN)
Date of First Priority Issue: Friday November 12th, 1993
Patent Number: 5605822
This patent teaches culture systems for growing and expanding hematopoietic stem cells.
The culture system consists of a gene-transfected stromal layer that produces growth factors, as well as a continuous perfusion system which allows media to pass over the cells. Inventors: Emerson, Stephen G. (Ann Arbor, MI); Clarke, Michael F. (Ann Arbor, MI); Palsson, Bernhard O. (Ann Arbor, MI)
Assignee: The Regents of The University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Sunday January 15th, 1989
Patent Number: 5595973
This patent is useful in the treatment of patients with radiation or chemotherapy. Since hematopoietic stem cell toxicity is usually the dose limiting factor in radiation or chemotherapy, this patent teaches a way how to overcome this.
Specifically, the patent claims inhibiting hematopoietic stem cell proliferation through administration of AcSDKP, then providing the chemotherapy and/or... Inventor: Bogden, Arthur E. (Hopedale, MA)
Assignee: Biomeasure Incorporated (Milford, MA)
Date of First Priority Issue: Wednesday September 21st, 1994
Patent Number: 5591625
This patent covers mesenchymal stem cells that are transfected with anything. Mesenchymal stem cells are very useful for clinical development since that do not need to be matched with HLA of the recipient in many situations, thus allowing for the use of an "off the shelf" product.
The advantage of transfecting mesenchymal stem cells with genes is that the mesenchymal stem cells can act as a... Inventors: Gerson, Stanton L. (Pepper Pike, OH); Caplan, Arnold I. (Cleveland Heights, OH); Haynesworth, Stephen E. (Cleveland Heights, OH)
Assignee: Case Western Reserve University (Cleveland, OH)
Date of First Priority Issue: Wednesday November 24th, 1993
Patent Number: 5589376
This patent covers a type of neural stem cell that is derived from the neural crest and expresses a specific phenotypic profile that allows not only for isolation, but also in vitro and in vivo identification.
This stem cell type is capable of differentiating into neurons similar to those found in the peripheral nervious system, as well as microglia.
The cell has a phenotype of LNGFR... Inventors: Anderson, David J. (Altadena, CA); Stemple, Derek L. (Pasadena, CA)
Assignee: California Institute of Technology (Pasadena, CA)
Date of First Priority Issue: Monday July 27th, 1992
Patent Number: 5583033
This patent covers the stem cell that gives rise to T cells. The claims actually comprise methods of isolation of a precursor that is CD34+, Leu8+ and CD7+. This patent is useful not only for purifying T cell stem cells for ex vivo growth and expansion, but also for identifying the T cell precursor pool in patients with various diseases. Inventors: Terstappen, Leon W. M. M. (Palo Alto, CA); Picker, Louis J. (Dallas, TX)
Assignee: Becton Dickinson and Company (Franklin Lakes, NJ)
Date of First Priority Issue: Tuesday May 1st, 1990
Patent Number: 5582823
This patent covers the use of human pluripotent granulocyte colony stimulating factor for induction of granulocyte production, as well as for reducing bacterially mediated inflammation.
The use of growth factors such as the one described has expanded in recent years to other types of stem cells besides hematopoietic stem cells. It will be interesting to see first what the new name for the... Inventor: Souza, Lawrence M. (Thousand Oaks, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Date of First Priority Issue: Friday August 23rd, 1985
Patent Number: 5580777
This patent covers neural stem cells that have been immortalized with c-myc or n-myc. These cells are useful not only for in vitro study and drug discovery, but also for therapy if differentiated properly so as to not possess malignant potential.
The owner of the patent, Amrad, possesses numerous powerful patents in the area of stem cells. Inventors: Bernard, Ora (North Balwyn, AU); Bartlett, Perry F. (North Carlton, AU)
Assignee: Amrad Corporation Limited (AU)
Date of First Priority Issue: Wednesday December 28th, 1988
Patent Number: 5580755
This patent covers a growth factor called human pluripotent granulocyte colony stimulating factor. Since names of growth factors have been standardized, it is difficult to tell which modern-day cytokine this is referring to.
In any case, this growth factor is an expander of hematopoietic stem cells, and is useful for treatment of patients whose hematopoietic system has been minimized either... Inventor: Souza, Lawrence M. (Thousand Oaks, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Date of First Priority Issue: Friday August 23rd, 1985
Patent Number: 5580724
This patent teaches how to expand fetal cells found in the maternal blood so as to be able to perform genetic tests without the need for amniocentesis.
Since some have reported fetal stem cells in maternal circulation, it may be possible to use the technique in this patent, or a variation thereof, for obtaining fetal stem cells at various stages of development. Inventor: Alter, Blanche P. (Galveston, TX)
Assignee: Board of Regents, The University of Texas System (Austin, TX)
Date of First Priority Issue: Friday March 25th, 1994
Patent Number: 5574205
This patent covers generation of mice that lack MHC I and/or MHC II. Stem cell transplants are one of the transplants that the inventor believes can be performed with donor cells that lack MHC I and/or MHC II. Unfortunately the issue of rejection has to do not only with "major" histoincompatibility, but also with "minor" histoincompatibility. Inventors: Kucherlapati, Raju (Darien, CT); Koller, Beverly H. (Carrboro, NC); Smithies, Oliver (Chapel Hill, NC); Dubridge, Robert B. (Belmont, CA); Greenburg, Gary (San Carlos, CA); Capon, Daniel J. (Hillsborough, CA); Williams, Steven R. (San Francisco, CA); De R
Assignee: Cell Genesys (Foster City, CA)
Date of First Priority Issue: Tuesday July 25th, 1989
Patent Number: 5559022
Liver stem cells are very interesting to study, in part because of the very potent regenerative ability of the liver. In this patent a type of liver stem cell is claimed called the "liver reserve cell".
These cells are characterized by ability to be stained by methylene blue and Azure A, adherence, multinucleation, ability to differentated, and specific density on percoll. Inventors: Naughton, Brian A. (El Cajon, CA); Sibanda, Benson (Oceanside, CA)
Assignee: Advanced Tissue Sciences, Inc. (La Jolla, CA)
Date of First Priority Issue: Friday October 9th, 1992
Patent Number: 5556954
This patent covers the promoter for CD34. CD34 is a classical marker of stem cells, not only of the hematopoietic type but also of the hepatic type. CD34 is highly glycosylated and acts as an adhesion molecule. Mice that are knocked out for CD34 still have hematopoiesis, however the stem cells to not migrate properly.
The current patent can be used for many things, including placing... Inventors: Burn, Timothy C. (Bedford, MA); Satterthwaite, Anne B. (Brighton, MA); Tenen, Daniel G. (Boston, MA)
Assignee: Beth Israel Hospital Boston Association (Boston, MA)
Date of First Priority Issue: Thursday February 13th, 1992
Patent Number: 5556783
This patent covers methods of expanding stem cells derived from the hair follicle. One of the methods of expanding hair follicle stem cells is through growing then on 3T3 fibroblasts. Hair stem cells are somewhat similar to mesenchymal stem cells and may be useful for a wide variety of applications in addition to Inventors: Lavker, Robert M. (Malvern, PA); Sun, Tung-Tien (Scarsdale, NY); Yang, Jing-Shan (New York, NY)
Assignee: Trustees of Univ. of Penna (Philadelphia, PA); New York Univ. (New York, NY)
Date of First Priority Issue: Wednesday March 27th, 1991
Patent Number: 5550050
Microencapsulation allows delivery of immunologically incompatible cells to a recipient. The technology of microencapsulation has been used clinically for a variety of uses, including administration of cell therapy ranging from neurons to islets.
The use of embryonic stem cells may require encapsulation so has to not only overcome the allogeneic barriers, but also to prevent growth and... Inventors: Holland, Laura M. (Providence, RI); Hammang, Joseph P. (Barrington, RI); Rudnick, Seth A. (Barrington, RI); Lysaght, Michael J. (E. Greenwich, RI); Dionne, Keith E. (Rehoboth, MA)
Assignee: CytoTherapeutics, Inc. (Providence, RI)
Date of First Priority Issue: Friday April 15th, 1994
Patent Number: 5549674
This patent covers an artificial kidney system designed in a manner so as to combine hollow fiber technology with living, fresh endothelial cells.
This patent does mention that in some embodiments stem cells may be used for providing the necessary cells.
Various artificial kidneys have been designed and the author of this patent has actually been involved in their clinical development... Inventors: Humes, H. David (Ann Arbor, MI); Cieslinski, Deborah A. (Ann Arbor, MI)
Assignee: The Regents of The University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Monday March 2nd, 1992
Patent Number: 5541107
In this patent regarding bone marrow stem cell culture, Advanced Tissue Sciences continues their tour de force in three dimensional culture IP, through covering the use of three dimensional cultures for expanding bone marrow stem cells.
Specifically, the patent teaches that stromal cells and a three dimensional matrix can be used for expansion of hematopoietic stem cell. Inventors: Naughton, Gail K. (Groton, VT); Naughton, Brian A. (Groton, VT)
Assignee: Advanced Tissue Sciences, Inc. (La Jolla, CA)
Date of First Priority Issue: Friday April 18th, 1986
Patent Number: 5529982
TGF-beta is a cytokine with numerous anti-inflammatory functions. The importance of TGF-beta at controlling inflammation is seen not only in its ability to prevent autoimmunity in several animal models, but also by the fact that tumor cells secrete large quantities of it in order to escape immune-mediated killing.
This patent teaches that TGF-beta can be administered in order to stimulate... Inventors: Carlino, Joseph (San Leandro, CA); Singh, Naina (Santa Clara, CA); Ellingsworth, Larry (San Jose, CA)
Assignee: Celtrix Pharmaceuticals, Inc. (Santa Clara, CA)
Date of First Priority Issue: Tuesday August 6th, 1985
Patent Number: 5527776
This patent teaches that IGF-1 together with IGF Binding Protein-3 (IGFBP-3) can be used for stimulation of hematopoiesis and specifically upregulation of erythroid production in anemic patients. This is one example of a patent covering compounds that are traditionally seen as in the domain of endocrinologists, that are applied to hematology for new uses.
The importance of IGF+IGFBP3 in... Inventors: Carlino, Joseph A. (San Leandro, CA); Higley, Howard R. (Mountain View, CA); Maack, Christopher A. (El Cerrito, CA)
Assignee: Celtrix Pharmaceuticals
Date of First Priority Issue: Monday September 20th, 1993
Patent Number: 5523286
This patent provides a proteoglycan matrix that can be used for growth and expansion of hematopoietic stem cells. Interestingly this patent promotes not just growth of CD34+ hematopoietic stem cells, but specifically, hematopoietic stem cells that are capable of supporting long term cultures.
This patent can be used for expanding hematopoietic stem cells for autologous bone marrow... Inventors: McGlave, Philip B. (St. Paul, MN); Verfaillie, Catherine M. (St. Paul, MN)
Assignee: Regents of the University of Minnesota (Minneapolis, MN)
Date of First Priority Issue: Friday November 12th, 1993
Patent Number: 5516681
This patent teaches the use of stromal cells to support growth, proliferation, and differentiation of islet-like pancreatic structures after addition of pancreatic acinar cells to the culture. This technology can be a great basis for the numerous other stem cell technologies currrently available for islet regeneration. Inventors: Naughton, Gail K. (Groton, VT); Naughton, Brian A. (Groton, VT)
Assignee: Advanced Tissue Sciences, Inc. (La Jolla, CA)
Date of First Priority Issue: Friday April 18th, 1986
Patent Number: 5516680
This patent teaches the generation of artificial kidneys through culturing of various cells that comprise the functional kidney in a three dimensional stromal preparation. The patent may be used not only for addition of kidney stem cells, but can incorporate various types of adult and embryonic stem cells for generation of "younger" kidneys. Inventors: Naughton, Gail K. (Groton, VT); Naughton, Brian A. (Groton, VT)
Assignee: Advanced Tissue Sciences, Inc. (La Jolla, CA)
Date of First Priority Issue: Friday April 18th, 1986
Patent Number: 5512475
This patent teaches how to generate artificial skin through culturing of stem cells in a three dimensional matrix. Artificial skin is very useful not only for burn patients, but also for in vitro testing of topical drug formulations. The invention uses a stromal cell preparation onto which melanocytes and keratinocytes are added. Inventors: Naughton, Gail K. (Groton, VT); Naughton, Brian A. (Groton, VT)
Assignee: Advanced Tissue Sciences, Inc. (La Jolla, CA)
Date of First Priority Issue: Friday April 18th, 1986
Patent Number: 5498698
This patent discloses a protein that stimulates production of platelets. This protein may be similar to thrombopoietin and should be investigated further. Inventors: Yamaguchi, Nozomi (Kyoto, JP); Oh-Eda, Masayoshi (Shizuoka, JP); Hattori, Kunihiro (Shizuoka, JP)
Assignee: Chugai Seiyaku Kabushiki Kaisha (JP)
Date of First Priority Issue: Friday December 27th, 1991
Patent Number: 5496722
This patent teaches the generation of three dimensional tissues through culture under microgravity conditions. This patent discloses several culture conditions, as well as scaffolds, that can be utilized for the generation of the three dimensional organ or organoid structure. Inventors: Goodwin, Thomas J. (Friendswood, TX); Wolf, David A. (Houston, TX); Spaulding, Glenn F. (Houston, TX); Prewett, Tacey L. (Friendswood, TX)
Assignee: The United States of America as represented by the Administrator of the (Washington, DC)
Date of First Priority Issue: Thursday June 30th, 1988
Patent Number: 5496720
Parthenogenesis comes from Greece and essentially means "virgin birth". This patent teaches how to induce parthenogenesis in a bovine oocyte through induction of calcium flux. The induction of parthenogenesis leads to activation of the oocyte and can be used as a method of generating autologous stem cells for woman. Inventors: Susko-Parrish, Joan L. (Monona, WI); Northey, David L. (Middleton, WI); Leibfried-Rutledge, M. Lorraine (Madison, WI); Stice, Steven L. (DeForest, WI)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Wednesday February 10th, 1993
Patent Number: 5488040
beta.(1-3) glucan is used clinically as an immune stimulator. This patent teaches that beta glucan can be used to stimulate production of platelets by acting at the level of the hematopoietic stem cell. Beta glucan's mechanism of doing this appears to be currently unknown.
Given the wide availablity and safety profile of beta glucan, this patent is useful for clinical development if proper... Inventors: Jamas, Spiros (Boston, MA); Easson, Jr., D. Davidson (Shrewsbury, MA); Ostroff, Gary R. (Worcester, MA)
Assignee: Alpha-Beta Technology, Inc. (Worcester, MA)
Date of First Priority Issue: Friday September 8th, 1989
Patent Number: 5486359
Mesenchymal stem cells are propably the most advanced in terms of clinical development of all stem cell types, second only to bone marrow stem cell. This patent covers mesenchymal stem cells in general. Specifically a cell is claimed that is positive for the markers SH2, SH3, and SH4. The claimed cell is capable of differentiating into connective tissue.
Mesenchymal stem cells are very... Inventors: Caplan, Arnold I. (Cleveland Heights, OH); Haynesworth, Stephen E. (Cleveland Heights, OH)
Assignee: Osiris Therapeutics, Inc. (Cleveland, OH)
Date of First Priority Issue: Friday November 16th, 1990
Patent Number: 5484770
This patent discloses peptides that specifically inhibit proliferation of epidermal and/or epithelial stem cells. On the one hand this patent is useful for protection of such stem cells when the patient is treated with a cytotoxic agent that targets proliferating cells, such as in the case of cancer therapy. On the other hand, this patent may be used in combination with other patents or... Inventor: Laerum, Ole D. (Sandviken, NO)
Assignee: Hafslund Nycomed Bioreg AS (Oslo, NO)
Date of First Priority Issue: Friday September 16th, 1988
Patent Number: 5476780
The stem cells that generate T cells originate in the bone marrow and differentiate in the thymus. This patent teaches that T cell precursors can be expanded in high oxygen conditions in a thymic-like microenvironment. This patent is very interesting not only from the point of view of generating T cells for immune stimulation, but also because theoretically it can be applied to the generation of... Inventor: Watanabe, Yoshihiro (Yokohama, JP)
Assignee: Japan Tobacco, Inc. (Tokyo, JP)
Date of First Priority Issue: Thursday July 4th, 1991
Patent Number: 5466676
This patent teaches methods of transfecting various stem cells with therapeutic or marker genes. Particularly, muscle stem cells, called satellite cells are discussed as target cells suitable for transfection. Inventors: Booth, Frank W. (Houston, TX); Thomason, Donald B. (Memphis, TN); Morrison, Paul R. (Indianapolis, IN); Stancel, George M. (Houston, TX)
Assignee: Board of Regents, The University of Texas at Austin (
Date of First Priority Issue: Monday February 12th, 1990
Patent Number: 5464753
This patent teaches that stem cells have an active efflux mechanism similar to the way that cancer cells have an efflux mechanism that makes them drug resistant. The only question about this patent is whether it also covers stem cells that are already identified using other markers. For example, it is very likely that the stem cells, at least hematopoietic stem cells that possess the efflux... Inventors: Chaudhary, Preet M. (Chicago, IL); Roninson, Igor B. (Chicago, IL)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday March 8th, 1991
Patent Number: 5461034
This patent covers a composition of matter (peptide) that is derived from bone marrow, that stimulates bone formation. The peptide may be useful for healing through stimulation of endogenous stem cells, as well as through administration in combination with a stem cell source so as to accelerate bone healing. Inventors: Rodan, Gideon A. (Bryn Mawr, PA); Jacobs, John W. (Irvine, CA); Sardana, Mohinder K. (Lansdale, PA); Gazit, Dan (Jerusalem, IL); Chorev, Michael (Jerusalem, IL); Muhlrad, Andras (Jerusalem, IT); Shteyer, Arye (Jerusalem, IL); Mansur, Nura (Jerusalem, IL);
Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem (Jerusalem, IL)
Date of First Priority Issue: Thursday February 23rd, 1989
Patent Number: 5460964
This patent teaches the culture of hematopoietic stem cells in a manner that the cells do not adhere to the stromal cells that provide various trophic growth factors. IL-3 and MIP-1 alpha are also covered for use in the hematopoietic stem cell culture system described herein. Inventors: McGlave, Philip B. (St. Paul, MN); Verfaillie, Catherine M. (St. Paul, MN); Miller, Jeffrey S. (Little Canada, MN)
Assignee: Regents of the University of Minnesota (Minneapolis, MN)
Date of First Priority Issue: Friday April 3rd, 1992
Patent Number: 5459069
This patent provides tissue culture devices that can be used for expansion of hematopoietic stem cells. The tissue culture devices allow for a culture of stem cells to be performed so that the stromal cells that provide various factors to the stem cells do not come into direct contact with the stem cells. Inventors: Palsson, Bernhard O. (Ann Arbor, MI); Emerson, Stephen G. (Ann Arbor, MI); Schwartz, Richard M. (Ann Arbor, MI)
Assignee: The Regents of the University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Thursday June 15th, 1989
Patent Number: 5453357
This is one of the early embryonic stem cell patents. In this one embryonic stem cells are maintained in LIF, stem cell factor, and fibroblast growth factor. It is interesting to analyze this patent in light of the WARF patents because there is some very interesting similarities to the approaches. Inventor: Hogan, Brigid L. M. (Brentwood, TN)
Assignee: Vanderbilt University (Nashville, TN)
Date of First Priority Issue: Thursday October 8th, 1992
Patent Number: 5449620
Generation of knockout animals, as well as other chimeras, involves insertion of a gene-targeted embryonic stem cell into an embryo. This patent discloses a device that can physically hold the embryo so that injection of the stem cell can be performed with increased ease and accuracy. Inventor: Khillan, Jaspal S. (Cherry Hill, NJ)
Assignee: Thomas Jefferson University (Philadelphia, PA)
Date of First Priority Issue: Tuesday January 25th, 1994
Patent Number: 5443950
This patent claims a three dimensional structure that can be grown in vitro using stromal cells, stem cells, and other cell types, for the generation of tissue. The structure can then be introduced in vivo either to function as an organ, or to assist the function of an existing body component. Inventors: Naughton, Gail K. (Groton, VT); Naughton, Brian A. (Groton, VT)
Assignee: Advanced Tissue Sciences, Inc. (La Jolla, CA)
Date of First Priority Issue: Friday April 18th, 1986
Patent Number: 5437994
This patent teaches methods of expanding human hematopoietic cells ex vivo using various cytokine cocktails. The patent is heavily cited by other patents and its claims appear to be far-reaching. Inventors: Emerson, Stephen G. (Ann Arbor, MI); Clarke, Michael F. (Ann Arbor, MI); Palsson, Bernhard O. (Ann Arbor, MI)
Assignee: Regents of The University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Thursday June 15th, 1989
Patent Number: 5437863
Gut epithelial cells are proliferating, well at least the stem cells that give rise to them, are in a state of constant proliferation. This is one of the reasons why after chemotherapy and/or radiation therapy, there is adverse effects associated with the GI tract. This patent teaches that proliferation of these cells can be stimulated by IL-6, IL-11, LIF, Oncostatin M, and CNTF. Inventors: Williams, David A. (Indianapolis, IN); Clark, Steven C. (Winchester, MA)
Assignee: Genetics Institute, Inc. (Cambridge, MA)
Date of First Priority Issue: Wednesday September 2nd, 1992
Patent Number: 5436151
This patent teaches how to culture hematopoietic stem cells so as to expand the hematopoietic repopulating ability through the culture on top of stromal cells, however under conditions so that the stromal cells are not in physical contact with the hematopoietic stem cells.
There is great interest in methods of culturing and expanding stem cell populations using various types of "feeder" cells... Inventors: McGlave, Philip B. (St. Paul, MN); Verfaillie, Catherine M. (St. Paul, MN); Miller, Jeffrey S. (Little Canada, MN)
Assignee: Regents of the University of Minnesota (Minneapolis, MN)
Date of First Priority Issue: Friday April 3rd, 1992
Patent Number: 5435999
Satellite cells are muscle stem cells. This patent teaches that LIF either alone, or together with TGF-beta, EGF, or FGF, is capable of stimulating proliferation of muscle satellite cells.
This technology is useful not only for stimulating proliferation of endogenous satellite cells after injury, but also for cells that have been transplanted to an area of need. Inventor: Austin, Lawrence (Mount Waverley, AU)
Assignee: Monash University (Clayton, AU)
Date of First Priority Issue: Friday November 24th, 1989
Patent Number: 5429938
This patent covers the isolation, expansion, and use of kidney stem cells in order to generate in vitro renal tubules. The compounds used for kidney stem cell expansion include retinoic acid, TGF, and EGF. Inventor: Humes, H. David (Ann Arbor, MI)
Assignee: University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Monday March 2nd, 1992
Patent Number: 5426098
This patent leverages the ability of TGF-beta to protect stem cells from cytotoxic agents by inhibiting proliferation of stem cells. Specifically, since chemotherapy kills proliferating cells, if the hematopoietic stem cells are first stopped from proliferating by administration of TGF-beta, then the hematopoietic system should be preserved, at least in part. Inventor: Carlino, Joseph A. (San Leandro, CA)
Assignee: Celtrix Pharmaceuticals, Inc. (Santa Clara, CA)
Date of First Priority Issue: Thursday September 2nd, 1993
Patent Number: 5423778
This patent teaches the expansion of stem cells and progeny of the stem cells in vivo in a patient. The patent discloses various chambers, as well as methods of introducing the cells into a patient so that the cells can be truly cultured "in vivo". Inventors: Eriksson, Elof (Wellesley Hills, MA); Vogt, Peter M. (Newton, MA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Thursday December 14th, 1989
Patent Number: 5413923
This patent teaches how to genetically delete the MHC antigens in order to have stem cells and progeny of the stem cells that are capable of acting as universal donor cells. Although this technology is at face value very interesting, the fact that other antigens besides MHC cause rejection of tissue dampens enthusiasm for this approach. Additionally, the ability of recipient immune system to... Inventors: Kucherlapati, Raju (Darien, CT); Koller, Beverly H. (Carrboro, NC); Smithies, Oliver (Chapel Hill, NC)
Assignee: Cell Genesys, Inc. (Foster City, CA); Univ. of North Carolina at Chapel Hill (Chapel Hill, NC)
Date of First Priority Issue: Monday November 6th, 1989
Patent Number: 5409825
This patent uses mast cell growth factor as an additive to tissue culture media in order to generate a liquid composition that is useful for expansion of hematopoietic stem cells. The ability of this media to expand other types of stem cells should be assessed. Inventors: Hoffman, Ronald (Indianapolis, IN); Brandt, John (Indianapolis, IN)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Tuesday April 9th, 1991
Patent Number: 5405772
This patent is for a tissue culture media that is capable of expanding, as well as allowing differentiation of various cell types in vitro, including hematopoietic stem cells. The media is different than other approaches since it comprises several growth factors, as well as extracellular matrix components. Importantly the media does not use serum, this is applicable for clinical ex vivo... Inventor: Ponting, Ian L. O. (Woodland Hills, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Date of First Priority Issue: Friday June 18th, 1993
Patent Number: 5399493
The genetic engineering of hematopoietic stem cells offers the potential to cure several disease, including severe combined immunodeficiency, sickle cell anemia, beta thalessemia, etc. This patent teaches how to ex vivo genetically engineer hematopoietic stem cells through the use of retroviral vectors. This patent is highly cited by other patents. Inventors: Emerson, Stephen G. (Ann Arbor, MI); Clarke, Michael F. (Ann Arbor, MI); Palsson, Bernhard O. (Ann Arbor, MI); Schwartz, Richard M. (Ann Arbor, MI)
Assignee: The Regents of the University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Thursday June 15th, 1989
Patent Number: 5397706
This patent teaches the making of a serum free media for growth hematopoietic stem cells. Such a media is useful since the addition of fetal serum and especially fetal calf serum in culture medium for cell therapy is associated with regulatory hurdles. Inventors: Correa, Paulo N. (Concord, Ontario, CA); Alexrad, Arthur A. (Willowdale, Ontario, CA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Wednesday November 6th, 1991
Patent Number: 5384331
Ketamine is used as an anasthetic in veterinary medicine, as well as for some human uses. This patent teaches various chemical modifications of ketamine that stimulate production of stem cells that are committed to generating platelets.
The importance of stimulating platelet production is seen by the number of companies working on either thrombopoietin analogues or antibodies to the... Inventors: Kogan, Timothy P. (Half Moon Bay, CA); Somers, Todd C. (Montara, CA)
Assignee: Genentech, Inc. (San Francisco, CA)
Date of First Priority Issue: Thursday July 18th, 1991
Patent Number: 5369030
Ceramides are generated from membrane components by the enzyme sphingomyelinase. The importance of ceramides in cell biology is noted by their pro-apoptotic activity in certain cells, as well as ability to induce differentiation. This patent teaches that certain ceramides may be used to guide differentiation of stem cells into various lineages. It may be possible the through taking the concepts... Inventors: Hannun, Yusuf A. (Chapel Hill, NC); Bielawska, Alicja (Apex, NC)
Assignee: Duke University (Durham, NC)
Date of First Priority Issue: Friday September 11th, 1992
Patent Number: 5368051
This patent teaches how to use growth hormone, as well as other factors for the repair of articular cartilage. The method is useful for developing not only therapeutic kits, but also as a stepping stop for new methods of using stem cells, both endogenous and exogeneous in cartilage repair. Inventors: Dunn, Allan R. (North Miami, FL); Dunn, Susan L. (North Miami, FL)
Assignee: Not Stated
Date of First Priority Issue: Wednesday June 30th, 1993
Patent Number: 5366888
This patent is assigned to Amrad, a company whose patents have recently been used to challenge the WARF patents. The current patent involves the use of LIF in enhancing ability of implanted embryos to develop into normal offspring. The relevance of this patent to embryonic stem cells is that LIF has been used consistently for generation of embryonic stem cells from a variety of species. The... Inventors: Fry, Richard C. (Altona North, AU); Parr, Ronald A. (Hoppers Crossing, AU)
Assignee: Amrad Corporation Limited (AU)
Date of First Priority Issue: Monday July 9th, 1990
Patent Number: 5362853
G-CSF is used clinically for stimulation of neutrophil production in pateints that have taken chemotherapy, radiation therapy (in some cases), as well as post bone marrow tranplant.
This patent covers peptide derivatives of G-CSF that are useful for stimulation of hematopoiesis. It may be interesting to use this patent to compete with currently used G-CSF formulations. Inventors: Kuga, Tetsuro (Yamaguchi, JP); Miyaji, Hiromasa (Tokyo, JP); Sato, Moriyuki (Tokyo, JP); Okabe, Masami (Shizuoka, JP); Morimoto, Makoto (Shizuoka, JP); Itoh, Seiga (Kanagawa, JP); Yamasaki, Motoo (Tokyo, JP); Yokoo, Yoshiharu (Kanagawa, JP); Yamaguchi, Ka
Assignee: Kyowa Hakko Kogyo Co., Ltd. (Tokyo, JP)
Date of First Priority Issue: Tuesday December 23rd, 1986
Patent Number: 5362716
This patent covers stimulation of hematopoietic stem cells by administration of hepatocyte growth factor with either IL-3 or GM-CSF.
Hepatocyte growth factor has been used clinically in a variety of situations including to stimulate angiogenesis. It may be interesting, in light of the claimed pro-hematopoietic stem cell activity of hepatocyte growth factor, to try using this cytokine... Inventors: Kmiecik, Thomas E. (Frederick, MD); Vande Woude, George F. (Berryville, VA)
Assignee: The United States of America as represented by the Department of Health (Washington, DC)
Date of First Priority Issue: Wednesday December 27th, 1989
Patent Number: 5358711
Bryostatin is a drug derived from a type of symbiont bacteria. Although bryostatin has been used in clinical trials for oncology, results have not been excellent.
This patent teaches that bryostatin and various derivatives thereof are useful for stimulation of hematopoietic stem cell proliferation.
It will be interesting to see if bryostatin works on stimulating stem cell activity of other... Inventors: May, W. Stratford (Baltimore, MD); Sensenbrenner, Lyle L. (Grosse Pointe Park, MI)
Assignee: Johns Hopkins University (Baltimore, MD)
Date of First Priority Issue: Monday November 23rd, 1987
33 Comments
Patent Number: 5316937
Colonic crypt cells are a population of self renewing stem cells that are depleted after radiation and in some situations chemotherapy due to their rapid basal proliferation. In this patent a method of stimulating crypt cell proliferation is disclosed through administration of a conditioned media.
This patent may be useful for identifying the active ingredient in the conditioned media and... Inventors: Whitehead, R. H. (Victoria, AU); Burgess, Anthony (Victoria, AU); Zhang, Hui-Hua (Victoria, AU)
Assignee: Ludwig Institute for Cancer Research (NY)
Date of First Priority Issue: Monday March 16th, 1992
Patent Number: 5278145
TGF-beta is an inhibitor of hematopoietic stem cell proliferation. It is known that autologous TGF-b is involved in keeping stem cells in a quiescent G0 state. This patent teaches the systemic administration of TGF-b before administration of a chemotherapeutic drug so as to protect the stem cells from damage. Inventors: Keller, Jonathan R. (Frederick, MD); Ruscetti, Francis W. (Rockville, MD); Wiltrout, Robert (Frederick, MD)
Assignee: The United States of America as represented by the Department of Health (Washington, DC)
Date of First Priority Issue: Thursday June 29th, 1989
Patent Number: 5264418
This patent claims a hematopoietic stem cell growth factor called HLGF. This factor seems to synergize with other stem cell stimulator factors such as G-CSF, GM-CSF, and IL-3. The modern identify of this factor will be of interest since it may be developed into a therapeutic. Inventors: Quesenberry, Peter J. (Charlottesville, VA); McNiece, Ian K. (Charlottesville, VA)
Assignee: The University of Virginia Alumni Patents Foundation (Charlottesville, VA)
Date of First Priority Issue: Friday January 24th, 1986
Patent Number: 5258367
This patent teaches that uteroferrin (placental Type V acid phosphatase) is a stimulator of hematopoietic stem cells. Uteroferrin is made during pregnancy and is associated with iron transport. The use of uteroferrin for hematopoiesis may be a potent new way of approaching the problem of neutropenia. Inventors: Bazer, Fuller W. (Gainesville, FL); Gross, Samuel (Gainesville, FL)
Assignee: University of Florida (Gainesville, FL)
Date of First Priority Issue: Friday June 29th, 1990
Patent Number: 5256560
There are numerous stem cell types in the bone marrow. Specific stem cells of the hematopoietic lineage were originally identified as being CD34+. In this patent, a CD34-stem cell is claimed that produces growth factors capable of stimulating hematopoiesis.
This patent may be a really great candidate for developing since at first appearance it does not seem to be under... Inventors: Lawman, Michael J. P. (Gainsville, FL); Ohmann, Helle B. (Saskatchewan, CA); Attah-Poku, Samuel K. (Saskatchewan, CA); Heise-Qualtiere, Janette (Saskatchewan, CA)
Assignee: University of Saskatchewan (Saskatoon, CA)
Date of First Priority Issue: Friday October 7th, 1988
Patent Number: 5256534
This patent covers a model of HIV infection. Specifically HIV infected stem cells of the hematopoietic type are infected and infection remains latent. HIV treatments may be assessed using this model of "stem cell" HIV infection. Inventors: Butera, Salvatore T. (Stone Mountain, GA); Folks, Thomas M. (Lithonia, GA); Perez, Victor L. (Rio Piedras, PR)
Assignee: The United States of America as represented by the Department of Health (Washington, DC)
Date of First Priority Issue: Friday August 9th, 1991
Patent Number: 5246699
This patent teaches a really interesting way of stimulating myelopoiesis by exposing myeloid precursor cells to a compound called IgE binding factor. Myeloid precursors are important for generation of neutrophils and therefore protecting from opportunistic diseases.
Stimulation of myeloid cells by this approach may be useful for immune modulation as well, some papers suggest that myeloid... Inventors: Debre, Patrice (Paris, FR); Mossalayi, Mohammad D. (Boussy St Antoine, FR)
Assignee: Ciba-Geigy Corporation (Ardsley, NY)
Date of First Priority Issue: Wednesday May 9th, 1990
Patent Number: 5223428
This patent teaches methods of culturing and expanding cells, including stem cells, through a unique culture system that uses hollow fiber technology. Since tissue culture is usually performed under static conditions and very derived from the in vivo situation, numerous failures to expand stem cells can be explained. The culture system of this invention seeks to provide a more in vivo like... Inventor: Rose, Sam (San Francisco, CA)
Assignee: Baxter International Inc. (Deerfield, IL)
Date of First Priority Issue: Tuesday December 14th, 1982
Patent Number: 5214133
This patent is for a transcription factor associated with stem cell activity. The factor is a basic helix-loop-helix transcription factor called SCL/Tal1.
It is expressed in cells that possess hematopoietic stem cell activity and controls numerous genes associated with stem cell functions.
Modification of activity of this transcription factor may be used theoretically for manipulation... Inventors: Kirsch, Ilan R. (Potomac, MD); Begley, C. Glenn (North Carlton, AU)
Assignee: The United States of America as represented by the Secretary of the (Washington, DC)
Date of First Priority Issue: Friday November 17th, 1989
Patent Number: 5206345
This patent covers a molecule associated with adhesion of cells to the endothelium that is induced by IL-4 and TNF and is recognized by the antibody 6G10 .
This molecule may be important in order to alter migration not only of stem cells but also in situations where migration of cells is sought to be avoided such as cancer. Inventors: Masinovsky, Boris (Bellevue, WA); Gallatin, William M. (Mercer Island, WA); Simmons, Paul J. (Seattle, WA)
Assignee: Fred Hutchinson Cancer Research Center (Seattle, WA)
Date of First Priority Issue: Thursday August 2nd, 1990
Patent Number: 5200395
This patent covers the use of a peptide called BUF-5 for the treatment of anemia. Based on the literature we could not find what exactly BUF-5 is. This could be a very interesting patent for treatment not only of various forms of anemia, but also other hematological diseases in which stimulation of the erythrocyte progenitor is beneficial. Inventors: Eto, Yuzuru (Kawasaki, JP); Koyama, Naoto (Kawasaki, JP); Ejima, Daisuke (Kawasaki, JP); Washitake, Masayo (Kawasaki, JP); Shibai, Hiroshiro (Kawasaki, JP)
Assignee: Ajinomoto Company, Inc. (Tokyo, JP)
Date of First Priority Issue: Sunday October 18th, 1998
Patent Number: 5199942
Anyone performing autologous hematopoietic stem cell transplants should watch out for this patent !! This patent teaches essentially autologous transplantation with ex vivo expansion of stem cells. Numerous companies and scientists are doing or have done clinical investigations which potentially infringe on this patent. Inventor: Gillis, Steven (Mercer Island, WA)
Assignee: Immunex Corporation (Seattle, WA)
Date of First Priority Issue: Friday June 7th, 1991
Patent Number: 5197985
Mesenchymal stem cells are a topic of intense investigation and subject to several clinical trials, including by Osiris Therapeutics who are currently in Phase III for treatment of graft versus host disease.
This is one of the older patents on mesenchymal stem cells that teaches the differentiation of mesenchymal stem cells into bone forming cells. This is performed through the use of... Inventors: Caplan, Arnold I. (Cleveland Heights, OH); Haynesworth, Stephen E. (Cleveland Heights, OH)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday November 16th, 1990
Patent Number: 5192553
This is a patent on freezing cord blood stem cells. This is an important patent since it is generating revenue. The company Pharmastem used this patent and several others in order to position itself in the cord blood industry. Additionally, this patent stood the test of litigation. Inventors: Boyse, Edward A. (Tucson, AZ); Broxmeyer, Hal E. (Indianapolis, IN); Douglas, Gordon W. (New York, NY)
Assignee: Biocyte Corporation (New York, NY)
Date of First Priority Issue: Thursday November 12th, 1987
Patent Number: 5187193
This patent teaches the in vivo use of dithiocarbamate for hematopoietic reconstitution after bone marrow transplantation or myelosuppression.
The dithiocarbamate or its analogs that are mentioned in the patent may be administered systemically without adverse effects. Inventors: Borch, Richard F. (Pittsford, NY); Schmalbach, Therese K. (Newton, MA)
Assignee: University of Rochester (Rochester, NY)
Date of First Priority Issue: Monday September 12th, 1988
Patent Number: 5186931
This patent provides a composition of cytokines for stimulating hematopoiesis after a bone marrow transplant, as well as for the in vitro stimulation of hematopoiesis. The composition involves B cell differentiation factor and some commonly used cytokines today. Inventors: Kishimoto, Tadamitsu (Nakano Tondabayashi-shi, Oosaka-fu, JP); Hirano, Toshio (Ibaraki, JP); Akiyama, Yukio (Kawasaki, JP); Okano, Akira (Kawasaki, JP); Matsui, Hiroshi (Kawasaki, JP); Takahara, Yoshiyuki (Kawasaki, JP)
Assignee: Ajinomoto Co., Inc. (Tokyo, JP); Kishimoto, Tadamitsu (Tondabayashi, JP)
Date of First Priority Issue: Wednesday August 6th, 1986
Patent Number: 5175103
This patent covers one of the few stem cell therapies that actually entered clinical trials. The patent is for a teratocarcinoma cell line that is induced to differentiate into neurons with retinoic acid (and/or other factors) and then stops proliferating and can be used for cell therapy in stroke.
The technology was eventually developed clinically by Layton Biosciences. Administration of the... Inventors: Lee, Virginia (Philadelphia, PA); Pleasure, Samuel (Philadelphia, PA)
Assignee: Trustees of University of Pennsylvania (Philadelphia, PA)
Date of First Priority Issue: Monday October 21st, 1991
Patent Number: 5175004
This is a very interesting patent for generation of new cells and new stem cells. This patent is way ahead of its time. It teaches to take recipient cells from a degenerated organ, "rejuvenate" the cells by transplanting the nucleus of the old cell into a cytoplasm of a newer cell, generating a histocompatible cell population through this fusion, and transplanting the cells back into a... Inventor: Matsumura, Kenneth N. (Berkeley, CA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Tuesday December 27th, 1988
Patent Number: 5171527
This patent provides a medical device for rapidly extracting cord blood from an umbilical cord. This may be useful for collection of cord blood stem cells, which is a common practice in current medicine. Inventors: Knippscheer, Hermann (Baldwin, NY); Richard, Daniel D. (Sedona, AZ)
Assignee: Cryo-Cell International, Inc. (Baldwin, NY)
Date of First Priority Issue: Friday January 26th, 1990
Patent Number: 5169765
This patent teaches that dithiocarbamate and its analogues have the ability to stimulate bone marrow production of hematopoietic growth factors. Dithiocarbamate may be used according to the invention for stimulation of hematopoietic cells to produce growth factors, and subsequently the dithiocarbamate may be taken off the cells.
While this patent seems like a really interesting method of... Inventors: Borch, Richard F. (Pittsford, NY); Schmalbach, Therese K. (Newton, MA)
Assignee: University of Rochester (Rochester, NY)
Date of First Priority Issue: Tuesday September 12th, 1989
Patent Number: 5166180
This patent teaches ways to increase hematopoiesis through administration of some chemical compositions. The patent has 2 independent claims that essentially cover these compositions. This seems like an interesting patent but I need to actually look up and see if these compositions have been developed or not. Inventor: Jenkins, Vernon K. (Houston, TX)
Assignee: Duphar International Research B.V. (Weesp, NL)
Date of First Priority Issue: Tuesday November 1st, 1988
Patent Number: 5166065
This patent was used to argue that the WARF patents were anticipated. The patent has two independent claims. The first covering a method of isolating embryonic stem cells, and the second covering a method of maintaining embryonic stem cells. Both independent claims use leukemia inhibitory factor to allow for the ex vivo growth of stem cells without loss of pluripotency. Inventors: Williams, Robert L. (Warrandyte, AU); Gough, Nicholas M. (North Balwyn, AU); Hilton, Douglas J. (Warrandyte, AU)
Assignee: Amrad Corporation Limited (Kew, AU)
Date of First Priority Issue: Friday April 8th, 1988
Patent Number: 5135915
This is a patent covering the de-immunization of an organ by treatment with TGF-b before transplantation. The organs that may be used include heart, liver, spleen, pancreas, thyroid lobe, lung, kidney, intestine, blood vessel, and esophagus. The use of TGF bet to decrease immunogenecity is supported by other observations that this molecule inhibits expression of MHC, which is one of the... Inventors: Czarniecki, Christine W. (San Francisco, CA); Palladino, Michael A. (Foster City, CA); Shefter, Eli (San Francisco, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Date of First Priority Issue: Friday October 14th, 1988
Patent Number: 5130144
This patent is similar to 5035994 and 4965204 by Civin. Essentially the current patent has 3 independent claims that cover similar subject matter as the other two mentioned patents. Specifically, "A method of transplanting stem cells comprising: (a) providing a suspension of human cells comprising pluripotent lympho-hematopoietic stem cells substantially free of mature lymphoid and myeloid... Inventor: Civin, Curt I. (Baltimore, MD)
Assignee: The Johns Hopkins University (Baltimore, MD)
Date of First Priority Issue: Saturday June 2nd, 1984
Patent Number: 5130142
This patent teaches the production of a chemical composition useful for growing hair in bald people. The composition is made from media conditioned by growing epithelial cells. The composition is mitogenic to dermal papilla cells and 3T3 fibroblasts but not to epidermal cells. The molecular weight of the active ingredient is > 3 kDa. Inventors: Wong, Teresa K. (Cincinnati, OH); Warren, Raphael (Cincinnati, OH)
Assignee: The Practer & Gamble Company (Cincinnati, OH)
Date of First Priority Issue: Wednesday October 31st, 1990
Patent Number: 5126325
This patent covers the use of B cell differentiation factor (BCDF) for treatment of thrombocytopenia. This may be interesting if the BCDF is still not characterized. It may be an interesting new way of stimulating hematpoietic stem cells to preferentially go towards the path of a specific lineage. I do have a feeling, however that the BCDF is actually IL-6. Inventors: Kishimoto, Tadamitsu (Tondabayashi-shi, Osaka-fu, JP); Hirano, Toshio (Ibaraki, JP); Kimura, Hideo (Fukushima, JP); Ishibashi, Toshiyuki (Fukushima, JP); Akiyama, Yukio (Kawasaki, JP); Okano, Akira (Kawasaki, JP)
Assignee: Ajinomoto Co., Inc. (Tokyo, JP); Kishimoto, Tadamitsu (Tondabayashi, JP)
Date of First Priority Issue: Friday January 13th, 1989
Patent Number: 5114926
This invention covers the synthethized form of a tetrapeptide that inhibits bone marrow stem cell entery into cell cycle. The original inhibitory activity was derived from fetal calf bone marrow as a biological "soup" but in this patent synthesis and structure are revealed. The use of agents that inhibit stem cell entry into cell cycle could occur when chemotherapy or radiation is... Inventors: Frindel, Emilia (Paris, FR); Lenfant, Maryse (Gif Sur Yvette, FR); Guigon, Martine (Neuilly, FR); Bakala, Johanna (Paris, FR)
Assignee: Institut National De La Sante Et De La Recherche Medicale (Paris, FR); Institut Gustave Roussy (Paris, FR)
Date of First Priority Issue: Friday July 18th, 1986
Patent Number: 5087570
This patent covers the use of the stem cell antigen (SCA-1) for determination of murine hematopoieitic stem cells. The patent has 1 independent claim that covers "A cell composition consisting essentially of as the cellular population viable murine hematopoietic Sca-1+ stem cells from a genetically identical or congenic source." Inventors: Weissman, Irving L. (Stanford, CA); Spangrude, Gerald J. (N/A); N/A (VIC 3050, AU); Muller-Sieburg, Christa (San Diego, CA); Heimfeld, Shelly
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Wednesday October 5th, 1988
Patent Number: 5061620
This is another patent on the hematopoietic stem cell. It is filed later than Civin's, that is why this is an interesting patent. Furthermore it actually mention's Civin's patent "U.S. Pat. No. 4,714,680 describes a composition comprising human stem cells. " In any case, this current patent has 3 independent claims. The first covers "A cellular composition comprising human... Inventors: Tsukamoto, Ann (Palo Alto, CA); Baum, Charles M. (Menlo Park, CA); Aihara, Yukoh (Hiratsuka, JP); Weissman, Irving (Palo Alto, CA)
Assignee: SyStemix, Inc. (Palo Alto, CA)
Date of First Priority Issue: Friday March 30th, 1990
Patent Number: 5035994
This patent futher strengthens Civin's claim (no pun intended) on the hematopoietic stem cell. The first independent claim covers "A method of isolating a population of human cells containing pluripotent lympho-hematopoletic stem cells" through ANY ANTIBODY that bind to the antigen that is recognized by the antibody deposited with ATCC under Accession No. HB-8483. The second... Inventor: Civin, Curt I. (Baltimore, MD)
Assignee: The Johns Hopkins University (Baltimore, MD)
Date of First Priority Issue: Monday January 5th, 1987
Patent Number: 5032507
This patent covers the discover that follicle stimulating hormone releasing protein (FRP) can potentiate the activity of erythropoitin in terms of induce erythropoiesis. The patent covers this concept from three perspectives in its three independent claims. The first perspective is "a method for determining the erythrodifferentiation-potentiating capacity of hematopoietic stem... Inventors: Yu, John (San Diego, CA); Yu, Alice L. (San Diego, CA); Vaughan, Joan (San Diego, CA); Rivier, Jean E. F. (La Jolla, CA); Vale, Jr., Wylie W. (La Jolla, CA)
Assignee: The Salk Institute for Biological Studies (San Diego, CA); The Regents of the University of California (Berkeley, CA); Scripps Clinic and Research Foundation (La Jolla, CA)
Date of First Priority Issue: Sunday December 13th, 1987
Patent Number: 5032407
This patent teaches that embryonic yolk sac, midbrain, and forbrain cells may be gene transfected with a useful gene and utilized as a vector for delivery of the gene to an area of need. Inventors: Wagner, Thomas E. (Athens, OH); Reed, Michael A. (Athens, OH); Corn, Barbara J. (Athens, OH)
Assignee: Ohio University Edison Animal Biotechnology Center (Athens, OH)
Date of First Priority Issue: Friday January 16th, 1987
Patent Number: 5004681
This patent covers freezing of cord blood for future use. The patent has one independent claim covering the composition of a cryopreservant, together with viable fetal or neonatal hematopoietic cells. PharmaStem is the successor to Biocyte Corporation, the assignee of this patent. This patent, together with patents 5 192 553, 6 461 645, 6 569 427 and 6 605 275 are used by Pharmastem to... Inventors: Boyse, Edward A. (New York, NY); Broxmeyer, Hal E. (Indianapolis, IN); Douglas, Gordon W. (New York, NY)
Assignee: Biocyte Corporation (New York, NY)
Date of First Priority Issue: Friday December 11th, 1987
Patent Number: 4976950
This patent has 2 independent claims, the first covering a method of suppressing the bone marrow, the second covering a sterile injectable capable of suppressing the bone marrow. The method by which this patent teaches to suppress the bone marrow is through administration of a sterile composition containing the radionuclide Yttrium-90 complexed with at least one macrocycle aminophosphonic acid... Inventors: Simon, Jaime (Angleton, TX); Garlich, Joseph R. (Lake Jackson, TX); Wilson, David A. (Richwood, TX); McMillan, Kenneth (Richwood, TX)
Assignee: The Dow Chemical Company (Midland, MI)
Date of First Priority Issue: Monday December 19th, 1988
Patent Number: 4965204
This patent is a division of application Ser.No. 670,740, filed Feb.6, 1984 which issued on Dec. 22, 1987 as U.S. Pat. No. 4,714,680 and was described below. This patent is similar to 4,714,680 with the exception that the one independent claim in this patent covers in more detail the antibody which is now known to recognize CD34. Essentially, this is the first time that an antibody has been... Inventor: Civin, Curt I. (Baltimore, MD)
Assignee: The Johns Hopkins University (Baltimore, MD)
Date of First Priority Issue: Tuesday December 22nd, 1987
Patent Number: 4959313
This patent covers a specific DNA enhancer sequence that is activated uniquely in embryonic stem cells. Such an enhancer is useful for numerous genetic engineering techniques, as well as, I believe, for generation of transgenic animals. Inventor: Taketo, Makoto (Bar Harbor, ME)
Assignee: The Jackson Laboratory (Bar Harbor, ME)
Date of First Priority Issue: Monday June 22nd, 1987
Patent Number: 4946437
This patent is a novel way to expand bone marrow cells ex vivo through contacting the bone marrow with a family of compounds. The single issued independent claim covers "A method for the transplantation of bone marrow cells" and the method involved contacting with a specific family of compounds. The first dependent claim states one member of this family of compounds as being... Inventors: Sredni, Benjamin (Beni Brak, IL); Albeck, Michael (Ramat Gan, IL)
Assignee: Bar-Ilan University (Ramat-Gan, IL)
Date of First Priority Issue: Friday February 12th, 1988
Patent Number: 4721096
This patent is broad reaching in that it covers the ex vivo expansion of bone marrow for treating a pateint whose bone marrow has been comprised. Essentially, this patent was ahead of its time since numerous companies are trying to perform this process even today. Essentially the patent's since independent claim covers extraction of bone marrow, ex vivo replication so that hematopoietic... Inventors: Naughton, Brian A. (Yorktown Heights, NY); Naughton, Gail K. (Yorktown Heights, NY)
Assignee: Marrow-Tech Incorporated (Albany, NY)
Date of First Priority Issue: Friday April 18th, 1986
Patent Number: 4714680
This is one of the most important patents in the history of stem cell IP. It essentially covers the hematopoietic CD34+ stem cell. The patent has 3 independent claims, the first covering a population of hematopoietic cells in general, the second covering hematopoietic cells from blood, and the third covering hematopoietic cells which are recognized by a specific antibody, whose target was... Inventor: Civin, Curt I. (Baltimore, MD)
Assignee: The Johns Hopkins University (Baltimore, MD)
Date of First Priority Issue: Saturday June 2nd, 1984
Patent Number: 4411990
Cancer stem cells have been known to exist for decades, as seen by the present patent whose actual first priority date is july 7, 1978.
Unfortunately, research into cancer stem cells is only recently gaining attention.
The cancer stem cell is the populatin which some believe is responsible for maintaining the tumor mass, while the other 99% of cancer cells are differentiated and have... Inventors: Salmon, Sydney E. (Tucson, AZ); Hamburger, Anne W. (Potomac, MD)
Assignee: University Patents, Inc. (Norwalk, CT)
Date of First Priority Issue: Tuesday January 1st, 1980
Patent Number: 4423145
This patent covers ways of growing mammary epithelial tissue in vitro. It teaches that such cells can be grown through dissociating stromal cells using enzymez and mechanical means so as to obtain a population of clumps of epithelial cells. The epithelial cells are then grown in a conditioned media that is either conditioned by human fetal intestine epithelial cells or human bladder epithelial... Inventors: Stampfer, Martha R. (Oakland, CA); Smith, Helene S. (Oakland, CA); Hackett, Adeline J. (Orinda, CA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Sunday July 5th, 1981
Patent Number: 4342828
This patent teaches how to make a hematopoietic-stimulatory substance through taking out blood, extracting monocytes and macrophages, culturing them with a glycoprotein from urine, and collecting/concentrating the resulting composition, which is useful for stimulating the proliferation and differentiation of human granulopoietic stem cells. This may be an interesting way to generate growth... Inventors: Takaku, Fumimaro (Utsunomiya, JP); Ogasa, Katsuhiro (Yokohama, JP); Kuboyama, Morio (Tokyo, JP); Yanai, Nobuya (Tokyo, JP); Yamada, Muneo (Kodaira, JP); Watanabe, Yoshiteru (Tokyo, JP)
Assignee: Morinaga Milk Industry Co., Ltd. (Tokyo, JP); The Green Cross Corp. (Osaka, JP)
Date of First Priority Issue: Friday July 20th, 1979
Patent Number: 5,728,581
This patent provides bioreactors and specific culture conditions for the in vitro and ex vivo expansion of hematopoietic stem cells. The patent discloses cytokines, oxygen tensions, and nutrients useful for expansion of cells. Inventors: Schwartz, Richard Merrill (San Mateo, CA); Tucker, Sean Newton (San Francisco, CA); Chary, Srikanth Ranga (Fremont, CA); Kuo, Suzanne Chang (Cupertino, CA)
Assignee: Systemix, Inc. (Palo Alto, CA)
Date of First Priority Issue: Tuesday January 1st, 1980
